INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Isotan 100% inhalation solution', 21043, 'ايزوتان 100% محلول استنشاق', '110', NULL, 'General anaesthesia', 'General anaesthesia', NULL, 'Isoflurane', 'Pharco > eimc', 'Solution', 'محلول', '100%', '1', NULL, NULL, 'description a stable non-explosive inhalation anesthetic relatively free from significant side effects. mechanism of action isoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap juncti', NULL, 932, '2022-07-17', NULL, 0, 'For induction and maintenance of general anesthesia.', 'Isoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Isoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. Also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Isoflurane also binds to the GABA receptor, the large conductance Ca<sup>2+</sup> activated potassium channel, the glutamate receptor and the glycine receptor.', 'Isoflurane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tenolidone 100/25mg 10 f.c. tabs.', 28018, 'تينوليدون 100/25مجم 10 اقراص', '9', NULL, 'Beta blocker and thiazide diuretics', 'Beta blocker and thiazide diuretics', NULL, 'Atenolol+chlorthalidone', 'Organopharma', 'Tab', 'أقراص', '25mg', '1', NULL, NULL, 'indications for atenolol + chlorthalidone beta blocker and thiazide diuretics are given in combination to treat hypertension. atenolol reduces the work load on the heart and chlorthalidone reduce the hypertension by increasing the flow of urine. 1. hypert', NULL, 764, '2022-07-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Halosoft 120 ml lotion', 24090, 'هالوسوفت لوشن 120 مل', '40', NULL, 'Skin lotion', 'Skin lotion', NULL, 'Zinc oxide + chamommile + thymol + menthol + glycerine + olive oil', 'Helwan pharmaceuticals', 'Lotion', 'لوشن', '120 ml', '1', NULL, NULL, NULL, '6225000246188', 836, '2022-07-09', NULL, 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rovapex 3m.i.u. 10 f.c.tab.', 26346, 'روفابكس 3مليون وحدة 10 اقراص', '20', NULL, 'Antibiotic.macrolide', 'Antibiotic.macrolide', NULL, 'Spiramycin', 'Multi-apex', 'Tab', 'أقراص', NULL, '1', NULL, NULL, 'about spiramycin macrolide antibiotic antibacterial (systemic antiprotozoal in toxoplasmosis cryptosporidiosis. mechanism of action of spiramycin spiramycin is a member of macrolide antibiotic. it binds to the 50s sub unit of bacterial ribosome and inhibi', NULL, 1146, '2022-12-03', NULL, 0, 'Macrolide antibiotic for treatment of various infections.', 'The mechanism of action of macrolides has been a matter of controversy for some time. Spiramycin, a 16-membered macrolide, inhibits translocation by binding to bacterial 50S ribosomal subunits with an apparent 1 : 1 stoichiometry. This antibiotic is a potent inhibitor of the binding to the ribosome of both donor and acceptor substrates. The primary mechanism of action is done by stimulation of dissociation of peptidyl-tRNA from ribosomes during translocation.I ', 'The absolute bioavailability of oral spiramycin is generally within the range of 30 to 40%. After a 1 g oral dose, the maximum serum drug concentration was found to be within the range 0.4 to 1.4 mg/L.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Skinnatra cleansing gel 150ml', 27075, 'سكيناترا جل منظف 150 مل', '120', '95', 'Skin care', 'Skin care', NULL, NULL, 'Hi-care > pharma zone', 'Gel', 'جل', '150ml', '1', 'جل منظف للجلد', NULL, 'ingredients: sorbitan sesquicaprylate (antil soft sc) + cucumis sativus (cucumber) extract + aloe vera extract + salicylic acid + glycolic acid + citric acid + panthenol + glycerin + imidazolidinyl urea + disodium edta + phenoxyethanol + ethylhexylglyceri', NULL, 2238, '2024-05-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mustela skin freshener 200ml', 23130, 'موستلا منعش للجلد 200 مل', '185', NULL, 'Baby care', 'Baby care', NULL, 'Avocado perseose', 'Laboratoires expanscience-france > biotech egypt', 'Unknown', 'غير محدد', '200ml', '1', NULL, NULL, 'specially formulated for use right from day one * mustela bï-bï- skin freshener is ideal for your babyï-s daily hygiene: perfect for rinsing mustela bï-bï- cleansing milk leaving the skin soft. can also be used for delicately scenting or refreshing your b', NULL, 676, '2022-07-28', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Skomidfare 120 ml syrup', 15153, 'سكوميدفير شراب 120 مل', '55', NULL, 'Multivitamin', 'Multivitamin', NULL, 'Iron+vitamin b3+b1+b6+b2+b12+zinc+folic acid+cooper+vitamin c', 'Cetcomed pharm', 'Syrup', 'شراب', '120 ml', '1', NULL, NULL, NULL, NULL, 1030, '2022-09-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Kapron 500 mg 20 f.c.tabs.', 21251, 'كابرون 500 مجم 20 قرص', '110', '72', 'Bleedding.fibrinolytics inhibitors', 'Bleedding.fibrinolytics inhibitors', NULL, 'Tranexamic acid', 'Amoun', 'Tab', 'أقراص', '500 mg', '2', 'يوقف النزيف في اي حالة نزيف -- يساعد عل تجلط الدم', NULL, 'about tranexamic acid lysine analog hemostatic competitive plasminogen activationinhibitor antifibrinolytic antihemophilic. mechanism of action of tranexamic acid tranexamic acid exerts antifibrinolytic effect by forming a reversible complex with plasmino', '6221025012692', 21600, '2025-06-24', NULL, 0, 'Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema,[L31883] cyclic heavy menstrual bleeding in premenopausal females,[L31858] and other instances of significant bleeding in the context of hyperfibrinolysis.[L31883] Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.[L31853]', 'Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage.[L31858]', 'Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin.[L31858] At much higher concentrations it behaves as a noncompetitive inhibitor of plasmin similar to [aminocaproic acid], a similar antifibrinolytic which is 10-fold less potent.[L31883] Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).[A230113] 



Off-target antagonism of GABA(A) receptors may be associated with the development of convulsions and hyperexcitability following tranexamic acid administration[A229383] - the risk appears higher with improper administration or administration during cardiovascular surgery.[L31883] Consider EEG monitoring of patients with a history of seizure.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lucente suncare - combined to oily spf 50+ - 50 ml', 931, 'لوسينت صنكير كومبايند اس بي اف 50+ - 50 مل', '350', NULL, 'Sun block', 'Sun block', NULL, 'Sebaryl+allantoin+vitamin e+parsol tx+uvinul a plus', 'Macro group pharmaceuticals', 'Oil', 'زيت', '50 ml', '1', NULL, NULL, NULL, NULL, 882, '2022-09-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Povidone skin cleanser 7.5% topical solution', 25097, 'بوفيدون منظف للجلد 7.5% محلول موضعي', '8', NULL, 'Antiseptic', 'Antiseptic', NULL, 'Povidone- iodine', 'Panax pharma > pharmacare', 'Solution', 'محلول', '7.5%', '1', NULL, NULL, NULL, NULL, 790, '2022-07-17', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rybelsus 14 mg 30 tabs.', 9298, 'ريبلسوس 14مجم 30 قرص', '3,150', '3150', 'Anti-diabetic.glp-1 receptor agonist', 'Anti-diabetic.glp-1 receptor agonist', NULL, 'Semaglutide', 'Novo nordisk', 'Tab', 'أقراص', '14 mg', '3', 'بديل اوزمبك لعمليات التخسيس والتنحيف--ريبلسوس: بديل الحقن الجديد لعلاج مرض السكري--ريبلسوس او سيماجلوتايد--ريبلسوس أو سيماجلوتيدهو عقار تم تطويره ليصبح كببتيد شبيه الجلوكاجون 1، وهو هرمون ببتيدي طويل يتكون من 30 حمض أميني يُفرز بشكل طبيعي في الجسم عند تناول الطعام، ويعمل مع الأنسولين على خفض مستويات السكر في الدم عن طريق تعزيز إفراز الأنسولين من خلايا بيتا في البنكرياس.تمت الموافقة على سيماجلوتيد من قبل إدارة الغذاء و الدواء الأمريكية (FDA) في عام 2017 كمنتج للحقن تحت الجلد لعلاج مرض السكري من النوع الثاني، ولاحقاً في عام 2019 تم إصدار أقراص من سيماجلوتيد لتكون بديلة عن الحقن لمساعدة مرضى السكري الذين لا يرغبون في استخدام أقلام الحقن في السيطرة على مستوى السكر في الدم.إرشادات يجب مراعاتها عند استخدام أقراص ريبلسوسأخبر طبيبك إذا كان لديك حساسية من المادة الفعالة أو أي مادة من مكونات الدواء.لا تتناول سيماجلوتيد إذا كنت تعاني من داء السكري النوع الأول أو أي مشكلة في الدم أو التهاب البنكرياس.أخبر طبيبك إن كنت تتناول أدوية أخرى أو مكملات غذائية.لا تأخذي هذا الدواء إذا كنتي حاملاً أو مرضعاً.اتباع حمية غذائية ونمط حياة صحي إلى جانب العلاج يساعد على السيطرة على مستوى منخفض من السكر في الدم، وفي حال عدم النجاح في السيطرة على مستوى السكر فإن الحالة تستدعي زيادة في الجرعة أو استخدام علاج آخر إلى جانب ريبلسوس وفق ما يرى الطبيب المعالج.لا تستخدم هذا الدواء إذا أصبت من قبل بأمراض في الغدة الدرقية أو ان كان في تاريخ العائلة إصابة بسرطان الغدة الدرقية.يؤخذ الدواء قبل 30 دقيقة من تناول أي شيء صباحاً ويجب عدم تناول المشروبات التي تحتوي على الكافيين معه.يجب الالتزام بالجرعة اليومية حتى وإن شعر المريض بأن مستوى السكر لديه طبيعي وأنه بغنى عنها.في حال تذكر المريض أنه لم يأخذ جرعة اليوم السابق فإنه يلتزم بالجرعة الحالية فقط ولا يجب أن يقوم بمضاعفة الجرعة.في حال كانت الجرعة اليومية قرص واحد 14 ملغم فإنه يستحسن أحذ قرص واحد وعدم الاعتماد على أخذ قرصين 7 ملغم وتقسيم الجرعة على فترات.', NULL, 'mechanism of action: *diabetes type 2: incretins such as glp-1 enhance glucose-dependent insulin secretion by pancreatic beta-cells suppress inappropriately elevated glucagon secretion and slow gastric emptying. *weight management: glp-1 is a physiologica', NULL, 2165, '2024-08-20', NULL, 0, 'Semaglutide is always intended to be used with a reduced calorie diet and increased physical activity. It is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus.[L8678,L8681] However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis.  Semaglutide is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosis.[L8678]



Semaglutide is indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol).[L34475,L41335]. Semaglutide it is also indicated for chronic weight management in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex.[L44552]



Semaglutide is also used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.[L50452]', '**Mechanism of glycemic control**



GLP-1 is a physiological hormone that promotes glycemic control via several different mechanisms, including insulin secretion, slowing gastric emptying, and reducing postprandial glucagon secretion. The homeostasis of glucose is dependent on hormones such as insulin and amylin, which are secreted by the beta cells of the pancreas.  Semaglutide is 94% similar to human GLP-1. Analogs of this hormone such as semaglutide stimulate the synthesis of insulin[A31424] by stimulating pancreatic islet cells and reducing glucagon secretion.[A31424]  They directly bind with selectivity to the GLP-1 receptor, causing various beneficial downstream effects that reduce blood glucose in a glucose-dependent fashion.[L8681] 



**Mechanism of cardiovascular benefit and weight loss**



 In hypercholesterolemia, semaglutide is believed to reduce the progression of atherosclerosis via decreased gut permeability and decreased inflammation.[A186065] Weight loss is believed to occur via the reduction of appetite and food cravings after semaglutide administration. [A31423,A186074]', 'Semaglutide reduces HbA1c, systolic blood pressure, and body weight.[A186062] After 12 weeks of treatment, semaglutide decreased fasting and postprandial glucose by increasing insulin production and decreasing glucagon secretion (which is normally associated with increases in blood sugar). Semaglutide also lowers fasting triglycerides and VLDL cholesterol, exerting beneficial effects on cardiovascular health.[A186053,L1067]



Semaglutide has been shown to cause medullary thyroid cell carcinoma in rodents. While its clinical relevance to humans is unknown, the FDA advises not to administer this drug in those with a personal or family history of medullary thyroid carcinoma.  Semaglutide also poses a risk of pancreatitis and dehydration. Patients must be adequately hydrated while on semaglutide and are advised to seek medical attention immediately in cases of abdominal pain radiating to the back. Because this drug delays gastric emptying, it is important to monitor for the efficacy or adverse effects of other drugs that are administered orally.[L8681]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rheuxicam 8mg 20 f.c.tab.', 26028, 'روكسيكام 8مجم 20 قرص', '72', '47', 'Nsaid.oxicam', 'Nsaid.oxicam', NULL, 'Lornoxicam', 'Chemipharm', 'Tab', 'أقراص', '8mg', '2', NULL, NULL, 'about lornoxicam non-steroidal anti-inflammatory drug (nsaid) of the oxicam class with analgesic (pain relieving) anti-inflammatory and antipyretic (fever reducing) properties. it is available in oral and parenteral formulations. mechanism of action of lo', '6222006501006', 3102, '2025-08-03', NULL, 0, 'For the treatment of acute mild to moderate pain, as well as pain and inflammation of the joints caused by certain types of rheumatic diseases.', 'Like other NSAIDS, lornoxicam''s anti-inflammatory and analgesic activity is related to its inhibitory action on prostaglandin and thromboxane synthesis through the inhibition of both COX-1 and COX-2. This leads to the reduction of inflammation, pain, fever, and swelling, which are mediated by prostaglandins. However, the exact mechanism of lornoxicam, like that of the other NSAIDs, has not been fully determined.', 'Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that belongs to the oxicam class. As with other NSAIDS, lornoxicam is a potent inhibitor of the cyclooxgenase enzymes, which are responsible for catalyzing the formation of prostaglandins (act as messenger molecules in the process of inflammation) and thromboxane from arachidonic acid. Unlike some NSAIDS, lornoxicam''s inhibition of cyclooxygenase does not lead to an increase in leukotriene formation, meaning that arachidonic acid is not moved to the 5-lipoxygenase cascade, resulting in the minimization of the risk of adverse events.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rampecardin 5 mg 7 tabs', 25675, 'رامبيكاردين 5مجم 7 اقراص', '10', NULL, 'Antihypertensive.ace', 'Antihypertensive.ace', NULL, 'Ramipril', 'Eipico', 'Tab', 'أقراص', '5 mg', '1', NULL, NULL, 'about ramipril angiotensin - converting enzyme inhibitor antihypertensive. mechanism of action of ramipril it is a prodrug and converted in to active ramiprilat; which is an angiotensin converting enzyme inhibitor prevents the conversion of angiotensin-1', '6221032117946', 1299, '2022-12-08', NULL, 0, 'For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. [FDA Label] To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy. [T116] ', 'Ramipril inhibits the RAAS system by binding to and inhibiting ACE thereby preventing the conversion of angiotensin I to angiotensin II. [T116] As plasma levels of angiotensin II fall, less activation of the G-protein coupled receptors angiotensin receptor I (AT<sub>1</sub>R) and angiotensin receptor II (AT<sub>2</sub>R) occurs. 



AT<sub>1</sub>R mediates vasoconstriction, inflammation, fibrosis, and oxidative stress through a variety of signaling pathways. [T116] These include G<sub>q</sub> coupling to the inositol triphosphate pathway, activation of phospholipases C, A<sub>2</sub>, and D which contribute to eicosanoid production, activation of Ca<sup>2+</sup>-dependent and MAP kinases, G<sub>i</sub> and G<sub>12/13</sub>, and eventual activation of the Jak/STAT pathway leading to cell growth and production of extracellular matrix components. AT<sub>1</sub>R activation also leads to increased activity of membrane-bound NADH/NADPH oxidase which contributes to production of reactive oxygen species. Decreased activation of this receptor mediates the renoprotective, antihypertensive, and cardioprotective effects of ramipril by reducing inflammation and vasoconstriction.



AT<sub>2</sub>R acts in opposition to the effects of AT<sub>1</sub>R by activating phosphotyrosine phosphatases which inhibit MAP kinases, inhibiting Ca<sup>2+</sup> channel opening, and stimulating cGMP and nitric oxide production leading to vasodilation. [T116] These counteracting effects are shared by the Mas receptor which is activated by Ang(1-7), a subtype of angiotensin produced by plasma esterases from AngI or by ACE2 from AngII produced through a secondary pathway by tonin and cathepsin G. Ang(1-7) also activates AT<sub>2</sub>R although the bulk of its effect is mediated by MasR.



ACE is also responsible for the breakdown of bradykinin. [T116] The resulting buildup of bradykinin due to ACE inhibition is thought to mediate the characteristic dry-cough as a side effect of ACE inhibitor medications.



', 'Ramipril is an ACE inhibitor similar to benazepril, fosinopril and quinapril. [T116] It is an inactive prodrug that is converted to ramiprilat in the liver, the main site of activation, and kidneys. Ramiprilat confers blood pressure lowing effects by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of ramiprilat by causing increased vasodilation and decreased blood pressure.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lady care vag.douche 125ml', 21548, 'ليدي كير غسول 125 مل', '35', NULL, 'Vaginal wash', 'Vaginal wash', NULL, 'Vaginal doushe formula', 'Hi-care > gamaces leader co.', 'Unknown', 'غير محدد', '125ml', '1', NULL, NULL, NULL, '6224555412871', 879, '2022-12-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Narji hair tonic lotion 120 ml', 10319, 'نارجي لوشن مقوي للشعر 120 مل', '247', '190', 'Hair tonic.hair fall', 'Hair tonic.hair fall', NULL, 'Keratin+panthenol+lactic acid+tea tree oil+caffeine', 'Egyptian co. for cosmetics', 'Lotion', 'لوشن', '120 ml', '1', NULL, NULL, NULL, NULL, 1247, '2024-09-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lipo 6 black ultra 60 cap', 7382, 'ليبو 6 بلاك الترا 60 كبسولة', '650', NULL, NULL, NULL, NULL, 'Accelerated fat loss formula', 'Company', 'Cap', 'كبسولة', NULL, '6', NULL, NULL, NULL, '853237000714', 1331, '2022-12-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Fibrocro 5 gm 15 sachets', 19031, 'فيبروكرو 5 جم 15 كيس', '140', '99', 'Weight loss', 'Weight loss', NULL, 'Chromium piclonate+psyllium husk fiber', 'Medcare > medicina medical ltd.', 'Sachet', 'أكياس', '5 gm', '1', 'يعمل على انقاص الوزن وخفض الشهية وزيادة معدل الحرق', NULL, 'dosage: one sachet to be dissolved in a big glass of water 30 minute before main meal.', NULL, 1069, '2024-11-22', NULL, 0, 'Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN), to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms [FDA Label].', 'Chromium is an essential nutrient involved in the metabolism of glucose, insulin and blood lipids. Its role in potentiating insulin signalling cascades has been implicated in several studies. Chromium upregulates insulin-stimulated insulin signal transduction via affecting effector molecules downstream of the insulin receptor (IR). IR-mediated signalling pathway involves phoshorylation of multiple intracellular domains and protein kinases, and downstream effector molecules [A32353]. Upon activation by ligands, intracellular β-subunit of IR autophosphorylates and activates tyrosine kinase domain of the IR, followed by activation and phosphorylation of regulatory proteins and downstream signalling effectors including phosphatidylinositol 2-kinase (PI3K). PI3K activates further downstream reaction cascades to activate protein kinase B (Akt) to ultimately promote translocation of glucose transporter-4 (Glut4)-vesicles from the cytoplasm to the cell surface and regulate glucose uptake [A32353]. Chromium enhances the kinase activity of insulin receptor β and increases the activity of downstream effectors, pI3-kinase and Akt. 



Under insulin-resistant conditions, chromium also promotes GLUT-4 transporter translocation that is independent of activity of IR, IRS-1, PI3-kinase, or Akt; chromium mediates cholesterol efflux from the membranes via increasing fluidity of the membrane by decreasing the membrane cholesterol and upregulation of sterol regulatory element-binding protein [A32353]. As a result, intracellular GLUT-4 transporters are stimulated to translocate from intracellular to the plasma membrane, leading to enhanced glucose uptake in muscle cells [L1990]. Chromium attenuates the activity of PTP-1B _in vitro,_ which is a negative regulator of insulin signaling. It also alleviates ER stress that is observed to be elevated the suppression of insulin signaling. ER stress is thought to activate c-Jun N-terminal kinase (JNK), which subsequently induces serine phosphorylation of IRS and aberration of insulin signalling [A32353]. Transient upregulation of AMPK by chromium also leads to increased glucose uptake [A32353]. ', 'Trivalent chromium is part of glucose tolerance factor, an essential activator of insulin-mediated reactions. Chromium helps to maintain normal glucose metabolism and peripheral nerve function. Chromium increases insulin binding to cells, increases insulin receptor density and activates insulin receptor kinase leading to enhanced insulin sensitivity [A32351]. In chromium deficiency, intravenous administration of chromium resulted in normalization of the glucose tolerance curve from the diabetic-like curve typical of chromium deficiency [FDA Label]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Serpass 50mg 30 f.c.tab.', 26867, 'سيرباس 50مجم 30 قرص', '102', '76.5', 'Psychiatric.antidepressants', 'Psychiatric.antidepressants', NULL, 'Sertraline', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '50mg', '3', NULL, NULL, 'about sertraline selective serotonin reuptake inhibitor (ssri) antidepressant antidepressant mechanism of action of sertraline sertraline blocks the re-uptake of neurotransmitter serotonin from the synapse in to the presynaptic nerve terminal in the cns.', '6223002142583', 3735, '2024-08-17', NULL, 0, 'Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]

', 'Sertraline selectively inhibits the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane, thereby increasing serotonergic activity. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission.[T28,L9016] These changes are believed to be responsible for the antidepressant action and beneficial effects in obsessive-compulsive (and other anxiety related disorders). It has been hypothesized that obsessive-compulsive disorder, like depression, is also caused by the disregulation of serotonin.[A187165]



In animal studies, chronic administration of sertraline results in down-regulation of brain norepinephrine receptors.[L9016] Sertraline displays affinity for sigma-1 and 2 receptor binding sites[A31941], but binds with stronger affinity to sigma-1 binding sites.[A31940] In vitro, sertraline shows little to no affinity for GABA, dopaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors.[L9016] It exerts weak inhibitory actions on the neuronal uptake of norepinephrine and dopamine[A1844] and exhibits no inhibitory effects on the monoamine oxidase enzyme.[L9016]', 'Sertraline improves or relieves the symptoms of depression, OCD, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder via the inhibition of serotonin reuptake.[A187075,L9016] Clinical studies have shown that it improves cognition in depressed patients.[A1846] It has less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because it does not exert significant anticholinergic, antihistamine, or adrenergic (alpha1, alpha2, beta) blocking activity.[A1844] The onset of action and beneficial effects are usually noticed after 4-6 weeks, for reasons that are not fully understood and currently under investigation.[A188493,L10677]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ducray nutricerat spray 75 ml', 17945, 'دوكري نيوتريسيرات سبراي 75مل', '325', '285', 'Hair care', 'Hair care', NULL, NULL, 'Pierre - fabre france > biotech egypt', 'Spray', 'بخاخ', '75 ml', '1', NULL, NULL, 'nutricerat anti-dryness spray acts on hair every time there s a risk of damage (at the sea swimming pool or during sun exposure etc.). it detangles hair seals the hair scales and creates a protective barrier preventing the hair shaft from drying out. hair', NULL, 623, '2023-09-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Depakine chrono 500mg 30 scored prolonged rel. f.c. tab.', 3416, 'ديباكين كرونو 500مجم 30 قرص', '144', '94', 'Anti-epileptic.fatty acid', 'Anti-epileptic.fatty acid', NULL, 'Sodium valproate+valproic acid', 'Sanofi winthrop > sanofi', 'Tab', 'أقراص', '500mg', '1', 'علاج للصرع', NULL, 'about sodium valproate histone deacetylase inhibitor gaba agent anticonvulsant antimanic migraine prophylaxis. mechanism of action of sodium valproate sodium valproate is the sodium salt of valproic acid.after oral administration it is quiickly converted', '3664798021899', 11139, '2024-11-10', NULL, 0, 'For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.', 'Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.', 'Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Baby nadif nasal spray 50 ml', 14857, 'بيبي ناديف بخاخ الانف 50 مل', '390', '340', 'Nasal decongestant', 'Nasal decongestant', NULL, 'Hypertonic seawater', 'Crab sinergy > rotabiogen for pharmaceutical invest.', 'Spray', 'بخاخ', '50 ml', '1', NULL, NULL, 'natural relief for nasal congestion suitable for children of any age.', '8033776700692', 1679, '2024-11-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bambec 10mg 30 tab.', 1282, 'بامبيك 10مجم 30 قرص', '45', NULL, 'Bronchodilator.long acting beta 2 agonist', 'Bronchodilator.long acting beta 2 agonist', NULL, 'Bambuterol', 'Astra zeneca > healthy family', 'Tab', 'أقراص', '10mg', '3', 'موسع للشعب الهوائية يساعد الأشخاص الذين يعانون من الربو، في تخفيف الأعراض مثل السعال، والصفير عند التنفس، والشعور بضيق التنفس خاصة في الليل.', NULL, 'about bambuterol long acting beta 2-adrenoceptor agonist anti asthmatic-bronchodilators. mechanism of action of bambuterol this prodrug of the 2-agonist terbutaline undergoes oxidation and hydrolysis in the body and converted into terbutaline. this terbut', '6223003270339', 1548, '2022-12-03', NULL, 0, 'For the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.', 'The pharmacologic effects of bambuterol are at least in part attributable to stimulation through beta-adrenergic receptors (beta 2 receptors) of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.', 'Bambuterol is a long acting beta2-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline. Bambuterol causes smooth muscle relaxation, resulting in dilation of bronchial passages.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Koolflex massage gel', 6657, 'كولفليكس مساج جل', '120', NULL, 'Massage gel', 'Massage gel', NULL, 'Menthol+camphor', 'Evera', 'Gel', 'جل', NULL, '1', NULL, NULL, NULL, NULL, 690, '2025-08-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bonefit 10.000 i.u. 30 tabs.', 31808, 'بونفيت 10000 وحدة دولية 30 قرص', '180', '110', 'Vitamin d', 'Vitamin d', NULL, 'Cholecalciferol(vitamin d3)', 'Dulex lab > rotabiogen', 'Tab', 'أقراص', NULL, '3', NULL, NULL, 'description derivative of 7-dehydroxycholesterol formed by ultraviolet rays breaking of the c9-c10 bond. it differs from ergocalciferol in having a single bond between c22 and c23 and lacking a methyl group at c24 indication for the treatment of vitamin d', '6224011378451', 1160, '2024-05-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Neo-digestin syrup 120 ml', 23361, 'نيو-ديجستين شراب 120 مل', '6', NULL, 'Digestive enzymes', 'Digestive enzymes', NULL, 'Papain+pepsin+sanzyme 3500', 'Pharco', 'Syrup', 'شراب', '120 ml', '1', NULL, NULL, NULL, '6223000010259', 2217, '2022-12-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Freezlleza massage spray 120 ml', 2124, 'فريزليزا مساج سبراي 120 مل', '220', NULL, 'Massage', 'Massage', NULL, 'Camphor oil+menthol+eucalyptus oil', 'Belleza pharma', 'Spray', 'بخاخ', '120 ml', '1', NULL, NULL, NULL, NULL, 877, '2025-01-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sate cream 50 gm', 10206, 'سيت كريم 50 جم', '70', '55', 'Moisturizing topicals', 'Moisturizing topicals', NULL, 'Bee propolis+salicylic acid+casein+vitamin e+vitamin a+calendula extract+aloe vera+chamomile+tea trea oil', 'Hi-care > pixel pharmaceutical company', 'Cream', 'كريم', '50 gm', '1', 'مرطب للجلد -- يتستخدم في حالات الصدفية والاكزيما', NULL, NULL, '6224001202353', 2243, '2025-02-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lovegra 100mg tab', 7572, 'لوفيجرا 100مجم قرص', '9', NULL, 'Tonic for men', 'Tonic for men', NULL, 'Sildenafil', 'Sini pharma', 'Tab', 'أقراص', '100mg', '1', 'مقوي للرجال', NULL, NULL, NULL, 2386, '2023-05-12', NULL, 0, 'Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:



(1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and



(2) treatment of pulmonary hypertension, where:

a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850];



b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and



c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].', 'Sildenafil is an oral therapy for erectile dysfunction [A175582, F3853, F3856, F3886, L5611]. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis [A175582, F3853, F3856, F3886, L5611].



The physiological mechanism responsible for the erection of the penis involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation [A175582, F3853, F3856, F3886, L5611]. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood [A175582, F3853, F3856, F3886, L5611].



Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP [A175582, F3853, F3856, F3886, L5611]. Sildenafil has a peripheral site of action on erections [A175582, F3853, F3856, F3886, L5611]. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of NO on this tissue [A175582, F3853, F3856, F3886, L5611]. When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP [A175582, F3853, F3856, F3886, L5611]. Therefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects [A175582, F3853, F3856, F3886, L5611].



Moreover, apart from the presence of PDE5 in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature [A175579, F3850, F3859, F3883, L5614]. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation [A175579, F3850, F3859, F3883, L5614]. In patients with pulmonary arterial hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation [A175579, F3850, F3859, F3883, L5614].', 'In vitro studies have shown that sildenafil is selective for phosphodiesterase-5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Its effect is more potent on PDE5 than on other known phosphodiesterases [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. In particular, there is a 10-times selectivity over PDE6 which is involved in the phototransduction pathway in the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. There is an 80-times selectivity over PDE1, and over 700-times over PDE 2, 3, 4, 7, 8, 9, 10 and 11 [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. And finally, sildenafil has greater than 4,000-times selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (via the use of RigiScan®), after sildenafil administration compared with placebo [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Most studies assessed the efficacy of sildenafil approximately 60 minutes post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The erectile response, as assessed by RigiScan®, generally increased with increasing sildenafil dose and plasma concentration [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Sildenafil causes mild and transient decreases in systemic blood pressure which, in the majority of cases, do not translate into clinical effects [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mmHg respectively [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mmHg)[F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614] . At the recommended dose of 20 mg three times a day no reductions in systolic or diastolic pressure were seen [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension no clinically relevant effects on the ECG were reported either [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Mean pulmonary systolic blood pressure decreased by 9% [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil showed no effect on cardiac output and did not impair blood flow through the stenosed coronary arteries [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Mild and transient differences in color discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The postulated mechanism for this change in color discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil has no effect on visual acuity or contrast sensitivity. In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in visual tests conducted (which included visual acuity, Amsler grid, color discrimination simulated traffic light, and the Humphrey perimeter and photostress test) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Roxicin 300mg 5 f.c.tab.', 26363, 'روكسيسين 300مجم 5 اقراص', '20', NULL, 'Antibiotic with macrolide', 'Antibiotic with macrolide', NULL, 'Roxithromycin', 'El-obour', 'Tab', 'أقراص', '300mg', '1', NULL, NULL, 'about roxithromycin it is a semi-synthetic macrolide antibiotic. mechanism of action of roxithromycin roxithromycin is a semi synthetic long acting macrolide antibiotic. it binds to the 50s sub unit of bacterial ribosome and inhibits translocation.ie: the', NULL, 680, '2022-07-14', NULL, 0, 'Used to treat respiratory tract, urinary and soft tissue infections.', 'Roxithromycin prevents bacterial growth by interfering with their protein synthesis. It binds to the 50S subunit of bacterial ribosomes and inhibits the translocation of peptides.', 'Roxithromycin has the following antibacterial spectrum <i>in vitro</i>: <i>Streptococcus agalactiae</i>, <i>Streptococcus pneumoniae</i> (Pneumococcus), <i>Neisseria meningitides</i> (Meningococcus), <i>Listeria monocytogenes</i>, <i>Mycoplasma pneumoniae</i>, <i>Chlamydia trachomatis</i>, <i>Ureaplasma urealyticum</i>, <i>Legionella pneumophila</i>, <i>Helicobacter</i> (Campylobacter), <i>Gardnerella vaginalis</i>, <i>Bordetella pertussis</i>, <i>Moraxella catarrhalis</i> (<i>Branhamella Catarrhalis</i>), and <i>Haemophilus ducreyi</i>. Roxithromycin is highly concentrated in polymorphonuclear leukocytes and macrophages, achieving intracellular concentrations greater than those outside the cell. Roxithromycin enhances the adhesive and chemotactic functions of these cells which in the presence of infection produce phagocytosis and bacterial lysis. Roxithromycin also possesses intracellular bactericidal activity.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Recormon 5000 i.u. 6 prefilled syringe', 25773, 'ريكورمون 5000 وحدة دولية 6 سرنجات معبأة', '3,163', '2570', 'Hematopoietic.erythropoiesis-stimulating agent (esa)', 'Hematopoietic.erythropoiesis-stimulating agent (esa)', NULL, 'Erythropoietin-beta', 'F.hoffman la roche', 'Syringe', 'حقنة', NULL, '6', 'علاج الانيميا', NULL, NULL, '7640128012887', 5383, '2025-01-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ferro plus 20 tablets', 18984, 'فيرو بلس 20 قرص', '38', NULL, 'Iron supplement', 'Iron supplement', NULL, 'Iron+zinc+niacin+folic acid+vitamins(c-e-b6-b12)', 'Miracle > medical group pharma', 'Tablet', 'أقراص', NULL, '2', 'مكمل غذائي بالحديد', NULL, NULL, NULL, 1965, '2023-01-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Allergstop 2.5mg/5ml syp. 100 ml(n/a)', 13786, 'الرجستوب 2.5 مجم / 5 مل شراب', '6', NULL, 'Antihistamine.non-sedative.third-generation', 'Antihistamine.non-sedative.third-generation', NULL, 'Levocetirizine', 'Hikma pharma > egyptian promotion center', 'Unknown', 'غير محدد', '2.5mg', '1', NULL, NULL, 'about levocetirizine a third-generation non-sedative h1 antagonist antihistamine. mechanism of action of levocetirizine this active enantiomer of cetrizine is a potent nonsedative and selective h1 receptor antagonist. it antagonizes the allergic symptoms', NULL, 987, '2022-10-22', NULL, 0, 'Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria.[L7694] It is also used over the counter for a variety of mild allergy symptoms.[A181748]', 'Levocetirizine selectively inhibits histamine H<sub>1</sub> receptors.[L7694] This action prevents histamine from activating this receptor and causing effects like smooth muscle contraction, increased permeability of vascular endothelium, histidine uptake in basophils, stimulation of cough receptors, and stimulation of flare responses in the nervous system.[A181790]', 'Levocetirizine is a second generation histamine H<sub>1</sub> antagonist used to treat various allergic symptoms.[A181748,A181790,L7694] It has a long duration of action as it is generally taken once daily, and a wide therapeutic window as animal studies show the maximal nonlethal dose is over 100x a normal dose.[L7694] Patients are cautioned to avoid tasks that require complete alertness, avoid alertness, and use caution in patients with factors predisposing urinary retention.[L7694]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Pollen forte 20 capsules', 25029, 'بولين فورت 20 كبسول', '18', NULL, 'Multivitamins', 'Multivitamins', NULL, 'Pollen grains+nigella sativa+ginseng', 'Mepaco', 'Capsule', 'كبسولة', NULL, '2', NULL, NULL, NULL, '6223002211555', 707, '2022-12-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tecafo 30 tab', 359, 'تيكافو 30 قرص', '75', '60', 'Folic acid and vitamins', 'Folic acid and vitamins', NULL, 'Folic acid+vitamin b12+vitamin b6', 'Organix > janso pharm', 'Tab', 'أقراص', NULL, '3', 'مكمل غذائى', NULL, NULL, '6225000501140', 6823, '2025-05-21', NULL, 0, 'Folic acid is indicated for the treatment of folic acid deficiency, megaloblastic anemia, and in anemias of nutritional origins, pregnancy, infancy, or childhood.', 'Folic acid, as it is biochemically inactive, is converted to tetrahydrofolic acid and methyltetrahydrofolate by dihydrofolate reductase (DHFR). These folic acid congeners are transported across cells by receptor-mediated endocytosis where they are needed to maintain normal erythropoiesis, synthesize purine and thymidylate nucleic acids, interconvert amino acids, methylate tRNA, and generate and use formate. Using vitamin B12 as a cofactor, folic acid can normalize high homocysteine levels by remethylation of homocysteine to methionine via methionine synthetase.', 'Folic acid is a water-soluble B-complex vitamin found in foods such as liver, kidney, yeast, and leafy, green vegetables. Also known as folate or Vitamin B9, folic acid is an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic acid is the precursor of tetrahydrofolic acid, which is involved as a cofactor for transformylation reactions in the biosynthesis of purines and thymidylates of nucleic acids. Impairment of thymidylate synthesis in patients with folic acid deficiency is thought to account for the defective deoxyribonucleic acid (DNA) synthesis that leads to megaloblast formation and megaloblastic and macrocytic anemias. Folic acid is particularly important during phases of rapid cell division, such as infancy, pregnancy, and erythropoiesis, and plays a protective factor in the development of cancer. As humans are unable to synthesize folic acid endogenously, diet and supplementation is necessary to prevent deficiencies. In order to function properly within the body, folic acid must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted by anti-metabolite therapies such as [DB00563] as they function as DHFR inhibitors to prevent DNA synthesis in rapidly dividing cells, and therefore prevent the formation of DHF and THF. 



In general, folate serum levels below 5 ng/mL indicate folate deficiency, and levels below 2 ng/mL usually result in megaloblastic anemia.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Femiday vaginal wash 320 ml', 18924, 'فيميداي غسول مهبلي 320 مل', '48', NULL, 'Vaginal wash', 'Vaginal wash', NULL, 'Calendula ext.+thyme ext.+chamomile ext.', 'Joyce cosmetics > aug pharma', 'Vaginal wash', 'غسول مهبلي', '320 ml', '1', NULL, NULL, NULL, NULL, 709, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nervi-biobots 60 caps', 16021, 'نيرفي-بيوبوتس 60 كبسولة', '450', '400', 'Neurotonic', 'Neurotonic', NULL, 'Ala+benfotiamine+vitamin b6+vitamin b12+folate+vitamin d3', 'Biobots', 'Cap', 'كبسولة', NULL, '1', NULL, NULL, NULL, NULL, 3479, '2025-05-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Genebaby multivitamin oral drops 30 ml', 32046, 'جينيبيبي مالتيفيتامين قطرات فموية 30 مل', '90', NULL, 'Multivitamin', 'Multivitamin', NULL, 'Vitamins(a+d3+e+c+b1+b2+b3+b6+b12)+folic acid+iron+zinc+pantothenic acid+l-lysine+malt extract', 'Copad egypt > genesis pharma', 'Drops', 'نقط', '30 ml', '1', NULL, NULL, 'vitamin a .... (1167 i.u) vitamin d3 ... (400 i.u) vitamin e .... 2 mg vitamin c .... 12 mg vitamin b1 .... 0.2 mg vitamin b2 .... 0.25 mg vitamin b3 .... 3 mg folic acid ..... 50 mcg vitamin b6 .... 0.25 mcg vitamin b12 .... 0.4 mcg pantothenic acid ....', NULL, 545, '2023-03-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Gastorelive 50 mg 30 f.c.tabs.', 5350, 'جاستوريليف 50مجم 30 قرص', '90', '61.5', 'Motility stimulant', 'Motility stimulant', NULL, 'Itopride', 'Sigma > hochster pharmaceutical industries', 'Tab', 'أقراص', '50 mg', '3', NULL, NULL, 'about itopride dopamine(d2) antagonist a prokinetic benzamide derivative motility stimulant. mechanism of action of itopride itopride has three way action. it inhibits the dopamine d2 receptor at the parasympathetic nerve ends.it increases the release of', '6224007751091', 2950, '2024-07-30', NULL, 0, 'Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous).', 'Itopride has anticholinesterase (AchE) activity as well as dopamine D2 receptor antagonistic activity. It is well established that M3 receptors exist on the smooth muscle layer throughout the gut and acetylcholine (ACh) released from enteric nerve endings stimulates the contraction of smooth muscle through M3 receptors. The enzyme AChE hydrolyses the released ACh, inactivates it and thus inhibits the gastric motility leading to various digestive disorders. Besides ACh, dopamine is present in significant amounts in the gastrointestinal tract and has several inhibitory effects on gastrointestinal motility, including reduction of lower esophageal sphincter and intragastric pressure. These effects appear to result from suppression of ACh release from the myenteric motor neurons and are mediated by the D2 subtype of dopamine receptors. Itopride, by virtue of its dopamine D2 receptor antagonism, removes the inhibitory effects on Ach release. It also inhibits the enzyme AchE which prevents the degradation of ACh. The net effect is an increase in ACh concentration, which in turn, promotes gastric motility, increases the lower esophageal sphincter pressure, accelerates gastric emptying and improves gastro-duodenal coordination. This dual mode of action of Itopride is unique and different from the actions of other prokinetic agents available in the market.

', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Aaa', 23083, 'ششش', '8', NULL, NULL, NULL, NULL, NULL, NULL, 'Unknown', 'غير محدد', NULL, '1', NULL, NULL, NULL, NULL, 728, '2022-12-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mustela stretch marks recovery serum 45 ml', 23140, 'موستلا لعلاج اثار الحمل وعلامات التمدد سيرم 75مل', '525', NULL, 'Firming topical', 'Firming topical', NULL, NULL, 'Laboratoires expanscience-france > biotech egypt', 'Serum', 'سيروم', '45 ml', '1', NULL, NULL, 'specially formulated for expectand and new mothers stretch marks recovery serum helps reduce the appearance of stretch marks thanks to its unique combination of active ingredients and ingredients of natural origin: - avocado peptides a patented ingredient', NULL, 671, '2022-07-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Omegra 10 sachets', 3822, 'اوميجرا 10 اكياس', '80', NULL, NULL, NULL, NULL, 'Omega 3+fish oil', 'Marvel', 'Sachet', 'أكياس', NULL, '1', NULL, NULL, NULL, '6224000738464', 780, '2022-12-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Canephron uno 30 f.c. tabs.', 4110, 'كانيفرون اونو 30 قرص', '180', NULL, NULL, NULL, NULL, 'Centaurium erythaea+levisticum officinale koch+rosmarinus officinalis', 'Technomed group', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, '4029799173005', 1555, '2025-06-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Unistafusin 2% oint. 15 gm', 28756, 'يونيستافوسين 2% مرهم 15جم', '15', NULL, 'Antibiotic topical', 'Antibiotic topical', NULL, 'Fusidic acid', 'Unipharma co.', 'Oint', 'مرهم', '2%', '1', NULL, NULL, 'about fusidic acid a bacteriostatic steroid antibiotic systemic antibacterial anti-infective. mechanism of action of fusidic acid fusidic acid is a bactericidal or bacteriostatic drug depending upon the concentration. it inhibits the transfer of aminoacid', NULL, 877, '2022-07-15', NULL, 0, 'For the treatment of bacterial infections.', 'Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes.', 'Fusidic acid is a bacteriostatic antibiotic and helps prevent bacterial growth while the immune system clears the infection.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Trulicity 0.75mg/0.5ml 4 pre-filled pens', 28586, 'تروليسيتي 0.75مجم/0.5مل 4 اقلام', '3,250', '2500', 'Glp-1 agonist', 'Glp-1 agonist', NULL, 'Dulaglutide', 'Eli lilly > egyptian pharmex', 'Pen', 'قلم', '0.75mg', '4', NULL, NULL, 'dulaglutide is a glucagon-like peptide 1 receptor agonist (glp-1 agonist) consisting of glp-1(7-37) covalently linked to an fc fragment of human igg4. it is used for the treatment of type 2 diabetes that can be used once weekly. glp-1 is a hormone that is', NULL, 2517, '2024-09-27', NULL, 0, 'Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus.[L30380] It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.[L30380]', 'Dulaglutide activates the GLP-1 receptor found in pancreatic beta cells, increasing intracellular cyclic AMP (cAMP) in beta cells, leading to insulin release and subsequent reduction of blood glucose concentrations. Additionally, dulaglutide decreases glucagon secretion and slows gastric emptying.[A236075,L30380]', 'Dulaglutide reduces fasting glucose concentrations and reduces postprandial glucose (PPG) concentrations in patients with type 2 diabetes mellitus through the agonism of the GLP-1 receptor.[L30380] This drug primarily acts as an incretin mimetic hormone or analog of human glucagon-like peptide-1, which normally acts on the GLP-1 receptor.[A236075]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hidrasec 100 mg 10 caps.', 20474, 'هيدراسيك 100مجم 10 كبسولات', '109', '73', 'Antidiarrheal', 'Antidiarrheal', NULL, 'Racecadotril', 'Abbott laboratories', 'Cap', 'كبسولة', '100 mg', '1', NULL, NULL, 'about racecadotril a peripherally acting enkephalinase inhibitor antidiarrheal. mechanism of action of racecadotril racecadotril is a dipeptide. it is an enkephalinase inhibitor which prevents the degradation of enkephalins. enkephalins are endogenous opi', '8002660032294', 2199, '2024-11-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Concentrated haemodialysis solution-acetate( a4 ) b.p. 2008', 16708, 'هيموديليسيس مركز محلول اسيتات', '40', NULL, 'Sterile solution', 'Sterile solution', NULL, 'Haemodialysis solution', 'El-fath for the industry of medicine & cosmetics-egypt', 'Solution', 'محلول', NULL, '1', NULL, NULL, 'the concentrated haemodialysis solutions are electrolyte water solutions with or without glucoses used in the haemodialysis process for patients with non-functioning kidneys.', NULL, 718, '2022-07-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Apo-mefloquine 250 mg 8 tab.', 14317, 'ابو-ميفلوكين 250 مجم 8 اقراص', '65', NULL, 'Antimalarial', 'Antimalarial', NULL, 'Mefloquine', 'Apotex inc. canada > egyptian pharmex', 'Tab', 'أقراص', '250 mg', '1', NULL, NULL, 'about mefloquine a synthetic quinine analogue antimalarial. mechanism of action of mefloquine the exact mechanism of action of mefloquine is not known. malarial parasites digest their own haemoglobin and release highly toxic heme.this free haeme cause mem', NULL, 1058, '2022-07-12', NULL, 0, 'Mefloquine is indicated for the treatment of mild to moderate cases of malaria caused by Plasmodium falciparum and Plasmodium vivax.  It is effective against chloroquine-resistant forms of Plasmodium falciparum.  Mefloquine is also indicated for the prophylaxis of malaria caused by Plasmodium falciparum and Plasmodium vivax, including chloroquine-resistant forms of Plasmodium falciparum.[L8953] ', 'The mechanism of action of mefloquine is not completely understood. Some studies suggest that mefloquine specifically targets the 80S ribosome of the Plasmodium falciparum, inhibiting protein synthesis and causing subsequent schizonticidal effects.[A172000] There are other studies in the literature with limited in vitro data on mefloquine''s mechanism of action.[A226938,A15758]', 'Sporozoites located in the salivary glands of mosquitoes infected with malaria parasites are introduced into the bloodstream of a human host during mosquito feeding. These sporozoites rapidly invade the liver, where they mature into liver-stage schizonts, rupturing and releasing 2,000 - 40,000 merozoites that invade red blood cells.[L30688] Mefloquine is an antimalarial drug acting as a blood schizonticide, preventing and treating malaria.[A226823,A226833]

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Serdolect 4mg 10 f.c. tab.', 26823, 'سيردولكت 4مجم 10اقراص', '159', '90', 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Sertindole', 'Lundbeck > multipharma', 'Tab', 'أقراص', '4mg', '1', NULL, NULL, 'indication used in the treatment of schizophrenia. mechanism of action sertindole is an antipsychotic drug with affinity for dopamine d2 serotonin 5-ht2a and 5-ht2c and alpha1-adrenoreceptors. preclinical studies suggest that sertindole acts preferentiall', '5702157141371', 884, '2024-11-17', NULL, 0, 'Used in the treatment of schizophrenia.', 'Sertindole is an antipsychotic drug with affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and alpha1-adrenoreceptors. Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a low dopamine D2 occupancy level. ', 'Sertindole is an atypical antipsychotic at least as effective as haloperidol and risperidone in the treatment of neuroleptic-responsive schizophrenia. Sertindole improves negative symptoms, and is also effective for the treatment of neuroleptic-resistant schizophrenia. Sertindole is generally well tolerated and is associated with a low rate of extrapyramidal symptoms (EPS).', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nino sereno spray', 6576, 'نينو سيرينو سبراي', '140', NULL, 'Soothing spray sea water', 'Soothing spray sea water', NULL, 'Viscous liquid', 'Gmcks', 'Spray', 'بخاخ', NULL, '1', NULL, NULL, NULL, NULL, 915, '2025-08-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cardiomep 150mg/3ml 6 i.v. amp.', 6837, 'كارديوميب 150مجم/3مل 6 امبولات', '78', NULL, 'Antiarrhythmias.class iii', 'Antiarrhythmias.class iii', NULL, 'Amiodarone', 'Mepaco', 'Amp', 'أمبول', '150mg', '6', NULL, NULL, NULL, NULL, 779, '2025-08-16', NULL, 0, 'The FDA approved indications for amiodarone are recurrent ventricular fibrillation (VF) and recurrent hemodynamically unstable ventricular tachycardia (VT). The FDA emphasizes that this drug should only be given in these conditions when they are clinically documented and have not responded to normal therapeutic doses of other antiarrhythmic agents, or when other drugs are not tolerated by the patient.[L3561]



Off-label indications include atrial fibrillation and supraventricular tachycardia.[A189666,A189720,A189723,L11286]', 'Amiodarone is considered a class III anti-arrhythmic drug. It blocks potassium currents that cause repolarization of the heart muscle during the third phase of the cardiac action potential. As a result amiodarone increases the duration of the action potential as well as the effective refractory period for cardiac cells (myocytes). Therefore, cardiac muscle cell excitability is reduced, preventing and treating abnormal heart rhythms.[A183137,A189747]



Unique from other members of the class III anti-arrhythmic drug class, amiodarone also interferes with the functioning of beta-adrenergic receptors, sodium channels, and calcium channels channels. These actions, at times, can lead to undesirable effects, such as hypotension, bradycardia, and Torsades de pointes (TdP).[L11265] In addition to the above, amiodarone may increase activity of peroxisome proliferator-activated receptors, leading to steatogenic changes in the liver or other organs.[A20227,A20650] Finally, amiodarone has been found to bind to the thyroid receptor due to its iodine content, potentially leading to amiodarone induced hypothyroidism or thyrotoxicosis.[A182168]', 'After intravenous administration, amiodarone acts to relax smooth muscles that line vascular walls, decreases peripheral vascular resistance (afterload), and increases the cardiac index by a small amount. Administration by this route also decreases cardiac conduction, preventing and treating arrhythmias.[A1901,A189666,L3561] When it is given orally, however, amiodarone does not lead to significant changes in the left ventricular ejection fraction. Similar to other anti-arrhythmic agents, controlled clinical trials do not confirm that oral amiodarone increases survival.[L3561] 



Amiodarone prolongs the QRS duration and QT interval.  In addition, a decreased SA (sinoatrial) node automaticity occurs with a decrease in AV node conduction velocity. Ectopic pacemaker automaticity is also inhibited.[L11265] Thyrotoxicosis or hypothyroidism may also result from the administration of amiodarone, which contains high levels of iodine, and interferes with normal thyroid function.[A182168]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Villa borghini volume shampoo', 29349, 'فيلابورجيني فوليم شامبو', '195', NULL, 'Hair care', 'Hair care', NULL, NULL, 'Villa borghini s.r.l > spring', 'Amp', 'أمبول', NULL, '1', NULL, NULL, NULL, NULL, 628, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Micardis 40 mg 28 tabs.', 22693, 'ميكارديس 40مجم 28 اقراص', '150', '112', 'Antihypertensive.angiotensin blocker', 'Antihypertensive.angiotensin blocker', NULL, 'Telmisartan', 'Boehringer ingelheim', 'Tab', 'أقراص', '40 mg', '4', NULL, NULL, 'about telmisartan angiotensin ii receptor antagonist antihypertensive. mechanism of action of telmisartan it is a competitive antagonist of angiotensin-2 at at-1 receptor. it decreases peripheral resistance and lowers bp in hypertensive individuals. it bl', '4048846007230', 1504, '2024-01-06', NULL, 0, 'Used alone or in combination with other classes of antihypertensives for the treatment of hypertension.[L44652] Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).[A255892]', 'Telmisartan interferes with the binding of angiotensin II to the angiotensin II AT<sub>1</sub>-receptor by binding reversibly and selectively to the receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. Telmisartan does not inhibit the angiotensin converting enzyme, other hormone receptors, or ion channels.[L44652] Studies also suggest that telmisartan is a partial agonist of PPAR&gamma;, which is an established target for antidiabetic drugs. This suggests that telmisartan can improve carbohydrate and lipid metabolism, as well as control insulin resistance without causing the side effects that are associated with full PPAR&gamma; activators.[A1492]', 'Telmisartan is an orally active nonpeptide angiotensin II antagonist that acts on the AT<sub>1</sub> receptor subtype. It has the highest affinity for the AT<sub>1</sub> receptor among commercially available ARBs and has minimal affinity for the AT<sub>2</sub> receptor.[L44652] New studies suggest that telmisartan may also have PPAR&gamma; agonistic properties that could potentially confer beneficial metabolic effects, as PPAR&gamma; is a nuclear receptor that regulates specific gene transcription, and whose target genes are involved in the regulation of glucose and lipid metabolism, as well as anti-inflammatory responses. This observation is currently being explored in clinical trials.[A1492] Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan works by blocking the vasoconstrictor and aldosterone secretory effects of angiotensin II.[A1490,L44652]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Relpax 40mg 3 f.c. tab.', 25845, 'ريلباكس 40مجم 3 قرص', '72', NULL, 'Antimigraine', 'Antimigraine', NULL, 'Eletriptan', 'Pfizer', 'Tab', 'أقراص', '40mg', '1', NULL, NULL, 'about eletriptan selective 5 ht 1b/1d agonist antimigraine agent mechanism of action of eletriptan eletriptan is a selective 5-hydroxytryptamine (serotonin5-ht) type 1b and 1d (5-ht1b/1d) receptor agonist. it is thought to be related to activation of 5-ht', NULL, 1673, '2022-07-12', NULL, 0, 'For the acute treatment of migraine with or without aura in adults.', 'Eletriptan binds with high affinity to 5-HT1B, 5-HT1D and 5-HT1F receptors, has modest affinity for 5-HT1A, 5-HT1E, 5-HT2B and 5-HT7 receptors, and little or no affinity for 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, 5-HT5A and 5-HT6 receptors. In contrast, eletriptan displays insignificant pharmacological activity at adrenergic alpha1, alpha2, or beta; dopaminergic D1 or D2; muscarinic; or opioid receptors. While the full mechanism of action of 5-HT receptor agonists in relieving migrains is not fully elucidated, it is proposed that the activation of 5-HT1 receptors located on intracranial blood vessels leads to vasoconstriction that correlates with the relief of migraine headaches. It is also proposed that the activation of 5-HT1 receptors on sensory nerve endings in the trigeminal system leads to the inhibition of release of pro-inflammatory neuropeptides. ', 'Eletriptan is a selective 5-hydroxytryptamine 1B/1D receptor agonist. In the anesthetized dog, eletriptan has been shown to reduce carotid arterial blood flow, with only a small increase in arterial blood pressure at high doses. While the effect on blood flow was selective for the carotid arterial bed, decreases in coronary artery diameter were observed. Eletriptan has also been shown to inhibit trigeminal nerve activity in the rat.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vatika hair cream 125 ml', 1675, 'فاتيكا كريم شعر 125 مل', '70', NULL, NULL, NULL, NULL, NULL, 'Company', 'Cream', 'كريم', '125 ml', '1', NULL, NULL, NULL, '6224007940488', 924, '2022-12-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Young line massage spray 120 ml', 5147, 'يانغ لاين مساج سبراي 120 مل', '150', NULL, 'Massage', 'Massage', NULL, NULL, 'Prime pharma', 'Spray', 'بخاخ', '120 ml', '1', NULL, NULL, NULL, NULL, 732, '2025-06-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Octagam 2.5 gm/50ml vial 50 ml', 9123, 'اوكتاجام 2.5جم/50مل فيال 50مل', '8,620', '2658', NULL, NULL, NULL, 'Human normal immunoglobulin', 'Octapharma > ramco', 'Vial', 'فيال', '2.5 gm', '1', NULL, NULL, NULL, NULL, 2795, '2025-02-01', NULL, 0, 'Human immunoglobulin G is indicated for the following conditions:



### Primary Immunodeficiency

- for the treatment of primary immunodeficiency in adult and pediatric patients[L39920, L39930, L39935, L39940, L39945, L39950, L39955, L39960, L39965, L39975, L39980, L40029, L40034, L40044]

- in combination with [hyaluronidase (human recombinant)] for the treatment of primary immunodeficiency in patients ≥2 years of age.[L42760]



### Immune Thrombocytopenic Purpura (ITP)

- for the treatment of acute or chronic immune thrombocytopenic purpura in adult and pediatric patients[L39940, L39950, L39960, L39965, L39970, L39975, L39980]



### Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

- for the treatment of CIDP in adult patients[L39955, L39965, L39975, L39980, L40034]

- in combination with hyaluronidase (human recombinant) as a maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)[L40039]



### Multifocal Motor Neuropathy (MMN)

- for maintenance therapy to improve muscle strength and disability in adult patients with MMN[L39955]



### Prophylaxis of Bacterial Infection

- for the prevention of bacterial infections in patients with hypogammaglobulinemia and/or B-cell chronic lymphocytic leukemia[L39960]



### Coronary Artery Aneurysm Associated With Kawasaki Syndrome

- for the prevention of coronary artery aneurysms in pediatric patients with Kawasaki syndrome[L39960]



### Dermatomyositis

- for the treatment of dermatomyositis in adult patients[L39970]

', 'IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab'')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab′)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.', 'Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immunoglobulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Unitopfin 250 mg 7 f.c. tabs.', 28775, 'يونيتوبفين 250مجم 7 اقراص', '25', NULL, 'Antifungals.allylamines', 'Antifungals.allylamines', NULL, 'Terbinafine', 'Unipharma co.', 'Tab', 'أقراص', '250 mg', '1', NULL, NULL, 'about terbinafine a synthetic allylamine derivative antifungal. mechanism of action of terbinafine terbinafine is a fungicidal drug. it interfere the conversion of squalene to ergosterol by inhibiting the enzyme squalene epoxidase.this results in accumula', NULL, 1020, '2022-07-09', NULL, 0, 'Terbinafine hydrochloride is indicated to treat fungal skin and nail infections caused by _Trichophyton_ species, _Microsporum canis_, _Epidermophyton floccosum_,[L9068] and _Tinea_ species.[L9065] Terbinafine hydrochloride also treats yeast infections of the skin caused by _Candida_ species and _Malassezia furfur_.[L9068]', 'Terbinafine inhibits the enzyme squalene monooxygenase (also called squalene epoxidase), preventing the conversion of squalene to 2,3-oxydosqualene, a step in the synthesis of ergosterol.[A1279,A1281,L9068] This inhibition leads to decreased ergosterol, which would normally be incorporated into the cell wall, and accumulation of squalene.[A1281,L9068]



Generation of a large number of squalene containing vesicles in the cytoplasm may leach other lipids away from, and further weaken, the cell wall.[A1281]', 'Terbinafine is an allylamine antifungal that inhibits squalene epoxidase (also known as squalene monooxygenase) to prevent the formation of ergosterol and cause an accumulation of squalene, weakening the cell wall of fungal cells.[A1279,A1281,L9068] Terbinafine distributes into tissues and has a long terminal elimination half life, so the duration of action is long.[A1279] Overdose with terbinafine is rare, even above the therapeutic dose, so the therapeutic index is wide.[L9065,L9068] Patients taking oral terbinafine should have liver function tests performed prior to treatment to reduce the risk of liver injury.[L9065]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Unimox 1gm 8 f.c.tab.', 28742, 'يونيموكس 1جم 8 اقراص', '8', NULL, 'Penicillins.monocomponent', 'Penicillins.monocomponent', NULL, 'Amoxicillin', 'Hikma pharma', 'Tab', 'أقراص', '1gm', '1', NULL, NULL, '(indications): is a penicillin-like beta-lactam antibiotic. it is used to treat bacterial infections caused by susceptible microorganisms. it prevents the bacterial growth and is used in the treatment of a number of infections such as pneumonia bronchitis', NULL, 1060, '2022-07-18', NULL, 0, 'Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract.[L11656,L11659] Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections.[L11650,L7880,L11653] Amoxicillin is given with omeprazole in the treatment of _Helicobacter pylori_ (_H. pylori_) infection.[L9743,L11647]



Amoxicillin is used in combination with [vonoprazan] and [clarithromycin] as co-packaged triple therapy or in combination with [vonoprazan] as co-packaged dual therapy to treat _H. pylori_ infection in adults.[L41695]', 'Amoxicillin competitively inhibits penicillin-binding protein 1 and other high molecular weight penicillin binding proteins.[A6205,A190678]  Penicillin bind proteins are responsible for glycosyltransferase and transpeptidase reactions that lead to cross-linking of D-alanine and D-aspartic acid in bacterial cell walls.[A190678] Without the action of penicillin binding proteins, bacteria upregulate autolytic enzymes and are unable to build and repair the cell wall, leading to bacteriocidal action.[A190642,A190678]', 'Amoxicillin competitively inhibit penicillin binding proteins, leading to upregulation of autolytic enzymes and inhibition of cell wall synthesis.[A6205,A190678,A190642] Amoxicillin has a long duration of action as it is usually given twice daily.[L7880] Amoxicillin has a wide therapeutic range as mild overdoses are not associated with significant toxicity.[L11650] Patients should be counselled regarding the risk of anaphylaxis, _Clostridium difficile_ infections, and bacterial resistance.[L11656]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Fucin 2% 10x30cm sterile gauze dressing', 19453, 'فيوسين 2% 10×30 سم شاش معقم', '6', NULL, 'Antibiotic', 'Antibiotic', NULL, 'Sodium fusidate', 'Alexandria', 'Unknown', 'غير محدد', '2%', '1', NULL, NULL, 'about sodium fusidate steroidal antibiotic (topical). mechanism of action of sodium fusidate sodium fusidate is a bactericidal or bacteriostatic drug depending upon the concentration. it inhibits the transfer of aminoacid from aminoacyl srna to the protei', NULL, 780, '2022-07-12', NULL, 0, 'For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.', 'Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.', 'Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Picasto 30 tabs', 7227, 'بيكاستو 30 قرص', '120', NULL, 'Multivitamin', 'Multivitamin', NULL, 'Calcium citrate+magnesium+vitamin d3', 'Prime solutions', 'Tab', 'أقراص', NULL, '1', NULL, NULL, NULL, NULL, 511, '2025-08-31', NULL, 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Jadenu 90mg 30 f.c. tabs.', 21120, 'جادينو 90 مجم 30 قرص', '2,025', NULL, 'Iron chelating agents', 'Iron chelating agents', NULL, 'Deferasirox', 'Novartis', 'Tab', 'أقراص', '90mg', '3', NULL, NULL, 'about deferasirox a synthetic achiral tridentate triazole derived from salicylic acid oral iron chelating agents. indication for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and', NULL, 1181, '2022-07-24', NULL, 0, 'For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.', 'Two molecules of deferasirox are capable of binding to 1 atom of iron. Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys.', 'Deferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Pepzol 40mg 14 caps', 24724, 'بيبزول 40مجم 14 كبسولة', '81', '75', 'Peptic ulcer.proton pump inhibitor', 'Peptic ulcer.proton pump inhibitor', NULL, 'Omeprazole', 'Hikma pharma', 'Cap', 'كبسولة', '40mg', '1', NULL, NULL, NULL, '6221000001017', 3561, '2024-08-20', NULL, 0, 'Omeprazole, according to the FDA label [FDA label] is a proton pump inhibitor (PPI) used for the following purposes:



• Treatment of active duodenal ulcer in adults 



• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer

recurrence in adults 



• Treatment of active benign gastric ulcer in adults 



• Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients.



• Treatment of symptomatic gastroesophageal reflux disease (GERD) in

patients 1 year of age and older 



• Treatment of erosive esophagitis (EE) due to acid-mediated GERD in

patients 1 month of age and older 



• Maintenance of healing of EE due to acid-mediated GERD in patients 1

year of age and older 



• Pathologic hypersecretory conditions in adults', 'Hydrochloric acid (HCl) secretion into the gastric lumen is a process regulated mainly by the H(+)/K(+)-ATPase of the proton pump [A175180], expressed in high quantities by the parietal cells of the stomach. ATPase is an enzyme on the parietal cell membrane that facilitates hydrogen and potassium exchange through the cell, which normally results in the extrusion of potassium and formation of HCl (gastric acid) [A174295].



Omeprazole is a member of a class of antisecretory compounds, the substituted _benzimidazoles_, that stop gastric acid secretion by selective inhibition of the _H+/K+ ATPase_ enzyme system. Proton-pump inhibitors such as omeprazole bind covalently to cysteine residues via disulfide bridges on the alpha subunit of the _H+/K+ ATPase_ pump, inhibiting gastric acid secretion for up to 36 hours [A175192].  This antisecretory effect is dose-related and leads to the inhibition of both basal and stimulated acid secretion, regardless of the stimulus [FDA label].  



**Mechanism of H. pylori eradication**



Peptic ulcer disease (PUD) is frequently associated with _Helicobacter pylori_ bacterial infection (NSAIDs) [A175195]. The treatment of H. pylori infection may include the addition of omeprazole or other proton pump inhibitors as part of the treatment regimen [FDA label], [A175198]. 

_H. pylori_ replicates most effectively at a neutral pH [A175213]. Acid inhibition in H. pylori eradication therapy, including proton-pump inhibitors such as omeprazole, raises gastric pH, discouraging the growth of H.pylori [A175198]. It is generally believed that proton pump inhibitors inhibit the _urease_ enzyme, which increases the pathogenesis of H. pylori in gastric-acid related conditions [A175216].   ', '**Effects on gastric acid secretion**



This drug decreases gastric acid secretion [FDA label]. After oral administration, the onset of the antisecretory effect of omeprazole is usually achieved within one hour, with the maximum effect occurring by 2 hours after administration. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days [FDA label].



**Effects on serum gastrin**



In studies of 200 or more patients, serum gastrin levels increased during the first 1-2 weeks of daily administration of therapeutic doses of omeprazole. This occurred in a parallel fashion with the inhibition of acid secretion. No further increase in serum gastrin occurred with continued omeprazole administration. Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum Chromogranin A (CgA) levels. The increased CgA levels may lead to false positive results in diagnostic studies for neuroendocrine tumors [FDA label].



**Enterochromaffin-like (ECL) cell effects**



Human gastric biopsy samples have been obtained from more than 3000 pediatric and adult patients treated with omeprazole in long-term clinical studies. The incidence of enterochromaffin-like cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia have been identified in these patients. These studies, however, are of insufficient in power and duration to draw conclusions on the possible influence of long-term administration of omeprazole in the development of any premalignant or malignant conditions [FDA label]. 



**Other effects**



Systemic effects of omeprazole in the central nervous system, cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40 mg for 2-4 weeks, showed no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin [FDA label]. 





', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dexiclave 375 mg 10 f.c. tabs.', 17443, 'ديكسيكلاف 375 مجم 10 اقراص', '22', NULL, 'Penicillins.penicillin with b-lactamase inhibitor', 'Penicillins.penicillin with b-lactamase inhibitor', NULL, 'Amoxicillin+clavulanic acid', 'Rameda > novell pharma', 'Tab', 'أقراص', '375 mg', '1', NULL, NULL, 'amoxicillin is an analog of ampicillin derived from the basic penicillin nucleus 6-aminopenicillanic acid clavulanic acid is produced by the fermentation of streptomyces clavuligerus. it is a beta-lactam structurally related to the penicillins and possess', NULL, 948, '2022-07-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Seraval hair serum 120 ml', 26814, 'سيرافال سيرم للشعر 120 مل', '250', '165', 'Hair care', 'Hair care', NULL, NULL, 'Hi-care > revano pharm', 'Serum', 'سيروم', '120 ml', '1', 'سيرم للشعر لترطيبه --الحفاظ علي شكله -- تقليل الهيشان و التقصف', NULL, NULL, NULL, 5044, '2025-01-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Zolifutal 500 mg 12 f.c. tablets', 30011, 'زوليفيوتال 500مجم 12 قرص', '37', NULL, 'Antihelminthic', 'Antihelminthic', NULL, 'Nitazoxanide', 'Future pharmaceutical industries (fpi)', 'Tablet', 'أقراص', '500 mg', '1', 'مطهر معوي - للديدان والطفيليات', NULL, NULL, NULL, 3361, '2023-02-04', NULL, 0, 'For the treatment of diarrhea in adults and children caused by the protozoa <i>Giardia lamblia</i>,  and for the treatment of diarrhea in children caused by the protozoan,  <i>Cryptosporidium parvum</i> [FDA label].



Nitazoxanide has not been shown to be superior to placebo medication for the management of diarrhea caused by Cryptosporidium parvum in patients with HIV/immunodeficiency [FDA label, A31973, A31976]. ', 'The most widely accepted mechanism of NTZ is believed to be the disruption of the energy metabolism in anaerobic microbes by inhibition of the pyruvate: ferredoxin/flavodoxin oxidoreductase (PFOR) cycle [A31981]. In parasitic-protozoa, Nitazoxanide also induces lesions in the cell membranes and depolarizes the mitochondrial membrane while inhibiting quinone oxidoreductase NQO1, nitroreductase-1 and protein disulphide isomerase enzymes. In addition, this drug also inhibits the glutathione-S-transferase (a major detoxifying enzyme) and modulates the Avr-14 gene, encoding for the alpha-type subunit of glutamate-gated chloride ion channel present in nematodes. Aside from its well understood non-competitive inhibition of the PFOR in anaerobic bacteria, NTZ also demonstrates various other antibacterial mechanisms. It inhibits pyruvate dehydrogenase in E Coli, disrupts the membrane potential and pH homeostasis in the Mycobacterium tuberculosis, suppresses the chaperone/usher (CU) pathway of the gram-negative bacteria,  and stimulates host macrophage autophagy in tuberculosis patients [A31976]. NTZ also suppresses viral replication by inhibiting the maturation of the viral hemagglutinin and the viral transcription factor immediate early 2 (IE2) as well as by activating the eukaryotic translation initiation factor 2α (an antiviral intracellular protein). Lastly, NTZ exhibits an inhibitory effect on tumor cell progression by altering drug detoxification (glutathione-S-transferase P1), unfolded protein response, autophagy, anti-cytokines activity, and c-Myc inhibition [A31976].', 'The general effect of this medication is the prevention of microbe activity through disruption of important energy pathways for survival and proliferation [FDA label, A31976].  Nitazoxanide exhibits antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction, an essential reaction need for anaerobic energy metabolism of various microorganisms.  Sporozoites of Cryptosporidium parvum and trophozoites of Giardia lamblia are therefore inhibited, relieving symptoms of diahrrea [L1425]. Interference with the PFOR enzyme-dependent electron transfer reaction may only be one of the many pathways by which nitazoxanide exhibits antiprotozoal activity [FDA label, A31973, L1425]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ch alpha 10 sachets', 2468, 'سي اتش الفا 10 اكياس', '350', '330', 'Antirheumatic.osteoarthritis.anabolic agents', 'Antirheumatic.osteoarthritis.anabolic agents', NULL, 'Gelatin (collagen) hydrolysate+vitamin c', 'Gelita health > biotech pharma ltd.', 'Sachet', 'أكياس', NULL, '1', 'التهاب المفاصل . مضاد للروماتيزم', NULL, 'for health joints', '4260133180048', 13056, '2025-11-04', NULL, 0, 'Gelatin is used for weight loss and for treating osteoarthritis, rheumatoid arthritis, and brittle bones (osteoporosis). Some people also use it for strengthening bones, joints, and fingernails. Gelatin is also used for improving hair condition and to shorten the recovery after exercise and sports-related injury [L2113]. Gelatin is used in preparations of foods, cosmetics, and medicine [L2113].



Plasma volume expander in hypovolaemic shock [L2115]. Haemostatic [L2115].



Gelatin-based hydrogels are being used in drug delivery and tissue engineering because they are able to promote cell adhesion and proliferation. In addition, these hydrogels can be used as wound dressings because of their attractive fluid absorbance properties. Manufacturing technologies such as ultraviolet stereolithography and two-photon polymerization can be used to prepare structures containing photosensitive gelatin-based hydrogels [L2111].', 'It works as a hemostatic by providing a physical framework within which clotting may occur [L2115].



As a volume expander, gelatin remains in the vascular space. When used in the treatment of hypovolaemia gelatin can produce a significant increase in blood volume, cardiac output, stroke volume, blood pressure, urinary output and oxygen delivery, increasing volume and pressure [L2117].



For intravascular volume expansion, the majority or gelatins produce an effect which is almost equivalent to of which are mild, although severe reactions albumin, with a duration of action of 3 to 4 hours to have been reported [L2118].



Gelatin or collagen chains suspended in solution can be covalently cross-linked to form matrices that are able to swell in the presence of aqueous solutions, forming what are called _gelatin hydrogels_. Hydrogels, characterized by their hydrophilicity and insolubility in water, have the capability of swelling into an equilibrium volume while maintaining their shape. The chemical cross-linkers used may be either small bifunctional molecules or polyfunctional macromolecules, for example, glutaraldehyde [L2122].', 'Gelatin contains collagen, which is one of the materials that make up cartilage and bone [L2113].



In addition to their well-established value as a nutritional protein source, collagen and collagen-derived products may exhibit various potential biological activities on cells and the extracellular matrix through the corresponding food-derived peptides post-ingestion.  This could justify their applications in dietary supplements and pharmaceutical agents [A32426].



Gelatin is a protein that is used as a hemostatic in surgical procedures.  It is also used as a plasma volume expander in hypovolemic shock. Gelatin rods structures may also be used to temporarily block tear outflow in cases of dry eye [L2115].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tomazine 10mg 20 f.c. tabs.', 11497, 'تومازين 10مجم 20 اقراص', '31', NULL, 'Antihistamine.antiallergy', 'Antihistamine.antiallergy', NULL, 'Cetirizine', 'Alfacure pharmaceuticals', 'Tab', 'أقراص', '10mg', '2', 'مضاد للحساسية', NULL, 'about cetirizine second generation h1 antagonist metabolite of hydroxyzine antihistamine. mechanism of action of cetirizine this drug is a selective peripheral h1 receptor antagonist. thus it inhibits the allergic symptoms produced by histamines like cold', '6224000875251', 2101, '2023-05-30', NULL, 0, '**Seasonal Allergic Rhinitis**: Indicated for the relief of symptoms associated with seasonal allergic rhinitis caused by allergens such as ragweed, grass and tree pollens in adults and children 2 years of age and above. Symptoms treated effectively include sneezing, rhinorrhea, nasal pruritus, ocular pruritus, tearing, and redness of the eyes [FDA label]. 



**Perennial allergic rhinitis**: This drug is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens including dust mites, animal dander, and molds in adults and children 6 months of age and older. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing [FDA label]. 



**Chronic urticaria**: Cetirizine is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. It markedly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus [FDA label].', 'Cetirizine, a metabolite of _hydroxyzine_, is an antihistamine drug.  Its main effects are achieved through selective inhibition of peripheral H1 receptors. The antihistamine activity of cetirizine has been shown in a variety of animal and human models. _In vivo_ and _ex vivo_ animal models have shown insignificant anticholinergic and antiserotonergic effects. In clinical studies, however, dry mouth was found to be more frequent with cetirizine than with a placebo. In vitro receptor binding studies have demonstrated no detectable affinity of cetirizine for histamine receptors  other than the H1 receptors. Studies with radiolabeled cetirizine administration in the rat have demonstrated insignificant penetration into the brain. _Ex vivo_ studies in the mouse have shown that systemically administered cetirizine does not occupy cerebral H1 receptors significantly [FDA label].', '**General effects and respiratory effects**



Cetirizine, the active metabolite of the piperazine H<sub>1</sub>-receptor antagonist hydroxyzine, minimizes or eliminates the symptoms of chronic idiopathic urticaria, perennial allergic rhinitis, seasonal allergic rhinitis, allergic asthma, physical urticaria, and atopic dermatitis.

The clinical efficacy of cetirizine for allergic respiratory diseases has been well established in numerous trials [FDA label]. 



**Effects on urticaria/anti-inflammatory effects**



It has anti-inflammatory properties that may play a role in asthma management [A175051]. There is evidence that cetirizine improves symptoms of urticaria. Marked clinical inhibition of a wheal and flare response occurs in infants, children as well as adults within 20 minutes of one oral dose and lasts for 24 h [A175051].  Concomitant use of cetirizine reduces the duration and dose of topical anti-inflammatory formulas used for the treatment of atopic dermatitis [A175051]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Qv kids balm 100 gm', 25592, 'كيو في للاطفال 100جم', '205', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Ego pharmaceuticals pty ltd. > vamer pharma', 'Unknown', 'غير محدد', '100 gm', '1', NULL, NULL, 'relieve and soothe dry skin. qv kids balm provides gentle but effective moisturisation for children with extremely dry skin.', NULL, 422, '2022-08-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Solarine 36 spf sun block lotion 100ml', 27240, 'سولارين معامل حماية ضد اشعة الشمس 36 صن بلوك لوشن 100 مل', '155', '105', 'Sun block', 'Sun block', NULL, 'Sun protection formula', 'Weiser', 'Lotion', 'لوشن', '100ml', '1', NULL, NULL, 'water resistance during swimming. for sensitive & delicate skin of children and adults.', '6223002260966', 1811, '2024-06-14', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Eko vag.douche 200 ml', 18137, 'ايكو غسول مهبلي 200 مل', '14', NULL, 'Vaginal wash', 'Vaginal wash', NULL, 'Chlorhexidine+hexamidine+cetrimide+sodium lauryl sulphate+aloe vera+glycerin', 'Leader cosmetics > vertex pharm', 'Unknown', 'غير محدد', '200 ml', '1', NULL, NULL, NULL, NULL, 805, '2022-07-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Monopril 20mg 10 tab.', 22931, 'مونوبريل 20مجم 10 اقراص', '29', NULL, 'Antihypertensive.ace', 'Antihypertensive.ace', NULL, 'Fosinopril', 'Smithkline beecham', 'Tab', 'أقراص', '20mg', '1', NULL, NULL, 'about fosinopril phosphonate-containing angiotensin-converting enzyme (ace) inhibitor antihypertensive. mechanism of action of fosinopril it is a prodrug and converted in to active fosinoprilat; which is an angiotensin converting enzyme inhibitor prevents', '6224001007347', 875, '2022-12-06', NULL, 0, 'For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. ', 'There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Fosinoprilat, the active metabolite of fosinopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Fosinoprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors. ', 'Following oral administration, fosinopril is rapidly and completely hydrolyzed to its principle active metabolite, fosinoprilat. Hydrolysis is thought to occur in the gastrointestinal mucosa and liver. Fosinoprilat is a competitive inhibitor of ACE, a peptidyl dipeptidase that is part of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of fosinoprilat by causing increased vasodilation and decreased blood pressure. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nuxe body melting shower gel 200 ml', 23863, 'نوكس شاور جل 200مل', '185', '179', 'Skin care', 'Skin care', NULL, NULL, 'Nuxe laboratory > biotech egypt', 'Gel', 'جل', '200 ml', '1', NULL, NULL, 'formulated using plant ingredients this soap-free shower gel with orange blossom and almond blossom petals gently cleanses skin. an essential part of your daily routine you will love its smooth foam and delicate fragrance. use use your fondant shower gel', NULL, 610, '2023-09-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Viscal 5mg 10 tab.', 29417, 'فيسكال 5مجم 10 اقراص', '10', NULL, 'Antihypertensive.selective calcium channel blocker', 'Antihypertensive.selective calcium channel blocker', NULL, 'Amlodipine', 'Up pharma', 'Tab', 'أقراص', '5mg', '1', NULL, NULL, NULL, NULL, 950, '2022-07-15', NULL, 0, 'Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions [FDA label]:



• Hypertension 



• Coronary artery disease



• Chronic stable angina



• Vasospastic angina (Prinzmetal’s or Variant angina) 



• Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%', '**Mechanism of action on blood pressure**



Amlodipine is considered a peripheral arterial vasodilator that exerts its action directly on vascular smooth muscle to lead to a reduction in peripheral vascular resistance, causing a decrease in blood pressure. Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the influx of calcium ions into both vascular smooth muscle and cardiac muscle. Experimental studies imply that amlodipine binds to both _dihydropyridine_ and _nondihydropyridine_ binding sites, located on cell membranes. The contraction of cardiac muscle and vascular smooth muscle are dependent on the movement of extracellular calcium ions into these cells by specific ion channels. Amlodipine blocks calcium ion influx across cell membranes with selectivity. A stronger effect of amlodipine is exerted on vascular smooth muscle cells than on cardiac muscle cells [FDA label]. Direct actions of amlodipine on vascular smooth muscle result in reduced blood pressure [F3757]. 



**Mechanism of action in angina**



The exact mechanism by which amlodipine relieves the symptoms of angina have not been fully elucidated to this date, however, the mechanism of action is likely twofold:



Amlodipine has a dilating effect on peripheral arterioles, reducing the total peripheral resistance (afterload) against which the cardiac muscle functions. Since the heart rate remains stable during amlodipine administration, the reduced work of the heart reduces both myocardial energy use and oxygen requirements [F3757].



Dilatation of the main coronary arteries and coronary arterioles, both in healthy and ischemic areas, is another possible mechanism of amlodipine reduction of blood pressure. The dilatation causes an increase in myocardial oxygen delivery in patients experiencing coronary artery spasm (Prinzmetal''s or variant angina) and reduces coronary vasoconstriction caused by smoking [F3757].', '**General pharmacodynamic effects**



Amlodipine has a strong affinity for cell membranes, modulating calcium influx by inhibiting selected membrane calcium channels. This drug''s unique binding properties allow for its long-acting action and less frequent dosing regimen [A573], [FDA label].  



**Hemodynamic effects**



After the administration of therapeutic doses of amlodipine to patients diagnosed with hypertension, amlodipine causes vasodilation, which results in a reduction of supine and standing blood pressure. During these blood pressure reductions, there are no clinically significant changes in heart rate or plasma catecholamine levels with long-term use. Acute intravenous administration of amlodipine reduces arterial blood pressure and increases heart rate in patients with chronic stable angina, however, chronic oral administration of amlodipine in clinical studies did not cause clinically significant alterations in heart rate or blood pressures in patients diagnosed with angina and normal blood pressure. With long-term, once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours [FDA label]. 



**Electrophysiologic effects**



Amlodipine does not change sinoatrial (SA) nodal function or atrioventricular (AV) conduction in animals or humans. In patients who were diagnosed with chronic stable angina, the intravenous administration of 10 mg of amlodipine did not cause clinically significant alterations A-H and H-V conduction and sinus node recovery time after cardiac pacing. Patients administered amlodipine with concomitant beta-blockers produced similar results. In clinical trials in which amlodipine was given in combination with beta-blockers to patients diagnosed with hypertension or angina, no adverse effects on electrocardiographic parameters were noted. In clinical studies comprised of angina patients alone, amlodipine did not change electrocardiographic intervals or produce high degrees of AV block [FDA label]. 



**Effects on angina**



Amlodipine relieves the symptoms of chest pain associated with angina. In patients diagnosed with angina, daily administration of a single amlodipine dose increases total exercise time, the time to angina onset, and the time to 1 mm ST-segment depression on ECG studies, decreases anginal attack frequency, and decreases the requirement for nitroglycerin tablets [F3757]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sigmacyn 250mg/5ml susp. 60ml', 26934, 'سيجماسين 250مجم/5مل شراب معلق 60مل', '38', NULL, 'Penicillins.penicillin with b-lactamase inhibitor', 'Penicillins.penicillin with b-lactamase inhibitor', NULL, 'Ampicillin+sulbactam', 'Sigma', 'Susp', 'معلق', '250mg', '1', NULL, NULL, NULL, '6221172002263', 837, '2022-07-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dexaglobe 1 amp. 2ml', 3535, 'ديكساجلوب 1 امبول 2 مل', '30', '20', 'Glucocorticoid', 'Glucocorticoid', NULL, 'Betamethasone dipropionate+betamethasone sodium phosphate', 'Sunny medical > marcyrl co.', 'Amp', 'أمبول', '2ml', '1', 'مضاد موضعى للالتهابات والاستجابة المناعية بالجسم', NULL, 'about betamethasone dipropionate a synthetic glucocorticoid anti-inflammatory. indications for betamethasone dipropionate 1.eczema 2.psoriasis 3.contact dermatitis 4.anal and vulval pruritis 5.inflammation of the skin contra-indications of betamethasone d', '6223003570590', 5261, '2024-09-23', NULL, 0, 'As a member of the corticosteroid family, betamethasone is indicated for the treatment of several inflammatory conditions. As topical monotherapy, betamethasone is indicated to relieve pruritic and inflammatory symptoms of corticosteroid-responsive-dermatoses.[L11991,L10782,L11997] Betamethasone can be used topically in combination with a vitamin D analog such as calcipotriene to treat plaque psoriasis.[L12000] The corticosteroid is also available as an injectable suspension and can be used to manage a range of inflammatory conditions including endocrine disorders, gastrointestinal disorders, and rheumatic disorders among other conditions.[L11994]

', 'Glucocorticoids inhibit neutrophil apoptosis and demargination, and inhibit NF-Kappa B and other inflammatory transcription factors.[A187463] They also inhibit phospholipase A2, leading to decreased formation of arachidonic acid derivatives.[A187463] In addition, glucocorticoids promote anti-inflammatory genes like interleukin-10.[A187463]



Corticosteroids like betamethasone can act through nongenomic and genomic pathways.[A31458] The genomic pathway is slower and occurs when glucocorticoids activate glucocorticoid receptors and initiate downstream effects that promote transcription of anti-inflammatory genes including phosphoenolpyruvate carboxykinase (PEPCK), IL-1-receptor antagonist, and tyrosine amino transferase (TAT).[A31458] On the other hand, the nongenomic pathway is able to elicit a quicker response by modulating T-cell, platelet and monocyte activity through the use of existing membrane-bound receptors and second messengers.[A31458]', 'Corticosteroids bind to the glucocorticoid receptor inhibiting pro-inflammatory signals, while promoting anti-inflammatory signals.[A187463] Corticosteroids have a wide therapeutic window as patients may require doses that are multiples of what the body naturally produces.[A187463] Patients who require long-term treatment with a corticosteroid should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.[A187463]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Atrakta re/force hair shampoo 250 ml', 14588, 'اتراكتا ريفورس شامبو للشعر 250 مل', '300', NULL, 'Hair care', 'Hair care', NULL, NULL, 'Ce.is.co srl > macro group pharmaceuticals', 'Amp', 'أمبول', '250 ml', '1', NULL, NULL, 'atrakta re-force shampoo improves perifollicular vascularization assuring maximum nutrients absorption strengthens the hair against seasonal fall and helps to reduce hair loss caused by weak hair roots. ingredients: panax ginseng root extract equisetum ar', NULL, 737, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Premier lactoferrin+vitamin c 14 sachets', 33424, 'بريمير لاكتوفيرين +فيتامين سي 14 كيس', '125', '87', 'Nutraceutical', 'Nutraceutical', NULL, 'Lactoferrin 100mg + vitamin c 40 mg', 'Premier international', 'Sachet', 'أكياس', NULL, '1', NULL, NULL, NULL, NULL, 954, '2024-08-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cymevene 250mg 84 capsules', 17010, 'سيميفين 250مجم 84 كبسولة', '2,640', NULL, 'Antiviral.nucleoside', 'Antiviral.nucleoside', NULL, 'Ganciclovir', 'F.hoffman la roche', 'Capsule', 'كبسولة', '250mg', '4', 'مضاد للفيروسات', NULL, NULL, NULL, 1935, '2022-05-28', NULL, 0, 'For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.', 'Ganciclovir''s antiviral activity inhibits virus replication. This inhibitory action is highly selective as the drug must be converted to the active form by a virus-encoded cellular enzyme, thymidine kinase (TK). TK catalyzes phosphorylation of ganciclovir to the monophosphate, which is then subsequently converted into the diphosphate by cellular guanylate kinase and into the triphosphate by a number of cellular enzymes. <i>In vitro</i>, ganciclovir triphosphate stops replication of herpes viral DNA. When used as a substrate for viral DNA polymerase, ganciclovir triphosphate competitively inhibits dATP leading to the formation of ''faulty'' DNA. This is where ganciclovir triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand. Ganciclovir inhibits viral DNA polymerases more effectively than it does cellular polymerase, and chain elongation resumes when ganciclovir is removed.', 'Ganciclovir is a synthetic nucleoside analogue of 2''-deoxyguanosine that inhibits replication of herpes viruses both <i>in vitro</i> and <i>in vivo</i>. Sensitive human viruses include cytomegalovirus (CMV), herpes simplex virus -1 and -2 (HSV-1, HSV-2), Epstein-Barr virus (EBV) and varicella zoster virus (VZV), however clinical studies have been limited to assessment of efficacy in patients with CMV infection. Ganciclovir is a prodrug that is structurally similar to acyclovir. It inhibits virus replication by its encorporation into viral DNA. This encorporation inhibits dATP and leads to defective DNA, ceasing or retarding the viral machinery required to spread the virus to other cells.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Friston bio-cleansing hair shampoo 250 ml', 19413, 'فريستون بايو شامبو للشعر 250 مل', '110', NULL, 'Hair care', 'Hair care', NULL, 'Biotin+saw palmetto+aloe vera+garlic+ginseng+hydrolyzed keratin+panthenol+niacin', 'Leader cosmetics > ncs pharma', 'Amp', 'أمبول', '250 ml', '1', NULL, NULL, 'for fine & thinning hair. use: apply twice weekly. indications: -prevent hair fall. -increase hair density. -protect hair from harmful environmental conditions. -controls split ends and hair damage.', NULL, 711, '2022-08-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Isopto maxitrol eye drops 5 ml', 21026, 'ايزوبتو ماكسيترول قطرة عين 5 مل', '27', '18', 'Antibiotic with glucocorticoid', 'Antibiotic with glucocorticoid', NULL, 'Dexamethasone+neomycin sulphate+polymyxin b sulphate', 'Novartis > novartis scientific office', 'Drops', 'نقط', '5 ml', '1', 'مضاد حيوى يعالج الالتهابات العين ويعالج التورم والاحمرار والحكة', NULL, 'about dexamethasone a potent synthetic glucocorticoid antiasthmatic anti-inflammatory and immunosuppressant. mechanism of action of dexamethasone the drug exerts it`s pharmacological action by penetrating and binding to cytoplasmic receptor protein and ca', '7612797426609', 4376, '2024-10-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Opikast 4 mg 21 chew. tabs.', 24145, 'اوبيكاست 4مجم 21 اقراص مضغ', '33', NULL, 'Asthma.anti-inflammatory.leukotriene antagonist', 'Asthma.anti-inflammatory.leukotriene antagonist', NULL, 'Montelukast', 'El-obour', 'Tab', 'أقراص', '4 mg', '3', NULL, NULL, 'about montelukast leukotriene(cyslt1) receptor antagonist antiinflammatory antiasthma. mechanism of action of montelukast montelukast is competitively and selectively antagonizes cyslt1 receptor (leukotrienes receptor) mediated bronchoconstriction.montelu', NULL, 1182, '2022-06-17', NULL, 0, 'Montelukast is indicated for:



(a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304];



(b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307]; and



(c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307].



Furthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331]



Moreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328]



Additionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an ''as required'' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]', 'Cysteinyl leukotrienes (CysLT) like LTC4, LTD4, and LTE4, among others, are eicosanoids released by a variety of cells like mast cells and eosinophils.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] When such CysLT bind to corresponding CysLT receptors like CysLT type-1 receptors located on respiratory airway smooth muscle cells, airway macrophages, and on various pro-inflammatory cells like eosinophils and some specific myeloid stem cells activities that facilitate the pathophysiology of asthma and allergic rhinitis are stimulated.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, CysLT-mediated airway bronchoconstriction, occluding mucous secretion, vascular permeability, and eosinophil recruitment are all types of effects that facilitate asthma.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Alternatively, in allergic rhinitis, CysLTs are released by the nasal mucosa when exposed to allergens during both early and late phase reactions and participate in eliciting symptoms of allergic rhinitis like a congested nose and airway.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Subsequently, montelukast is a leukotriene receptor antagonist that binds with high affinity and selectivity to the CysLT type 1 receptor, which consequently assists in inhibiting any physiological actions of CysLTs like LTC4, LTD4, and LTE4 at the receptor that may facilitate asthma or allergic rhinitis.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'Montelukast is a leukotriene receptor antagonist that demonstrates a marked affinity and selectivity to the cysteinyl leukotriene receptor type-1 in preference to many other crucial airway receptors like the prostanoid, cholinergic, or beta-adrenergic receptors.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] As a consequence, the agent can elicit substantial blockage of LTD4 leukotriene-mediated bronchoconstriction with doses as low as 5 mg.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Moreover, a placebo-controlled, crossover study (n=12) demonstrated that montelukast is capable of inhibiting early and late phase bronchoconstriction caused by antigen challenge by 75% and 57% respectively.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, it has been documented that montelukast can cause bronchodilation as soon as within 2 hours of oral administration.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] This action can also be additive to the bronchodilation caused by the concomitant use of a beta agonist.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Nevertheless, clinical investigations performed with adults 15 years of age and older revealed that no additional clinical benefit is obtained when doses of montelukast greater than 10 mg a day are used.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Additionally, in clinical trials with adults and pediatric asthmatic patients aged 6 to 14 years, it was also determined that montelukast can reduce mean peripheral blood eosinophils by about 13% to 15% from baseline in comparison to placebo during double-blind treatment periods.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] At the same time, in patients aged 15 years and older who were experiencing seasonal allergic rhinitis, the use of montelukast caused a median reduction of 13% in peripheral blood eosinophil counts when compared to placebo as well.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Clindanoid topical gel 30 gm', 16522, 'كليندانويد جل 30 جرام', '9', NULL, 'Anti-acne', 'Anti-acne', NULL, 'Clindamycin+tretinoin', 'Eva pharma', 'Gel', 'جل', '30 gm', '1', NULL, NULL, NULL, NULL, 1305, '2022-06-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cholilysis 40mg 10 tab.', 16272, 'كوليليسيس 40 مجم 10 قرص', '32', NULL, 'Antihyperlipidemic.statins', 'Antihyperlipidemic.statins', NULL, 'Lovastatin', 'El-obour', 'Tab', 'أقراص', '40mg', '1', NULL, NULL, 'about lovastatin statin class hmg-coa reductase inhibitor hypolipidemic agent. mechanism of action of lovastatin it is a precursor lactone hydrolyzed in to active beta-hydroxy acid which competitively inhibits the conversion of 3-hydroxy-3-methyl glutaryl', NULL, 727, '2022-07-19', NULL, 0, 'Lovastatin is indicated to reduce the risk of myocardial infarction, unstable angina, and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C. It is indicated as an intervention alternative in individuals presenting dyslipidemia at risk of developing atherosclerotic vascular disease. The administration of this agent should be accompanied by the implementation of a fat and cholesterol-restricted diet.[F4661]



Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb2), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate.[F4661,F4664]



Lovastatin is also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels.[F4661]



Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls with Heterozygous Familial Hypercholesterolemia (HeFH) who are at least one year post-menarche, 10 to 17 years of age, with HeFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than 189 mg/dL or LDL-C remains greater than 160 mg/dL and there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the adolescent patient.



Before administering lovastatin, it is important to rule out the presence of secondary causes of hypercholesterolemia and a lipid profile should be performed.



Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]', 'Lovastatin is a lactone which is readily hydrolyzed _in vivo_ to the corresponding β-hydroxyacid and strong inhibitor of HMG-CoA reductase, a hepatic microsomal enzyme which catalyzes the conversion of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A ) to mevalonate, an early rate-limiting step in cholesterol biosynthesis.[A181421,A174553] At therapeutic lovastatin doses, HMG-CoA reductase is not completely blocked, thereby allowing biologically necessary amounts of mevalonate to be available. Because the conversion of HMG-CoA to mevalonate is an early step in the biosynthetic pathway for cholesterol, therapy with lovastatin would not be expected to cause an accumulation of potentially toxic sterols.[F4664]



Lovastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low density lipoprotein (LDL) receptors which increase hepatic uptake of LDL. Lovastatin also inhibits hepatic synthesis of very low density lipoprotein (VLDL). The overall effect is a decrease in plasma LDL and VLDL and a significant reduction in the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475]



A significant effect on LDL-C reduction was seen within 2 weeks of initiation of lovastatin, and the maximum therapeutic response occurred within 4-6 weeks. The response was maintained during continuation of therapy. Single daily doses given in the evening were more effective than the same dose given in the morning, perhaps because cholesterol is synthesized mainly at night. When therapy with lovastatin is stopped, total cholesterol has been shown to return to pre-treatment levels.[F4664]



In vitro and in vivo animal studies also demonstrate that lovastatin exerts vasculoprotective effects independent of its lipid-lowering properties, also known as the pleiotropic effects of statins.[A181424] This includes improvement in endothelial function, enhanced stability of atherosclerotic plaques, reduced oxidative stress and inflammation, and inhibition of the thrombogenic response.



Statins have also been found to bind allosterically to β2 integrin function-associated antigen-1 (LFA-1), which plays an important role in leukocyte trafficking and in T cell activation.[A181559]



Lovastatin has been reported to have beneficial effects on certain cancers. This includes a multi-factorial stress-triggered cell death (apoptosis) and DNA degradation response in breast cancer cells.[A181937] It has also been shown to inhibit histone deacetylase 2 (HDAC2) activity and increase the accumulation of acetylated histone-H3 and the expression of p21(WAF/CIP) in human cancer cells, suggesting that statins might serve as novel HDAC inhibitors for cancer therapy and chemoprevention.[A15235]', 'Lovastatin is an oral antilipemic agent which reversibly inhibits HMG-CoA reductase. It is used to lower total cholesterol, low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), non-high density lipoprotein-cholesterol (non-HDL-C), and trigleride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, lovastatin reduces the risk of cardiovascular morbidity and mortality.[A174580,A181087,A181406,A181925]



Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A174580,A181397,A181403] Clinical studies have shown that lovastatin reduces LDL-C and total cholesterol by 25-40%.[A174580] The 50% inhibitory dose is known to be of 46 mcg/kg which is translated into a reduction of approximately 30% of plasma cholesterol.[A174553]



**Myopathy/Rhabdomyolysis**



Lovastatin, like other inhibitors of HMG-CoA reductase, occasionally causes myopathy manifested as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (ULN). Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare fatalities have occurred. The risk of myopathy is dose-related and is increased by high levels of HMG-CoA reductase inhibitory activity in plasma. In a clinical study (EXCEL)[A181925] in which patients were carefully monitored and some interacting drugs were excluded, there was one case of myopathy among 4933 patients randomized to lovastatin 20 to 40 mg daily for 48 weeks, and 4 among 1649 patients randomized to 80 mg daily.



Predisposing factors for myopathy include advanced age (≥65 years), female gender, uncontrolled hypothyroidism, and renal impairment. Chinese patients may also be at increased risk for myopathy. In most cases, muscle symptoms and CK increases resolved when treatment was promptly discontinued.



The risk of myopathy during treatment with lovastatin may be increased with concurrent administration of interacting drugs such as [fenofibrate], [niacin], [gemfibrozil], [cyclosporine], and strong inhibitors of the CYP3A4 enzyme.  Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors coadministered with [colchicine], and caution should therefore be exercised when prescribing these two medications together.[F4661,F4664]



Real-world data from observational studies has suggested that 10-15% of people taking statins may experience muscle aches at some point during treatment.[A182258]



**Liver Dysfunction**



Persistent increases (to more than 3 times the upper limit of normal) in serum transaminases occurred in 1.9% of adult patients who received lovastatin for at least one year in early clinical trials. When the drug was interrupted or discontinued in these patients, the transaminase levels usually fell slowly to pretreatment levels. The increases usually appeared 3 to 12 months after the start of therapy with lovastatin, and were not associated with jaundice or other clinical signs or symptoms.[F4661] In the EXCEL study,[A181925] the incidence of persistent increases in serum transaminases over 48 weeks was 0.1% for placebo, 0.1% at 20 mg/day, 0.9% at 40 mg/day, and 1.5% at 80 mg/day in patients on lovastatin. However, in post-marketing experience with lovastatin, symptomatic liver disease has been reported rarely at all dosages.[F4661]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Requib-prolib 4 mg 28 prolonged rel. tabs.', 25905, 'ريكويب بروليب 4مجم 28 اقراص', '117', NULL, 'Parkinson s disease.dopamine agonist', 'Parkinson s disease.dopamine agonist', NULL, 'Ropinirole', 'Glaxo smithkline > modern pharma', 'Tab', 'أقراص', '4 mg', '4', NULL, NULL, 'about ropinirole a non-ergoline dopamine agonist anti-parkinson`s agent. mechanism of action of ropinirole ropinirole is a non-ergoline dopamine agonist. the antiparkinsonian activity is due to stimulatory effect on post synaptic dopamine receptors (d2) w', NULL, 667, '2022-08-02', NULL, 0, 'For the treatment of the signs and symptoms of Parkinson''s disease and for the treatment of primary moderate-severe restless legs syndrome [FDA label].', 'Ropinirole is a non-ergoline dopamine agonist. Ropinirole has the highest affinity at the D3 receptors, which are concentrated in the limbic areas of the brain and may be responsible for some of the neuropsychiatric effects [A35711]. The exact mechanism of action of ropinirole as a treatment for Parkinson’s disease is unknown, however, it is believed to be related to its ability to selectively stimulate dopamine D2 receptors within the caudate-putamen system in the brain.  This system affects body movement.  Negligible affinity is seen for ropinirole at α2 adrenoreceptors in the periphery and 5HT-1 receptor. Ropinirole has no affinity at the D1-like receptors, benzodiazepine or GABA receptors [A35711].





 The precise mechanism of action of ropinirole as a treatment for Restless Legs Syndrome is unknown, however, it is believed to be related to its ability to stimulate dopamine receptors [FDA label].', '**Effects on Parkinson''s and restless leg syndrome**



This drug promotes the relief or improvement of symptoms of Parkinson''s or restless leg syndrome by stimulatory actions on dopamine receptors, which regulate movement.



**Effects on blood pressure**



Clinical experience with dopamine agonists, including ropinirole, suggests an association with impaired abilities in regulating blood pressure with resulting orthostatic hypotension, especially with patients undergoing dose escalation. In some patients in clinical studies, blood pressure changes were associated with orthostatic symptoms, bradycardia, and, in one case in a healthy volunteer, transient sinus arrest accompanied by syncope [FDA label]. The mechanism of orthostatic hypotension caused by ropinirole is assumed to be due to a D2-mediated blunting of noradrenergic response to a standing position, followed by a decrease in peripheral vascular resistance. Nausea is also a frequent symptom which accompanies orthostatic signs and symptoms [FDA label].



**Effects on prolactin**



At oral doses as low as 0.2 mg, ropinirole suppressed serum prolactin concentrations in healthy male volunteers.

Ropinirole had no dose-related effect on ECG wave form and rhythm in young, healthy, male volunteers in the range of 0.01 to 2.5 mg [FDA label].



**Effects on QT interval**



Ropinirole had no dose- or exposure-related effect on average QT intervals in healthy male and female volunteers at doses up to 4 mg/day. The effect of ropinirole on QTc intervals at higher exposures reached either due to drug interactions, hepatic dysfunction, or at higher doses has not been adequately evaluated [FDA label]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sugarfall 1mg 10 tabs', 27607, 'سوجارفول 1مجم 10 اقراص', '4', NULL, 'Anti-diabetic.combined secretagogues+sensitizers', 'Anti-diabetic.combined secretagogues+sensitizers', NULL, 'Glimepiride', 'Copad pharma', 'Tab', 'أقراص', '1mg', '1', NULL, NULL, NULL, '6223000911037', 809, '2022-07-30', NULL, 0, 'Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy. 



It may also be indicated for use in combination with metformin or insulin to lower blood glucose in patients with type 2 diabetes whose high blood sugar levels cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic (a drug used to lower blood sugar levels) agent alone.[L10322]', 'ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.[A177730] In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).[A177727] When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.[A177727] In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.[A177727] Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.[A177715] Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.[A177715] ', 'Glimepiride stimulates the secretion of insulin granules from the pancreatic beta cells and improves the sensitivity of peripheral tissues to insulin to increase peripheral glucose uptake, thus reducing plasma blood glucose levels and glycated hemoglobin (HbA1C) levels. A multi-center, randomized, placebo-controlled clinical trial evaluated the efficacy of glimepiride (1–8 mg) as monotherapy titrated over 10 weeks compared with placebo in T2DM subjects who were not controlled by diet alone.[A177703] In this study, there was a reduction in fasting plasma glucose (FPG) by 46 mg/dL, post-prandial glucose (PPG) by 72 mg/dL, and HbA1c by 1.4% more than the placebo.[A177703] In another randomized study comprising of patients with T2DM receiving either placebo or one of the three doses (1, 4, or 8 mg) of glimepiride during a 14-week study period, all glimepiride regimens significantly reduced FPG, PPG, and HbA1c values (P < 0.001) compared to placebo by the end of the study period.[A177703] The 4- and 8-mg doses of glimepiride were more effective than the 1-mg dose; however, the 4-mg dose provided a nearly maximal antihyperglycemic effect.[A177703]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Starocal syrup 100 ml', 1142, 'ستاروكال شراب 100 مل', '50', NULL, 'Calcium supplement', 'Calcium supplement', NULL, 'Calcium+magnesium+vitamin d3+zinc+copper', 'Star group', 'Syrup', 'شراب', '100 ml', '1', NULL, NULL, NULL, NULL, 910, '2024-06-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Omegastazole 20mg 14 caps.', 24064, 'اوميجاستازول 20مجم 14 كبسولة', '18', NULL, 'Peptic ulcer.proton pump inhibitor', 'Peptic ulcer.proton pump inhibitor', NULL, 'Omeprazole', 'Riva pharma s.a.e.', 'Cap', 'كبسولة', '20mg', '2', 'للحموضة وقرحة المعدة', NULL, 'about omeprazole proton pump inhibitor substituted benzimidazole anti-secretory antiulcer. mechanism of action of omeprazole omeprazole is a proton pump inhibitor and it is a prodrug. after administration it diffuses in to the parietal cell of the stomach', NULL, 1825, NULL, NULL, 0, 'Omeprazole, according to the FDA label [FDA label] is a proton pump inhibitor (PPI) used for the following purposes:



• Treatment of active duodenal ulcer in adults 



• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer

recurrence in adults 



• Treatment of active benign gastric ulcer in adults 



• Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients.



• Treatment of symptomatic gastroesophageal reflux disease (GERD) in

patients 1 year of age and older 



• Treatment of erosive esophagitis (EE) due to acid-mediated GERD in

patients 1 month of age and older 



• Maintenance of healing of EE due to acid-mediated GERD in patients 1

year of age and older 



• Pathologic hypersecretory conditions in adults', 'Hydrochloric acid (HCl) secretion into the gastric lumen is a process regulated mainly by the H(+)/K(+)-ATPase of the proton pump [A175180], expressed in high quantities by the parietal cells of the stomach. ATPase is an enzyme on the parietal cell membrane that facilitates hydrogen and potassium exchange through the cell, which normally results in the extrusion of potassium and formation of HCl (gastric acid) [A174295].



Omeprazole is a member of a class of antisecretory compounds, the substituted _benzimidazoles_, that stop gastric acid secretion by selective inhibition of the _H+/K+ ATPase_ enzyme system. Proton-pump inhibitors such as omeprazole bind covalently to cysteine residues via disulfide bridges on the alpha subunit of the _H+/K+ ATPase_ pump, inhibiting gastric acid secretion for up to 36 hours [A175192].  This antisecretory effect is dose-related and leads to the inhibition of both basal and stimulated acid secretion, regardless of the stimulus [FDA label].  



**Mechanism of H. pylori eradication**



Peptic ulcer disease (PUD) is frequently associated with _Helicobacter pylori_ bacterial infection (NSAIDs) [A175195]. The treatment of H. pylori infection may include the addition of omeprazole or other proton pump inhibitors as part of the treatment regimen [FDA label], [A175198]. 

_H. pylori_ replicates most effectively at a neutral pH [A175213]. Acid inhibition in H. pylori eradication therapy, including proton-pump inhibitors such as omeprazole, raises gastric pH, discouraging the growth of H.pylori [A175198]. It is generally believed that proton pump inhibitors inhibit the _urease_ enzyme, which increases the pathogenesis of H. pylori in gastric-acid related conditions [A175216].   ', '**Effects on gastric acid secretion**



This drug decreases gastric acid secretion [FDA label]. After oral administration, the onset of the antisecretory effect of omeprazole is usually achieved within one hour, with the maximum effect occurring by 2 hours after administration. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days [FDA label].



**Effects on serum gastrin**



In studies of 200 or more patients, serum gastrin levels increased during the first 1-2 weeks of daily administration of therapeutic doses of omeprazole. This occurred in a parallel fashion with the inhibition of acid secretion. No further increase in serum gastrin occurred with continued omeprazole administration. Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum Chromogranin A (CgA) levels. The increased CgA levels may lead to false positive results in diagnostic studies for neuroendocrine tumors [FDA label].



**Enterochromaffin-like (ECL) cell effects**



Human gastric biopsy samples have been obtained from more than 3000 pediatric and adult patients treated with omeprazole in long-term clinical studies. The incidence of enterochromaffin-like cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia have been identified in these patients. These studies, however, are of insufficient in power and duration to draw conclusions on the possible influence of long-term administration of omeprazole in the development of any premalignant or malignant conditions [FDA label]. 



**Other effects**



Systemic effects of omeprazole in the central nervous system, cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40 mg for 2-4 weeks, showed no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin [FDA label]. 





', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Flix nasal spray 50 mcg/metered spray dose', 19136, 'فليكس بخاخ للانف 50مكجم/جرعة سبراي', '76', '51', 'Anti-inflammatory.glucocorticoid.bronchodilator', 'Anti-inflammatory.glucocorticoid.bronchodilator', NULL, 'Fluticasone propionate', 'Eva pharma', 'Spray', 'بخاخ', '50 mcg', '1', 'بخاخ موسع للشعب الهوائية ومضاد للالتهابات', NULL, 'description fluticasone propionate a medium-potency synthetic corticosteroid is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis intranasally to manage symptoms of allergic and non-allergic rhinitis and orally for t', '6223002455904', 3289, '2024-07-09', NULL, 0, 'Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label]as well as inflammatory and pruritic dermatoses[F4355]. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis[L8309,F4358].', 'Fluticasone propionate works through an unknown mechanism to  affect the action of various cell types and mediators of inflammation[F4358]. Fluticasone propionate activates glucocorticoid receptors and inhibits lung eosinophilia in rats[F4358,F4355].', 'Systemically, fluticasone propionate activates glucocorticoid receptors, and inhibits lung eosinophilia in rats[F4358][FDA Label]. Fluticasone propionate as a topical formulation is also associated with vasoconstriction in the skin[F4355,A177118].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Anastrozol sandoz 1 mg 30 f.c. tab.', 14108, 'اناستروزول ساندوز 1مجم 30 قرص', '495', '330', 'Non-steroidal aromatase-inhibitor', 'Non-steroidal aromatase-inhibitor', NULL, 'Anastrozole', 'Sandoz > novartis', 'Tab', 'أقراص', '1 mg', '3', 'علاج سرطان الثدي', NULL, NULL, '4030855503780', 6486, '2025-01-24', NULL, 0, 'Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women.[L8863] It may also be used in the treatment of advanced breast cancer in postmenopausal women who experience disease progression despite treatment with [tamoxifen].[L8866,L8863] ', 'Anastrazole exerts its anti-estrogenic effects via selective and competitive inhibition of the aromatase enzyme found predominantly in the adrenal glands, liver, and fatty tissues.[A186877] Many breast cancers are hormone receptor-positive, meaning their growth is stimulated and/or maintained by the presence of hormones such as estrogen or progesterone.[L8863] In postmenopausal women, estrogen is primarily derived from the conversion of adrenally-produced androgens into estrogens by the aromatase enzyme - by competitively inhibiting the biosynthesis of estrogen at these enzymes, anastrozole effectively suppresses circulating estrogen levels and, subsequently, the growth of hormone receptor-positive tumours.[A186877,A186958]', 'Anastrozole prevents the conversion of adrenal androgens (e.g. [testosterone]) to estrogen in peripheral and tumour tissues. As the growth of many breast cancers is stimulated and/or maintained by the presence of estrogen, anastrozole helps to treat these cancers by decreasing the levels of circulating estrogens.[L8869,A186958] Anastrozole has a relatively long duration of action allowing for once daily dosing - serum estradiol is reduced by approximately 70% within 24 hours of beginning therapy with 1mg once daily, and levels remain suppressed for up to 6 days following cessation of therapy.[L8863] 



The incidence of ischemic cardiovascular events was increased during anastrozole therapy and patients with pre-existing ischemic heart disease should consider the risks and benefits of anastrozole before beginning therapy. Anastrozole has also been reported to decrease spine and hip bone mineral density (BMD), so consideration should be given to monitoring of BMD in patients receiving long-term therapy.[L8863,A186955]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Centrum advance 30 tablets (illegal import)', 16109, 'سينتروم ادفانس 30 قرص', '0', '0', 'Multivitamins', 'Multivitamins', NULL, 'Multivitamins+minerals', 'Pfizer', 'Tablet', 'أقراص', NULL, '3', NULL, NULL, '-centrum advance contains 24 key nutrients. -supports energy release and immunity and contributes to normal metabolism. -supports the general wellbeing of adults. vitamin a : 800 mcg vitamin e : 15 mg vitamin c : 100 mg vitamin k : 30 mcg vitamin b1 (thia', '6251613000497', 1305, '2023-06-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Spasmex 30 mg 50 f.c. tabs.', 27326, 'سبازمكس 30مجم 50قرص', '170', NULL, 'Urge incontinence', 'Urge incontinence', NULL, 'Trospium chloride', 'Ferring pharmaceuticals > multipharma', 'Tab', 'أقراص', '30 mg', '5', NULL, NULL, 'trospium chloride is used for the treatment of overactive bladder with symptoms of urge incontinence and frequent urination. it shouldn t be used with people who retain urine who have severe digestive conditions myasthenia gravis narrow-angle glaucoma or', '4028305000934', 1450, '2022-12-09', NULL, 0, 'Trospium is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.[L36823] It is also indicated in combination with [xanomeline] for the treatment of adult patients with schizophrenia.[L51629]', 'Trospium antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder.', 'Trospium is an antispasmodic, antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. According to receptor assays, it displays higher affinity towards muscarininc receptors compared to nicotinic receptors at therapeutic concentrations. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Atarax 25mg 25 tab.', 14519, 'اتراكس 25مجم 25 قرص', '12', NULL, 'Antihistamine.sedative.first generation', 'Antihistamine.sedative.first generation', NULL, 'Hydroxyzine hydrochloride', 'Cid', 'Tab', 'أقراص', '25mg', '1', NULL, NULL, NULL, '6221043013411', 2371, '2022-10-24', NULL, 0, 'Hydroxyzine is indicated for the symptomatic relief of anxiety and tension associated with psychoneuroses, and as an adjunct in organic disease states in which anxiety is manifested.[L9677] It is also indicated in the treatment of histamine-mediated pruritus and pruritus due to allergic conditions such as chronic urticaria.[L9677]



Canadian labeling states that hydroxyzine is also indicated in adults and children as a premedication prior to medical procedures, such as dental surgery.[L9680] It is also used in the control of nausea and vomiting, excluding nausea and vomiting of pregnancy.[L9680]', 'The H<sub>1</sub> histamine receptor is responsible for mediating hypersensitivity and allergic reactions. Exposure to an allergen results in degranulation of mast cells and basophils, which then release histamine and other inflammatory mediators. Histamine binds to, and activates, H<sub>1</sub> receptors, which results in the further release of pro-inflammatory cytokines, such as interleukins, from basophils and mast cells. These downstream effects of histamine binding are responsible for a wide variety of allergic symptoms, such as pruritus, rhinorrhea, and watery eyes.[A1495]



Hydroxyzine is a potent inverse agonist of histamine H<sub>1</sub>-receptors[A1257] - inverse agonists are agents that are considered to have a "negative efficacy", so rather than simply blocking activity at a receptor they actively dampen its activity.[T707] Inverse agonism at these receptors is responsible for hydroxyzine''s efficacy in the treatment of histaminic edema, flare, and pruritus.



Hydroxyzine is not a cortical depressant, so its sedative properties likely occur at the subcortical level of the CNS.[L9677] These sedative properties allow activity as an anxiolytic. Antiemetic efficacy is likely secondary to activity at off-targets.[A189753]', 'Hydroxyzine blocks the activity of histamine to relieve allergic symptoms such as pruritus.[L9677] Activity at off-targets also allows for its use as a sedative anxiolytic and an antiemetic in certain disease states.[L9680]



Hydroxyzine is relatively fast-acting, with an onset of effect that occurs between 15 and 60 minutes and a duration of action between 4-6 hours.[A1257] Hydroxyzine may potentiate the effects of central nervous system (CNS) depressants following general anesthesia - patients maintained on hydroxyzine should receive reduced doses of any CNS depressants required.[L9677] Hydroxyzine is reported to prolong the QT/QTc interval based on postmarketing reports of rare events of Torsade de Pointes, cardiac arrest, and sudden death, and should be used with caution in patients with an increased baseline risk for QTc prolongation.[L9680,A189726] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Oxelacure 0.2% syrup 125 ml', 24392, 'اوكسيلاكيور 0.2% شراب 125 مل', '6', NULL, 'Anti-cough', 'Anti-cough', NULL, 'Oxeladin', 'Arab drug company.', 'Syrup', 'شراب', '0.2%', '1', NULL, NULL, 'oxeladin is a cough suppressant. it is a highly potent and effective drug used to treat all types of cough of various etiologies. it is not related to opium or its derivatives so treatment with oxeladin is free of risk of dependence or addiction. oxeladin', NULL, 883, '2022-06-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Starf 30 ml drops', 15894, 'ستارف نقط فم 30 مل', '35', NULL, 'Iron support', 'Iron support', NULL, 'Ferrous sulphate + ascorbic acid + citric acid', 'Mpco', 'Drops', 'نقط', '30 ml', '1', NULL, NULL, NULL, '6223002821280', 798, '2022-10-28', NULL, 0, 'Ferrous sulfate is used for the prevention and treatment of iron deficiency anemia in adults and children.[A190804,L2240,L11800]

', 'Iron is required to maintain optimal health, particularly for helping to form red blood cells (RBC) that carry oxygen around the body. A deficiency in iron indicates that the body cannot produce enough normal red blood cells.[A32514,L11800] Iron deficiency anemia occurs when body stores of iron decrease to very low levels, and the stored iron is insufficient to support normal red blood cell (RBC) production. Insufficient dietary iron, impaired iron absorption, bleeding, pregnancy, or loss of iron through the urine can lead to iron deficiency.[A32514,L11794]  Symptoms of iron deficiency anemia include fatigue, breathlessness, palpitations, dizziness, and headache.



Taking iron in supplement form, such as ferrous sulfate, allows for more rapid increases in iron levels when dietary supply and stores are not sufficient.[L2175] Iron is transported by the divalent metal transporter 1 (DMT1) across the endolysosomal membrane to enter the macrophage. It can then can be incorporated into ferritin and be stored in the macrophage or carried of the macrophage by ferroportin. This exported iron is  oxidized by the enzyme to ceruloplasmin to Fe3+, followed by sequestration by transferrin for transport in the serum to various sites, including the bone marrow for hemoglobin synthesis or into the liver.[A32524] Iron combines with porphyrin and globin chains to form hemoglobin, which is critical for oxygen delivery from the lungs to other tissues.[L2263]', 'Ferrous sulfate replenishes iron, an essential component in hemoglobin, myoglobin, and various enzymes. It replaces the iron that is usually found in hemoglobin and myoglobin. Iron participates in oxygen transport and storage, electron transport and energy metabolism, antioxidant and beneficial pro-oxidant functions, oxygen sensing, tissue proliferation and growth, as well as DNA replication and repair.[A32524,A32514]



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Attivo shampoo 250 ml', 14608, 'اتيفو شامبو 250 مل', '195', '125', 'Hair care', 'Hair care', NULL, NULL, 'El-helou perfumes & cosmetics > safety pharma', 'Amp', 'أمبول', '250 ml', '1', 'شامبو للشعر -- نظافة الشعر -- الحفاظ علي حيوية ولمعان الشعر', NULL, 'anti-dandruff', NULL, 1278, '2025-08-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ribomustin 100 mg vial', 26065, 'ريبوموستين 100مجم فيال', '3,784', '2646', 'Antineoplastic agent.alkylating agent', 'Antineoplastic agent.alkylating agent', NULL, 'Bendamustine hydrochloride', 'Astellas pharma inc > multipharma', 'Vial', 'فيال', '100 mg', '1', NULL, NULL, 'pharmacology:bendamustine is an alkylating agent (nitrogen mustard derivative). use: labeled indications chronic lymphocytic leukemia: treatment of chronic lymphocytic leukemia (cll) non-hodgkin lymphoma: treatment of indolent b-cell non-hodgkin lymphoma', NULL, 914, '2025-08-19', NULL, 0, 'Bendamustine is indicated for use in the treatment of  indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with [rituximab] or a rituximab-containing regimen.[L50632]



The indication for chronic lymphocytic leukemia (CLL) was removed from the US drug label in April 2024.[L50632]', ' Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death.  It is active against both active and quiescent cells, although the exact mechanism of action is unknown. ', 'No mean changes in QTc interval greater than 20 milliseconds were detected up to one hour post-infusion.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Drakon facial wash for dry skin 200 ml', 17900, 'دراكون غسول وجه للبشرة الجافة 200 مل', '200', NULL, 'Skin care', 'Skin care', NULL, 'Liquorice+dragostat+vitamin c+salicylic acid+glycolic acid', 'Xfactor medical > pharma cruise medical', 'Facial wash', 'غسول للوجه', '200 ml', '1', NULL, NULL, 'drakon facial wash for dry skin gently removes face and eye make up dirt and impurities. its gentle cream formula helps restore skin comfort and retains essential moisture leaving skin feeling comfortable and hydrated drakon facial wash for dry skin brigh', NULL, 733, '2022-08-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Normelan oilysal face lotion 50 ml', 6739, 'نورميلان اوليسال لوشن للوجه 50 مل', '300', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Green pharmaceutical', 'Lotion', 'لوشن', '50 ml', '1', NULL, NULL, NULL, NULL, 784, '2022-08-14', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Solvadine mouth freshener solution spray 40 ml', 17669, 'سولفادين محلول سبراي منعش للفم 40 مل', '110', NULL, 'Soothing & refreshing spray', 'Soothing & refreshing spray', NULL, 'Glycerol+honey+eucalyptus oil+clove oil+ginger extract+rosemary extract+licorice extracts+vitis vinifera extract+sambucus nigra extract+thymus vulgaris+propolis extract+menthol', 'Shine pharma', 'Solution', 'محلول', '40 ml', '1', 'بخاخ ملطف للفم يعمل على قتل الجراثيم وينعش النفس لمدة تصل إلى 12 ساعة ويعمل على تخفيف ألتهاب الحلق', NULL, NULL, NULL, 1114, '2023-01-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bepanthen ointment 30 gm', 15086, 'بيبانثين مرهم 30 جم', '195', '125', 'Skin care', 'Skin care', NULL, 'Dexapanthenol', 'Bayer healthcare > ramco', 'Ointment', 'مرهم', '30 gm', '1', NULL, NULL, 'oil-rich ointment for skin care breast care and baby care which forms a protective film', '4008500109434', 990, '2025-11-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sandostatin 0.1mg/ml 5 s.c. amp.', 10188, 'ساندوستاتين 0.1مجم/مل 5 امبولات', '406', '295', 'Hypothalmic hormones.somatostatin analogues', 'Hypothalmic hormones.somatostatin analogues', NULL, 'Octreotide', 'Novartis', 'Amp', 'أمبول', '0.1mg', '5', NULL, NULL, NULL, '8699504750508', 3991, '2023-12-26', NULL, 0, 'Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors.[L14513] The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide and [lanreotide].[L14507,L45528]', 'Octreotide binds to somatostatin receptors coupled to phospholipase C through G proteins and leads to smooth muscle contraction in the blood vessels.[L14519] Downstream effects that stimulate phospholipase C, the production of 1, 4,5-inositol triphosphate, and action on the L-type calcium channels lead to the inhibition of growth hormone, treating the various growth-hormone and metabolic effects of acromegaly.[L14519]



Octreotide''s suppression of luteinizing hormone (LH)[A214724], reduction in splanchnic blood flow[A214727], and inhibition of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide provide relief for the gastrointestinal and flushing symptoms of carcinoid and/or VIPoma tumors.[A214721]', 'Octreotide mimics the naturally occurring hormone known as somatostatin. Like somatostatin, it demonstrates activity against growth hormone and glucagon, treating the disordered tissue growth and insulin regulation in patients with acromegaly.[L14501,L14513] In addition, octreotide relieves the flushing and diarrhea associated with gastrointestinal tumors by reducing splanchnic blood flow[A214727] and various gastrointestinal hormones associated with diarrhea.[A214721]



Product labeling warns that octreotide may reduce gallbladder contractility, bile secretion, and the release of thyroid-stimulating hormone (TSH) in healthy volunteers.[L14513] In addition, reports of decreased vitamin B12 in patients treated with octreotide have been made. Ensure to monitor vitamin B12 levels in patients taking octreotide.[L14528]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cal-mag-d 30 capsules', 1985, 'كال ماج 30 مجم اقراص', '165', '147', 'Calcium magnesium vit. d3 vit k2-mk7', 'Calcium magnesium vit. d3 vit k2-mk7', NULL, 'Calcium citrate+magnesium citrate+vit. d3 1000 iu+vit. k2 - mk7 25 mcg', 'Hochster pharmaceutical industries', 'Capsule', 'كبسولة', NULL, '3', NULL, NULL, NULL, '6224007751879', 1636, '2025-04-22', NULL, 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Locarten 0.02% cream 10 gm', 21973, 'لوكارتين 0.02% كريم 10 جم', '6', NULL, 'Glucocorticoid', 'Glucocorticoid', NULL, 'Flumethasone', 'Chemipharm', 'Cream', 'كريم', '0.02%', '1', NULL, NULL, 'about flumethasone topical steroids anti inflammatory and antipruritic drugs mechanism of action of flumethasone its mechanism of action is to inhibit arachidonic acids role in the biosynthesis of prostaglandins and leukotrienes. flumethasone is active wh', '6223002641741', 832, '2022-12-06', NULL, 0, 'For the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions', 'Flumethasone is a glucocorticoid receptor agonist. This complex binds to the nucleus causing a variety of genetic activation and repressions. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flumethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.', 'Flumethasone pivalate is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application. This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sanso pregna plus 28 f.c. tabs.', 13438, 'سانسو بريجنا بلس 28 قرص', '220', '100', 'Multivitamin', 'Multivitamin', NULL, 'Vitamin d3+vitamin e+vitamin k+vitamin c+vitamin b1+vitamin b2+vitamin b3+vitamin b6+vitamin b12+folic acid+biotin+pantothenic acid+magnesium+iron+zinc+copper+selenium', 'Aug pharma', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, '6223005465412', 1449, '2025-05-11', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sandoglobulin 3g i.v.infusion(n/a)', 26496, 'ساندوجلوبيولين 3جم', '1,150', NULL, 'Iv.ig', 'Iv.ig', NULL, 'Human normal immunoglobulin', 'Csl ag-switzerland > 2s pharma group', 'Unknown', 'غير محدد', NULL, '1', NULL, NULL, NULL, NULL, 737, '2022-07-27', NULL, 0, 'Human immunoglobulin G is indicated for the following conditions:



### Primary Immunodeficiency

- for the treatment of primary immunodeficiency in adult and pediatric patients[L39920, L39930, L39935, L39940, L39945, L39950, L39955, L39960, L39965, L39975, L39980, L40029, L40034, L40044]

- in combination with [hyaluronidase (human recombinant)] for the treatment of primary immunodeficiency in patients ≥2 years of age.[L42760]



### Immune Thrombocytopenic Purpura (ITP)

- for the treatment of acute or chronic immune thrombocytopenic purpura in adult and pediatric patients[L39940, L39950, L39960, L39965, L39970, L39975, L39980]



### Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

- for the treatment of CIDP in adult patients[L39955, L39965, L39975, L39980, L40034]

- in combination with hyaluronidase (human recombinant) as a maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)[L40039]



### Multifocal Motor Neuropathy (MMN)

- for maintenance therapy to improve muscle strength and disability in adult patients with MMN[L39955]



### Prophylaxis of Bacterial Infection

- for the prevention of bacterial infections in patients with hypogammaglobulinemia and/or B-cell chronic lymphocytic leukemia[L39960]



### Coronary Artery Aneurysm Associated With Kawasaki Syndrome

- for the prevention of coronary artery aneurysms in pediatric patients with Kawasaki syndrome[L39960]



### Dermatomyositis

- for the treatment of dermatomyositis in adult patients[L39970]

', 'IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab'')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab′)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.', 'Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immunoglobulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ema max cream 100 gm', 18215, 'ايما ماكس كريم 100 جم', '140', NULL, 'Skin care', 'Skin care', NULL, 'Licorice+sodium formate+chamomile+green tea+tea tree oil+panthenol+glycerin+allantoin+vitamin e', 'Italian cosmetics company > feel good canada', 'Cream', 'كريم', '100 gm', '1', NULL, NULL, '** ph5.5 soft healthy skin - post peeling - hair growth retardant - soft & silky - sensitive skin ** directions: apply morning and evening onto cleansed face hand & body', NULL, 848, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ephedrine sulphate 50mg/ml 100 amp.', 4225, 'ايفيدرين سلفات 50 مجم / مل 100 امبول', '700', '398', 'Alpha and beta adrenergic agonist', 'Alpha and beta adrenergic agonist', NULL, 'Ephedrine', 'Misr', 'Amp', 'أمبول', '50mg', '100', 'محفز للجهاز العصبي', NULL, NULL, NULL, 2864, '2024-11-28', NULL, 0, 'Ephedrine intravenous injections are indicated to treat hypotension under anesthesia,[L12972,L34645] ephedrine injections by multiple routes are indicated to treat allergic conditions such as bronchial asthma,[L12996] ephedrine nasal spray is and OTC medication used as a decongestant.[L12993]', 'Ephedrine is a direct and indirect sympathomimetic amine.[A193650] As a direct effect, ephedrine activates alpha-adrenergic and beta-adrenergic receptors. As an indirect effect, it inhibits norepinephrine reuptake and increases the release of norepinephrine from vesicles in nerve cells.[A193650] These actions combined lead to larger quantities of norepinephrine present in the synapse for more extended periods of time, increasing stimulation of the sympathetic nervous system.[A193650]



Ephedrine acts as an agonist of alpha-1, beta-1 and beta-2-adrenergic receptors. The stimulation of alpha-1-adrenergic receptors causes the constriction of veins and a rise in blood pressure, the stimulation of beta-1-adrenergic receptors increases cardiac chronotropy and inotropy, and the stimulation of beta-2-adrenergic receptors causes vasodilation and bronchodilation.[A193650]', 'Ephedrine increases blood pressure by stimulating heart rate and cardiac output and variably increasing peripheral resistance.[L12975] It causes bronchodilation due to the activation of beta-adrenergic receptors in the lungs. By stimulating alpha-adrenergic receptors in bladder smooth muscle cells, ephedrine also increases the resistance to the outflow of urine.[L12972,L12975] The therapeutic window of ephedrine is wide, as patients can be given doses of 5mg up to 50mg.[L12993] Patients should be counselled regarding the pressor effects of sympathomimetic amines and the risk of tachyphylaxis.[A193650] Also, the use of ephedrine for hypotension prophylaxis is associated with a higher risk of hypertension, compared to when ephedrine is used to treat hypotension.[L12975]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Migaura 5mg/500mg 20 tab.', 8165, 'ميجورا 20 قرص', '11', NULL, 'Antiemetic', 'Antiemetic', NULL, 'Metoclopramide+paracetamol(acetaminophen)', 'Memphis', 'Tab', 'أقراص', '5mg', '2', 'علاج الترجيع -- مسكن وخافض للحرارة', NULL, 'about metoclopramide it is a dopamine antagonist - antiemetic gastroprokinetic agent. mechanism of action of metoclopramide metoclopramide acts through both serotonergic and dopaminergic receptors. metoclopramide binds to serotonin (5 ht3 &5ht4) and dopam', '6221050030937', 1252, '2022-12-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bridion 200mg/2ml sol. i.v. 10 vials (net price)', 15480, 'بريديون 200 مجم / 2 مل 10 فيال', '7,521', NULL, 'Neuromuscular blockade reversal', 'Neuromuscular blockade reversal', NULL, 'Sugammadex', 'Merck sharp & dohme > ramco', 'Vial', 'فيال', '200mg', '10', NULL, NULL, 'bridion is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. dosage and administration *monitor for twitch responses to determine the timing and dose for bridion adminis', NULL, 1235, '2022-08-03', NULL, 0, 'Sugammadex is indicated for the reversal of neuromuscular blockade induced by [rocuronium] bromide or [vecuronium] bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.[L15766]', 'Sugammadex is a modified gamma-cyclodextrin which forms very tight water soluble complexes at a 1:1 ratio with steroidal neuromuscular blocking drugs (rocuronium > vecuronium >> pancuronium). Sugammadex creates a concentration gradient which favors movement of rocurionium from the neuromuscular junction into the plasma, which quickly reverses rocuronium-induced neuromuscular blockade. The free rocuronium  in the plasma are then bound tightly to sugammadex, assisting the diffusion of the remaining rocuronium molecules out of the neuromuscular junction and increasing bound and free rocuronium in the plasma.', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sleepback 10 mg 14 caps.', 27084, 'سليباك 10مجم 14 كبسول', '9', NULL, 'Psychiatric.anxiolytics-hypnotics', 'Psychiatric.anxiolytics-hypnotics', NULL, 'Zaleplon', 'Arab drug company.', 'Cap', 'كبسولة', '10 mg', '1', NULL, NULL, 'about zaleplon pyrazolopyrimidine derivative( a nonbenzodiazepine sedative-hypnotic. mechanism of action of zaleplon zaleplon is a non benzodiazepine sedative-hypnotic drug. it binds to the benzodiazepine binding site on gaba-a receptors containing the al', NULL, 766, '2022-07-15', NULL, 0, 'For the treatment of short-term treatment of insomnia in adults.', 'Zaleplon exerts its action through subunit modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex. Zaleplon also binds selectively to the brain omega-1 receptor located on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding.', 'Zaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABA<sub>B</sub>Z) receptor complex. Subunit modulation of the GABA<sub>B</sub>Z receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zaleplon also binds selectively to the CNS GABA<sub>A</sub>-receptor chloride ionophore complex at benzodiazepine(BZ) omega-1 (BZ1, ο1) receptors. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Trosyd 1% dermal lotion 30 gm', 11737, 'تروسيد 1% لوشن 30 جم', '10', NULL, 'Antifungals.imidazoles', 'Antifungals.imidazoles', NULL, 'Tioconazole', 'Pfizer', 'Lotion', 'لوشن', '1%', '1', NULL, NULL, NULL, '6221180000688', 801, '2022-12-13', NULL, 0, 'For the local treatment of vulvovaginal candidiasis (moniliasis).', 'Tioconazole interacts with 14-&alpha; demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an essential component of the yeast membrane. In this way, tioconazole inhibits ergosterol synthesis, resulting in increased cellular permeability. Tioconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms and the uptake of purine, impair triglyceride and/or phospholipid biosynthesis, and inhibit the movement of calcium and potassium ions across the cell membrane by blocking the ion transport pathway known as the Gardos channel.', 'Tioconazole is a broad-spectrum imidazole antifungal agent that inhibits the growth of human pathogenic yeasts. Tioconazole exhibits fungicidal activity in vitro against <i>Candida albicans</i>, other species of the genus Candida, and against <i>Torulopsis glabrata</i>. Tioconazole prevents the growth and function of some fungal organisms by interfering with the production of substances needed to preserve the cell membrane. In addition to its broad spectrum antifungal effects with tioconazole being effective against commonly occurring dermatophyte and yeast-like fungal species, tioconazole also has antibacterial effects on certain Gram-positive cocci bacteria.[L50166]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Fentanilo 25 mcg/hr 5 transdermal patch (net price)', 30532, 'فنتانيلو 25مكجم/ساعة 5 لاصقة', '150', NULL, 'Analgesics.opioid', 'Analgesics.opioid', NULL, 'Fentanyl', '> onco pharm', 'Patch', 'لصقة', '25 mcg', '1', NULL, NULL, 'about fentanyl citrate synthetic primary opioid agonist anilidopiperidine derivative narcotic analgesic general anesthetic. mechanism of action of fentanyl citrate this drug primarily acts on the cns. fentanyl is a pure opioid agonist and primarily acts o', NULL, 4566, '2023-05-04', NULL, 0, 'Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia.[Label] These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia.[Label] Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.[Label]



Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.[L6598,L6601,L6604,L6607,L922,L6610]', 'Fentanyl binds to opioid receptors, especially the mu opioid receptor, which are coupled to G-proteins.[A179533] Activation of opioid receptors causes GTP to be exchanged for GDP on the G-proteins which in turn down regulates adenylate cyclase, reducing concentrations of cAMP.[A179533] Reduced cAMP decreases cAMP dependant influx of calcium ions into the cell.[A179533] The exchange of GTP for GDP results in hyperpolarization of the cell and inhibition of nerve activity.[A179533]', 'Fentanyl produces strong analgesia through its activation of opioid receptors.[Label,A179533] It has a duration of action of several hours and a wider therapeutic index as patients develop tolerance to opioids.[Label] Fentanyl is associated with a risk of addiction and abuse and should not be mixed with alcohol or benzodiazepines.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Isotretinoin 10mg 10 soft gelatin caps.', 6652, 'ايزوتريتينوين 10مجم 10 كبسولات', '64', NULL, 'Anti-acne', 'Anti-acne', NULL, 'Isotretinoin', 'Ranbaxy', 'Cap', 'كبسولة', '10mg', '1', NULL, NULL, 'about isotretinoin vitamin a isomer retinoic acid derivative anti-acne. mechanism of action of isotretinoin isotretinoin is a 13-cis-retinoic acid and is used in the treatment of severe nodulocystic acne. isotretinoin decreases sebocyte number and reduces', '6224009052509', 8690, '2022-10-24', NULL, 0, 'Isotretinoin is indicated to treat severe recalcitrant nodular acne and patients ≥12 years enrolled in the iPLEDGE program.[Label,L6579]', 'Isotretinoin produces its effects through altering progress through the cell cycle, cell differentiation, survival, and apoptosis.[A179091] These actions reduce sebum production, preventing the blockage of pores, and growth of acne causing bacteria.[A179091] Isotretinoin and 4-oxo-isotretinoin both significantly reduce the production of sebum.[A179091,Label] Isotretinoin has little to no affinity for retinol binding proteins (RBPs) and retinoic acid nuclear receptors (RARs).[A179091] Tretinoin and 4-oxo-tretinion bind to the RAR-γ receptor, which is suspected to be part of the action of acne treatment by isotretinoin.[A179091] Isotretinoin induces apoptosis in sebocytes, leading to a decrease in sebum production.[A179091] Isotretinoin also reduces the formation of comedones by reducing hyperkeratinization through an unknown mechanism.[A179091] Isotretinoin does not directly kill bacteria but it does reduce the size of sebum ducts and makes the microenvironment less hospitable to acne causing bacteria.[A179091] It may also increase immune mechanisms and alter chemotaxis of monocytes to reduce inflammation.[A179091]



There is preliminary evidence suggesting isotretinoin may interact with FoxO1, which may explain a substantial number of isotretinoin''s unexplained actions.[A179122]', 'The pharmacodynamics of isotretinoin are poorly understood.[Label]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vitamin d3 10.000 iu 100 softgels (puritans pride)', 29501, 'فيتامين دي3 10000 وحدة دولية - مستورد', '775', '600', 'Vitamin d', 'Vitamin d', NULL, 'Vitamin d3', 'Puritans pride', 'Gel', 'جل', '10.000 iu', '10', NULL, NULL, 'this new formula packs 10 000 ius of vitamin d. vitamin d is known as essential when it comes to building strong teeth and bones.** vitamin d3 is a more potent and bioavailable form compared to d2. assists the body with calcium absorption.** bolsters the', NULL, 1196, '2024-07-29', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Trixomash 500mg vial for i.m. inj.', 28566, 'تريكسوماش 500مجم فيال', '37', '16.5', 'Antibiotic.cephalosporin.third-generation', 'Antibiotic.cephalosporin.third-generation', NULL, 'Ceftriaxone', 'Rameda > mash premiere', 'Inj', 'حقن', '500mg', '1', NULL, NULL, 'about ceftriaxone third generation cephalosporin antibiotic(parenteral). mechanism of action of ceftriaxone ceftriaxone is a 3rd generation cephalosporin which exerts its bactericidal action against both gram positive & gram negative organisms by inhibiti', NULL, 1039, '2025-02-17', NULL, 0, 'Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms.[L15082] Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabilis, E. coli, Klebsiella spp, M. catarrhalis, B. burgdorferi, and some oral anaerobes.[A215582] ', 'Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall.[T324,L15082] The beta-lactam moiety of ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. Binding of ceftriaxone to these enzymes causes the enzyme to lose activity; therefore, the bacteria produce defective cell walls, causing cell death.', 'Ceftriaxone is a cephalosporin/cephamycin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms.[L15082] Ceftriaxone has <i>in vitro</i> activity against gram-positive aerobic, gram-negative aerobic, and anaerobic bacteria.[L15087] The bactericidal activity of ceftriaxone results from the inhibition of cell wall synthesis and is mediated through ceftriaxone binding to penicillin-binding proteins (PBPs).[T324] Ceftriaxone is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended-spectrum beta-lactamases.[L15082] However, resistance to ceftriaxone usually occurs through beta-lactamase hydrolysis, altered PBPs, or reduced bacterial cell permeability.[T324] Ceftriaxone should not be mixed with or giving in the same IV line as diluents/products containing calcium as they may cause ceftriaxone to precipitate.[L15082] Ceftriaxone use may also cause biliary sludge or gallbladder pseudolithiasis.[L15082,A215602] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Folligant hair serum spray 120 ml', 19287, 'فوليجانت سبراي سيروم للشعر 120 مل', '240', '219', 'Hair care', 'Hair care', NULL, 'Silicone oil+wheat germ oil+rosemary+jojoba+thyme+vitamin e', 'Hi-care > novex', 'Spray', 'بخاخ', '120 ml', '1', NULL, NULL, 'stimulates hair growth - rejuvenates hair & scalp. *indications : hair loss for men and women. damaged and brittle hair. split ended hair.', '769503325385', 1569, '2025-01-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rofa gel 30 gm', 26240, 'روفا جل 30جم', '32', NULL, NULL, NULL, NULL, 'Econazole+fucidic acid+tannic acid+triamcinolone', 'Amoun', 'Gel', 'جل', '30 gm', '1', NULL, NULL, 'about econazole synthetic imidazole derivative antifungal. mechanism of action of econazole econazole exerts its effects by altering cellular membrane and interfering with cellular enzymes.it is active against many fungi dermatophytes and yeasts as well a', '6221025010612', 435, '2022-12-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Baby gar 15 ml drops', 9591, 'بيبي جار نقط بالفم 15 مل', '89', '79', NULL, NULL, NULL, 'Agar agar extract', 'Company', 'Drops', 'نقط', '15 ml', '1', NULL, NULL, NULL, '6224002280077', 1143, '2025-07-26', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vildaglip 50 mg 30 tabs.', 29319, 'فيلداجليب 50مجم 30 قرص', '174', '96.75', 'Anti-diabetic.secretagogues.dpp-4 inhibitors', 'Anti-diabetic.secretagogues.dpp-4 inhibitors', NULL, 'Vildagliptin', 'El-obour modern pharm. ind. > sovalue pharma', 'Tab', 'أقراص', '50 mg', '3', NULL, NULL, NULL, NULL, 1225, '2025-08-15', NULL, 0, 'Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.[L32803] It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thiazolidinedione in adults patients with insufficient glycemic control despite maximal tolerated dose of monotherapy.[L32803] 



Vildagliptin is also marketed in a combination product with [metformin] for the treatment of adults with type II diabetes mellitus who inadequately respond to either monotherapy of vildagliptin or metformin. This fixed-dose formulation can be used in combination with a sulphonylurea or insulin (i.e., triple therapy) as an adjunct to diet and exercise in adults who do not achieve adequate glycemic control with monotherapy or dual therapy.[L32813]', 'Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are incretin hormones that regulate blood glucose levels and maintain glucose homeostasis. It is estimated that the activity of GLP-1 and GIP contribute more than 70% to the insulin response to an oral glucose challenge. They stimulate insulin secretion in a glucose-dependent manner via G-protein-coupled GIP and GLP-1 receptor signalling. In addition to their effects on insulin secretion, GLP-1 is also involved in promoting islet neogenesis and differentiation, as well as attenuating pancreatic beta-cell apoptosis. Incretin hormones also exert extra-pancreatic effects, such as lipogenesis and myocardial function.[A232523] In type II diabetes mellitus, GLP-1 secretion is impaired, and the insulinotropic effect of GIP is significantly diminished.[A232488]



Vildagliptin exerts its blood glucose-lowering effects by selectively inhibiting dipeptidyl peptidase-4 (DPP-4), an enzyme that rapidly truncates and inactivates GLP-1 and GIP upon their release from the intestinal cells. DPP-4 cleaves oligopeptides after the second amino acid from the N-terminal end. Inhibition of DPP-4 substantially prolongs the half-life of GLP-1 and GIP, increasing the levels of active circulating incretin hormones.[A232523] The duration of DPP-4 inhibition by vildagliptin is dose-dependent.[A232533] Vildagliptin reduces fasting and prandial glucose and HbA1c. It enhances the glucose sensitivity of alpha- and beta-cells and augments glucose-dependent insulin secretion. Fasting and postprandial glucose levels are decreased, and postprandial lipid and lipoprotein metabolism are also improved.[A232488,A232528]', 'Vildagliptin works to improve glycemic control in type II diabetes mellitus by enhancing the glucose sensitivity of beta-cells (β-cells) in pancreatic islets and promoting glucose-dependent insulin secretion. Increased GLP-1 levels leads to enhanced sensitivity of alpha cells to glucose, promoting glucagon secretion. Vildagliptin causes an increase in the insulin to glucagon ratio by increasing incretin hormone levels: this results in a decrease in fasting and postprandial hepatic glucose production. Vildagliptin does not affect gastric emptying. It also has no effects on insulin secretion or blood glucose levels in individuals with normal glycemic control.[L32803]



In clinical trials, treatment with vildagliptin 50-100 mg daily in patients with type 2 diabetes significantly improved markers of beta-cells, proinsulin to insulin ratio, and measures of beta-cell responsiveness from the frequently-sampled meal tolerance test. [L32803] Vildagliptin has improves glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) levels.[A232488]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Atrabesylate 50 mg i.v. inj. & inf. 5 amps.', 14575, 'اترابيسيلات 50مجم 5 امبولات', '240', '127.5', 'Skeletal muscle relaxant', 'Skeletal muscle relaxant', NULL, 'Atracurium besylate', 'Alexandria > egypharma-egypt', 'Inj', 'حقن', '50 mg', '5', NULL, NULL, NULL, '6224000870065', 1095, '2024-07-27', NULL, 0, 'For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.', 'Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.', 'Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Polyfresh 0.2% eye drops 20*0.4 ml sdu', 25037, 'بولي فريش 0.2% قطرة للعين 20*0.4مل', '50', NULL, 'Analgesic anti-inflammatory.eye surgery.tissue lubricant', 'Analgesic anti-inflammatory.eye surgery.tissue lubricant', NULL, 'Sodium hyaluronate', 'Orchidia pharmaceutical industries', 'Drops', 'نقط', '0.2%', '1', NULL, NULL, NULL, '6223005441270', 2701, '2023-01-09', NULL, 0, 'For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.', 'Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.', 'Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Crudo iron 30 ml syrup', 23952, 'كرودو ايرون شراب 30 مل', '60', NULL, 'Multivitamins', 'Multivitamins', NULL, 'Iron+vitamin a+vitamin e+vitamin d3+vitamin b(1&2&3&6&12)', 'Nutramed', 'Syrup', 'شراب', '30 ml', '1', NULL, NULL, NULL, NULL, 901, '2024-08-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Agario 10 sachets', 11532, 'اجاريو 10 اكياس', '55', NULL, NULL, NULL, NULL, NULL, 'Tol egypt', 'Sachet', 'أكياس', NULL, '10', NULL, NULL, NULL, NULL, 692, '2023-01-14', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Zincomycin eye drops 10 ml', 29947, 'زنكومايسين قطرة للعين 10مل', '4', NULL, 'Antibiotic', 'Antibiotic', NULL, 'Gentamicin+zinc sulphate', 'Kahira', 'Drops', 'نقط', '10 ml', '1', NULL, NULL, 'about gentamicin aminoglycoside antibiotic. mechanism of action of gentamicin gentamicin exerts its bactericidal action against gram negative organisms & some of gram positive organisms by inhibiting bacterial protein synthesis. the process involves 1. pe', '6223000012246', 1016, '2022-12-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Glovitron 30 capsule', 17263, 'جلوفيترون 30 كبسولة', '99', NULL, 'Multivitamin', 'Multivitamin', NULL, 'Ferrous bisglycinate35mg+vitamin b12 1000mcg+vit c+vit b1+vit b3+vit b2+vit b6+folate 600mcg+copper', 'Medicina', 'Capsule', 'كبسولة', NULL, '3', NULL, NULL, NULL, NULL, 876, '2024-05-20', NULL, 0, 'Ferrous sulfate is used for the prevention and treatment of iron deficiency anemia in adults and children.[A190804,L2240,L11800]

', 'Iron is required to maintain optimal health, particularly for helping to form red blood cells (RBC) that carry oxygen around the body. A deficiency in iron indicates that the body cannot produce enough normal red blood cells.[A32514,L11800] Iron deficiency anemia occurs when body stores of iron decrease to very low levels, and the stored iron is insufficient to support normal red blood cell (RBC) production. Insufficient dietary iron, impaired iron absorption, bleeding, pregnancy, or loss of iron through the urine can lead to iron deficiency.[A32514,L11794]  Symptoms of iron deficiency anemia include fatigue, breathlessness, palpitations, dizziness, and headache.



Taking iron in supplement form, such as ferrous sulfate, allows for more rapid increases in iron levels when dietary supply and stores are not sufficient.[L2175] Iron is transported by the divalent metal transporter 1 (DMT1) across the endolysosomal membrane to enter the macrophage. It can then can be incorporated into ferritin and be stored in the macrophage or carried of the macrophage by ferroportin. This exported iron is  oxidized by the enzyme to ceruloplasmin to Fe3+, followed by sequestration by transferrin for transport in the serum to various sites, including the bone marrow for hemoglobin synthesis or into the liver.[A32524] Iron combines with porphyrin and globin chains to form hemoglobin, which is critical for oxygen delivery from the lungs to other tissues.[L2263]', 'Ferrous sulfate replenishes iron, an essential component in hemoglobin, myoglobin, and various enzymes. It replaces the iron that is usually found in hemoglobin and myoglobin. Iron participates in oxygen transport and storage, electron transport and energy metabolism, antioxidant and beneficial pro-oxidant functions, oxygen sensing, tissue proliferation and growth, as well as DNA replication and repair.[A32524,A32514]



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Descar gel 10 gm', 17387, 'ديسكار جل 10 جرام', '285', NULL, 'Scar therapy', 'Scar therapy', NULL, 'Silicon', '> eva pharma', 'Gel', 'جل', '10 gm', '1', 'علاج للندبات.', NULL, NULL, NULL, 2128, '2023-02-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Do-spa 40mg/2ml 5 amp.', 3856, 'دوسبا 40مجم/2مل 5 امبولات', '9', NULL, 'Antispasmodic', 'Antispasmodic', NULL, 'Drotaverine', 'Alexandria', 'Amp', 'أمبول', '40mg', '5', NULL, NULL, 'about drotaverine drotaverine is an effective spasmolytic drug. mechanism of action of drotaverine drotaverine has spasmolytic and vasodilating action. it exerts its action by inhibiting phosphodiesterase enzyme iv. this will leads to a decrease in cyclic', '6223000175941', 1302, '2023-01-12', NULL, 0, 'Drotaverine is used to alleviate gastrointestinal and genitourinary smooth muscle spasms, such as cholecystitis and gallbladder disorders.[L22689]', 'Drotaverine is a selective inhibitor of phosphodiesterase 4 (PDE4), which is an enzyme responsible for the degradation of cyclic adenosine monophosphate (cAMP). Inhibition of PDE4 leads to elevated levels of cAMP, leading to smooth muscle relaxation. Recent research showed that low levels of cAMP have been associated with brain tumorigenesis, leading to the investigation of PDE4 inhibitors as potential anticancer agents.[A231619]', 'Drotaverine is an e spasmolytic agent with a relaxing effect on smooth muscles. It works to relieve visceral spasms and improve cervical dilation. _In vitro_, drotaverine mediated cytostatic effects on several human tumor cell lines and nonmalignant mouse fibroblasts.[A231619] Drotaverine may have minor allosteric calcium channel blocking properties: _in vitro_, drotaverine behaves like voltage-dependent L-type calcium channel blockers.[A231624]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Wash mix mouth spray 60ml', 29617, 'ووش مكس سبراي للفم 60مل', '25', NULL, 'Oral care', 'Oral care', NULL, 'Cocamido propyl betaine+chlorhexidine gluconate+ethanol+sodium benzoate+clove oil+chamomile+menthol+', 'Egyptian company for cosmetics > pharmix', 'Spray', 'بخاخ', '60ml', '1', NULL, NULL, NULL, NULL, 683, '2022-07-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Heroinera facial cleanser gel 200 g', 8009, 'هيروينيرا جل منظف للوجه 200 جم', '235', NULL, 'Facial cleanser for acne prone skin', 'Facial cleanser for acne prone skin', NULL, 'Centella asiatica+ceramide np+hyaluronic acid+allantoin+salicylic acid+glycolic acid+niacinamide+panthenol+liquorice extract+melaleuca alternifolia leaf oil(tea tree oil)+zinc pca+xanthan gum+rosmarinus officinalis leaf extract(rosemary extract)', 'Era egypt pharma', 'Gel', 'جل', NULL, '1', NULL, NULL, NULL, NULL, 736, '2025-11-17', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Limitless lactoferrin 100 mg 14 sachets', 19204, 'ليميتلس لاكتوفيرين 100 مجم 14 كيس', '245', '195', 'Iron supplement', 'Iron supplement', NULL, 'Lactoferrin', 'Eva pharma', 'Sachet', 'أكياس', '100 mg', '1', 'علاج الانيميا -- مصدر للحديد -- مصدر للطاقة', NULL, 'ï- supports a healthy immune system for all family.', '6223012481733', 1947, '2025-11-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Allergyna 120mg 10 f.c. tab.', 13792, 'اليرجينا 120 مجم 10 قرص', '15', NULL, 'Antihistamine.antiallergy', 'Antihistamine.antiallergy', NULL, 'Fexofenadine', 'Global napi pharmaceuticals > rexcel', 'Tab', 'أقراص', '120mg', '1', NULL, NULL, 'about fexofenadine second generation h1 antagonist antihistamine. mechanism of action of fexofenadine fexofenadine blocks one type of peripheral receptor for histamine (the h1 receptor) and thus prevents activation of h1 receptor-containing cells by hista', NULL, 803, '2022-07-24', NULL, 0, 'In the United States, fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months old.[L4269] In Canada, fexofenadine carries the same indications but is approved only for patients ≥12 years old.[L10779] Fexofenadine is also available in combination with [pseudoephedrine] for the symptomatic treatment of season allergic rhinitis in patients ≥12 years old.[L10800]', 'The H<sub>1</sub> histamine receptor is responsible for mediating hypersensitivity and allergic reactions. Exposure to an allergen results in degranulation of mast cells and basophils, which then release histamine and other inflammatory mediators. Histamine binds to, and activates, H<sub>1</sub> receptors, which results in the further release of pro-inflammatory cytokines, such as interleukins, from basophils and mast cells. These downstream effects of histamine binding are responsible for a wide variety of allergic symptoms, such as pruritus, rhinorrhea, and watery eyes.[A1495]



Fexofenadine is considered an “inverse agonist” of the H<sub>1</sub> receptor because it binds to and stabilizes the inactive form of the receptor, preventing its activation and subsequent downstream effects.[A1495] It has a potent and selective affinity for H<sub>1</sub> receptors, and there is no evidence that it carries antidopaminergic, antiserotonergic, anticholinergic, sedative, or adrenergic blocking activity.[L10779] Fexofenadine does not cross the blood-brain barrier and thus is unlikely to cause significant CNS effects.[L10779]', 'Fexofenadine relieves allergy symptoms by antagonizing the actions of histamine, an endogenous compound predominantly responsible for allergic symptomatology.[L4269] The relatively long duration of action of fexofenadine (approximately 24 hours)[A1495] allows for once or twice daily dosing, and its rapid absorption allows for an onset of action within 1-3 hours. Fexofenadine should not be taken with fruit juice, as this may impair its absorption.[L4269]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tinifloxacin 20 tab.', 33768, 'تينيفلوكساسين 20 قرص', '152', '103.5', 'Quinolone antibiotic with antiprotozoal', 'Quinolone antibiotic with antiprotozoal', NULL, 'Ciprofloxacin+tinidazole', 'Organo', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, '6224000908232', 1602, '2024-07-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Semahemo tab 20 tablets', 33613, 'سيماهيمو 20 قرص', '90', '78', 'Multivitamin', 'Multivitamin', NULL, 'Iron+vit c+vit b6+vit b12+folic acid', 'Semaf pharma', 'Tablet', 'أقراص', NULL, '2', NULL, NULL, NULL, NULL, 1508, '2024-09-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Erastapex trio 5/20/12.5mg 30 f.c. tab', 4335, 'ايراستابكس تريو 5/20/12.5مجم 30 قرص', '114', '87', 'Antihypertensive', 'Antihypertensive', NULL, 'Olmesratan+amlodipine+hydrochlorothiazide', 'Multi-apex', 'Tab', 'أقراص', '12.5mg', '3', 'علاج ضغط الدم المرتفع', NULL, NULL, '6223003205546', 16368, '2024-10-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Noodril 250mg 10 tab.', 23693, 'نودريل 250مجم 10 اقراص', '4', NULL, 'Cerebral circulatory inhancer', 'Cerebral circulatory inhancer', NULL, 'Meclofenoxate', 'Alfacure pharmaceuticals', 'Tab', 'أقراص', '250mg', '1', 'يعمل على زيادة تدفق الدم للمخ', NULL, 'one of the most used nootropics. the only drug reported to cause lipofuscin regression. has a unique mechanism of action used in cases of cerebral insufficiency dementia stroke and cerebral aging. indications: 1- manifestations of cerebral insufficiency ï', NULL, 2076, '2022-05-19', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hair act 5% topical soln. 60 ml', 20186, 'هير اكت 5% محلول 60 مل', '61', '45', 'Hair regrowth.vasodilator agents', 'Hair regrowth.vasodilator agents', NULL, 'Minoxidil', 'Egpi > rector pharma', 'Sol', 'محلول', '5%', '1', NULL, NULL, 'about minoxidil a potassium channel agonist direct-acting vasodilator hair- growth stimulant in androgenic alopecia. mechanism of action of minoxidil minoxidil works by activating pghs 1 (prostaglandin endoperoxide synthase-1) which helps promote hair gro', NULL, 945, '2024-12-13', NULL, 0, 'For the treatment of severe hypertension and in the topical treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia.', 'Minoxidil is thought to promote the survival of human dermal papillary cells (DPCs) or hair cells by activating both extracellular signal-regulated kinase (ERK) and Akt and by preventing cell death by increasing the ratio of BCl<sup>-</sup>2/Bax. Minoxidil may stimulate the growth of human hairs by prolonging anagen through these proliferative and anti-apoptotic effects on DPCs. Minoxidil, when used as a vasodilator, acts by opening adenosine triphosphate-sensitive potassium channels in vascular smooth muscle cells. This vasodilation may also improve the viability of hair cells or hair follicles.', 'Minoxidil is an orally effective direct acting peripheral vasodilator that reduces elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance. Minoxidil is also used topically to treat androgenetic alopecia. Microcirculatory blood flow in animals is enhanced or maintained in all systemic vascular beds. In man, forearm and renal vascular resistance decline; forearm blood flow increases while renal blood flow and glomerular filtration rate are preserved. The predominant site of minoxidil action is arterial. Venodilation does not occur with minoxidil; thus, postural hypotension is unusual with its administration. The antihypertensive activity of minoxidil is due to its sulphate metabolite, minoxidil sulfate.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Thyroxine 100mcg 100 tab.', 11401, 'ثيروكسين 100مكجم 100 قرص', '58', '42', 'Thyroid hormone', 'Thyroid hormone', NULL, 'Levothyroxine', 'T3a pharma', 'Tab', 'أقراص', '100mcg', '1', 'يستخدم كعلاج بديل في قصور الغدة الدرقية الأولي (الغدة الدرقية) والثانوي (الغدة النخامية) والثالث (الوطاء) الخلقي أو المكتسب.', NULL, 'indication for use alone or in combination with antithyroid agents to treat hypothyroidism goiter chronic lymphocytic thyroiditis myxedema coma and stupor. mechanism of action levothyroxine acts like the endogenous thyroid hormone thyroxine (t4 a tetra-io', '6221508522816', 16168, '2024-07-25', NULL, 0, 'Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.', 'Levothyroxine is a synthetically prepared levo-isomer of the thyroid hormone thyroxine (T<sub>4</sub>, a tetra-iodinated tyrosine derivative) that acts as a replacement in deficiency syndromes such as hypothyroidism. T<sub>4</sub> is the major hormone secreted from the thyroid gland and is chemically identical to the naturally secreted T<sub>4</sub>: it increases metabolic rate, decreases thyroid-stimulating hormone (TSH) production from the anterior lobe of the pituitary gland, and, in peripheral tissues, is converted to T<sub>3</sub>. Thyroxine is released from its precursor protein thyroglobulin through proteolysis and secreted into the blood where is it then peripherally deiodinated to form triiodothyronine (T<sub>3</sub>) which exerts a broad spectrum of stimulatory effects on cell metabolism. T<sub>4</sub> and T<sub>3</sub> have a relative potency of ~1:4. 



Thyroid hormone increases the metabolic rate of cells of all tissues in the body. In the fetus and newborn, thyroid hormone is important for the growth and development of all tissues including bones and the brain. In adults, thyroid hormone helps to maintain brain function, food metabolism, and body temperature, among other effects. The symptoms of thyroid deficiency relieved by levothyroxine include slow speech, lack of energy, weight gain, hair loss, dry thick skin and unusual sensitivity to cold.



The thyroid hormones have been shown to exert both genomic and non-genomic effects.[A179950] They exert their genomic effects by diffusing into the cell nucleus and binding to thyroid hormone receptors in DNA regions called thyroid hormone response elements (TREs) near genes.[A179605] This complex of T<sub>4</sub>, T<sub>3</sub>, DNA, and other coregulatory proteins causes a conformational change and a resulting shift in transcriptional regulation of nearby genes, synthesis of messenger RNA, and cytoplasmic protein production.[A179605,A179935] For example, in cardiac tissues T<sub>3</sub> has been shown to regulate the genes for α- and β-myosin heavy chains, production of the sarcoplasmic reticulum proteins calcium-activated ATPase (Ca2+-ATPase) and phospholamban, β-adrenergic receptors, guanine-nucleotide regulatory proteins, and adenylyl cyclase types V and VI as well as several plasma-membrane ion transporters, such as Na+/K+–ATPase, Na+/Ca2+ exchanger, and voltage-gated potassium channels, including Kv1.5, Kv4.2, and Kv4.3. [A179938] As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status.



The non-genomic actions of the thyroid hormones have been shown to occur through binding to a plasma membrane receptor integrin aVb3 at the Arg-Gly-Asp recognition site.[A179959] From the cell-surface, T<sub>4</sub> binding to integrin results in down-stream effects including activation of mitogen-activated protein kinase (MAPK; ERK1/2) and causes subsequent effects on cellular/nuclear events including angiogenesis and tumor cell proliferation.[A179935, A179956]', 'Oral levothyroxine is a synthetic hormone that exerts the same physiologic effect as endogenous T<sub>4</sub>, thereby maintaining normal T<sub>4</sub> levels when a deficiency is present. 



Levothyroxine has a narrow therapeutic index and is titrated to maintain a euthyroid state with TSH (thyroid stimulating hormone) within a therapeutic range of 0.4–4.0 mIU/L.[A35722] Over- or under-treatment with levothyroxine may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, gastrointestinal function and glucose and lipid metabolism. The dose of levothyroxine should be titrated slowly and carefully and patients should be monitored for their response to titration to avoid these effects. TSH levels should be monitored at least yearly to avoid over-treating with levothyroxine which can result in hyperthyroidism (TSH <0.1mIU/L) and symptoms of increased heart rate, diarrhea, tremor, hypercalcemia, and weakness to name a few.[F4636]



As many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status,[A179938] over-treatment with levothyroxine may result in increases in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. In populations with any cardiac concerns, levothyroxine should be initiated at lower doses than those recommended in younger individuals or in patients without cardiac disease. Patients receiving concomitant levothyroxine and sympathomimetic agents should be monitored for signs and symptoms of coronary insufficiency. If cardiac symptoms develop or worsen, reduce the levothyroxine dose or withhold for one week and restart at a lower dose.[F4636]



Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase and suppressed serum parathyroid hormone levels. Administer the minimum dose of levothyroxine that achieves the desired clinical and biochemical response to mitigate this risk.



Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing or discontinuing levothyroxine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vegaskine compound 5 rectal supp.', 12142, 'فيجاسكين مركب لبوس 5 اقماع للكبار', '28', '6.75', 'Analgesic', 'Analgesic', NULL, 'Acetylsalicylic acid+caffeine+codeine+paracetamol(acetaminophen)+phenobarbitone', 'Alexandria', 'Supp', 'لبوس', NULL, '1', 'علاج ارتفاع درجات الحرارة -- علاج آلام الاسنان -- علاج الحمي والصداع', NULL, 'acetylsalicylic acid indication for use in the temporary relief of various forms of pain inflammation associated with various conditions (including rheumatoid arthritis juvenile rheumatoid arthritis systemic lupus erythematosus osteoarthritis and ankylosi', '6223000173046', 1681, '2024-11-21', NULL, 0, '**Pain, fever, and inflammation**



Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures [FDA label]. 



The _extra strength_ formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound)[FDA label].



**Other indications**



ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include: 



Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) [FDA label]. 



Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction [FDA label].



For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) [FDA label].



For the prevention of thromboembolism after hip replacement surgery [FDA label]. 



For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) [FDA label].



Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site [FDA Label]. 



**Important note regarding use of the extended-release formulation [F4405]**



In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action [Label, F4405]. The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA [F4405].





 ', 'Acetylsalicylic acid (ASA) blocks prostaglandin synthesis. It is non-selective for COX-1 and COX-2 enzymes [A177241, A10989, A32682]. Inhibition of COX-1 results in the inhibition of platelet aggregation for about 7-10 days (average platelet lifespan). The acetyl group of acetylsalicylic acid binds with a serine residue of the cyclooxygenase-1 (COX-1) enzyme, leading to irreversible inhibition. This prevents the production of pain-causing prostaglandins. This process also stops the conversion of arachidonic acid to thromboxane A2 (TXA2), which is a potent inducer of platelet aggregation [FDA label].  Platelet aggregation can result in clots and harmful venous and arterial thromboembolism, leading to conditions such as pulmonary embolism and stroke. 



It is important to note that there is 60% homology between the protein structures of COX-1 and COX-2. ASA binds to serine 516 residue on the active site of COX-2 in the same fashion as its binding to the serine 530 residue located on the active site of COX-1. The active site of COX-2 is, however, slightly larger than the active site of COX-1, so that arachidonic acid (which later becomes prostaglandins) manages to bypass the aspirin molecule inactivating COX-2 [A32682, A177256].  ASA, therefore, exerts more action on the COX-1 receptor rather than on the COX-2 receptor [A177268]. A higher dose of acetylsalicylic acid is required for COX-2 inhibition [A177325]. ', '**Effects on pain and fever**



Acetylsalicylic acid disrupts the production of prostaglandins throughout the body by targeting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) [A177241, A10989, A32682]. Prostaglandins are potent, irritating substances that have been shown to cause headaches and pain upon injection into humans.  Prostaglandins increase the sensitivity of pain receptors and substances such as histamine and bradykinin. Through the disruption of the production and prevention of release of prostaglandins in inflammation, this drug may stop their action at pain receptors, preventing symptoms of pain. Acetylsalicylic acid is considered an antipyretic agent because of its ability to interfere with the production of brain prostaglandin E1. Prostaglandin E1 is known to be an extremely powerful fever-inducing agent [FDA label]. 



**Effects on platelet aggregation**



The inhibition of platelet aggregation by ASA occurs because of its interference with thromboxane A2 in platelets, caused by COX-1 inhibition. Thromboxane A2 is an important lipid responsible for platelet aggregation, which can lead to clot formation and future risk of heart attack or stroke  [FDA label]. 



**A note on cancer prevention**



ASA has been studied in recent years to determine its effect on the prevention of various malignancies [A177325]. In general, acetylsalicylic acid is involved in the interference of various cancer signaling pathways, sometimes inducing or upregulating tumor suppressor genes [A177325, A177403]. Results of various studies suggest that there are beneficial effects of long-term ASA use in the prevention of several types of cancer, including stomach, colorectal, pancreatic, and liver cancers [A177400].   Research is ongoing.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Scandonest 2% special 50 carpule 1.8ml', 26587, 'سكاندونيست 2% سبيشيال 50 كاربولة 1.8 مل', '392', NULL, 'Dental anaesthetic', 'Dental anaesthetic', NULL, 'Adrenaline+mepivacaine', 'Acrostone for manuf. and import', 'Unknown', 'غير محدد', '2%', '1', NULL, NULL, NULL, NULL, 677, '2022-08-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Diamofer 30 caps', 1584, 'دياموفير 30 كبسولة', '120', NULL, 'Dietery supplement', 'Dietery supplement', NULL, 'Iron+follic acid+zinc+copper+vit b12+vit b6', 'Noval', 'Cap', 'كبسولة', NULL, '3', NULL, NULL, NULL, NULL, 961, '2022-07-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sudocrem cream 60 gm', 27601, 'سودوكريم كريم 60 جم', '120', NULL, 'Soothing topical', 'Soothing topical', NULL, 'Zinc oxide+benzyl alcohol+benzyl benzoate+benzyl cinnamate+lanolin', 'Forest tosara ltd. > unitrade-egypt', 'Cream', 'كريم', '60 gm', '1', NULL, NULL, 'soothing antiseptic cream for napkin rash sunburn and suitable for acne prone skin', '5017007601333', 999, '2022-12-09', NULL, 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sodium bicarbonate 5% (mottahedoon) i.v. inf. 500 ml', 27130, 'صوديوم بيكربونات 5% المتحدون محلول وريدي 500 مل', '28', '13.5', 'Alkalinizer', 'Alkalinizer', NULL, 'Sodium bicarbonate', 'Al mottahedoon pharma', 'Unknown', 'غير محدد', '5%', '1', NULL, NULL, NULL, NULL, 851, '2024-11-17', NULL, 0, 'Sodium bicarbonate is used for the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturateprotein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.', 'Sodium bicarbonate is a systemic alkalizer, which increases plasma bicarbonate, buffers excess hydrogen ion concentration, and raises blood pH, thereby reversing the clinical manifestations of acidosis. It is also a urinary alkalizer, increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. Sodium bicarbonate acts as an antacid and reacts chemically to neutralize or buffer existing quantities of stomach acid but has no direct effect on its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms. [PharmGKB]', 'Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ecrinal anp after shampoo conditioning balm 150ml', 18044, 'اكرينال ايه ان بي بلسم ترطيب بعد الشامبو 150 مل', '459', NULL, 'Hair care', 'Hair care', NULL, NULL, 'Asepta laboratoires > biotech egypt', 'Amp', 'أمبول', '150ml', '1', NULL, NULL, 'proprietes this balm is particularly recommended for dry damaged hair with a tendency to tangle easily. anpï¿½ and d panthenol in this shampoo have a stimulating and regenerating effect on hair roots which need to be strengthened and fortified. it can be', NULL, 813, '2022-08-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Unitrexate 1 gm sol. for i.m. i.v. inj. i.v. inf.(n/a yet)', 28776, 'يونيتركسات 1جم محلول وريد/عضل', '195', NULL, 'Antineoplastic', 'Antineoplastic', NULL, 'Methotrexate', 'Hikma specialized pharmaceuticals', 'Inj', 'حقن', '1 gm', '1', NULL, NULL, 'about methotrexate antimetabolite antifolate immunosuppressant antineoplastic antirheumatic. mechanism of action of methotrexate drug inhibits the enzyme dihydrofolate reductase (dhfr) which catalyses the conversion of dihydrofolate to active tetrahydrofo', NULL, 915, '2022-07-19', NULL, 0, 'Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis.[L7144] Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.[L7147,L7150,L10457] It has also been approved by the EMA for the treatment of adult patients requiring systemic therapy for moderate-to-severe plaque psoriasis.[L48796]



Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin''s lymphoma.[L7180] It is also used in the maintenance of acute lymphocytic leukemia.[L7180] Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.[L7180]', 'Methotrexate enters tissues and is converted to a methotrexate polyglutamate by folylpolyglutamate.[A180322]



Methotrexate''s mechanism of action is due to its inhibition of enzymes responsible for nucleotide synthesis including  dihydrofolate reductase, thymidylate synthase, aminoimidazole caboxamide ribonucleotide transformylase (AICART), and amido phosphoribosyltransferase.[A180322] Inhibtion of nucleotide synthesis prevents cell division.



In rheumatoid arthritis, methotrexate polyglutamates inhibit AICART more than methotrexate.[A180322] This inhibition leads to accumulation of AICART ribonucleotide, which inhibits adenosine deaminase, leading to an accumulation of adenosine triphosphate and adenosine in the extracellular space, stimulating adenosine receptors, leading to anti-inflammatory action.[A180322]', 'Methotrexate inhibits enzymes responsible for nucleotide synthesis which prevents cell division and leads to anti-inflammatory actions.[A180322] It has a long duration of action and is generally given to patients once weekly.[A180322,L7144,L7147,L7150] Methotrexate has a narrow therapeutic index.[A180325]



Do not take methotrexate daily.[L7147,L7150]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Plaquenil 200mg 60 f.c.tab.', 24986, 'بلاكونيل 200مجم 60 قرص', '246', '120', 'Antiprotozoal.antimalarial.antirheumatic', 'Antiprotozoal.antimalarial.antirheumatic', NULL, 'Hydroxychloroquine sulphate', 'Sanofi', 'Tab', 'أقراص', '200mg', '6', NULL, NULL, NULL, '6223003991050', 12757, '2024-02-12', NULL, 0, 'Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by _P. falciparum_, _P. malariae_, _P. ovale_, or _P. vivax_), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.[L8072]', 'The exact mechanisms of hydroxychloroquine are unknown. It has been shown that hydroxychloroquine accumulates in the lysosomes of the malaria parasite, raising the pH of the vacuole.[A183074] This activity interferes with the parasite''s ability to proteolyse hemoglobin, preventing the normal growth and replication of the parasite.[A183074] Hydroxychloroquine can also interfere with the action of parasitic heme polymerase, an enzyme that uses ferriprotoporphyrin IX (FP) released from hemoglobin as a substrate to form beta-hematin. By reducing the activity of heme polymerase without inhibiting the release of FP, hydroxychloroquine leads to the accumulation of FP in a toxic form.[A183080]



Hydroxychloroquine accumulation in human organelles also raise their pH, which inhibits antigen processing, prevents the alpha and beta chains of the major histocompatibility complex (MHC) class II from dimerizing, inhibits antigen presentation of the cell, and reduces the inflammatory response.[A183074] Elevated pH in the vesicles may alter the recycling of MHC complexes so that only the high affinity complexes are presented on the cell surface.[A183074] Self peptides bind to MHC complexes with low affinity and so they will be less likely to be presented to autoimmune T cells.[A183074] Hydroxychloroquine also reduces the release of cytokines like interleukin-1 and tumor necrosis factor, possibly through inhibition of Toll-like receptors.[A183074,A198852]



The raised pH in endosomes, prevent virus particles (such as SARS-CoV and SARS-CoV-2) from utilizing their activity for fusion and entry into the cell.[A191625]



Hydroxychloroquine inhibits terminal glycosylation of ACE2, the receptor that SARS-CoV and SARS-CoV-2 target for cell entry.[A191628,A191625] ACE2 that is not in the glycosylated state may less efficiently interact with the SARS-CoV-2 spike protein, further inhibiting viral entry.[A191625]', 'Hydroxychloroquine affects the function of lysosomes in humans as well as plasmodia.[A183074] Altering the pH of the lysosomes reduces low-affinity self-antigen presentation in autoimmune diseases and interferes with the ability of plasmodia to proteolyze hemoglobin for their energy requirements.[A183074] Hydroxychloroquine has a long duration of action as it may be taken on a weekly basis for some indications.[L8072] Hydroxychloroquine may lead to severe hypoglycemia and so diabetic patients are advised to monitor their blood glucose levels.[L8072] 



Hydroxychloroquine is active against the erythrocytic forms of chloroquine-sensitive strains of P. falciparum, P. malariae, P. vivax, and P. ovale. Hydroxychloroquine is not active against the gametocytes and exoerythrocytic forms including the hypnozoite liver stage forms of P. vivax and P. ovale.[L47576] Hydroxychloroquine is not effective against malaria in areas where chloroquine resistance has been reported.[L8072]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sabfrinate 2.5 mg 2 f.c. tabs.', 26429, 'سابفرينيت 2.5مجم 2 قرص', '14', NULL, NULL, NULL, NULL, 'Frovatriptan', 'Sab trading', 'Tab', 'أقراص', '2.5 mg', '1', NULL, NULL, NULL, NULL, 491, '2022-08-05', NULL, 0, 'For the acute treatment of migraine attacks with or without aura in adults.', 'Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT<sub>1D</sub> receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT<sub>1B/1D</sub> receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT<sub>1B</sub> receptor agonism.', 'Frovatriptan is a second generation triptan 5-HT receptor agonist that binds with high affinity for 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors. It is structurally distinct from, but pharmacologically related to other selective 5-HT<sub>1B/1D</sub> receptor agonists. Frovatriptan has no significant effects on GABA<sub>A</sub> mediated channel activity and has no significant affinity for benzodiazepine binding sites. Frovatriptan is believed to act on extracerebral, intracranial arteries and to inhibit excessive dilation of these vessels in migraine. Research has shown that migraine can be caused by the swelling of blood vessels around the brain. Frovatriptan eases the pain associated with migraine by narrowing these blood vessels. Frovatriptan has one of the highest affinities for the 5-HT<sub>1B</sub> of the second-generation triptan agonists.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Neuroglopentin 100 mg 30 caps.', 8755, 'نيوروجلوبنتين 100مجم 30 كبسولة', '54', '36', 'Anti-epileptic.gaba analogs', 'Anti-epileptic.gaba analogs', NULL, 'Gabapentin', 'Global napi pharmaceuticals', 'Cap', 'كبسولة', '100 mg', '3', 'علاج للصرع', NULL, 'about gabapentin a gaba analogue anticonvulsant mood stabilizer. mechanism of action of gabapentin gabapentin is a gaba derivative and it bounds to lipophilic molecule. the mechanism of action of gabapentin is not exactly known. it crosses blood brain bar', '6223002145690', 4825, '2024-07-04', NULL, 0, 'In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older.[L8717] In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalization, in patients 6 years of age and older and as monotherapy in patients 12 years of age and older. It is also used in adults for the treatment of various types of peripheral neuropathic pain, such as painful diabetic neuropathy.[L8732]', 'The precise mechanism through which gabapentin exerts its therapeutic effects is unclear.[L8717,L8720] The primary mode of action appears to be at the auxillary α2δ-1 subunit of voltage-gated calcium channels (though a low affinity for the α2δ-2 subunit has also been reported).[A186179,A14097,A186277] The major function of these subunits is to facilitate the movement of pore-forming α1 subunits of calcium channels from the endoplasmic reticulum to the cell membrane of pre-synaptic neurons.[A186179] There is evidence that chronic pain states can cause an increase in the expression of α2δ subunits and that these changes correlate with hyperalgesia.[A14097] Gabapentin appears to inhibit the action of α2δ-1 subunits, thus decreasing the density of pre-synaptic voltage-gated calcium channels and subsequent release of excitatory neurotransmitters.[A186179] It is likely that this inhibition is also responsible for the anti-epileptic action of gabapentin.[A186277]



There is some evidence that gabapentin also acts on adenosine receptors[A11009, A186209] and voltage-gated potassium channels,[A186212] though the clinical relevance of its action at these sites is unclear.', 'Gabapentin is an anti-convulsant medication that inhibits the release of excitatory neurotransmitters, allowing for its use against pathologic neurotransmission such as that seen in neuropathic pain and seizure disorders.[L8717,L8732] It has a wide therapeutic index, with doses in excess of 8000 mg/kg failing to cause a fatal reaction in rats.[L8765]



Gabapentin is ineffective in absence seizures and should be used in caution in patients with mixed seizure disorders involving absence seizures. Gabapentin has been associated with drug reaction with eosinophilia and systemic symptoms (DRESS), otherwise known as multi-organ hypersensitivity. This reaction can prove fatal and early symptoms such as fever, lymphadenopathy, and rash should be promptly investigated.[L8717,L8720,L8732]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ampicillin-nile 500mg vial', 14052, 'امبيسلين-النيل 500 مجم فيال', '8', NULL, 'Penicillins.monocomponent', 'Penicillins.monocomponent', NULL, 'Ampicillin', 'El nile.', 'Amp', 'أمبول', '500mg', '1', NULL, NULL, 'description : ssemi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic .ssindication :sfor treatment of infection (respiratory gi uti and meningitis) due to e. coli p. mirabilis enterococci shigella s. typhosa', NULL, 878, '2022-07-21', NULL, 0, 'For treatment of infection (Respiratory, GI, UTI and meningitis) due to E. coli, P. mirabilis, enterococci, Shigella, S. typhosa and other Salmonella, nonpenicillinase-producing N. gononhoeae, H. influenzae, staphylococci, streptococci including streptoc', 'By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Ampicillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Ampicillin interferes with an autolysin inhibitor.', 'Ampicillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Ampicillin has <i>in vitro</i> activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Ampicillin results from the inhibition of cell wall synthesis and is mediated through Ampicillin binding to penicillin binding proteins (PBPs). Ampicillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Indamide 2.5mg 30 tab.', 6442, 'انداميد 2.5 جم 30 قرص', '24', NULL, 'Antihypertensive.diuretic', 'Antihypertensive.diuretic', NULL, 'Indapamide', 'Alexandria', 'Tab', 'أقراص', '2.5mg', '3', 'علاج إرتفاع ضغط الدم', NULL, NULL, '6223000174111', 2373, '2022-05-22', NULL, 0, 'Indapamide is a diuretic indicated for use as monotherapy or in combination with other blood pressure-lowering agents to treat hypertension.[L13982] It may also be used to treat fluid and salt retention associated with congestive heart failure.[L13982]

', 'Indapamide acts on the nephron, specifically at the proximal segment of the distal convoluted tubule where it inhibits the Na+/Cl- cotransporter, leading to reduced sodium reabsorption.[A203519,A16729] As a result, sodium and water are retained in the lumen of the nephron for urinary excretion.[A185180] The effects that follow include reduced plasma volume, reduced venous return, lower cardiac output, and ultimately decreased blood pressure.[A16729]



Interestingly, it is likely that thiazide-like diuretics such as indapamide have additional blood pressure lowering mechanisms that are unrelated to diuresis.[A16729] This is exemplified by the observation that the antihypertensive effects of thiazides are sustained 4-6 weeks after initiation of therapy, despite recovering plasma and extracellular fluid volumes.[A16729] 



Some studies have suggested that indapamide may decrease responsiveness to pressor agents while others have suggested it can decrease peripheral resistance.[A203627] Although it is clear that diuresis contributes to the antihypertensive effects of indapamide, further studies are needed to investigate the medication’s ability to decrease peripheral vascular resistance and relax vascular smooth muscle.[A203627]', 'Classified as a sulfonamide diuretic, indapamide is an effective antihypertensive agent and by extension, has shown efficacy in the prevention of target organ damage.[A203627,A203660]

Administration of indapamide produces water and electrolyte loss, with higher doses associated with increased diuresis.[A203627,A204068] Severe and clinically significant electrolyte disturbances may occur with indapamide use - for example, hypokalemia resulting from renal potassium loss may lead to QTc prolongation.[A203627,A204062] Further electrolyte imbalances may occur due to renal excretion of sodium, chloride, and magnesium.[A203627,A204062,A204068] 



Other indapamide induced changes include increases in plasma renin and aldosterone, and reduced calcium excretion in the urine.[A203627,A204074,A204131] In many studies investigating the effects of indapamide in both non-diabetic and diabetic hypertensive patients, glucose tolerance was not significantly altered.[A203627] However, additional studies are necessary to assess the long term metabolic impacts of indapamide, since thiazide related impaired glucose tolerance can take several years to develop in non-diabetic patients.[A203627]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Erricovan 20 tab', 30486, 'ايري كوفان 20 قرص', '79', '59', 'Iron', 'Iron', NULL, 'Ferrous bisglycinate 320 mg (60 mg elemental iron )+b12 =100 microgram+zinc+vit c+dedorized garlic', 'Brand nutrition > force pharma', 'Tab', 'أقراص', NULL, '2', 'مكمل غذائى غنى بالحديد ومضادات الاكسدة لعلاج حالات فقر الدم وتحسين الجهاز المناعى', NULL, 'iron supplement', NULL, 1488, '2025-08-13', NULL, 0, 'Ferrous sulfate is used for the prevention and treatment of iron deficiency anemia in adults and children.[A190804,L2240,L11800]

', 'Iron is required to maintain optimal health, particularly for helping to form red blood cells (RBC) that carry oxygen around the body. A deficiency in iron indicates that the body cannot produce enough normal red blood cells.[A32514,L11800] Iron deficiency anemia occurs when body stores of iron decrease to very low levels, and the stored iron is insufficient to support normal red blood cell (RBC) production. Insufficient dietary iron, impaired iron absorption, bleeding, pregnancy, or loss of iron through the urine can lead to iron deficiency.[A32514,L11794]  Symptoms of iron deficiency anemia include fatigue, breathlessness, palpitations, dizziness, and headache.



Taking iron in supplement form, such as ferrous sulfate, allows for more rapid increases in iron levels when dietary supply and stores are not sufficient.[L2175] Iron is transported by the divalent metal transporter 1 (DMT1) across the endolysosomal membrane to enter the macrophage. It can then can be incorporated into ferritin and be stored in the macrophage or carried of the macrophage by ferroportin. This exported iron is  oxidized by the enzyme to ceruloplasmin to Fe3+, followed by sequestration by transferrin for transport in the serum to various sites, including the bone marrow for hemoglobin synthesis or into the liver.[A32524] Iron combines with porphyrin and globin chains to form hemoglobin, which is critical for oxygen delivery from the lungs to other tissues.[L2263]', 'Ferrous sulfate replenishes iron, an essential component in hemoglobin, myoglobin, and various enzymes. It replaces the iron that is usually found in hemoglobin and myoglobin. Iron participates in oxygen transport and storage, electron transport and energy metabolism, antioxidant and beneficial pro-oxidant functions, oxygen sensing, tissue proliferation and growth, as well as DNA replication and repair.[A32524,A32514]



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tadamance 20 mg 4 f.c.tabs.', 32072, 'تادامانس 20مجم اقراص', '100', NULL, 'Tonic for men', 'Tonic for men', NULL, 'Tadalafil', 'Hp pharma', 'Tab', 'أقراص', '20 mg', '1', 'مقوى للرجال', NULL, NULL, '6224011394109', 6393, '2023-05-04', NULL, 0, 'Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with [finasteride] for the treatment of benign prostatic hypertrophy (BPH).[L39095,L39439] It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with [macitentan] or other endothelin-1 antagonists.[L39100,L39105,L50622]', 'Tadalafil is a selective phosphodiesterase-5 (PDE5) inhibitor that produces several downstream effects with the most common therapeutic effect being smooth muscle relaxation. [L39095] Patients may experience ED due to a variety of causes including psychogenic, neurogenic, vasculogenic, iatrogenic, or endocrine. [A242392] These causes result in dysfunction of penile smooth muscle relaxation through either disrupted neuronal signaling or direct influence on smooth muscle cells. During sexual arousal, non-adrenergic non-cholinergic (NANC) neurons release nitric oxide (NO). Nitric oxide stimulates guanylate cyclase which converts guanosine triphosphate to cyclic guanosine monophosphate (cGMP).[A242287, A242377] cGMP activates the cGMP-dependent kinase (PKG) in a signal cascade which activates K+ channels leading to inhibition of Ca2+ channels, inhibits platelet activation, and inhibits smooth muscle cell proliferation while inducing apoptosis. This signal cascade is attenuated by PDE5 which breaks the phosphodiester bond of cGMP, converting it to GMP. Inhibition of PDE5 by tadalafil increases signaling via the PKG cascade which supports penile smooth muscle relaxation during sexual arousal by decreasing Ca2+ entry into smooth muscle cells. This smooth muscle relaxation allows blood to fill the corpus cavernosum thereby producing an erection.



In PAH, blood pressure in the pulmonary arteries is raised due to a variety of mechanisms stemming from endothelial dysfunction.[A242377] Decreased production of NO and prostacyclin reduce vasodilatory signaling while overproduction of endothelin-1 and thromboxane increase vasoconstriction. Inflammation, thromboses, and hypoxia later contribute to vascular remodeling which further reduces luminal size. The resultant increase in blood pressure reduces the capacity for gas exchange and increases afterload at the right ventricle, producing symptoms of dyspnea, fatigue, and dizziness as well as leading to right-sided heart failure. Tadalafil exerts its therapeutic effect in PAH through boosting NO-cGMP signaling to contribute to smooth muscle relaxation as with ED.



Lastly, tadalafil is used to treat BPH.[L39095] BPH produces urinary dysfunction through hyperproliferation of the epithelial and smooth muscle layers of the prostate.[A242382] The increased size of the prostate blocks urine flow through the urethra resulting in higher residual volumes due to incomplete emptying. Tadalafil does not appear to exert its benefit via smooth muscle relaxation of the prostate. It may instead exert its effect through a mix of increased oxygenation and decreased inflammation, which decreases tissue remodeling, and inhibition of cell proliferation through the cGMP cascade.



The decreased affinity for PDE6 compared to other PDE5 inhibitors may explain the decreased incidence of visual side effects as PDE6 is present in the eye and contributes to color vision.[L39100, L39105, A242287]', 'Tadalafil exerts a therapeutic effect in ED by increasing sexual stimulation-dependant smooth muscle relaxation in the penis, allowing the corpus cavernosum to fill with blood to produce an erection.[A242287, A242377] Smooth muscle relaxation in the pulmonary vasculature helps to produce vasodilation in PAH which reduces blood pressure in the pulmonary arteries.[A242377] In BPH, tadalafil may contribute to decreased smooth muscle cell proliferation which may reduce the size of the prostate and relieve the anatomical obstruction which produces urinary symptoms of BPH.[A242382] The decreased affinity of tadalafil for PDE6 compared to other PDE5 inhibitors may explain the reduced incidence of visual side effects.[L39100, L39105, A242287]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bacilomisk 10 billion 20 capsules', 7900, 'باسيلوميسك 10 بليون 20 كبسولة', '180', NULL, 'Food supplemet', 'Food supplemet', NULL, 'Lactobacillus reuteri', 'Mts-med', 'Capsule', 'كبسولة', NULL, '2', NULL, NULL, NULL, NULL, 784, '2025-11-04', NULL, 0, NULL, 'Lactobacillus coryniformis has immunomodulatory activity. Administration of a Lc K8 probiotic prior to the influenza vaccine in adults over the age of 65 showed a higher percentage of vaccine responders and a significantly lower incidence of respiratory symptoms associated with respiratory infections.', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Scaling vit hair serum 120 ml', 32342, 'سكالينج فيت سيروم للشعر 120 مل', '300', '250', 'Hair serum', 'Hair serum', NULL, 'Argan oil+aloe vera extract+emu oil+saw palmetto+keratin+silicone oil+procapil+biacapil', 'E.c.c > megamed', 'Serum', 'سيروم', '120 ml', '1', NULL, NULL, NULL, NULL, 1728, '2024-04-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Montekal 10mg 10 tab.', 22942, 'مونتكال 10مجم 10 قرص', '40', NULL, 'Asthma.anti-inflammatory.leukotriene antagonist', 'Asthma.anti-inflammatory.leukotriene antagonist', NULL, 'Montelukast', 'European egyptian pharm. ind.', 'Tab', 'أقراص', '10mg', '1', 'علاج أعراض الربو والوقاية منها مثل الأزيز وضيق التنفس. كما أنها تستخدم لمنع مشاكل التنفس أثناء ممارسة الرياضة قبل التمرين (تشنج قصبي).', NULL, 'about montelukast leukotriene(cyslt1) receptor antagonist antiinflammatory antiasthma. mechanism of action of montelukast montelukast is competitively and selectively antagonizes cyslt1 receptor (leukotrienes receptor) mediated bronchoconstriction.montelu', '6221076010500', 2105, '2022-12-06', NULL, 0, 'Montelukast is indicated for:



(a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304];



(b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307]; and



(c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307].



Furthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331]



Moreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328]



Additionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an ''as required'' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]', 'Cysteinyl leukotrienes (CysLT) like LTC4, LTD4, and LTE4, among others, are eicosanoids released by a variety of cells like mast cells and eosinophils.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] When such CysLT bind to corresponding CysLT receptors like CysLT type-1 receptors located on respiratory airway smooth muscle cells, airway macrophages, and on various pro-inflammatory cells like eosinophils and some specific myeloid stem cells activities that facilitate the pathophysiology of asthma and allergic rhinitis are stimulated.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, CysLT-mediated airway bronchoconstriction, occluding mucous secretion, vascular permeability, and eosinophil recruitment are all types of effects that facilitate asthma.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Alternatively, in allergic rhinitis, CysLTs are released by the nasal mucosa when exposed to allergens during both early and late phase reactions and participate in eliciting symptoms of allergic rhinitis like a congested nose and airway.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Subsequently, montelukast is a leukotriene receptor antagonist that binds with high affinity and selectivity to the CysLT type 1 receptor, which consequently assists in inhibiting any physiological actions of CysLTs like LTC4, LTD4, and LTE4 at the receptor that may facilitate asthma or allergic rhinitis.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'Montelukast is a leukotriene receptor antagonist that demonstrates a marked affinity and selectivity to the cysteinyl leukotriene receptor type-1 in preference to many other crucial airway receptors like the prostanoid, cholinergic, or beta-adrenergic receptors.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] As a consequence, the agent can elicit substantial blockage of LTD4 leukotriene-mediated bronchoconstriction with doses as low as 5 mg.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Moreover, a placebo-controlled, crossover study (n=12) demonstrated that montelukast is capable of inhibiting early and late phase bronchoconstriction caused by antigen challenge by 75% and 57% respectively.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, it has been documented that montelukast can cause bronchodilation as soon as within 2 hours of oral administration.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] This action can also be additive to the bronchodilation caused by the concomitant use of a beta agonist.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Nevertheless, clinical investigations performed with adults 15 years of age and older revealed that no additional clinical benefit is obtained when doses of montelukast greater than 10 mg a day are used.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Additionally, in clinical trials with adults and pediatric asthmatic patients aged 6 to 14 years, it was also determined that montelukast can reduce mean peripheral blood eosinophils by about 13% to 15% from baseline in comparison to placebo during double-blind treatment periods.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] At the same time, in patients aged 15 years and older who were experiencing seasonal allergic rhinitis, the use of montelukast caused a median reduction of 13% in peripheral blood eosinophil counts when compared to placebo as well.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Namix 20 film coated tablets', 14233, 'ناميكس 20 قرص', '100', '85', 'Iron supplement', 'Iron supplement', NULL, 'Iron35mg+zinc15mg+copper1mg+vitamin b6 1.711mg+vitamin b12 150mcg+folic acid 400 mcg+vitamin c', 'Geoxil pharma', 'Tablet', 'أقراص', NULL, '2', NULL, NULL, NULL, NULL, 2030, '2025-07-28', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Spasmofree 50mg 20 f.c. tabs.', 10764, 'سبازموفري 50مجم 20 قرص', '42', '29', 'Antispasmodic', 'Antispasmodic', NULL, 'Tiemonium methylsulphate', 'Adwia', 'Tab', 'أقراص', '50mg', '2', 'مضاد للتقلصات.', NULL, NULL, '6223002971770', 14039, '2024-09-10', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Emicaneurin 3 amp. for i.m. inj.', 18246, 'ايميكانيورين 3 امبول عضل حقن', '11', NULL, 'Vitamin b', 'Vitamin b', NULL, 'Vitamin b1+vitamin b6+vitamin b12', 'Eimc', 'Inj', 'حقن', NULL, '3', NULL, NULL, 'about vit b1 physiological functions: thiamine pyrophosphate is a coenzyme and the active form of vitamin b. it functions as coenzyme in decarboxylation of a-keto acid and in hexose monophosphate shunt. deficiency symptoms: in severe vitamin b1 deficiency', NULL, 897, '2022-08-17', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dolcyl 1mg 30 tab.', 17765, 'دولسيل 1 مجم 30 قرص', '36', '27', 'Anti-diabetic.secretagogues.sulfonylurea', 'Anti-diabetic.secretagogues.sulfonylurea', NULL, 'Glimepiride', 'Mup', 'Tab', 'أقراص', '1mg', '3', NULL, NULL, 'indications : this medication is a sulfonylurea antidiabetic agent prescribed for type 2 diabetes. it works by causing the pancreas to produce insulin dosage : the recommended starting dose is 1-2 mg once daily with food.maximum: 2mg/day contraindications', '6221508018029', 2452, '2024-12-10', NULL, 0, 'Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy. 



It may also be indicated for use in combination with metformin or insulin to lower blood glucose in patients with type 2 diabetes whose high blood sugar levels cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic (a drug used to lower blood sugar levels) agent alone.[L10322]', 'ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.[A177730] In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).[A177727] When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.[A177727] In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.[A177727] Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.[A177715] Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.[A177715] ', 'Glimepiride stimulates the secretion of insulin granules from the pancreatic beta cells and improves the sensitivity of peripheral tissues to insulin to increase peripheral glucose uptake, thus reducing plasma blood glucose levels and glycated hemoglobin (HbA1C) levels. A multi-center, randomized, placebo-controlled clinical trial evaluated the efficacy of glimepiride (1–8 mg) as monotherapy titrated over 10 weeks compared with placebo in T2DM subjects who were not controlled by diet alone.[A177703] In this study, there was a reduction in fasting plasma glucose (FPG) by 46 mg/dL, post-prandial glucose (PPG) by 72 mg/dL, and HbA1c by 1.4% more than the placebo.[A177703] In another randomized study comprising of patients with T2DM receiving either placebo or one of the three doses (1, 4, or 8 mg) of glimepiride during a 14-week study period, all glimepiride regimens significantly reduced FPG, PPG, and HbA1c values (P < 0.001) compared to placebo by the end of the study period.[A177703] The 4- and 8-mg doses of glimepiride were more effective than the 1-mg dose; however, the 4-mg dose provided a nearly maximal antihyperglycemic effect.[A177703]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dal-port 400 i.u./ml oral drops 30 ml', 32145, 'دال-بورت 400وحدة دولية/مل نقط فم 30 مل', '36', NULL, 'Vitamin d', 'Vitamin d', NULL, 'Cholecalciferol(vitamin d3)', 'Pharmazad > la porte pharma', 'Drops', 'نقط', '30 ml', '1', 'مكمل عذائى لدعم النمو الطبيعي للعظام والوقاية من الكساح ولين العظام', NULL, NULL, NULL, 1219, '2023-04-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ibumentol top. gel 50 gm', 20689, 'ابيومنتول جل 50 جرام', '47', '33.5', 'Nsaid.propionic acid derivatives', 'Nsaid.propionic acid derivatives', NULL, 'Ibuprofen+levomenthol', 'Dbk pharma > parkville pharmaceuticals', 'Gel', 'جل', '50 gm', '1', 'مسكن مضاد التهاب', NULL, 'about ibuprofen nsaid a propionic acid derivative analgesic and anti-inflammatory. mechanism of action of ibuprofen ibuprofen has analgesic anti-inflammatory and antipyretic action. it acts by inhibiting prostaglandin (pgs) synthesis and their release at', '6224008073321', 1400, '2025-08-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ribavirin 400mg 12 caps.', 26059, 'ريبافيرين 400مجم 12 كبسول', '38', NULL, 'Antiviral.nucleoside', 'Antiviral.nucleoside', NULL, 'Ribavirin', 'Mina pharm', 'Cap', 'كبسولة', '400mg', '1', NULL, NULL, 'about ribavirinsa nucleoside antimetabolite triazole derivative antiviral.smechanism of action of ribavirinsribavirin is a nucleoside analogue and it is phosphorylated by adenosine kinase enzyme in the host cell to form ribavirin monophosphate.this will i', '6222003701751', 1162, '2022-12-08', NULL, 0, 'Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates [A19644].



The addition of ribavirin in Technivie therapy indicated for treating HCV genotype 1a and 4 infections is recommended in patients with or without cirrhosis. 



Resistance: viral genetic determinants resulting in variable response to ribavirin therapy has not been yet determined. ', 'Ribavirin is reported to have several mechanism of actions that lead to inhibition of viral RNA and protein synthesis. 

After activation by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites. Ribavirin triphosphate (RTP) is the predominant metabolite which directly inhibits viral mRNA polymerase by binding to the nucleotide binding site of the enzyme. This prevents the binding of the correct nucleotides, leading to a reduction in viral replication or to the production of defective virions [A19645]. RTP also demonstrates an inhibitory action on viral mRNA guanylyltransferase and mRNA 2′-O-methyltransferase of dengue virus. Inhibition of these enzymes disrupts the posttranslational capping of the 5′ end of viral mRNA through ribavirin being incorporated at the 5′ end in place of guanosine and preventing the cap methylation step. 



Inhibition of host inosine monophosphate dehydrogenase (IMPDH) and subsequent depletion of GTP pool is proposed to be another mechanism of action of ribavirin. IMPDH catalyzes the rate-limiting step where inosine 5′-monophosphate is converted to xanthine monophosphate during guanosine monophosphate (GMP) synthesis. GMP is later converted to guanosine triphoshpate (GTP). Ribavirin monophosphate mimics inosine 5′-monophosphate and acts as a competitive inhibitor of IMPDH. Inhibited de novo synthesis of guanine nucleotides and decreased intracellular GTP pools leads to a decline in viral protein synthesis and limit replication of viral genomes [A19645].



Ribavirin acts as a mutagen in the target virus to cause an ''error catastrophe'' due to increased viral mutations. RTP pairs with cytidine triphosphate or uridine triphosphate with equal efficiency and to block HCV RNA elongation. It causes premature termination of nascent HCV RNA and increases mutagenesis by producing defective virions [A19645].



Ribavirin also exerts an immunomodulatory action of the host to the virus by shifting a Th2 response in favor of a Th1 phenotype. Th2 response and production of type 2 cytokines such as IL-4, IL-5, and IL-10 stimulates the humoral response which enhances immunity toward the virus [A19645]. Ribavirin enhanced induction of interferon-related genes, including the interferon-α receptor, and down-regulation of genes involved in interferon inhibition, apoptosis, and hepatic stellate cell activation in vitro [A19644]. ', 'Ribavirin mediates direct antiviral activity against a number of DNA and RNA viruses by increasing the mutation frequency in the genomes of several RNA viruses. It is a member of the nucleoside antimetabolite drugs that interfere with duplication of the viral genetic material. The drug inhibits the activity of the enzyme RNA dependent RNA polymerase, due to its resemblence to building blocks of the RNA molecules. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bapcal-d 20 tabs', 12416, 'بابكال دي 20 قرص', '110', NULL, 'CALCIUM', 'CALCIUM', NULL, 'CALCIUM CARBONATE + VITAMIN D3 + MAGNESIUM', 'BAP PHARMA FOR TRADING AND EXPORT', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, NULL, 1057, '2022-08-25', NULL, 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Pinmed hair oil spray 120 ml', 24944, 'بينميد زيت سبراي للشعر 120 مل', '75', NULL, 'Hair care', 'Hair care', NULL, 'Eruca oil+panthenol+biotin+nigella sativa+wheat germ oil+vitamin e+aloe vera+castor oil+tea tree oil', 'Egyptian company for cosmetics > ramacin pharmaceutical company', 'Spray', 'بخاخ', '120 ml', '1', NULL, NULL, NULL, NULL, 348, '2022-08-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Myfortic 360mg 120 f.c. tab.', 8493, 'ماي فورتك 360مجم 120 قرص', '6,091', '3669', 'Immunosuppressants', 'Immunosuppressants', NULL, 'Mycophenolate sodium', 'Novartis', 'Tab', 'أقراص', '360mg', '12', NULL, NULL, 'indication for the prophylaxis of organ rejection in patients receiving allogeneic renal cardiac or hepatic transplants. mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids. mechanism of action mycophenolate mofetil is', NULL, 6485, '2024-10-08', NULL, 0, 'Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old.[L42020] Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy.[A180814] Other off-label uses of this drug include lupus-associated nephritis and dermatitis in children.[A180817]', 'The active metabolite of mycophenolate, mycophenolic acid, prevents T-cell and B-cell proliferation and the production of cytotoxic T-cells and antibodies. Lymphocyte and monocyte adhesion to endothelial cells of blood vessels that normally part of inflammation is prevented via the glycosylation of cell adhesion molecules by MPA.[A180892] MPA inhibits de novo purine biosynthesis (that promotes immune cell proliferation) by inhibiting inosine 5’-monophosphate dehydrogenase enzyme (IMPDH), with a preferential inhibition of IMPDH II.[A180826] IMPDH normally transforms inosine monophosphate (IMP) to xanthine monophosphate (XMP), a metabolite contributing to the production of guanosine triphosphate (GTP).[A180799,A180805,A180817] GTP is an important molecule for the synthesis of ribonucleic acid (RNA), deoxyribonucleic acid (DNA), and protein. As a result of the above cascade of effects, mycophenolate mofetil reduces de-novo production of guanosine nucleotides, interfering with the synthesis of DNA, RNA, and protein required for immune cell production.[A180826] Further contributing to the above anti-inflammatory effects, MMF depletes tetrahydrobiopterin, causing the decreased function of inducible nitric oxide synthase enzyme, in turn decreasing the production of peroxynitrite, a molecule that promotes inflammation.[A180907]', 'Mycophenolate mofetil is a prodrug of mycophenolic acid (MPA). The active form of mycophenolate, MPA, prevents the proliferation of immune cells and the formation of antibodies that cause transplant rejection.[A180805] The above effects lead to higher rates of successful transplantation, avoiding the devastating effects of graft rejection.



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Uptravi 1000 mcg 60 f.c.tabs.', 28797, 'يبتورافي 1000مكجم 60 اقراص', '51,693', NULL, 'Prostacyclin receptor agonist', 'Prostacyclin receptor agonist', NULL, 'Selexipag', 'Excella gmbh-germany > janssen pharmaceutica nv', 'Tab', 'أقراص', '1000 mcg', '6', NULL, NULL, 'indication uptraviï- (selexipag) is indicated for the treatment of pulmonary arterial hypertension (pah who group i) to delay disease progression and reduce the risk of hospitalization for pah. effectiveness was established in a long-term study in pah pat', NULL, 451, '2022-08-05', NULL, 0, 'Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.', 'Selexipag is a selective prostacyclin (IP, also called PGI2) receptor agonist. The key features of pulmonary arterial hypertension include a decrease in prostacyclin and prostacyclin synthase (enzyme that helps produce prostacyclin) in the lung. Prostacyclin is a potent vasodilator with anti-proliferative, anti-inflammatory, and anti-thrombotic effects; therefore, there is strong rationale for treatment with IP receptor agonists. Selexipag is chemically distinct as it is not PGI2 or a PGI2 analogue and has high selectivity for the IP receptor. It is metabolized by carboxylesterase 1 to yield an active metabolite (ACT-333679) that is approximately 37 times more potent than selexipag. Both selexipag and its metabolite are selective for the IP receptor over other prostanoid receptors. ', 'At the maximum tolerated dose of 1600 mcg twice per day, selexipag was not found to prolong the QT interval to a clinically relevant extent. Both selexipag and its metabolite caused concentration-dependent inhibition of platelet aggregation in vitro with IC50 of 5.5 µM and 0.21 µM, respectively. However, at clinically relevant concentrations, there was no effect on platelet aggregation test parameters following multiple dose administration of selexipag in healthy patients. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sustanon 250mg amp', 11073, 'سوستانون 250مجم امبول', '6', NULL, 'Androgen', 'Androgen', NULL, 'Testosterone', 'Organon', 'Amp', 'أمبول', '250mg', '1', 'يمد الجسم بالتستستيرون لتعزيز نمو الاعضاء التناسلية للذكور -- تعزيز ظهور علامات الذكورة', NULL, NULL, '6221077121519', 3375, '2023-05-19', NULL, 0, 'Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995]', 'The androgen receptor exists in the cytoplasm bound to the heat shock proteins HSP90, HSP70, and other chaperones.[A187114] After binding to an androgen, the androgen receptor dissociates from HSP90 and undergoes a conformational change to slow the rate of dissociation from the androgen receptor.[A187114] The androgen-receptor complex is transported into the nucleus where it binds to DNA and recruits other transcriptional regulators to form a pre-initiation complex and eventually induce expression of specific genes.[A187114]



Testosterone and its active metabolite dihydrotestosterone (DHT) antagonize the androgen receptor to develop masculine sex organs including the prostate, seminal vesicles, penis, and scrotum.[A187111,L8983,L8935,L8938,L8986,L8989,L8992,L8995]



Antagonism of the androgen receptor is also responsible for the development of secondary sexual characteristics including facial and body hair, enlargement of the larynx, thickening of the vocal cords, and changes in muscle and fat distribution.[A187111,L8983,L8935,L8938,L8986,L8989,L8992,L8995]', 'Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] The duration of action of testosterone is variable from patient to patient with a half life of 10-100 minutes.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] The therapeutic index is wide considering the normal testosterone levels in an adult man range from 300-1000ng/dL.[L8983,L8938,L8986,L8989,L8992,L8995] Counsel patients regarding the risk of secondary exposure of testosterone topical products to children.[L8983,L8938,L8986,L8989,L8992]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bidalkin vaginal douche powder 12 sachets', 15187, 'بيدالكين غسول مهبلي 12 كيس', '58', '36', 'Vaginal wash', 'Vaginal wash', NULL, 'Borax+aluminium potassium sulphate+chlorophyll+sodium bicarbonate', 'Kahira', 'Powder', 'بودرة', NULL, '1', NULL, NULL, 'vaginal douche powder astringent - antiseptic - mucolytic', '6221068201848', 5161, '2025-01-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vitamin d3 sublingual 30 tablets', 12456, 'فيتامين دال 3 اقراص تحت اللسان 30 قرص', '150', NULL, 'Vitamin d', 'Vitamin d', NULL, 'Vitamin d3', 'Pdrtc', 'Tablet', 'أقراص', NULL, '3', NULL, NULL, NULL, NULL, 1028, '2022-11-30', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Zondex gel 75 gm', 30019, 'زوندكس جل 75جم', '69', '55', 'Massage', 'Massage', NULL, 'Glautheria oil+willow bark extract+eucalyptus oil+turpentine oil+thyme oil', 'Leader cosmetics > advance pharma-egypt', 'Gel', 'جل', '75 gm', '1', NULL, NULL, 'massage gel', NULL, 998, '2024-04-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Furyxel 200mg 10 capsules', 19496, 'فيوريكسل 200مجم 10 كبسولات', '13', NULL, 'Anti-ischemic', 'Anti-ischemic', NULL, 'Naftidrofuryl', 'Hikma pharma', 'Capsule', 'كبسولة', '200mg', '1', 'علاج قصور الدورة الدموية -- يعمل علي تحسين وصول الدم لجميع اجزاء الجسم', NULL, 'naftidrofuryl oxalate works in two main ways. firstly it causes the blood vessels to widen. secondly it increases the ability of cells to remove waste products. in peripheral vascular diseases the blood vessels in the extremities are narrowed and the bloo', NULL, 2109, '2022-04-14', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Furosemide-alex 40mg 5 i.m. i.v. amp.', 5244, 'فيوروسيميد 40مجم 5 امبولات', '23', NULL, 'Diuretic.loop', 'Diuretic.loop', NULL, 'Furosemide', 'Alexandria', 'Amp', 'أمبول', '40mg', '5', 'مدر بول', NULL, 'description a benzoic-sulfonamide-furan. it is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. mechanism of action furosemide a loop diuretic inhibits water reabsorption in the nephron by blocking the', '6223000171646', 962, '2023-02-06', NULL, 0, 'Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.[L7958] 



Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.[L9659]



Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired.[L7958]



Subcutaneous furosemide is indicated for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure. This drug formulation is not indicated for emergency situations or in patients with acute pulmonary edema.[L43408]', 'Furosemide promotes diuresis by blocking tubular reabsorption of sodium and chloride in the proximal and distal tubules, as well as in the thick ascending loop of Henle. This diuretic effect is achieved through the competitive inhibition of sodium-potassium-chloride cotransporters (NKCC2) expressed along these tubules in the nephron, preventing the transport of sodium ions from the lumenal side into the basolateral side for reabsorption. This inhibition results in increased excretion of water along with sodium, chloride, magnesium, calcium, hydrogen, and potassium ions.[L7961] As with other loop diuretics, furosemide decreases the excretion of uric acid.[T28] 



Furosemide exerts direct vasodilatory effects, which results in its therapeutic effectiveness in the treatment of acute pulmonary edema. Vasodilation leads to reduced responsiveness to vasoconstrictors, such as angiotensin II and noradrenaline, and decreased production of endogenous natriuretic hormones with vasoconstricting properties. It also leads to increased production of prostaglandins with vasodilating properties. Furosemide may also open potassium channels in resistance arteries.[T28] The main mechanism of action of furosemide is independent of its inhibitory effect on carbonic anhydrase and aldosterone.[L7958] ', 'Furosemide manages hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome. Furosemide is a potent loop diuretic that works to increase the excretion of Na+ and water by the kidneys by inhibiting their reabsorption from the proximal and distal tubules, as well as the loop of Henle.[L7958] It works directly acts on the cells of the nephron and indirectly modifies the content of the renal filtrate.[T28] Ultimately, furosemide increases the urine output by the kidney. Protein-bound furosemide is delivered to its site of action in the kidneys and secreted via active secretion by nonspecific organic transporters expressed at the luminal site of action.[A31831,L7958] 



Following oral administration, the onset of the diuretic effect is about 1 and 1.5 hours [L7958], and the peak effect is reached within the first 2 hours.[L7961] The duration of effect following oral administration is about 4-6 hours but may last up to 8 hours.[L9659] Following intravenous administration, the onset of effect is within 5 minutes, and the peak effect is reached within 30 minutes. The duration of action following intravenous administration is approximately 2 hours. Following intramuscular administration, the onset of action is somewhat delayed.[L7958]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Zmaxe 2 gm e.r. 1 bottle susp.', 29983, 'زماكس 2جم 1 شراب معلق', '70', NULL, 'Antibiotic.macrolide', 'Antibiotic.macrolide', NULL, 'Azithromycin', 'Pfizer', 'Susp', 'معلق', '2 gm', '1', NULL, NULL, 'description: azithromycin is a semi-synthetic macrolide antibiotic of the azalide class. dose: adult: po- respiratory tract skin and soft tissue infections- 500 mg once daily for 3 days. or 500mg on day 1 followed by 250mg on days 2 to 5. typhoid- 500 mg', NULL, 767, '2022-07-22', NULL, 0, 'Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin [FDA label].



Azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below. Recommended dosages, duration of therapy and considerations for various patient populations may vary among these infections. Refer to the FDA label and "Indications" section of this drug entry for detailed information [FDA label]. 



**Adults**:



Acute bacterial exacerbations of chronic obstructive pulmonary disease due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Acute bacterial sinusitis due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.

Uncomplicated skin and skin structure infections due to _Staphylococcus aureus_, _Streptococcus pyogenes_, or _Streptococcus agalactiae_. Abscesses usually require surgical drainage.



Urethritis and cervicitis due to _Chlamydia trachomatis_ or _Neisseria gonorrhoeae_.



Genital ulcer disease in men due to _Haemophilus ducreyi_ (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established.



**Pediatric Patients**



Acute otitis media caused by _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy.



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.', 'In order to replicate, bacteria require a specific process of protein synthesis, enabled by ribosomal proteins [A6505]. Azithromycin binds to the 23S rRNA of the bacterial 50S ribosomal subunit. It stops bacterial protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit [FDA label], [A14179]. This results in the control of various bacterial infections [A174193], [FDA label].   The strong affinity of macrolides, including azithromycin, for bacterial ribosomes, is consistent with their broad‐spectrum antibacterial activities [A174193].





Azithromycin is highly stable at a low pH, giving it a longer serum half-life and increasing its concentrations in tissues compared to erythromycin [A174175]. 



', 'Macrolides stop bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections [A174175].

Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose [A174172].



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mega bright cream 50 gm', 22459, 'ميجا بريت كريم 50جم', '25', NULL, 'Whitening topical', 'Whitening topical', NULL, 'Licorice extract+stearic acid+vitamin c+jojoba oil+mineral oil+titanium dioxide', 'Leader cosmetics > otaci med pharma', 'Cream', 'كريم', '50 gm', '1', NULL, NULL, 'whitening cream', NULL, 894, '2022-07-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nutri powder 10 sachets', 23841, 'نوتري باودر 10 اكياس', '100', '34', 'Dietary supplement', 'Dietary supplement', NULL, 'Skimmed milk+whey protein+calcium carbonate+vitamin d', 'Nutrixia > trust pharma', 'Powder', 'بودرة', NULL, '1', NULL, NULL, 'fortified with calcium magnesium and vitamin d3', NULL, 1271, '2025-08-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cordalen 50 gm massage gel', 29069, 'كوردالين مساج جل 50 جم', '60', '55', 'Massage gel', 'Massage gel', NULL, 'Carbomer+trithanolamine+menthol+eugenia caryophyllus flower extract+avocado oil+mentha piperita ( peppermint oil )+ethyl alcohol+eucalyptus oil+camphor+thymol+glycerin+d- panthenol+propylene glycol+polysorbate 20+allantoin+niacinamide+almond oil+dmdm hydantoin', 'Bme pharma', 'Gel', 'جل', '50 gm', '1', NULL, NULL, NULL, NULL, 1037, '2025-08-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Covaprendo 5/10mg 30 tabs.', 16865, 'كوفابريندو 10/5 مجم 30 قرص', '150', '111', 'Antihypertensive.combined ace with calcium channel blocker', 'Antihypertensive.combined ace with calcium channel blocker', NULL, 'Amlodipine+perindopril', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '10mg', '3', NULL, NULL, 'indication for the treatment of mild to moderate essential hypertension mild to moderate congestive heart failure and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease. about amlod', '6223002143436', 1185, '2025-08-10', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Malinda cream 120 gm', 33144, 'ماليندا كريم 120 جم', '290', '250', 'Skin care.moisturizing', 'Skin care.moisturizing', NULL, NULL, 'Bluebell pharmaceuticals', 'Cream', 'كريم', '120 gm', '1', NULL, NULL, NULL, '6224008235255', 1224, '2025-01-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('D3 candy children 30 pieces', 17046, 'دي3 كاندي اطفال 20 قطعة', '59', NULL, 'Vitamin d', 'Vitamin d', NULL, 'Cholecalciferol(vitamin d3)', 'El delta for sweets and food industries > devartlab pharma', 'Piece', 'قطعة', NULL, '1', NULL, NULL, NULL, NULL, 1015, '2022-07-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Isofill focus cream rich 50 ml', 20994, 'ايزوفيل فوكس كريم ريتش 50 مل', '275', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Uriage dermatological laboratories > biotech egypt', 'Cream', 'كريم', '50 ml', '1', NULL, NULL, 'this rich cream contains the bio-active iso-3r complex which is capable of stimulating fundamental anti-ageing mechanisms for optimal effectiveness. its lightly powdery rich and smooth texture is enriched with shea butter for a long-lasting and pleasant f', NULL, 735, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dapoxtard 60 mg 3 f.c. tabs.', 17110, 'دابوكستارد 60مجم 3 قرص', '58', '39', 'Delay action', 'Delay action', NULL, 'Dapoxetine', 'Aug pharma', 'Tab', 'أقراص', '60 mg', '1', 'للتأخير لدى الرجال', NULL, 'about dapoxetine dapoxetine is a short-acting selective serotonin reuptake inhibitor (ssri) marketed for the treatment of premature ejaculation in men. mechanism of action of dapoxetine the mechanism of action of dapoxetine in premature ejaculation is pre', '6223005460905', 3424, '2025-04-03', NULL, 0, 'For the treatment of premature ejaculation.', 'The drug''s mechanism of action is thought to be related to inhibition of neuronal reuptake of serotonin and subsequent potentiation of serotonin activity. The central ejaculatory neural circuit comprises spinal and cerebral areas that form a highly interconnected network. The sympathetic, parasympathetic, and somatic spinal centers, under the influence of sensory genital and cerebral stimuli integrated and processed at the spinal cord level, act in synergy to command physiologic events occurring during ejaculation. Experimental evidence indicates that serotonin (5-HT), throughout brain descending pathways, exerts an inhibitory role on ejaculation. To date, three 5-HT receptor subtypes (5-HT(1A), 5-HT(1B), and 5-HT(2C)) have been postulated to mediate 5-HT''s modulating activity on ejaculation.', 'Dapoxetine is a selective serotonin reuptake inhibitor currently undergoing trials through Alza (under license from GenuPro, a collaboration between Eli Lilly and PPD). Dapoxetine is a short-acting SSRI drug currently being considered for approval by the Food and Drug Administration (FDA) for the treatment of premature ejaculation in men, which would make it the first drug approved for such treatment. Despite two clinical trials finished in 2006, experts doubt it will be approved by the FDA soon because SSRIs come with undesirable side-effects after long-term use, such as psychiatric problems, dermatological reactions, increase in body weight, lower sex-drive, nausea, headache, upset stomach and weakness, thus not significantly outweighing the benefit of premature ejaculation medication versus the risks. By contrast with SSRIs approved for depression, which take 2 weeks or longer to reach steady-state concentration, dapoxetine has a unique pharmacokinetic profile, with a short time to maximum serum concentration (about 1 h) and rapid elimination (initial half-life of 1-2 h).', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Prismaven 100 mg 30 ext. rel. tab.', 25267, 'بريسمافين 100مجم 30 اقراص', '204', '156', 'Psychiatric.antidepressants', 'Psychiatric.antidepressants', NULL, 'Desvenlafaxine', 'Rameda', 'Tab', 'أقراص', '100 mg', '3', NULL, NULL, 'it s a serotonin and norepinephrine reuptake inhibitor(snri) is indicated for the treatment of major depressive disorder (mdd).', '6223003970925', 1917, '2025-01-05', NULL, 0, 'Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.[L47936] It has also been used off-label to treat hot flashes in menopausal women.[A261166]', 'The exact mechanism of the antidepressant action of desvenlafaxine is unknown but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.[L47936] Particularly, desvenlafaxine has been found to inhibit the serotonin, norepinephrine, and dopamine transporters with varying degrees of affinity. Desvenlafaxine inhibits serotonin transporters with 10 times the affinity of norepinephrine transporters, and dopamine transporters with the lowest affinity.[A6991] ', 'Desvenlafaxine is a selective serotonin and norepinephrine reuptake inhibitor.[A6990,A6991,L47936] It lacks significant activity on muscarinic-cholinergic, H<sub>1</sub>-histaminergic, or &alpha;<sub>1</sub>-adrenergic receptors <i>in vitro</i>, or inhibitory activity against monoamine oxidase.[L47936] Desvenlafaxine does not appear to exert activity against calcium, chloride, potassium and sodium ion channels and also lacks monoamine oxidase (MAO) inhibitory activity.[A6991] It was also shown to lack significant activity against the cardiac potassium channel, hERG, <i>in vitro</i>.[A36975]



Electrocardiograms were obtained from 1,492 desvenlafaxine treated patients with major depressive disorder and 984 placebo-treated patients in clinical studies lasting up to 8 weeks. No clinically relevant differences were observed between desvenlafaxine treated and placebo-treated patients for QT, QTc, PR, and QRS intervals. In a thorough QTc study with prospectively determined criteria, desvenlafaxine did not cause QT prolongation. No difference was observed between placebo and desvenlafaxine treatments for the QRS interval.[L47936] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Terbafenol 1% top. spray 30 ml', 13902, 'تيربافينول 1% بخاخ موضعي 30 مل', '21', '13.25', 'Antifungals.allylamines', 'Antifungals.allylamines', NULL, 'Terbinafine', 'Acdima international trading', 'Spray', 'بخاخ', '1%', '1', NULL, NULL, NULL, '6224000588700', 966, '2024-04-22', NULL, 0, 'Terbinafine hydrochloride is indicated to treat fungal skin and nail infections caused by _Trichophyton_ species, _Microsporum canis_, _Epidermophyton floccosum_,[L9068] and _Tinea_ species.[L9065] Terbinafine hydrochloride also treats yeast infections of the skin caused by _Candida_ species and _Malassezia furfur_.[L9068]', 'Terbinafine inhibits the enzyme squalene monooxygenase (also called squalene epoxidase), preventing the conversion of squalene to 2,3-oxydosqualene, a step in the synthesis of ergosterol.[A1279,A1281,L9068] This inhibition leads to decreased ergosterol, which would normally be incorporated into the cell wall, and accumulation of squalene.[A1281,L9068]



Generation of a large number of squalene containing vesicles in the cytoplasm may leach other lipids away from, and further weaken, the cell wall.[A1281]', 'Terbinafine is an allylamine antifungal that inhibits squalene epoxidase (also known as squalene monooxygenase) to prevent the formation of ergosterol and cause an accumulation of squalene, weakening the cell wall of fungal cells.[A1279,A1281,L9068] Terbinafine distributes into tissues and has a long terminal elimination half life, so the duration of action is long.[A1279] Overdose with terbinafine is rare, even above the therapeutic dose, so the therapeutic index is wide.[L9065,L9068] Patients taking oral terbinafine should have liver function tests performed prior to treatment to reduce the risk of liver injury.[L9065]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Seretide evohaler 50/25mcg 120 metered actuations', 31342, 'سيريتايد ايفوهيلر 50/25مكجم 120 جرعة', '198', '132', 'Bronchodilator.glucocorticoid steroid and long-acting b2 agonist', 'Bronchodilator.glucocorticoid steroid and long-acting b2 agonist', NULL, 'Fluticasone+salmeterol', 'Glaxo smithkline > modern pharma', 'Unknown', 'غير محدد', '25mcg', '1', NULL, NULL, 'about fluticasone synthetic topical glucocorticoid anti inflammatory and antipruritic in corticosteroid-responsive dermatoses; atopic dermatitis. mechanism of action of fluticasone it reduces prostaglandin synthesis by inhibiting cyclo oxygenase enzymes b', NULL, 962, '2024-11-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Helixapront 120ml syrup', 6383, 'هيليكسابرونت شراب 120 مل', '60', NULL, 'Cough products', 'Cough products', NULL, 'Ivy leaf extract 35mg+thyme+licorice extract', 'First aid pharma', 'Syrup', 'شراب', '120ml', '1', NULL, NULL, NULL, NULL, 813, '2025-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Monodexin 0.1% eye drops 10*0.5 ml sdu', 22925, 'مونودكسين 0.1% قطرة عين 10 وحدات مفردة', '46', '32', 'Glucocorticoid', 'Glucocorticoid', NULL, 'Dexamethasone sodium phosphate', 'Global advanced pharmaceuticals (gap) > monopharma pharmaceuticals', 'Drops', 'نقط', '0.1%', '1', 'قطرة عين مضادة التهاب كورتيزوني', NULL, 'about dexamethasone a potent synthetic glucocorticoid antiasthmatic anti-inflammatory and immunosuppressant. mechanism of action of dexamethasone the drug exerts it`s pharmacological action by penetrating and binding to cytoplasmic receptor protein and ca', '6224009807093', 6570, '2024-09-26', NULL, 0, 'Dexamethasone and [ciprofloxacin] otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa.[L10698] Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Oral tablets are indicated for the treatment of multiple myeloma.[L10710] An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye.[L10719] Various ophthalmic formulations are indicated for inflammatory conditions of the eye.[L10704,L10707,L10713,L10716,L10722,L10725]', 'The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.[A187463] Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.[A187463]



Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.[A187463]



Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.[A187463] High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.[A187463]', 'Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.[A187463] Dexamethasone''s duration of action varies depending on the route.[L10698,L10701,L10704,L10707,L10710,L10713,L10716,L10719,L10722,L10725] Corticosteroids have a wide therapeutic window as patients may require doses that are multiples of what the body naturally produces.[A187463] Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.[A187463]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Loperasin 2mg 6 caps.', 22017, 'لوبيراسين 2مجم 6 كبسولات', '3', NULL, 'Antidiarrheal', 'Antidiarrheal', NULL, 'Loperamide', 'Alexandria', 'Cap', 'كبسولة', '2mg', '1', NULL, NULL, NULL, NULL, 1136, '2022-06-18', NULL, 0, 'Loperamide is indicated for the relief of diarrhea, including Travelers’ Diarrhea.[L42785] As an off-label use, it is often used to manage chemotherapy-related diarrhea.[A251610]', 'Enteric neurons synthesize and release endogenous opioid peptides and other neurotransmitters, such as acetylcholine and substance P. Endogenous opioids bind to opioid receptors expressed on these neurons to regulate gastrointestinal signalling, motility, and balance of fluids and electrolytes.[A251630]



Loperamide acts on the mu (μ)-opioid receptor expressed on the circular and longitudinal intestinal muscle.[A251610] Receptor binding leads to the recruitment of G-protein receptor kinases and the activation of downstream molecular cascades that inhibit enteric nerve activity.[A251630] By inhibiting the excitability of enteric neurons, loperamide suppresses neurotransmitter release, pre-synaptic and post-synaptic inhibition of transmission of excitatory and inhibitory motor pathways, and secretomotor pathways.[A251630] Loperamide inhibits the release of acetylcholine and prostaglandins,[L42790] thereby reducing propulsive peristalsis and increasing intestinal transit time.[A251615, L42790] Loperamide stimulates the intestinal absorption of water and electrolytes by inhibiting calmodulin.[A251615] Loperamide can bind to and hyperpolarize submucosal secretomotor neurons, promoting dry, hard stools.[A251630]', 'Loperamide is an anti-diarrheal agent that provides symptomatic relief of diarrhea.[L42790] It decreases peristalsis and fluid secretion in the gastrointestinal tract, delays colonic transit time, and increases the absorption of fluids and electrolytes from the gastrointestinal tract.[A6249, A251610, A251630] Loperamide also increases rectal tone,[A251610] reduces daily fecal volume, and increases the viscosity and bulk density of feces.[L42790] It also increases the tone of the anal sphincter, thereby reducing incontinence and urgency.[A251615, L42790] The onset of action is about one hour and the duration of action can be up to three days.[A251615]



While loperamide is a potent mu-opioid receptor agonist,[A251615] it does not mediate significant analgesic activity at therapeutic and supratherapeutic doses.[A6249, A251615] However, at high doses of loperamide, inhibition of P-glycoprotein-mediated drug efflux may allow loperamide to cross the blood-brain barrier, where loperamide can exert central opioid effects and toxicity.[A251610]



At very high plasma concentrations, loperamide can interfere with cardiac conduction.[A251625] Because loperamide inhibits the Na<sup>+</sup>-gated cardiac channels [A251610] and ether-a-go-go–related gene potassium channels,[A251625] the drug can prolong the QRS complex and the QTc interval, which can lead to ventricular dysrhythmias, monomorphic and polymorphic ventricular tachycardia, torsade de pointes, ventricular fibrillation, Brugada syndrome, cardiac arrest, and death.[A251610]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Epikavit 10mg 10 chew. tabs.', 18419, 'ابيكافيت 10 مجم 10 اقراص', '5', NULL, 'Vitamin k', 'Vitamin k', NULL, 'Vitamin k1', 'Eipico', 'Tab', 'أقراص', '10mg', '1', NULL, NULL, 'about vitamin k fat soluble vitamin antihemorrhagic. mechanism of action of vitamin k phytonadione (vitamin k1) is a synthetic form of vitamin k and is lipid soluble. vitamin k acts as a cofactor in the synthesis of coagulation proteins; prothrombin facto', NULL, 790, '2022-07-22', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bone care 1mcg 30 caps.', 15422, 'بون كير 1مكجم 30 كبسولة', '132', '91.5', 'Vitamin d', 'Vitamin d', NULL, 'Alfacalcidol', 'Arab caps > multicare', 'Cap', 'كبسولة', '1mcg', '3', 'مكمل غذائى لدعم نمو العظام و يستخدم في أمراض الكلى المزمنة واضطراب العظام والمعادن ونقص كالسيوم الدم في حديثي الولادة وهشاشة العظام والكساح', NULL, NULL, '6224007326107', 4957, '2024-08-20', NULL, 0, 'Alfacalcidol is indicated in adult patients with chronic renal failure for the management of hypocalcemia, secondary hyperparathyroidism, or osteodystrophy.[L33284]



Alfacalcidol is indicated in the management of nutritional and malabsorptive rickets and osteomalacia, vitamin D-dependent rickets and osteomalacia, and hypophosphataemic vitamin D resistant rickets and osteomalacia.[L33364,L33369]', 'In conditions like chronic renal failure, renal bone disease, hypoparathyroidism, and vitamin D dependent rickets, the kidneys'' capacity for 1α-hydroxylation is impaired, leading to reduced production of endogenous 1,25-dihydroxyvitamin D and aberrated mineral metabolism. As an active and potent analog of vitamin D, alfacalcidol works to restore the functions and activities of endogenous 1,25-dihydroxyvitamin D.[L33369]', 'Alfacalcidol works to increase serum levels of calcium by stimulating intestinal calcium absorption, reabsorption of calcium from bone, and possibly the renal reabsorption of calcium. It also modestly promotes intestinal phosphorus absorption.[L33284] In patients with renal failure, alfacalcidol increased intestinal calcium and phosphorus absorption in a dose-related manner. This increase in calcium and phosphorus levels occurs within three days following drug administration: this effect was reversed within three days of drug discontinuation. In patients with chronic renal failure, serum calcium levels were elevated while parathyroid hormone and alkaline phosphatase levels returned to normal levels within five days following alfacalcidol administration.[L33369] Since alfacalcidol suppresses parathyroid hormone, a reduction in parathyroid hormone levels is achieved more rapidly in patients on intermittent intravenous therapy, with significant reductions occurring within three months of therapy. In patients receiving daily oral therapy of alfacalcidol, the time it takes alfacalcidol to normalize plasma calcium levels may be up to several months, possibly reflecting calcium being utilized for bone mineralization.[L33284] In patients with nutritional osteomalacia, alfacalcidol increased calcium absorption with six hours of oral administration and the effects peaked at 24 hours.[L33369]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vanvilda plus 50/1000 mg 30 tabs.', 33832, 'فانفيلدا بلس 50/1000 مجم 30 قرص', '138', '108', 'Anti-diabetic.secretagogues.dpp-4 inhibitors', 'Anti-diabetic.secretagogues.dpp-4 inhibitors', NULL, 'Metformin hydrochloride+vildagliptin', 'Gypto pharma', 'Tab', 'أقراص', '1000 mg', '3', 'تستخدم للتحكم في مستويات السكر في الدم لدى مرضى السكري من النوع الثانى .', NULL, NULL, '6224008874201', 32529, '2024-10-16', NULL, 0, '**Metformin immediate-release formulations**

 

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.[L40243]



**Metformin extended-release tablet (XR)**



The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.[L12207]



**Metformin combination products**



Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263] in combination with SGLT2 inhibitors ([canagliflozin], [empagliflozin], [ertugliflozin], or [dapagliflozin]),[L11479,L30503,L1134,L13679,L38729] or in combination with [pioglitazone].[L11419]', 'Metformin''s mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.[L12207] It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.[A36534, A36557]   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.



After ingestion, the organic cation transporter-1 (OCT1) is responsible for the uptake of metformin into hepatocytes (liver cells). As this drug is positively charged, it accumulates in cells and in the mitochondria because of the membrane potentials across the plasma membrane as well as the mitochondrial inner membrane. Metformin inhibits mitochondrial complex I, preventing the production of mitochondrial ATP leading to increased cytoplasmic ADP:ATP and AMP:ATP ratios.[A36534] These changes activate AMP-activated protein kinase (AMPK), an enzyme that plays an important role in the regulation of glucose metabolism.[A176348] Aside from this mechanism, AMPK can be activated by a lysosomal mechanism involving other activators.  Following this process, increases in AMP:ATP ratio also inhibit _fructose-1,6-bisphosphatase_ enzyme, resulting in the inhibition of gluconeogenesis, while also inhibiting _adenylate cyclase_ and decreasing the production of cyclic adenosine monophosphate (cAMP),[A36534] a derivative of ATP used for cell signaling [A176351]. Activated AMPK phosphorylates two isoforms of acetyl-CoA carboxylase enzyme, thereby inhibiting fat synthesis and leading to fat oxidation, reducing hepatic lipid stores and increasing liver sensitivity to insulin.[A36534] 



In the intestines, metformin increases anaerobic glucose metabolism in enterocytes (intestinal cells), leading to reduced net glucose uptake and increased delivery of lactate to the liver. Recent studies have also implicated the gut as a primary site of action of metformin and suggest that the liver may not be as important for metformin action in patients with type 2 diabetes. Some of the ways metformin may play a role on the intestines is by promoting the metabolism of glucose by increasing glucagon-like peptide I (GLP-1) as well as increasing gut utilization of glucose.[A36534] 



In addition to the above pathway, the mechanism of action of metformin may be explained by other ways, and its exact mechanism of action has been under extensive study in recent years.[A36535, A36554, A36555, A36557]', '**General effects**



Insulin is an important hormone that regulates blood glucose levels.[T514] Type II diabetes is characterized by a decrease in sensitivity to insulin, resulting in elevations in blood glucose when the pancreas can no longer compensate. In patients diagnosed with type 2 diabetes, insulin is unable to exert adequate effects on tissues and cells (i.e. insulin resistance)[T514] and insulin deficiency may also be present.[L5753]



Metformin reduces hepatic production of glucose, decreases the intestinal absorption of glucose, and enhances insulin sensitivity by increasing both peripheral glucose uptake and utilization. In contrast with drugs of the sulfonylurea class, which lead to hyperinsulinemia, the secretion of insulin is unchanged with metformin use.[L12207]



**Effect on fasting plasma glucose (FPG) and Glycosylated hemoglobin (HbA1c)**



HbA1c is an important periodic measure of glycemic control used to monitor diabetic patients. Fasting plasma glucose is also a useful and important measure of glycemic control. In a 29-week clinical trial of subjects diagnosed with type II diabetes, metformin decreased the fasting plasma glucose levels by an average of 59 mg/dL from baseline, compared to an average increase of 6.3 mg/dL from baseline in subjects taking a placebo.[L12207]  Glycosylated hemoglobin (HbA1c) was decreased by about 1.4% in subjects receiving metformin, and increased by 0.4% in subjects receiving placebo only.[L12207]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nutri baby 2 milk 400 gm', 23839, 'نوتري بيبي لبن رقم 2 400جم', '150', NULL, 'Milk products.second stage (age 6-12 months)', 'Milk products.second stage (age 6-12 months)', NULL, 'Milk formula stage 2', 'Geo-poland co. ltd. > egyptian pharmaceutical trading company', 'Unknown', 'غير محدد', '400 gm', '1', NULL, NULL, 'not to replace mother s milk. for infants from 6 months to 1 year age. to be used within one month from opening.', NULL, 934, '2023-01-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Effox 40mg 20 tab', 4020, 'ايفوكس 40مجم 20 قرص', '14', NULL, 'Anti-ischemic', 'Anti-ischemic', NULL, 'Isosorbide mononitrate', 'Minapharm', 'Tab', 'أقراص', '40mg', '2', 'علاج الذبحات الصدرية --علاج تجلطات الدم', NULL, NULL, '6222003700129', 1071, '2022-10-19', NULL, 0, 'For the prevention of angina pectoris due to coronary artery disease.', 'Isosorbide dinitrate is converted to the active nitric oxide to activate guanylate cyclase. This activation increases levels of cyclic guanosine 3'',5''-monophosphate (cGMP). cGMP activates protein kinases and causes a series of phosphorylation reactions which leads to dephosphorylation of myosin light chains of smooth muscle fibres. Finally there is a release of calcium ions which causes smooth muscle relaxation and vasodilation.', 'Isosorbide Dinitrate is a moderate to long acting oral organic nitrate used for the relief and prophylactic management of angina pectoris. It relaxes the vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end- diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sebogine topical lotion 50 ml', 26654, 'سيبوجين لوشن 50 مل', '175', '93', 'Anti-acne', 'Anti-acne', NULL, NULL, 'Egyptian company for cosmetics > l origine laboratoire', 'Lotion', 'لوشن', '50 ml', '1', 'لوشن للعناية بالبشرةالدهنية ويمنع ظهورحب الشباب ويزيل حب الشب الشباب ويحتوي علي احماض الفواكه التي تساعدعلي تقشير الجلد وتزيل الرؤوس', NULL, 'use: apply a thin layer of sebogine on acne areas once at evening after cleansing the skin with a foaming gel.', NULL, 1291, '2025-08-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nizoderm 2% cream 15 gm', 8914, 'نيزوديرم 2% كريم 15 جم', '15', '9', 'Antifungals.imidazoles', 'Antifungals.imidazoles', NULL, 'Ketoconazole', 'Unipharma co.', 'Cream', 'كريم', '2%', '1', 'علاج حكة الجلد والاحمرار والحساسية', NULL, NULL, '6224000730680', 2065, '2024-12-22', NULL, 0, 'Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.[FDA Label] In Europe, it is also used in the treatment of endogenous Cushing''s syndrome.[L7736]', 'Ketoconazole interacts with 14-&alpha;-sterol demethylase, a cytochrome P-450 enzyme necessary for the conversion of lanosterol to ergosterol.[A181802,T116] This results in inhibition of ergosterol synthesis and increased fungal cellular permeability due to reduced amounts of ergosterol present in the fungal cell membrane. This metabolic inhibition also results in accumulation of 14α-methyl-3,6-diol, a toxic metabolite. The increase in membrane fluidity is also thought to produce impairment of membrane-bound enzyme systems as components become less closely packed.', 'Ketoconazole, similarly to other azole antifungals, is a fungistatic agent which causes growth arrest in fungal cells thereby preventing growth and spread of the fungus throughout the body.[T116]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dibavally plus 50/1000mg 28 tabs.', 17601, 'ديبافالي بلس 50/1000مجم 28 قرص', '184', '140', 'Anti-diabetic.secretagogues.dpp-4 inhibitors', 'Anti-diabetic.secretagogues.dpp-4 inhibitors', NULL, 'Metformin hydrochloride+vildagliptin', 'Aug pharma', 'Tab', 'أقراص', '1000mg', '4', NULL, NULL, NULL, '6223005460936', 3153, '2024-09-20', NULL, 0, '**Metformin immediate-release formulations**

 

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.[L40243]



**Metformin extended-release tablet (XR)**



The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.[L12207]



**Metformin combination products**



Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263] in combination with SGLT2 inhibitors ([canagliflozin], [empagliflozin], [ertugliflozin], or [dapagliflozin]),[L11479,L30503,L1134,L13679,L38729] or in combination with [pioglitazone].[L11419]', 'Metformin''s mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.[L12207] It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.[A36534, A36557]   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.



After ingestion, the organic cation transporter-1 (OCT1) is responsible for the uptake of metformin into hepatocytes (liver cells). As this drug is positively charged, it accumulates in cells and in the mitochondria because of the membrane potentials across the plasma membrane as well as the mitochondrial inner membrane. Metformin inhibits mitochondrial complex I, preventing the production of mitochondrial ATP leading to increased cytoplasmic ADP:ATP and AMP:ATP ratios.[A36534] These changes activate AMP-activated protein kinase (AMPK), an enzyme that plays an important role in the regulation of glucose metabolism.[A176348] Aside from this mechanism, AMPK can be activated by a lysosomal mechanism involving other activators.  Following this process, increases in AMP:ATP ratio also inhibit _fructose-1,6-bisphosphatase_ enzyme, resulting in the inhibition of gluconeogenesis, while also inhibiting _adenylate cyclase_ and decreasing the production of cyclic adenosine monophosphate (cAMP),[A36534] a derivative of ATP used for cell signaling [A176351]. Activated AMPK phosphorylates two isoforms of acetyl-CoA carboxylase enzyme, thereby inhibiting fat synthesis and leading to fat oxidation, reducing hepatic lipid stores and increasing liver sensitivity to insulin.[A36534] 



In the intestines, metformin increases anaerobic glucose metabolism in enterocytes (intestinal cells), leading to reduced net glucose uptake and increased delivery of lactate to the liver. Recent studies have also implicated the gut as a primary site of action of metformin and suggest that the liver may not be as important for metformin action in patients with type 2 diabetes. Some of the ways metformin may play a role on the intestines is by promoting the metabolism of glucose by increasing glucagon-like peptide I (GLP-1) as well as increasing gut utilization of glucose.[A36534] 



In addition to the above pathway, the mechanism of action of metformin may be explained by other ways, and its exact mechanism of action has been under extensive study in recent years.[A36535, A36554, A36555, A36557]', '**General effects**



Insulin is an important hormone that regulates blood glucose levels.[T514] Type II diabetes is characterized by a decrease in sensitivity to insulin, resulting in elevations in blood glucose when the pancreas can no longer compensate. In patients diagnosed with type 2 diabetes, insulin is unable to exert adequate effects on tissues and cells (i.e. insulin resistance)[T514] and insulin deficiency may also be present.[L5753]



Metformin reduces hepatic production of glucose, decreases the intestinal absorption of glucose, and enhances insulin sensitivity by increasing both peripheral glucose uptake and utilization. In contrast with drugs of the sulfonylurea class, which lead to hyperinsulinemia, the secretion of insulin is unchanged with metformin use.[L12207]



**Effect on fasting plasma glucose (FPG) and Glycosylated hemoglobin (HbA1c)**



HbA1c is an important periodic measure of glycemic control used to monitor diabetic patients. Fasting plasma glucose is also a useful and important measure of glycemic control. In a 29-week clinical trial of subjects diagnosed with type II diabetes, metformin decreased the fasting plasma glucose levels by an average of 59 mg/dL from baseline, compared to an average increase of 6.3 mg/dL from baseline in subjects taking a placebo.[L12207]  Glycosylated hemoglobin (HbA1c) was decreased by about 1.4% in subjects receiving metformin, and increased by 0.4% in subjects receiving placebo only.[L12207]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Glustin 30mg 7 tab.', 19956, 'جلوستين 30 مجم 7 اقراص', '56', NULL, 'Anti-diabetic.sensitizers.glitazone', 'Anti-diabetic.sensitizers.glitazone', NULL, 'Pioglitazone', 'Takeda', 'Tab', 'أقراص', '30mg', '1', NULL, NULL, 'about pioglitazone thiazolidinedione (tzd) derivative insulin sensitizer oral anti diabetic. mechanism of action of pioglitazone the drug exerts antidiabetic action by acting as a selective agonist for the nuclear peroxisome proliferator-activated recepto', NULL, 1026, '2022-07-30', NULL, 0, 'Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.[L11416] It is also available in combination with [metformin],[L11419] [glimepiride],[L11422] or [alogliptin][L11425] for the same indication.', 'Pioglitazone is a selective agonist at peroxisome proliferator-activated receptor-gamma (PPARγ) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver.[L11416,A19759] Activation of PPARγ increases the transcription of insulin-responsive genes involved in the control of glucose and lipid production, transport, and utilization.[A19759] Through this mechanism, pioglitazone both enhances tissue sensitivity to insulin and reduces the hepatic production of glucose (i.e. gluconeogenesis) - insulin resistance associated with type 2 diabetes mellitus is therefore improved without an increase in insulin secretion by pancreatic beta cells.[L11416,A19759]', 'Pioglitazone enhances cellular responsiveness to insulin, increases insulin-dependent glucose disposal, and improves impaired glucose homeostasis.[A19757] In patients with type 2 diabetes mellitus, these effects result in lower plasma glucose concentrations, lower plasma insulin concentrations, and lower HbA1c values.[A19757]

 

Significant fluid retention leading to the development/exacerbation of congestive heart failure has been reported with pioglitazone - avoid its use in patients in heart failure or at risk of developing heart failure.[L11416] There is some evidence that pioglitazone may be associated with an increased risk of developing bladder cancer. Pioglitazone should not be used in patients with active bladder cancer and should be used with caution in patients with a history of bladder cancer.[L11416]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Doxazosin stada 1 mg 20 tab', 17872, 'دوكسازوسين ستادا 1مجم 20 قرص', '15', NULL, 'Antihypertensive.selective alpha 1 receptor blockers', 'Antihypertensive.selective alpha 1 receptor blockers', NULL, 'Doxazosin', 'Global napi pharmaceuticals > stada', 'Tab', 'أقراص', '1 mg', '2', NULL, NULL, NULL, NULL, 2234, '2022-06-12', NULL, 0, 'Doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension.[L7282] Off-label uses of doxazosin include the treatment of pediatric hypertension[A180634] and the treatment of ureteric calculi.[A180637]', 'Doxazosin selectively inhibits the postsynaptic alpha-1 receptors on vascular smooth muscle by nonselectively blocking the alpha-1a, alpha-1b, and alpha-1d subtypes[A180688,A4649]. This action on blood vessels decreases systemic peripheral vascular resistance, reducing blood pressure, exerting minimal effects on the heart rate due to its receptor selectivity.[A180649,A180676] Norepinephrine-activated alpha-1 receptors located on the prostate gland and bladder neck normally cause contraction of regional muscular tissue, obstructing urinary flow and contributing to the symptoms of benign prostatic hypertrophy.  Alpha-1 antagonism causes smooth muscle relaxation in the prostate and bladder, effectively relieving urinary frequency, urgency, weak urinary stream, and other unpleasant effects of BPH.[A180655] Recently, doxazosin was found to cause apoptosis of hERG potassium channels in an in vitro setting, possibly contributing to a risk of heart failure with doxazosin use.[A15296,A180697,A180700] ', 'Doxazosin decreases standing and supine blood pressure[A180649] and relieves the symptoms of benign prostatic hypertrophy through the inhibition of alpha-1 receptors.

Doxazosin may cause hypotension due to its pharmacological actions. This frequently occurs in the upright position, leading to a feeling of dizziness or lightheadedness. The first dose of doxazosin may lead to such effects, however, subsequent doses may also cause them. The risk of these effects is particularly high when dose adjustments occur or there are long intervals between doxazosin doses. Treatment should be started with the 1 mg dose of doxazosin, followed by slow titration to the appropriate dose.[L7282] Patients must be advised of this risk and to avoid situations in which syncope and dizziness could be hazardous following the ingestion of doxazosin.[L7282] Interestingly doxazosin exerts beneficial effects on plasma lipids. It reduces LDL (low-density lipoprotein) cholesterol and triglyceride levels and increases HDL (high-density lipoprotein) cholesterol levels.[A180649]



A note on priapism risk



In rare cases, doxazosin and other alpha-1 blockers may cause priapism, a painful occurrence of persistent and unrelievable penile erection that can lead to impotence if medical attention is not sought as soon as possible. Patients must be advised of the priapism risk associated with doxazosin and to seek medical attention immediately if it is suspected.[A180670,L7282]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Anika hair shampoo 250 ml', 14187, 'انيكا شامبو للشعر 250 مل', '98', NULL, 'Hair care', 'Hair care', NULL, 'Glycerin+almond oil+aloe vera+panthenol+caffeine+jojoba oil+sesame oil+keratin+silicon oil', 'Cosmopack for cosmetics > care mid-east pharma', 'Amp', 'أمبول', '250 ml', '1', 'شامبو غنى بالفيتامينات ومضادات الاكسدة ويعمل على تغذية بصيلات الشعر ومنع التساقط', NULL, 'use: apply on wet hair then rub gently and rinse well with water.', NULL, 985, '2022-07-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rozone pure 20 tab', 3516, 'روزون بيور 20 قرص', '120', NULL, 'Mucolytic anti oxidant', 'Mucolytic anti oxidant', NULL, 'N-acetylene cysteine+selenium', 'Globe health pharmaceutical', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, NULL, 1348, '2025-04-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Collagenex 10 sachets', 16645, 'كولاجينكس 10 اكياس', '130', NULL, 'Antirheumatic.osteoarthritis.anabolic agents', 'Antirheumatic.osteoarthritis.anabolic agents', NULL, 'Gelatin (collagen) hydrolysate+vitamin c+vitamin d3', 'Nutrixia > bestrade pharma', 'Sachet', 'أكياس', NULL, '1', 'غني بالكولاجين -- مرضى الروماتيزم', NULL, 'for healthy joints - for strong bones - orange flavor ** one sachet once daily', '6225000299337', 1907, '2022-05-20', NULL, 0, 'Gelatin is used for weight loss and for treating osteoarthritis, rheumatoid arthritis, and brittle bones (osteoporosis). Some people also use it for strengthening bones, joints, and fingernails. Gelatin is also used for improving hair condition and to shorten the recovery after exercise and sports-related injury [L2113]. Gelatin is used in preparations of foods, cosmetics, and medicine [L2113].



Plasma volume expander in hypovolaemic shock [L2115]. Haemostatic [L2115].



Gelatin-based hydrogels are being used in drug delivery and tissue engineering because they are able to promote cell adhesion and proliferation. In addition, these hydrogels can be used as wound dressings because of their attractive fluid absorbance properties. Manufacturing technologies such as ultraviolet stereolithography and two-photon polymerization can be used to prepare structures containing photosensitive gelatin-based hydrogels [L2111].', 'It works as a hemostatic by providing a physical framework within which clotting may occur [L2115].



As a volume expander, gelatin remains in the vascular space. When used in the treatment of hypovolaemia gelatin can produce a significant increase in blood volume, cardiac output, stroke volume, blood pressure, urinary output and oxygen delivery, increasing volume and pressure [L2117].



For intravascular volume expansion, the majority or gelatins produce an effect which is almost equivalent to of which are mild, although severe reactions albumin, with a duration of action of 3 to 4 hours to have been reported [L2118].



Gelatin or collagen chains suspended in solution can be covalently cross-linked to form matrices that are able to swell in the presence of aqueous solutions, forming what are called _gelatin hydrogels_. Hydrogels, characterized by their hydrophilicity and insolubility in water, have the capability of swelling into an equilibrium volume while maintaining their shape. The chemical cross-linkers used may be either small bifunctional molecules or polyfunctional macromolecules, for example, glutaraldehyde [L2122].', 'Gelatin contains collagen, which is one of the materials that make up cartilage and bone [L2113].



In addition to their well-established value as a nutritional protein source, collagen and collagen-derived products may exhibit various potential biological activities on cells and the extracellular matrix through the corresponding food-derived peptides post-ingestion.  This could justify their applications in dietary supplements and pharmaceutical agents [A32426].



Gelatin is a protein that is used as a hemostatic in surgical procedures.  It is also used as a plasma volume expander in hypovolemic shock. Gelatin rods structures may also be used to temporarily block tear outflow in cases of dry eye [L2115].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Novacortin 1% oint. 15 gm', 23772, 'نوفاكورتين 1% مرهم 15جم', '5', NULL, 'Glucocorticoid', 'Glucocorticoid', NULL, 'Hydrocortisone acetate', 'Pharopharma', 'Oint', 'مرهم', '1%', '1', NULL, NULL, 'this medication is used to treat hemorrhoids and itching/swelling in the rectum and anus. it is also used with other medications to treat certain intestinal problems (such as ulcerative colitis of the rectum and other rectal/anal inflammatory conditions).', NULL, 1846, '2022-07-18', NULL, 0, 'For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn''s disease.', 'Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.', 'Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ketamine-sunny pharmaceutical 500 mg im/iv vial', 7331, 'كيتامين صاني فارماسيوتكال 500مجم فيال', '32', NULL, NULL, NULL, NULL, 'Ketamine', 'Sunny pharmaceutical', 'Vial', 'فيال', '500 mg', '1', NULL, NULL, NULL, NULL, 822, '2022-08-07', NULL, 0, 'Ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agents.[L1336, FDA label]



Reports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower doses.[A31873] These reports have increased the interest for ketamine in this area and several clinical trials are launched for this indication.[L1337, A31874]', 'Ketamine interacts with N-methyl-D-aspartate (NMDA) receptors, opioid receptors, monoaminergic receptors, muscarinic receptors and voltage sensitive Ca ion channels. Unlike other general anaesthetic agents, ketamine does not interact with GABA receptors.[A2187]', 'Ketamine is a rapid-acting general anesthetic producing an anesthetic state characterized by profound analgesia, normal pharyngeal-laryngeal reflexes, normal or slightly enhanced skeletal muscle tone, cardiovascular and respiratory stimulation, and occasionally a transient and minimal respiratory depression. The anesthetic state produced by Ketamine has been termed as "dissociative anesthesia" in that it appears to selectively interrupt association pathways of the brain before producing somesthetic sensory blockade. It may selectively depress the thalamoneocortical system before significantly obtunding the more ancient cerebral centers and pathways (reticular-activating and limbic systems).[A2180]



Ketamine enhances descending inhibiting serotoninergic pathways and can exert antidepressive effects. These effects are seen in concentrations ten times lower than the needed concentration for anesthetic proposes. The effect of ketamine can be described as analgesic by the prevention of central sensitization in dorsal horn neurons as well as by the inhibition on the synthesis of nitric oxide. Ketamine can present cardiovascular changes and bronchodilatation.[A31879]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Investa oil replacement 120 gm', 20919, 'انفستا بديل الزيت 120جم', '130', '80', 'Hair care', 'Hair care', NULL, 'Jojoba + caster oil +caffine +saw palmetto', 'Italian cosmetics co. > safe life', 'Oil', 'زيت', '120 gm', '1', 'زيت للشعر لتنعيمه وتقويته -- تقليل الهيشان والتقصف', NULL, NULL, NULL, 5468, '2024-06-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tragol Drops 15 ml', 3129, 'تراجول 15 مل نقط', '50', NULL, NULL, NULL, NULL, 'Allium sativum bulb oil+tea tree oil+almond oil+lactobbacillus+honey+apple cider vinegar+thymus vulgaris oil+aloevera leaf extract', 'Fonte beam company', 'Drops', 'نقط', '15 ml', '1', NULL, NULL, NULL, NULL, 1164, '2022-09-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Probiotic-seba oral drops 7 ml', 7842, 'ششش', '150', NULL, NULL, NULL, NULL, 'Lactobacillus plantarum 100 million cfu +lactobacillus salivarius 100 million cfu lactobacillus reuteri 100 million cfu +bifidobacterium breve 100 million cfu bifidobacterium longum 100 million cfu +bifidobacterium lactis 100 million cfu bifidobacterium bifidum 100 million cfu +lactobacillus johnsonii 100 million cfu bifidobacterium infantis 100 million cfu+lactobacillus gasseri 100 million cfu liposomal vitamin d3', 'Elsebaeypharma', 'Drops', 'نقط', '7 ml', '1', 'يدعم صحة الجهاز الهضمى', NULL, NULL, NULL, 835, '2025-11-02', NULL, 0, NULL, 'Lactobacillus coryniformis has immunomodulatory activity. Administration of a Lc K8 probiotic prior to the influenza vaccine in adults over the age of 65 showed a higher percentage of vaccine responders and a significantly lower incidence of respiratory symptoms associated with respiratory infections.', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Velosef 1gm 8 tab.', 12154, 'فيلوسيف 1جم 8 اقراص', '98', '68', 'Antibiotic.cephalosporin.first-generation', 'Antibiotic.cephalosporin.first-generation', NULL, 'Cephradine', 'Smithkline beecham > glaxo smithkline', 'Tab', 'أقراص', '1gm', '2', 'مضاد حيوي', NULL, NULL, '6224001007439', 14845, '2024-09-26', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mentovage 50 gm cream', 7960, 'منتوفاج كريم 50 جم', '50', '38.5', 'Antioxidant', 'Antioxidant', NULL, 'Peperrmint +glycerin+vitamin a+vitamin e', 'Scope', 'Cream', 'كريم', '50 gm', '1', 'كريم مسكن للالام -- تقليل الالام العضلات والمفاصل و العظام', NULL, NULL, '6224000547677', 2034, '2024-06-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Amoflux 500mg 16 caps.', 13988, 'اموفلوكس 500مجم 16 كبسولة', '18', NULL, 'Penicillins.penicillin with b-lactamase inhibitor', 'Penicillins.penicillin with b-lactamase inhibitor', NULL, 'Amoxicillin+flucloxacillin', 'Rameda > pioneer pharmaceutical industries', 'Cap', 'كبسولة', '500mg', '2', NULL, NULL, NULL, NULL, 849, '2022-10-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Duricef 500mg/5ml susp. 60ml', 3922, 'ديورسيف 500مجم/5مل معلق 60 مل', '78', '52.5', 'Antibiotic.cephalosporin.first-generation', 'Antibiotic.cephalosporin.first-generation', NULL, 'Cefadroxil', 'Smithkline beecham', 'Susp', 'معلق', '500mg', '1', 'مضاد حيوي.', NULL, 'about cefadroxil first generation cephalosporin para-hydroxy derivative of cefalexin oral broad-spectrum antibiotic mechanism of action cefadroxil is a 1st generation cephalosporin which exerts its bactericidal action against both gram positive & gram neg', '6224001007194', 12693, '2024-08-22', NULL, 0, 'For the treatment of the following infections (skin, UTI, ENT) caused by; <i>S. pneumoniae, H. influenzae, staphylococci, S. pyogenes</i> (group A beta-hemolytic streptococci), <i>E. coli, P. mirabilis, Klebsiella</i> sp, coagulase-negative staphylococci and <i>Streptococcus pyogenes</i>', 'Like all beta-lactam antibiotics, cefadroxil binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefadroxil interferes with an autolysin inhibitor.', 'Cefadroxil, a first-generation cephalosporin antibiotic, is used to treat urinary tract infections, skin and skin structure infections, pharyngitis, and tonsillitis.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Twingo top. lotion 120 ml', 33793, 'توينجو لوشن 120 مل', '69', '59.5', 'Skin care', 'Skin care', NULL, 'Calamine+panthenol', 'Cira pharma', 'Lotion', 'لوشن', '120 ml', '1', NULL, NULL, NULL, '6223008210095', 683, '2024-12-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Alumag 20 tab.', 13860, 'الوماج 20 قرص', '0', NULL, 'Antacid', 'Antacid', NULL, 'Aluminium hydroxide+magnesium trisilicate+peppermint oil', 'Misr', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, NULL, 1018, '2022-07-20', NULL, 0, NULL, 'Aluminum Acetate is an astringent.  An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application.  The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied.  Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete''s foot. ', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('H-formula cream 20 gm', 20445, 'اتش-فورميلا كريم 20 جرام', '24', '13', 'Haemorrhoids', 'Haemorrhoids', NULL, 'Dibucaine+phenylephrine+shark-liver oil', 'Pharopharma', 'Cream', 'كريم', '20 gm', '1', NULL, NULL, 'about dibucaine amide type most potent and toxic long-acting local anaesthetic. mechanism of action of dibucaine dibucaine is a local anesthetic. it works by blocking the pathway of pain signals along nerves. it inhibits conduction of nerve impulses and d', '6221094113344', 2725, '2025-01-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hypopress-d 20 tab.', 20642, 'هيبوبرس-دي 20 قرص', '18', NULL, 'Antihypertensive.combined ace with diuretic', 'Antihypertensive.combined ace with diuretic', NULL, 'Captopril+hydrochlorothiazide', 'Amoun', 'Tab', 'أقراص', NULL, '2', NULL, NULL, 'about captopril a specific competitive angiotensin-converting enzyme (ace) inhibitor antihypertensive. about hydrochlorothiazide thiazide derivatibve diuretic. mechanism of action of hydrochlorothiazide it is thiazide diuretic which exerts its action by a', '6221025017413', 828, '2022-12-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Melatonin shahd pharma 3 mg 30 capsules', 23958, 'ميلاتونين شهد فارما 3مجم 30 كبسولة', '120', NULL, 'Sleep aid', 'Sleep aid', NULL, 'Melatonin', 'Shahd pharma', 'Capsule', 'كبسولة', '3 mg', '3', NULL, NULL, NULL, '6224010912434', 923, '2024-08-31', NULL, 0, 'Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for this use. A number of studies have shown that melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. It appears to decrease the time to fall asleep in children with developmental disabilities, such as cerebral palsy, autism, and mental retardation. It may also improve secondary insomnia associated with various sleep-wake cycle disturbances. Other possible uses for which there is some evidence for include: benzodiazepine withdrawal, cluster headache, delayed sleep phase syndrome (DSPS), primary insomnia, jet lag, nicotine withdrawal, preoperative anxiety and sedation, prostate cancer, solid tumors (when combined with IL-2 therapy in certain cancers), sunburn prevention (topical use), tardive dyskinesia, thrombocytopenia associated with cancer, chemotherapy and other disorders. ', 'Melatonin is a derivative of tryptophan. It binds to melatonin receptor type 1A, which then acts on adenylate cylcase and the inhibition of a cAMP signal transduction pathway. Melatonin not only inhibits adenylate cyclase, but it also activates phosphilpase C. This potentiates the release of arachidonate. By binding to melatonin receptors 1 and 2, the downstream signallling cascades have various effects in the body. The melatonin receptors are G protein-coupled receptors and are expressed in various tissues of the body. There are two subtypes of the receptor in humans, melatonin receptor 1 (MT1) and melatonin receptor 2 (MT2). Melatonin and melatonin receptor agonists, on market or in clinical trials, all bind to and activate both receptor types.The binding of the agonists to the receptors has been investigated for over two decades or since 1986. It is somewhat known, but still not fully understood. When melatonin receptor agonists bind to and activate their receptors it causes numerous physiological processes.

MT1 receptors are expressed in many regions of the central nervous system (CNS): suprachiasmatic nucleus of the hypothalamus (SNC), hippocampus, substantia nigra, cerebellum, central dopaminergic pathways, ventral tegmental area and nucleus accumbens. MT1 is also expressed in the retina, ovary, testis, mammary gland, coronary circulation and aorta, gallbladder, liver, kidney, skin and the immune system. MT2 receptors are expressed mainly in the CNS, also in the lung, cardiac, coronary and aortic tissue, myometrium and granulosa cells, immune cells, duodenum and adipocytes.

The binding of melatonin to melatonin receptors activates a few signaling pathways. MT1 receptor activation inhibits the adenylyl cyclase and its inhibition causes a rippling effect of non activation; starting with decreasing formation of cyclic adenosine monophosphate (cAMP), and then progressing to less protein kinase A (PKA) activity, which in turn hinders the phosphorilation of cAMP responsive element-binding protein (CREB binding protein) into P-CREB. MT1 receptors also activate phospholipase C (PLC), affect ion channels and regulate ion flux inside the cell. The binding of melatonin to MT2 receptors inhibits adenylyl cyclase which decreases the formation of cAMP.[4] As well it hinders guanylyl cyclase and therefore the forming of cyclic guanosine monophosphate (cGMP). Binding to MT2 receptors probably affects PLC which increases protein kinase C (PKC) activity. Activation of the receptor can lead to ion flux inside the cell.', 'Melatonin is a hormone normally produced in the pineal gland and released into the blood. The essential amino acid L-tryptophan is a precursor in the synthesis of melatonin. It helps regulate sleep-wake cycles or the circadian rhythm. Production of melatonin is stimulated by darkness and inhibited by light. High levels of melatonin induce sleep and so consumption of the drug can be used to combat insomnia and jet lag.

MT1 and MT2 receptors may be a target for the treatment of circadian and non circadian sleep disorders because of their differences in pharmacology and function within the SCN. SCN is responsible for maintaining the 24 hour cycle which regulates many different body functions ranging from sleep to immune functions

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ebamoist cream 120 gm', 18019, 'ايبامويست كريم 50 جم', '159', '130', 'Diaper rash', 'Diaper rash', NULL, 'Dimethicone+panthenol+zinc oxide+glycerin+aloe vera+papaya+honey+allantoin+vitamin e', 'El-helou perfumes & cosmetics > beauty & beyond international', 'Cream', 'كريم', '120 gm', '1', NULL, NULL, 'for diaper rash', '6224007424575', 991, '2024-08-29', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Wincef 2gm vial i.m & i.v inj.', 29671, 'وينسيف 2جم فيال عضل.وريد', '119', '82.5', 'Antibiotic.cephalosporin.fourth-generation', 'Antibiotic.cephalosporin.fourth-generation', NULL, 'Cefepime', 'T3a pharma > adwia', 'Inj', 'حقن', '2gm', '1', NULL, NULL, NULL, NULL, 943, '2024-08-03', NULL, 0, 'Cefepime is indicated for the treatment of pneumonia caused by susceptible bacteria, and for empiric therapy for febrile neutropenic patients. Cefepime is also indicated for the treatment of uncomplicated and complicated urinary tract infections (cUTI) including pyelonephritis, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections (used in combination with [metronidazole]) in adults caused by susceptible bacteria.[L42095,L42100]



Cefepime is also used in combination with [enmetazobactam] to treat cUTI.[L50117]', 'Cefepime is a bactericidal cephalosporin with a mode of action similar to other beta-lactam antibiotics.[L42095,L42100] Cefepime disrupts bacterial cell walls by binding and inhibiting transpeptidases known as penicillin-binding proteins (PBPs), which are enzymes involved in the final stages of peptidoglycan layer synthesis. This results in the lysis and death of susceptible microorganisms.[A249050] Cefepime has a broad spectrum of _in vitro_ activity that includes both Gram-positive and Gram-negative bacteria.[L42095,L42100] Cefepime has affinity for PBP-3 and PBP-1 in _Escherichia coli_ and _Pseudomonas aeruginosa_, as well as PBP-2 in _E. coli_ and _Enterobacter cloacae_.[A249050]', 'Cefepime is a fourth-generation cephalosporin antibiotic.[L42095,L42100] It is active against Gram-negative bacteria such as _Enterobacter_ spp., _Escherichia coli_, _Klebsiella pneumoniae_, _Proteus mirabilis_ and _Pseudomonas aeruginosa_, and Gram-positive bacteria such as _Staphylococcus aureus_ (methicillin-susceptible isolates only), _Streptococcus pneumoniae_, _Streptococcus pyogenes_ and Viridans group streptococci.[L42095,L42100] Compared to third-generation cephalosporins, cefepime has an extended Gram-negative coverage. Whereas other cephalosporins are degraded by plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and not significantly hydrolyzed by these enzymes.[A2457,A249050] Cefepime is also a poor inducer of type 1 beta-lactamases and, therefore, a good alternative against bacteria resistant to third-generation cephalosporins.[A2457] 



In animal models of infection, the time that the unbound plasma concentration of cefepime exceeds the minimum inhibitory concentration (MIC) of infecting organisms has been shown to correlate with treatment efficacy.[L42095,L42100] It has been suggested that cefepime can cross the inflamed blood-brain barrier.[L42095,L42100] This, along with its ability to inhibit γ-aminobutyric acid (GABA), could lead to the neurotoxic effects observed in some of the patients treated with cefepime.[A249045,A249050]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('No-uric 300mg 20 tab.', 9026, 'نو-يوريك 300مجم 20 قرص', '38', '26', 'Antigout.xanthine oxidase inhibitor', 'Antigout.xanthine oxidase inhibitor', NULL, 'Allopurinol', 'Eipico', 'Tab', 'أقراص', '300mg', '2', NULL, NULL, NULL, '6221032114143', 8445, '2025-05-20', NULL, 0, 'Allopurinol is indicated in [FDA label]:



1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).



2) the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present.



3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.', 'Allopurinol is a structural analog of the natural purine base, hypoxanthine.  After ingestion, allopurinol is metabolized to its active metabolite, oxypurinol (_alloxanthine_) in the liver [T508], which acts as an inhibitor of xanthine oxidase enzyme [FDA label]. 



Allopurinol and its active metabolite inhibit xanthine oxidase, the enzyme that converts hypoxanthine to xanthine and xanthine to uric acid. Inhibition of this enzyme is responsible for the effects of allopurinol. This drug increases the reutilization of hypoxanthine and xanthine for nucleotide and nucleic acid synthesis by a process that involves the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase).  This process results in an increased nucleotide concentration, which causes feedback inhibition of de novo purine synthesis. The end result is decreased urine and serum uric acid concentrations [F3988], which decreases the incidence of gout symptoms. 



Accompanying the reduction of serum uric acid by allopurinol is an increase in the serum and urine concentrations of hypoxanthine and xanthine (due to inhibition of xanthine oxidase).  In the absence of allopurinol, regular urinary excretion of oxypurines almost entirely occurs in the form of uric acid. After the ingestion of allopurinol, the contents of excreted urine are hypoxanthine, xanthine, and uric acid. Because each substance has its own individual solubility, the concentration of uric acid in plasma is decreased without exposing the renal tissues to a high load of uric acid, thereby decreasing the risk of crystalluria. By lowering the uric acid concentration in the plasma below its limits of solubility, allopurinol encourages the dissolution of gout tophi. Although the levels of hypoxanthine and xanthine are found to be increased after allopurinol ingestion, the risk of deposition in renal tissues is less than that of uric acid, as they become more soluble and are rapidly excreted by the kidney [F3988]. ', '

Allopurinol decreases the production of uric acid by stopping the biochemical reactions that precede its formation [FDA label].  This process decreases urate and relieves the symptoms of gout, which may include painful tophi, joint pain, inflammation, redness, decreased range of motion, and swelling [A665].



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Atomoxetine 40mg 10 caps.', 1087, 'اتوموكستين 40مجم 10 كبسولات', '90', NULL, 'Attention-deficit hyperactivity disorder', 'Attention-deficit hyperactivity disorder', NULL, 'Atomoxetine', 'Sabaa', 'Cap', 'كبسولة', '40mg', '1', 'علاج لمرض فرط الحركة وتشتت الذهن.', NULL, 'description: atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (adhd). dose: dosing of children and adolescents up to 70 kg body weight initial: the recommended dose is 0.5 mg/kg and increas', '6224009704057', 2760, '2023-01-20', NULL, 0, 'Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.', 'Atomoxetine is known to be a potent and selective inhibitor of the norepinephrine transporter (NET),[A175723] which prevents cellular reuptake of norepinephrine throughout the brain, which is thought to improve the symptoms of ADHD. More recently, positron emission tomography (PET) imaging studies in rhesus monkeys have shown that atomoxetine also binds to the serotonin transporter (SERT),[A178111] and blocks the N-methyl-d-aspartate (NMDA) receptor,[A18263] indicating a role for the glutamatergic system in the pathophysiology of ADHD. ', 'Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Atomoxetine has been shown to specifically increase norepinephrine and dopamine within the prefrontal cortex, which results in improved ADHD symptoms.[A18262, A18262, F4639]



Due to atomoxetine''s noradrenergic activity, it also has effects on the cardiovascular system such as increased blood pressure and tachycardia.[T244] Sudden deaths, stroke, and myocardial infarction have been reported in patients taking atomoxetine at usual doses for ADHD. Atomoxetine should be used with caution in patients whose underlying medical conditions could be worsened by increases in blood pressure or heart rate such as certain patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease. It should not be used in patients with severe cardiac or vascular disorders whose condition would be expected to deteriorate if they experienced clinically important increases in blood pressure or heart rate. Although the role of atomoxetine in these cases is unknown, consideration should be given to not treating patients with clinically significant cardiac abnormalities. Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during atomoxetine treatment should undergo a prompt cardiac evaluation.[F4639]



In general, particular care should be taken in treating ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in patients at risk for bipolar disorder. Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by atomoxetine at usual doses. If such symptoms occur, consideration should be given to a possible causal role of atomoxetine, and discontinuation of treatment should be considered.[F4639]



Atomoxetine capsules increased the risk of suicidal ideation in short-term studies in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). All pediatric patients being treated with atomoxetine  should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.[F4639]



Postmarketing reports indicate that atomoxetine can cause severe liver injury. Although no evidence of liver injury was detected in clinical trials of about 6000 patients, there have been rare cases of clinically significant liver injury that were considered probably or possibly related to atomoxetine use in postmarketing experience. Rare cases of liver failure have also been reported, including a case that resulted in a liver transplant. Atomoxetine should be discontinued in patients with jaundice or laboratory evidence of liver injury, and should not be restarted. Laboratory testing to determine liver enzyme levels should be done upon the first symptom or sign of liver dysfunction (e.g., pruritus, dark urine, jaundice, right upper quadrant tenderness, or unexplained “flu like” symptoms).[F4639]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nuxe nuxuriance ultra fluid cream 50 ml', 23884, 'نوكس نوكسيلينس الترا كريم 50مل', '999', '915', 'Skin care', 'Skin care', NULL, NULL, 'Nuxe laboratory > biotech egypt', 'Cream', 'كريم', '50 ml', '1', NULL, NULL, 'this anti-ageing fluid cream with saffron and bougainvillea bi-floral cells helps regenerate the skin reshape facial contours and smooth away wrinkles. skin appears younger: smooth and dense seemingly replumped. its natural radiance is enhanced. pores are', NULL, 596, '2023-09-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('C-mix plus skin serum 10 vials', 16574, 'سي مكس بلس سيروم 10 فيال', '425', '295', 'Skin care', 'Skin care', NULL, 'Vitamin c+collagen+hylouronic acid', 'Egyptian company for cosmetics > pharmix', 'Vial', 'فيال', NULL, '1', NULL, NULL, 'concentrated vitamin c 10 %', NULL, 575, '2024-03-02', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ivy herb syrup 120 ml', 30724, 'ايفي هيرب شراب 120 مل', '60', '50', 'Anti-cough.anti-tussive.expectorant', 'Anti-cough.anti-tussive.expectorant', NULL, 'Ivy leaves', 'Organix > generica pharma', 'Syrup', 'شراب', '120 ml', '1', '1- يستخدم فى علاج اعراض الكحة.', NULL, 'due to their broncholytic and secretolytic proprties ivy leaf dried extract has long provided its worth in practice. their efficacy has been demonstrated in numerous scientific studies. according to a pharmacological investigation its constituent appears', '6225000527621', 25474, '2025-02-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Paclitax 100 mg vial', 9544, 'باكليتاكس 100مجم فيال', '800', NULL, 'Antineoplastic', 'Antineoplastic', NULL, 'Paclitaxel', 'Star international company', 'Vial', 'فيال', '100 mg', '1', NULL, NULL, 'about paclitaxel taxane derivative microtubule inhibitor(mitotic inhibitor) antineoplastic. mechanism of action of paclitaxel drug binds specifically to the beta- tubuline and then enhances the polymerization of tubuline to stable microtubules. it also in', NULL, 943, '2022-08-13', NULL, 0, 'Used in the treatment of Kaposi''s sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.', 'Paclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell''s ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the &beta; subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.', 'Paclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sonidair 0.25 mg/2ml 30 susp. amp. for inh.', 14925, 'سونيدير 0.25 مجم/2 مل 30 امبول للاستنشاق', '300', NULL, 'Bronchodilator.anti-inflammatory.glucocorticoid steroid', 'Bronchodilator.anti-inflammatory.glucocorticoid steroid', NULL, 'Budesonide', 'Mdi pharma', 'Susp', 'معلق', '0.25 mg', '1', NULL, NULL, NULL, '6224002249036', 974, '2022-09-04', NULL, 0, 'Budesonide extended-release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease.[L10601,L10604] Various inhaled budesonide products are indicated for prophylactic therapy in asthma [L10607,L10613,L10619] and to reduce exacerbations of COPD.[L10619] A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies.[L10616] Extended-release capsules are indicated to induce remission of mild to moderate ulcerative colitis[L10622] and a rectal foam is used for mild to moderate distal ulcerative colitis.[L10625] In addition, a delayed-release capsule formulation of budesonide is indicated to reduce proteinuria in adults with IgA nephropathy at risk of rapid disease progression.[L42515,L49540] Budesonide is indicated to treat eosinophilic esophagitis (EoE): For this indication, it is only approved for use in adults in Europe [L42525] while it is approved for short-term use (12 weeks) in patients 11 years of age and older in the US.[L50161]', 'The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.[A187463] Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.[A187463]



Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.[A187463]



Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.[A187463] High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.[A187463]', 'Budesonide is a glucocorticoid used to treat respiratory and digestive conditions by reducing inflammation.[L10601,L10604,L10607,L10613,L10619,L10622,L10625] It has a wide therapeutic index, as dosing varies highly from patient to patient.[L10601,L10604,L10607,L10613,L10619,L10622,L10625] Patients should be counselled regarding the risk of hypercorticism and adrenal axis suppression.[L10601,L10604,L10607,L10613,L10619,L10622,L10625]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Roma prom 30 tablets', 28459, 'روما بروم 30 قرص', '195', NULL, 'Dietary supplement', 'Dietary supplement', NULL, 'Glucosamine sulfate+condrotin sulfate+hyaluronic acid+msm+cacium', 'Promise pharm', 'Tablet', 'أقراص', NULL, '3', 'مكمل غذائى داعم لصحة المفاصل والغضاريف والعظام', NULL, NULL, NULL, 929, '2022-07-09', NULL, 0, 'Glucosamine is generally used over the counter in the symptomatic treatment of osteoarthritis and joint pain,[A2352] frequently combined with chondroitin sulfate and/or ibuprofen.[L32699]', 'The mechanism of action of glucosamine in joint health is unclear,[A231894] however there are several possible mechanisms that contribute to its therapeutic effects. Because glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage,[A232289] glucosamine supplements may help to rebuild cartilage and treat the symptoms of arthritis.  Some in vitro studies show evidence that glucosamine reduces inflammation via inhibition of interferon gamma[A12619,A12616,A12621]  and Nuclear factor kappa B subunit 65 (NF-κB p65),[A12616,A232284] improving the symptoms of arthritis and joint pain. Clinical relevance is unknown at this time.', 'The administration of glucosamine, in theory, provides a building block towards the synthesis of glycosaminoglycans, slowing the progression of osteoarthritis and relieving symptoms of joint pain. Studies to this date examining the efficacy of glucosamine sulfate have been inconclusive. Glycosaminoglycans contribute to joint cartilage elasticity, strength, and flexibility.[A232144] A systematic review of various studies and guidelines determined that modest improvements were reported for joint pain and function in patients taking glucosamine. A consistent joint space narrowing was observed, but with an unclear clinical significance.[A231894]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Quitcool xr 50mg 30 ext. rel. f.c. tabs.', 25566, 'كويتكول اكس ار 500مجم 30 قرص', '135', '102', 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Quetiapine', 'Hikma pharma', 'Tab', 'أقراص', '50mg', '3', NULL, NULL, 'indication for the treatment of schizophrenia and related psychotic disorders. pharmacodynamics quetiapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. quetiapine', '6221000001031', 1076, '2025-02-08', NULL, 0, 'Quetiapine is used in the symptomatic treatment of schizophrenia.  In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546]



Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson''s disease.[A185438,A185447,T685]

', 'Although the mechanism of action of quetiapine is not fully understood, several proposed mechanisms exist. In schizophrenia, its actions could occur from the antagonism of dopamine type 2 (D2) and serotonin 2A (5HT2A) receptors. In bipolar depression and major depression, quetiapine''s actions may be attributed to the binding of this drug or its metabolite to the norepinephrine transporter. Additional effects of quetiapine, including somnolence, orthostatic hypotension, and anticholinergic effects, may result from the antagonism of H1 receptors, adrenergic α1 receptors, and muscarinic M1 receptors, respectively.[A2189,A185438,L8546]', 'Quetiapine improves the positive and negative symptoms of schizophrenia and major depression by acting on various neurotransmitter receptors, such as the serotonin and dopamine receptors. In bipolar disorder, it improves both depressive and manic symptoms.[A2189,A185441,A185444]



**A note on suicidality in young patients and administration in the elderly**



Quetiapine can cause suicidal thinking or behavior in children and adolescents and should not be given to children under 10 years of age. It is important to monitor for suicidality if this drug is given to younger patients. In addition, this drug is not indicated for the treatment of psychosis related to dementia due to an increased death rate in elderly patients taking this drug.[L8546]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Glucose 40% (mottahedoon) i.v. inf. 25 ml', 19922, 'جلوكوز 40% المتحدون محلول وريدي 25 مل', '1', NULL, 'Antihypoglycemic', 'Antihypoglycemic', NULL, 'Glucose (dextrose)', 'Al mottahedoon pharma', 'Unknown', 'غير محدد', '40%', '1', NULL, NULL, 'about glucose monosaccharide aldohexose nutritive sweetner. mechanism of action of glucose glucose is a simple carbohydrate and is used as energy source in man. it is readily converted to fat which provides a rich store of energy in concentrated form. glu', NULL, 1037, '2022-07-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sanso collagen fit syrup 315 ml', 26518, 'سانسو كولاجين فيت شراب 315 مل', '400', NULL, 'Antirheumatic.osteoarthritis.anabolic agents', 'Antirheumatic.osteoarthritis.anabolic agents', NULL, 'Gelatin (collagen) hydrolysate+vitamin c', 'Aug pharma', 'Syrup', 'شراب', '315 ml', '1', 'مضاد للروماتيزم --علاج التهاب المفاصل -- عوامل بنائية لانسجة الجسم', NULL, 'each serving (15ml) contains: hydrolyzed collagen ... 1200 mg glucosamine sulfate ... 1500 mg chondroitin sulfate ... 500 mg msm ... 400 mg for osteoarthritis and joint stiffness. dose: 15 ml once daily.', NULL, 2291, '2022-02-12', NULL, 0, 'Gelatin is used for weight loss and for treating osteoarthritis, rheumatoid arthritis, and brittle bones (osteoporosis). Some people also use it for strengthening bones, joints, and fingernails. Gelatin is also used for improving hair condition and to shorten the recovery after exercise and sports-related injury [L2113]. Gelatin is used in preparations of foods, cosmetics, and medicine [L2113].



Plasma volume expander in hypovolaemic shock [L2115]. Haemostatic [L2115].



Gelatin-based hydrogels are being used in drug delivery and tissue engineering because they are able to promote cell adhesion and proliferation. In addition, these hydrogels can be used as wound dressings because of their attractive fluid absorbance properties. Manufacturing technologies such as ultraviolet stereolithography and two-photon polymerization can be used to prepare structures containing photosensitive gelatin-based hydrogels [L2111].', 'It works as a hemostatic by providing a physical framework within which clotting may occur [L2115].



As a volume expander, gelatin remains in the vascular space. When used in the treatment of hypovolaemia gelatin can produce a significant increase in blood volume, cardiac output, stroke volume, blood pressure, urinary output and oxygen delivery, increasing volume and pressure [L2117].



For intravascular volume expansion, the majority or gelatins produce an effect which is almost equivalent to of which are mild, although severe reactions albumin, with a duration of action of 3 to 4 hours to have been reported [L2118].



Gelatin or collagen chains suspended in solution can be covalently cross-linked to form matrices that are able to swell in the presence of aqueous solutions, forming what are called _gelatin hydrogels_. Hydrogels, characterized by their hydrophilicity and insolubility in water, have the capability of swelling into an equilibrium volume while maintaining their shape. The chemical cross-linkers used may be either small bifunctional molecules or polyfunctional macromolecules, for example, glutaraldehyde [L2122].', 'Gelatin contains collagen, which is one of the materials that make up cartilage and bone [L2113].



In addition to their well-established value as a nutritional protein source, collagen and collagen-derived products may exhibit various potential biological activities on cells and the extracellular matrix through the corresponding food-derived peptides post-ingestion.  This could justify their applications in dietary supplements and pharmaceutical agents [A32426].



Gelatin is a protein that is used as a hemostatic in surgical procedures.  It is also used as a plasma volume expander in hypovolemic shock. Gelatin rods structures may also be used to temporarily block tear outflow in cases of dry eye [L2115].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Clavocillin 625 mg 10 dispersible tabs.', 31799, 'كلافوسيلين 625مجم 10 اقراص', '32', NULL, 'Penicillins.penicillin with b-lactamase inhibitor', 'Penicillins.penicillin with b-lactamase inhibitor', NULL, 'Amoxicillin+clavulanic acid', 'Rameda > organopharma', 'Tab', 'أقراص', '625 mg', '1', NULL, NULL, 'amoxicillin is an analog of ampicillin derived from the basic penicillin nucleus 6-aminopenicillanic acid clavulanic acid is produced by the fermentation of streptomyces clavuligerus. it is a beta-lactam structurally related to the penicillins and possess', NULL, 1209, '2023-05-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Flustop 20 tab.', 19242, 'فلوستوب 20 قرص', '4', NULL, 'Cold drugs', 'Cold drugs', NULL, 'Caffeine+chlorpheniramine+paracetamol(acetaminophen)+pseudoephedrine', 'Glaxo smithkline', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, '6221045008743', 1473, '2022-12-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('White means white skin serum 40 ml', 29659, 'وايت مينز وايت سكين سيروم 40 مل', '280', '240', 'Skin care', 'Skin care', NULL, NULL, 'Egyptian co. for cosemetics > solo pharm co.', 'Serum', 'سيروم', '40 ml', '1', 'للعناية بالبشرة', NULL, '-anti-aging & anti-wrinkles. -lightening serum. -moisturizing. use: twice daily.', NULL, 1662, '2025-08-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mena q-90 20 caps.', 32227, 'مينا كيو-90 20 كبسولة', '130', NULL, 'Vitamin k supplement', 'Vitamin k supplement', NULL, 'Menaquinone-7=vitamin k2', 'Devartlab pharma', 'Cap', 'كبسولة', NULL, '2', NULL, NULL, NULL, '8990800307046', 1474, '2023-04-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Diet-sweet 115 gm jar', 3652, 'دايت-سويت 115 جرام برطمان بودرة', '19', NULL, 'Sweetener', 'Sweetener', NULL, 'Aspartame', 'Amriya', 'Unknown', 'غير محدد', '115 gm', '1', NULL, NULL, NULL, '6221075130018', 1102, '2022-12-04', NULL, 0, 'Used as a diet supplement and sugar substitute.', '180 to 200 times sweeter than sucrose, it is metabolized as a protein and its subsequent amino-acids used up in there respective mechanisms.', 'Aspartame (L-alpha-aspartyl-L-phenylalanine methyl ester) is a low-calorie sweetener used to sweeten a wide variety of low- and reduced-calorie foods and beverages, including low-calorie tabletop sweeteners. Aspartame is composed of two amino acids, aspartic acid and phenylalanine, as the methyl ester. Aspartic acid and phenylalanine are also found naturally in protein containing foods, including meats, grains and dairy products. Methyl esters are also found naturally in many foods such as fruits and vegetable and their juices. Upon digestion, aspartame breaks down into three components (aspartic acid, phenylalanine and methanol), which are then absorbed into the blood and used in normal body processes. Neither aspartame nor its components accumulates in the body. These components are used in the body in the same ways as when they are derived from common foods.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rheumisal linement 60 ml', 26025, 'روميسال لينيمنت 60مل', '6', NULL, 'Analgesic', 'Analgesic', NULL, 'Belladonna+camphor+methyl salicylate+turpentine oil', 'Mepaco', 'Unknown', 'غير محدد', '60 ml', '1', NULL, NULL, NULL, '6223002210022', 720, '2022-12-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Paramol 1000 mg 20 tabs.', 13336, 'بارامول 1000 مجم 20 قرص', '52', '32', 'Analgesic.antipyretic', 'Analgesic.antipyretic', NULL, 'Paracetamol(acetaminophen)', 'Misr', 'Tab', 'أقراص', '1000 mg', '2', 'مسكن الام . خافض حرارة', NULL, 'about paracetamol acetanilide derivative non narcotic analgesic antipyretic. mechanism of action of paracetamol paracetamol has analgesic and antipyretic action. it is more active on cyclo-oxygenase enzyme in brain. peripherally it is a poor inhibitor of', '6221035009606', 16754, '2024-12-31', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Compholex massage cream 50 gm', 16687, 'كومبوليكس كريم مساج 50 جم', '45', NULL, 'Massage', 'Massage', NULL, 'Massage cream formula', 'Egyptian company for cosmetics > eval pharma', 'Cream', 'كريم', '50 gm', '1', 'كريم مساج', NULL, NULL, NULL, 1206, '2022-05-28', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bariesun spf 50- mineral cream 50ml', 1301, 'باريصن اس بي اف مينرال كريم 50 مل', '275', NULL, 'Sun block', 'Sun block', NULL, NULL, 'Uriage dermatological laboratories > biotech egypt', 'Cream', 'كريم', '50ml', '1', NULL, NULL, NULL, NULL, 1156, '2022-09-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Egy ostoval 14 tabs', 32307, 'ايجي اوستوفال 14 قرص', '64', '46', 'Calcium supplement', 'Calcium supplement', NULL, 'Dibasic calcium phosphate anhydrous+cholecalciferol+pyridoxine+boron trioxide+phytomenadione+ascorbi', 'Egyphar', 'Tab', 'أقراص', NULL, '1', NULL, NULL, NULL, NULL, 1656, '2025-06-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Seragesta 30 chewable tablets', 4795, 'سيراجيستا 30 قرص', '135', NULL, 'Multivitamin', 'Multivitamin', NULL, 'Methylcobalamin+methylfolate', 'Theratica pharma', 'Tablet', 'أقراص', NULL, '3', NULL, NULL, NULL, NULL, 948, '2025-06-21', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Relikast 5mg 10 chewable tab.', 25842, 'ريليكاست 5مجم 10 اقراص', '25', NULL, 'Asthma.anti-inflammatory.leukotriene antagonist', 'Asthma.anti-inflammatory.leukotriene antagonist', NULL, 'Montelukast', 'Sigma', 'Tab', 'أقراص', '5mg', '1', NULL, NULL, 'about montelukast leukotriene(cyslt1) receptor antagonist antiinflammatory antiasthma. mechanism of action of montelukast montelukast is competitively and selectively antagonizes cyslt1 receptor (leukotrienes receptor) mediated bronchoconstriction.montelu', NULL, 873, '2022-07-16', NULL, 0, 'Montelukast is indicated for:



(a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304];



(b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307]; and



(c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307].



Furthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331]



Moreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328]



Additionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an ''as required'' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]', 'Cysteinyl leukotrienes (CysLT) like LTC4, LTD4, and LTE4, among others, are eicosanoids released by a variety of cells like mast cells and eosinophils.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] When such CysLT bind to corresponding CysLT receptors like CysLT type-1 receptors located on respiratory airway smooth muscle cells, airway macrophages, and on various pro-inflammatory cells like eosinophils and some specific myeloid stem cells activities that facilitate the pathophysiology of asthma and allergic rhinitis are stimulated.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, CysLT-mediated airway bronchoconstriction, occluding mucous secretion, vascular permeability, and eosinophil recruitment are all types of effects that facilitate asthma.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Alternatively, in allergic rhinitis, CysLTs are released by the nasal mucosa when exposed to allergens during both early and late phase reactions and participate in eliciting symptoms of allergic rhinitis like a congested nose and airway.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Subsequently, montelukast is a leukotriene receptor antagonist that binds with high affinity and selectivity to the CysLT type 1 receptor, which consequently assists in inhibiting any physiological actions of CysLTs like LTC4, LTD4, and LTE4 at the receptor that may facilitate asthma or allergic rhinitis.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'Montelukast is a leukotriene receptor antagonist that demonstrates a marked affinity and selectivity to the cysteinyl leukotriene receptor type-1 in preference to many other crucial airway receptors like the prostanoid, cholinergic, or beta-adrenergic receptors.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] As a consequence, the agent can elicit substantial blockage of LTD4 leukotriene-mediated bronchoconstriction with doses as low as 5 mg.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Moreover, a placebo-controlled, crossover study (n=12) demonstrated that montelukast is capable of inhibiting early and late phase bronchoconstriction caused by antigen challenge by 75% and 57% respectively.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, it has been documented that montelukast can cause bronchodilation as soon as within 2 hours of oral administration.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] This action can also be additive to the bronchodilation caused by the concomitant use of a beta agonist.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Nevertheless, clinical investigations performed with adults 15 years of age and older revealed that no additional clinical benefit is obtained when doses of montelukast greater than 10 mg a day are used.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Additionally, in clinical trials with adults and pediatric asthmatic patients aged 6 to 14 years, it was also determined that montelukast can reduce mean peripheral blood eosinophils by about 13% to 15% from baseline in comparison to placebo during double-blind treatment periods.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] At the same time, in patients aged 15 years and older who were experiencing seasonal allergic rhinitis, the use of montelukast caused a median reduction of 13% in peripheral blood eosinophil counts when compared to placebo as well.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Minirin 4mcg/ml 10 amp. for i.m./i.v./s.c. inj.', 22788, 'مينيرين 4مكجم/مل 10 امبول عضل وريد تحت الجلد حقن', '90', NULL, 'Urinary incotinence.antidiuretic', 'Urinary incotinence.antidiuretic', NULL, 'Desmopressin acetate', 'Ferring pharmaceuticals > multipharma', 'Inj', 'حقن', '4mcg', '10', NULL, NULL, NULL, NULL, 918, '2022-07-09', NULL, 0, '- Indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void (intranasal). 



- Indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral).



- Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% or mild to moderate classic von Willebrand''s Disease (Type I) with factor VIII levels greater than 5% during surgical procedures and postoperatively to maintain hemostasis (parenteral).', 'Upon binding of desmopressin to V2 receptors in the basolateral membrane of the cells of the distal tubule and collecting ducts of the nephron, adenylyl cyclase is stimulated. The resulting intracellular cascades in the collecting duct lead to increased rate of insertion of water channels, called aquaporins, into the lumenal membrane and enhanced the permeability of the membrane to water [T28]. ', 'By mimicking the actions of endogenous ADH, desmopressin acts as a selective agonist of V2 receptors expressed in the renal collecting duct (CD) to increase water re-absorption and reduce urine production. Desmopressin has been shown to be more potent than ADH in increasing plasma levels of factor VIII activity in patients with hemophilia and von Willebrand''s disease Type I [L1183]. Desmopressin demonstrates markedly diminished pressor activity. Desmopressin administered intranasally has an antidiuretic effect about one-tenth that of an equivalent dose administered by injection [L1182].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Itotaxime 0.5 gm vial', 6665, 'ايتوتاكسيم 0.5 جم فيال', '20', '15', 'Antibiotic.cephalosporin.third-generation', 'Antibiotic.cephalosporin.third-generation', NULL, 'Cefotaxime', 'Kahira > international trading office', 'Vial', 'فيال', '0.5 gm', '1', NULL, NULL, 'about cefotaxime third generation cephalosporin parenteral antibiotic. mechanism of action of cefotaxime cefotaxime is a 3rd generation cephalosporin which exerts its bactericidal action against both gram positive & aerobic gram negative organisms by inhi', '6223004199653', 852, '2024-05-20', NULL, 0, 'Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.', 'The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefotaxime shows high affinity for penicillin-binding proteins in the cell wall including PBP Ib and PBP III.', 'Cefotaxime is a third generation intravenous cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against <i>Pseudomonas aeruginosa</i>. Cefotaxime works by inhibiting bacterial cell wall biosynthesis. A positive feature of cefotaxime is that it display a resistance to penicillinases and is useful to treat infections that are resistant to penicillin derivatives.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Isis chamomile 12 filter bags', 30709, 'ايزيس كاموميل 12 فلتر باكو', '20', '18.5', 'Drinks', 'Drinks', NULL, 'Chamomile', 'Atos pharma', 'Unknown', 'غير محدد', NULL, '1', NULL, NULL, NULL, NULL, 944, '2025-08-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rivarospire 10 mg 20 f.c. tab.', 26200, 'ريفاروسبير 10مجم 20 قرص', '254', '210', 'Antiplatelet.direct factor xa inhibitor', 'Antiplatelet.direct factor xa inhibitor', NULL, 'Rivaroxaban', 'Sedico > inspire pharmaceutical company', 'Tab', 'أقراص', '10 mg', '2', 'مضاد للتجلط', NULL, NULL, '6224000866211', 11081, '2024-06-25', NULL, 0, 'Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Its use is also not recommended in those with severe renal impairment (<30mL/min).[L12819]



Rivaroxaban is also indicated for the treatment and prevention of VTE in pediatric patients (from birth to 18 years of age) and for thromboprophylaxis in pediatric patients ≥2 years old with congenital heart disease following the Fontan procedure.[L12819]

', 'Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible.

 

', 'Rivaroxaban is an anticoagulant which binds directly to factor Xa. Thereafter, it effectively blocks the amplification of the coagulation cascade, preventing the formation of thrombus. Rivaroxaban is a unqiue anticoagulant for two reasons. First of all, it is does not involve antithrombin III (ATIII) to exert its anticoagulant effects. Secondly, it is an oral agent whereas the widely used unfractionated heparin and low molecular weight heparins are for parenteral use only. Although the activated partial thromboplastin time (aPTT) and HepTest (a test developed to assay low molecular weight heparins) are prolonged in a dose-dependant manner, neither test is recommended for the assessment of the pharmacodynamic effects of rivaroxaban. Anti-Xa activity and inhibition of anti-Xa activity monitoring is also not recommended despite being influenced by rivaroxaban.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Glucose 25% (mottahedoon) i.v. inf. 500 ml', 19917, 'جلوكوز 25% المتحدون محلول وريدي 500 مل', '20', NULL, 'Sterile solution', 'Sterile solution', NULL, 'Glucose (dextrose)', 'Al mottahedoon pharma', 'Unknown', 'غير محدد', '25%', '1', NULL, NULL, 'about glucose monosaccharide aldohexose nutritive sweetner. mechanism of action of glucose glucose is a simple carbohydrate and is used as energy source in man. it is readily converted to fat which provides a rich store of energy in concentrated form. glu', '6223003950163', 753, '2022-07-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Zithrodose 2gm/60ml pd. for oral susp', 29971, 'زيثرودوز 2جرام/60مل باودر لعمل معلق بالفم', '34', NULL, 'Antibiotic.macrolide', 'Antibiotic.macrolide', NULL, 'Azithromycin', 'Averroes pharma-egypt', 'Susp', 'معلق', '2gm', '1', NULL, NULL, NULL, NULL, 1072, '2022-06-16', NULL, 0, 'Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin [FDA label].



Azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below. Recommended dosages, duration of therapy and considerations for various patient populations may vary among these infections. Refer to the FDA label and "Indications" section of this drug entry for detailed information [FDA label]. 



**Adults**:



Acute bacterial exacerbations of chronic obstructive pulmonary disease due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Acute bacterial sinusitis due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.

Uncomplicated skin and skin structure infections due to _Staphylococcus aureus_, _Streptococcus pyogenes_, or _Streptococcus agalactiae_. Abscesses usually require surgical drainage.



Urethritis and cervicitis due to _Chlamydia trachomatis_ or _Neisseria gonorrhoeae_.



Genital ulcer disease in men due to _Haemophilus ducreyi_ (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established.



**Pediatric Patients**



Acute otitis media caused by _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy.



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.', 'In order to replicate, bacteria require a specific process of protein synthesis, enabled by ribosomal proteins [A6505]. Azithromycin binds to the 23S rRNA of the bacterial 50S ribosomal subunit. It stops bacterial protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit [FDA label], [A14179]. This results in the control of various bacterial infections [A174193], [FDA label].   The strong affinity of macrolides, including azithromycin, for bacterial ribosomes, is consistent with their broad‐spectrum antibacterial activities [A174193].





Azithromycin is highly stable at a low pH, giving it a longer serum half-life and increasing its concentrations in tissues compared to erythromycin [A174175]. 



', 'Macrolides stop bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections [A174175].

Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose [A174172].



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sweetal 1g*60 sachets', 496, 'سويتال 1 جم 60 كيس', '75', '65', 'Sweetener', 'Sweetener', NULL, 'Sorbitol+sucralose', 'Biopharm egypt > hygint pharmaceuticals-egypt', 'Sachet', 'أكياس', NULL, '1', 'سكر صناعي', NULL, NULL, '6225000047730', 1039, '2024-01-31', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Butacid 10mg 6supp', 1809, 'بيوتاسيد 10 مجم 6 اقماع', '3', NULL, 'Antispasmodic', 'Antispasmodic', NULL, 'Hyoscine-n-butyl bromide', 'Cid', 'Supp', 'لبوس', '10mg', '1', NULL, NULL, NULL, NULL, 848, '2022-09-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Profusol 400mg 10 s.g caps.', 25319, 'بروفوسول 400مجم 10 كبسولات', '7', NULL, 'Nsaid.propionic acid derivatives', 'Nsaid.propionic acid derivatives', NULL, 'Ibuprofen', 'European egyptian pharm. ind.', 'Cap', 'كبسولة', '400mg', '1', NULL, NULL, 'about ibuprofen nsaid a propionic acid derivative analgesic and anti-inflammatory. mechanism of action of ibuprofen ibuprofen has analgesic anti-inflammatory and antipyretic action. it acts by inhibiting prostaglandin (pgs) synthesis and their release at', '6221076120544', 876, '2022-12-08', NULL, 0, 'Ibuprofen is the most commonly used and prescribed NSAID. It is a very common over-the-counter medication widely used as an analgesic, anti-inflammatory and antipyretic.[A39096]



The use of ibuprofen and its enantiomer [DB09213] in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea, headache, migraine, postoperative dental pain, spondylitis, osteoarthritis, rheumatoid arthritis, and soft tissue disorder.[A39097]



Due to its activity against prostaglandin and thromboxane synthesis, ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labour.[A39092]



As ibuprofen is a widely used medication, the main therapeutic indications are:



* Patent Ductus Arteriosus - it is a neonatal condition wherein the ductus arteriosus (blood vessel that connects the main pulmonary artery to the proximal descending aorta) fails to close after birth causing severe risk of heart failure. The prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin E2 is responsible for keeping the ductus arteriosus open.[A39100]



* Rheumatoid- and osteo-arthritis - ibuprofen is very commonly used in the symptomatic treatment of inflammatory, musculoskeletal and rheumatic disorders.[A39176]



* Cystic fibrosis - the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungs.[A39177]



* Orthostatic hypotension - ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotension.[A1651]



* Dental pain - ibuprofen is used to manage acute and chronic orofacial pain.[A10901]



* Pain - ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea. It is very commonly used for the relief of acute indications such as fever and tension headaches.[A39092] It is also used to manage mild to moderate pain and moderate to severe pain as an adjunct to opioid analgesics.[L40208]



* Investigational uses - efforts have been put into developing ibuprofen for the prophylaxis of Alzheimer''s disease, Parkinson disease, and breast cancer.[A39092]', 'The exact mechanism of action of ibuprofen is unknown. However, ibuprofen is considered an NSAID and thus it is a non-selective inhibitor of cyclooxygenase, which is an enzyme involved in prostaglandin (mediators of pain and fever) and thromboxane (stimulators of blood clotting) synthesis via the arachidonic acid pathway.[L4614]



Ibuprofen is a non-selective COX inhibitor and hence, it inhibits the activity of both COX-1 and COX-2. The inhibition of COX-2 activity decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever, and swelling while the inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration.[A39195]', 'Ibuprofen has multiple actions in different inflammatory pathways involved in acute and chronic inflammation. The main effects reported in ibuprofen are related to the control of pain, fever and acute inflammation by the inhibition of the synthesis of prostanoids by COX-1 and COX-2. Pain relief is attributed to peripheral affected regions and central nervous system effects in the pain transmission mediated by the dorsal horn and higher spinothalamic tract. Some reports have tried to link the pain regulation with a possible enhancement on the synthesis of endogenous cannabinoids and action on the NMDA receptors. The effect on pain has been shown to be related to the cortically evoked potentials.[A39190]



The antipyretic effect is reported to be linked to the effect on the prostanoid synthesis due to the fact that the prostanoids are the main signaling mediator of pyresis in the hypothalamic-preoptic region.[A39190]



The use of ibuprofen in dental procedures is attributed to the local inhibition of prostanoid production as well as to anti-oedemic activity and an increase of plasma beta-endorphins. Some reports have suggested a rapid local reduction of the expression of COX-2 in dental pulp derived by the administration of ibuprofen.[A39190]



The administration of ibuprofen in patients with rheumatic diseases has shown to control joint symptoms.[A39092] 



Ibuprofen is largely used in OTC products such as an agent for the management of dysmenorrhea which has been proven to reduce the amount of menstrual prostanoids and to produce a reduction in the uterine hypercontractility.[A39181] As well, it has been reported to reduce significantly the fever and the pain caused by migraines.[A39182, A39183] This effect is thought to be related to the effect on platelet activation and thromboxane A2 production which produces local vascular effects in the affected regions. This effect is viable as ibuprofen can enter in the central nervous system.[A39190]



In the investigational uses of ibuprofen, it has been reported to reduce neurodegeneration when given in low doses over a long time.[A39184] On the other hand, its use in Parkinson disease is related to the importance of inflammation and oxidative stress in the pathology of this condition.[A39185] The use of ibuprofen for breast cancer is related to a study that shows a decrease of 50% in the rate of breast cancer.[A39186]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Topamax 50 mg sprinkle 60 caps.', 28298, 'توباماكس 50مجم 60 كبسول', '200', NULL, 'Anti-epileptic.fructose derivative', 'Anti-epileptic.fructose derivative', NULL, 'Topiramate', 'Janssen cilag', 'Cap', 'كبسولة', '50 mg', '1', NULL, NULL, 'a sulfamate-substituted monosaccharide carbonic anhydrase inhibitor anticonvulsant antimigraine. you may swallow this medication whole or you may open the capsule and sprinkle the contents on a teaspoonful of soft food (such as applesauce yogurt). swallow', NULL, 1387, '2022-07-14', NULL, 0, 'Topiramate is indicated  for the following conditions: 1)Monotherapy for partial onset or primary generalized tonic-clonic seizures for patients 2 years of age and above 2)Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for both adult and pediatric patients above 2 years old 3)Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients above 2 years of age 4)Prophylaxis of migraine in children 12 years of age and older and adults.[L10544]



Topiramate is also used off-label as an adjunct therapy for weight management[L10550] and for mood disorders.[A188312]', 'A seizure is an abnormal and unregulated electrical discharge occurring in the brain. This leads to transient interruption in brain function, manifested by reduced alertness, abnormal sensations, and focal involuntary movements or convulsions. Several types of seizures exist, with common types including tonic-clonic seizures and partial onset seizures.[L5548]



The exact mechanisms by which topiramate exerts pharmacological actions on seizures and migraines are currently not fully characterized.[A188336,L10544]  Several properties of this drug, however, are likely to contribute to its therapeutic effects. Topiramate has been observed to exert actions on voltage-dependent sodium channels, GABA receptors, and glutamate receptors.[A175249,L10544] 



Topiramate stimulates GABA-A receptor activity at brain non-benzodiazepine receptor sites and reduces glutamate activity at both AMPA and kainate receptors. Normally, GABA-A receptors are inhibitory and glutaminergic receptors are stimulatory for neuronal activity.[A175243,T752] By increasing GABA activity and inhibiting glutamate activity, topiramate blocks neuronal excitability, preventing seizures and migraines.[A188333,A188309,L10544] Additionally, it blocks the voltage-dependent sodium channels, further blocking seizure activity.[A175243] Topiramate has been shown to inhibit various carbonic anhydrase isozymes, but the clinical significance of this is unknown at this time.[A10342,A10348,A20066,L10544]



', 'Topiramate prevents the occurrence of seizures and prevents migraine symptoms by reducing neural pathway excitability.[A188330,L10544] It is important to note that this drug may cause metabolic acidosis, mood changes, suicidal thoughts and attempts, as well as kidney stones. When topiramate is combined with [valproic acid], it is known to cause hypothermia.[L10544]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Protaci 10 sachets 25 gm', 3669, 'بروتاكي 10 اكياس 25 جم', '150', NULL, 'Dietary supplement', 'Dietary supplement', NULL, 'Protein+calcium', 'Esspero pharma', 'Sachet', 'أكياس', '25 gm', '1', NULL, NULL, NULL, NULL, 1090, '2022-12-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Carnivita 1gm/5ml 5 i.v. amp.', 15901, 'كارنيفيتا 1جم/5مل 5 امبولات وريد', '40', NULL, 'Antioxidant', 'Antioxidant', NULL, 'L-carnitine', 'Eva pharma', 'Amp', 'أمبول', '1gm', '5', NULL, NULL, 'about l-carnitine dietary supplement amino acid derivative antioxidant. mechanism of action of l-carnitine carnitine is an essential co-factor of fatty acid metabolism in the heart liver and skeletal muscle. it is normally synthesised in the liver brain a', '6222020803889', 1192, '2023-01-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hebitaxime 1 gm vial', 5974, 'هيبيتاكسيم 1 جرام فيال', '45', '30', 'Antibiotic.cephalosporin.third-generation', 'Antibiotic.cephalosporin.third-generation', NULL, 'Cefotaxime', 'Shifa medical products > advocure', 'Vial', 'فيال', '1 gm', '1', NULL, NULL, 'about cefotaxime third generation cephalosporin parenteral antibiotic. mechanism of action of cefotaxime cefotaxime is a 3rd generation cephalosporin which exerts its bactericidal action against both gram positive & aerobic gram negative organisms by inhi', '6224007364123', 1284, '2024-11-04', NULL, 0, 'Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.', 'The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefotaxime shows high affinity for penicillin-binding proteins in the cell wall including PBP Ib and PBP III.', 'Cefotaxime is a third generation intravenous cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against <i>Pseudomonas aeruginosa</i>. Cefotaxime works by inhibiting bacterial cell wall biosynthesis. A positive feature of cefotaxime is that it display a resistance to penicillinases and is useful to treat infections that are resistant to penicillin derivatives.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Scarnox gel 20 gm', 26597, 'سكارنوكس جل 20جم', '589', NULL, 'Scar therapy', 'Scar therapy', NULL, NULL, 'Neubelva > biosource', 'Gel', 'جل', '20 gm', '1', NULL, NULL, 'scarnoxï- is a non-silicone scar gel that is formulated to improve the appearance of both old and new scars. scarnoxï- contains innovative ingredients which have been shown to help flatten smooth and lessen the appearance of scars while also providing tem', NULL, 1215, '2022-07-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Avene xeracalm a.d cream 200ml', 14727, 'افين زيراكالم كريم مرطب 200 مل', '429', '355', 'Skin care', 'Skin care', NULL, NULL, 'Pierre - fabre france > biotech egypt', 'Cream', 'كريم', '200ml', '1', NULL, NULL, 'rich lipid-replenishing cream directly targets the cause and source of itching redness and irritation associated with skin prone to atopic dermatitis (eczema). the velvety non-greasy formula provides long-lasting hydration to very dry skin by sealing in m', NULL, 939, '2023-09-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Epifasi 5000 i.u. amp.', 4257, 'ابيفاسي 5000 وحدة دولية امبول', '500', '500', 'Infertility drugs.human chorionic gonadotrophin', 'Infertility drugs.human chorionic gonadotrophin', NULL, 'Human chorionic gonadotrophin', 'Eipico', 'Amp', 'أمبول', NULL, '1', 'علاج بعض حالات العقم -- في حالات اضطرابات الهرمونات في امراض النساء -- لتنشيط التبويض في حالات تأخر الانجاب', NULL, 'pharmacological action: chorionic gonadotropin is a hormone of human pregnancy; it is secreted by the syncytiotrophoblast of foetal placenta as early as 7 days after ovulation and it is absorbed into the blood in sufficient quantity to sustain luteal func', '6221032323699', 34958, '2025-08-03', NULL, 0, 'Human immunoglobulin G is indicated for the following conditions:



### Primary Immunodeficiency

- for the treatment of primary immunodeficiency in adult and pediatric patients[L39920, L39930, L39935, L39940, L39945, L39950, L39955, L39960, L39965, L39975, L39980, L40029, L40034, L40044]

- in combination with [hyaluronidase (human recombinant)] for the treatment of primary immunodeficiency in patients ≥2 years of age.[L42760]



### Immune Thrombocytopenic Purpura (ITP)

- for the treatment of acute or chronic immune thrombocytopenic purpura in adult and pediatric patients[L39940, L39950, L39960, L39965, L39970, L39975, L39980]



### Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

- for the treatment of CIDP in adult patients[L39955, L39965, L39975, L39980, L40034]

- in combination with hyaluronidase (human recombinant) as a maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)[L40039]



### Multifocal Motor Neuropathy (MMN)

- for maintenance therapy to improve muscle strength and disability in adult patients with MMN[L39955]



### Prophylaxis of Bacterial Infection

- for the prevention of bacterial infections in patients with hypogammaglobulinemia and/or B-cell chronic lymphocytic leukemia[L39960]



### Coronary Artery Aneurysm Associated With Kawasaki Syndrome

- for the prevention of coronary artery aneurysms in pediatric patients with Kawasaki syndrome[L39960]



### Dermatomyositis

- for the treatment of dermatomyositis in adult patients[L39970]

', 'IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab'')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab′)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.', 'Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immunoglobulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Alover 30 chew. pieces', 13818, 'الوفير 20 قرص مضغ', '120', NULL, 'Multivitamins', 'Multivitamins', NULL, 'Calcium+vitamin d3', 'Nutrixia > infinity pharm', 'Piece', 'قطعة', NULL, '3', NULL, NULL, 'calcium carbonate 1250 mg vitamin d3 400 i.u. alover vitamin d is a main supplement in the form of chocolate pieces that provides your body with essential energy and nutrition. important for immunity hair nail and skin. used for: immunity booster hair reg', NULL, 997, '2022-07-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Effegad 75 mg 14 e.r. caps.', 32779, 'ايفيجاد 75مجم 14 كبسولة', '76', '56', 'Psychiatric.antidepressants', 'Psychiatric.antidepressants', NULL, 'Venlafaxine', 'Hikma pharma', 'Cap', 'كبسولة', '75 mg', '2', NULL, NULL, NULL, '6221000010736', 911, '2024-11-16', NULL, 0, 'Venlafaxine is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.[L43030]', 'The exact mechanism of action of venlafaxine in the treatment of various psychiatric conditions has not been fully elucidated; however, it is understood that venlafaxine and its active metabolite O-desmethylvenlafaxine (ODV) potently and selectively inhibits the reuptake of both serotonin and norepinephrine at the presynaptic terminal.[A27600,A252065,L43030] This results in increased levels of neurotransmitters available at the synapse that can stimulate postsynaptic receptors.[A252075] It is suggested that venlafaxine has a 30-fold selectivity for serotonin compared to norepinephrine: venlafaxine initially inhibits serotonin reuptake at low doses, and with higher doses, it inhibits norepinephrine reuptake in addition to serotonin.[A252065,A252070] Venlafaxine and ODV are also weak inhibitors of dopamine reuptake.[L43030]', 'Venlafaxine is an antidepressant agent that works to ameliorate the symptoms of various psychiatric disorders by increasing the level of neurotransmitters in the synapse. Venlafaxine does not mediate muscarinic, histaminergic, or adrenergic effects.[L43030]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Shaddock eye contour cream 120 gm', 26897, 'شادوك كريم للعين 120جم', '220', NULL, 'Eye contour', 'Eye contour', NULL, NULL, 'Egyptian company for cosmetics > care mid-east pharma', 'Cream', 'كريم', '120 gm', '1', NULL, NULL, NULL, NULL, 641, '2022-07-28', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rocubromide 50mg/5ml i.v vial', 26238, 'روكوبرومايد 50مجم/5مل فيال للحقن وريد', '41', NULL, 'Skeletal muscle relaxant', 'Skeletal muscle relaxant', NULL, 'Rocuronium bromide', 'Sigma tec > pharco b', 'Vial', 'فيال', '50mg', '1', NULL, NULL, 'about rocuronium a nondepolarizing neuromuscular blocker skeletal muscle relaxant. mechanism of action of rocuronium rocuronium is a non depolarizing neuromuscular blocker. competes with acetylcholine for cholino- ceptive sites at the postjunctional membr', NULL, 787, '2022-06-28', NULL, 0, 'For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.', 'Rocuronium acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium. Rocuronium acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur. Evidence also suggests that nondepolarizing agents can affect ACh release. It has been hypothesized that nondepolarzing agents bind to postjunctional ("curare") receptors and may therefore interfere with the sodium and potassium flux, which is responsible for depolarization and repolarization of the membranes involved in muscle contraction. ', 'Neuromuscular blocking agents are drugs that cause skeletal muscle relaxation primarily by causing a decreased response to the neurotransmitter acetylcholine (ACh) at the myoneural (neuromuscular) junction of skeletal muscle. At that site, ACh normally produces electrical depolarization of the postjunctional membrane of motor end-plate, which leads to conduction of muscle action potential and subsequently induces skeletal muscle contraction. Neuromuscular agents are classified as depolarizing or nondepolarizing. Rocuronium is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. Rocuronium, like vecuronium is longer acting in infants than in children. However, unlike vecuronium, rocuronium retains the characteristics of an intermediate-acting NMBD in infants.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bright hirt 30 ml oral drops', 1157, 'برايت هيرت نقط للفم 30 مل', '149', NULL, 'Food supplement', 'Food supplement', NULL, 'Garcinia liquid', 'Hirta care', 'Drops', 'نقط', '30 ml', '1', NULL, NULL, NULL, NULL, 1364, '2024-07-10', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rheumafen 75 mg sr 10 caps.', 26009, 'رومافين 75مجم اس ار 10 كبسول', '11', NULL, 'Nsaid.acetic acid derivatives', 'Nsaid.acetic acid derivatives', NULL, 'Diclofenac sodium', 'Glaxo smithkline', 'Cap', 'كبسولة', '75 mg', '1', NULL, NULL, 'description a non-steroidal anti-inflammatory agent (nsaid) with antipyretic and analgesic actions. it is primarily available as the sodium salt. indication : for the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthr', '6221045000464', 747, '2022-12-08', NULL, 0, 'Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma. It is often used in combination with [misoprostol] as a gastro-protective agent in patients with high risk of developing NSAID-induced ulcers.', 'Diclofenac inhibits cyclooxygenase-1 and -2, the enzymes responsible for production of prostaglandin (PG) G<sub>2</sub> which is the precursor to other PGs.[label,T116] These molecules have broad activity in pain and inflammation and the inhibition of their production is the common mechanism linking each effect of diclofenac.



PGE<sub>2</sub> is the primary PG involved in modulation of nociception.[A179023] It mediates peripheral sensitization through a variety of effects.[T116,A179023] PGE<sub>2</sub> activates the G<sub>q</sub>-coupled EP<sub>1</sub> receptor leading to increased activity of the inositol trisphosphate/phospholipase C pathway. Activation of this pathway releases intracellular stores of calcium which directly reduces action potential threshold and activates protein kinase C (PKC) which contributes to several indirect mechanisms. PGE<sub>2</sub> also activates the EP<sub>4</sub> receptor, coupled to G<sub>s</sub>, which activates the adenylyl cyclase/protein kinase A (AC/PKA) signaling pathway. PKA and PKC both contribute to the potentiation of transient receptor potential cation channel subfamily V member 1 (TRPV1) potentiation, which increases sensitivity to heat stimuli. They also activate tetrodotoxin-resistant sodium channels and inhibit inward potassium currents. PKA further contributes to the activation of the P2X3 purine receptor and sensitization of T-type calcium channels. The activation and sensitization of depolarizing ion channels and inhibition of inward potassium currents serve to reduce the intensity of stimulus necessary to generate action potentials in nociceptive sensory afferents. PGE<sub>2</sub> act via EP<sub>3</sub> to increase sensitivity to bradykinin and via EP<sub>2</sub> to further increase heat sensitivity. Central sensitization occurs in the dorsal horn of the spinal cord and is mediated by the EP<sub>2</sub> receptor which couples to G<sub>s</sub>. Pre-synaptically, this receptor increases the release of pro-nociceptive neurotransmitters glutamate, CGRP, and substance P. Post-synaptically it increases the activity of AMPA and NMDA receptors and produces inhibition of inhibitory glycinergic neurons. Together these lead to a reduced threshold of activating, allowing low intensity stimuli to generate pain signals. PGI<sub>2</sub> is known to play a role via its G<sub>s</sub>-coupled IP receptor although the magnitude of its contribution varies. It has been proposed to be of greater importance in painful inflammatory conditions such as arthritis. By limiting sensitization, both peripheral and central, via these pathways NSAIDs can effectively reduce inflammatory pain.



PGI<sub>2</sub> and PGE<sub>2</sub> contribute to acute inflammation via their IP and EP<sub>2</sub> receptors.[T116,A179044] Similarly to β adrenergic receptors these are G<sub>s</sub>-coupled and mediate vasodilation through the AC/PKA pathway. PGE<sub>2</sub> also contributes by increasing leukocyte adhesion to the endothelium and attracts the cells to the site of injury.[T116] PGD<sub>2</sub> plays a role in the activation of endothelial cell release of cytokines through its DP<sub>1</sub> receptor.[A179044] PGI<sub>2</sub> and PGE<sub>2</sub> modulate T-helper cell activation and differentiation through IP, EP<sub>2</sub>, and EP<sub>4</sub> receptors which is believed to be an important activity in the pathology of arthritic conditions. By limiting the production of these PGs at the site of injury, NSAIDs can reduce inflammation.



PGE<sub>2</sub> can cross the blood-brain barrier and act on excitatory G<sub>q</sub> EP<sub>3</sub> receptors on thermoregulatory neurons in the hypothalamus.[T116] This activation triggers an increase in heat-generation and a reduction in heat-loss to produce a fever. NSAIDs prevent the generation of PGE<sub>2</sub> thereby reducing the activity of these neurons.

', 'Diclofenac reduces inflammation and by extension reduces nociceptive pain and combats fever.[label,T116] It also increases the risk of developing a gastrointestinal ulcer by inhibiting the production of protective mucus in the stomach.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nifedipine 60 mg sr 10 caps.', 23578, 'نفيدبين 60مجم 10 كبسول', '10', NULL, 'Antihypertensive.selective calcium channel blocker', 'Antihypertensive.selective calcium channel blocker', NULL, 'Nifedipine', 'Sigma', 'Cap', 'كبسولة', '60 mg', '1', NULL, NULL, 'about nifedipine a dihydropyridine calcium channel blocker antianginal antihypertensive tocolytic. mechanism of action of nifedipine nifedipine is a dihydropyridine ca channel blocker. it exerts it`s antianginal antihypertensive actions through blocking t', NULL, 771, '2022-07-28', NULL, 0, 'Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina.[L11383] Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.[L11389,L1245]', 'Nifedipine blocks voltage gated L-type calcium channels in vascular smooth muscle and myocardial cells.[A190204] This blockage prevents the entry of calcium ions into cells during depolarization, reducing peripheral arterial vascular resistance and dilating coronary arteries.[A190204] These actions reduce blood pressure and increase the supply of oxygen to the heart, alleviating angina.[A190204]', 'Nifedipine is an inhibitor of L-type voltage gated calcium channels that reduces blood pressure and increases oxygen supply to the heart.[A190204] Immediate release nifedipine''s duration of action requires dosing 3 times daily.[L11383] Nifedipine dosing is generally 10-120mg daily.[L11383] Patients should be counselled regarding the risk of excessive hypotension, angina, and myocardial infarction.[L11383]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Spectral.lash eye lash stimulator solutlon 2.4 ml', 27379, 'سبيكترال محلول للعين 2.4مل', '500', NULL, NULL, NULL, NULL, NULL, 'Ds laboratories > multitrade', 'Sol', 'محلول', '2.4 ml', '1', NULL, NULL, 'spectral.lash a cutting-edge treatment from ds laboratories is demonstrated through clinical research to result in eyelashes 25 percent longer in just four weeks. many users also enjoy greater thickness and density. for best results apply spectral.lashï-', NULL, 679, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Padele cream 60 gm', 2483, 'باديل كريم 60 جم', '75', NULL, 'Massage cream', 'Massage cream', NULL, NULL, 'Original group', 'Cream', 'كريم', '60 gm', '1', NULL, NULL, NULL, NULL, 919, '2025-01-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Zinkeem 20 tabs.', 31651, 'زنكيم 20 قرص', '48', NULL, 'Zinc supplement', 'Zinc supplement', NULL, 'Zinc', 'Copad egypt > ibm pharma', 'Tab', 'أقراص', NULL, '2', 'مكمل غذائى غنى بالزنك يحسن الشعر والبشرة ويدعم الجهاز المناعى وعملية الايض', NULL, 'zinc 50mg elemental support immunity', NULL, 2221, '2023-06-19', NULL, 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Movelex massage cream 120 gm', 30950, 'موفيليكس مساج كريم 120 جم', '120', '95', 'Massage', 'Massage', NULL, 'Peppermint oil+eucalyptus oil+camphor+tocopherol(vitamin e)+omega-3+omega-6', 'Nikim > majestic biopharma', 'Cream', 'كريم', '120 gm', '1', NULL, NULL, NULL, '6224010938137', 1979, '2025-10-14', NULL, 0, 'Indicated for the over-the-counter use for:



-the symptomatic relief of minor spasms of the gastrointestinal tract, flatulence and abdominal pain, especially in patients with irritable bowel syndrome.



-the temporary relief of itching associated with insect bites, eczema, minor burn, sunburn, minor skin irritations, minor cuts, scrapes, atopic dermatitis and other skin disorders.



-the temporary symptomatic relief of mild joint and muscle pain as a local topical analgesic.



-the temporary relief of tension-type headache.', 'Dose-dependent antispasmodic effect of peppermint oil is largely mediated by its menthol constituent [A33056]. It is proposed that peppermint oil relaxes gastrointestinal smooth muscle and attenuates contractile responses by reducing the influx of extracellular calcium ions. In rabbit jejunum smooth muscle cells investigated via whole cell clamp configuration technique, peppermint oil was shown to inhibit the potential-dependent calcium currents in a concentration-dependent manner [A33056]. Both a reduction in peak current amplitude and an increase in the rate of current decay were observed, indicating that the pharmacological activity peppermint oil resembles that of dihydropyridine calcium antagonists [A33056]. In a rat small intestine study, peppermint oil in the intestinal lumen inhibited enterocyte glucose uptake via a direct action on the brush border membrane and inhibited intestinal secretion [A33056]. There is also evidence that menthol is an antagonist of L-type Ca2+ channels via interacting with dihydropyridine binding sites and blocks the currents of low-voltage-activated calcium channels [A33056]. Peppermint oil may facilitate hair growth by promoting the conservation of vascularization of hair dermal papilla, which may contribute to the induction of early anagen stage of active growth phase of hair follicles [A33044]. ', 'Peppermint oil induces a dose-related antispasmodic effects on the gastrointestinal smooth muscles [A33056]. A meta-analysis study and additional clinical studies of patients with IBS demonstrated that the treatment with peppermint oil improves abdominal symptoms compared to the placebo group, resulting in reduced severity of abdominal pain, decreased abdominal distension, reduced stool frequency, and reduced flatulence [A33055, A33057]. The use of enteric-coated peppermint oil was shown to be effective in reducing gastrointestinal symptoms of non-ulcer dyspepsia [A33055]. In rats, peppermint oil promoted a time-dependent choleretic  effect in increasing bile production and biliary output [A33056]. In randomized controlled trials, topical application of peppermint oil was associated with a significant analgesic effect and a reduction in headache intensity compared to placebo [A33055]. In a study of C57BL/6 mice, topical application of peppermint oil for 4 weeks was associated with a prominent hair growth effects; a significant increase in dermal thickness, follicle number, and follicle depth [A33044]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vitamount syrup 120ml', 12505, 'فيتاماونت شراب فيتامينات 120 مل', '34', '21', 'Vitamins', 'Vitamins', NULL, 'Vitamins', 'Amoun', 'Syrup', 'شراب', '120ml', '1', 'فيتامينات و مقويات للأطفال', NULL, 'about vitamins vitamins are substances that are found in foods we eat. the term vitamin is derived from the words vital and amine because vitamins are required for life and were originally thought to be amines. all vitamins are not amines. vitamins are di', '6221025008978', 8335, '2024-12-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Blokium diu 100/25mg 15 tab.', 1633, 'بلوكيوم ديو 100/25مجم 15 قرص', '25', '17.5', 'Beta blocker and thiazide diuretics', 'Beta blocker and thiazide diuretics', NULL, 'Atenolol+chlorthalidone', 'Mup > almirall prodes-spain', 'Tab', 'أقراص', '25mg', '1', NULL, NULL, 'indications for atenolol + chlorthalidone beta blocker and thiazide diuretics are given in combination to treat hypertension. atenolol reduces the work load on the heart and chlorthalidone reduce the hypertension by increasing the flow of urine. 1. hypert', '6221508012812', 3597, '2024-09-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dexagrand eye drops 5 ml', 17417, 'ديكساجراند قطرة عين 5 مل', '12', '9', 'Antibiotic with glucocorticoid', 'Antibiotic with glucocorticoid', NULL, 'Dexamethasone+neomycin sulphate+polymyxin b sulphate', 'Delta grand pharma', 'Drops', 'نقط', '5 ml', '1', 'قطرة عين مضاد حيوي ومضاد التهاب', NULL, NULL, NULL, 5489, '2023-10-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Choriomon 5000 i.u. i.m. 10 vial', 2533, 'كوريومون 5000 وحدة دولية حقن عضل 10 فيال', '7,000', NULL, 'Infertility drugs.human chorionic gonadotrophin', 'Infertility drugs.human chorionic gonadotrophin', NULL, 'Human chorionic gonadotrophin', 'Ibsa - switzerland > habib scientific office', 'Vial', 'فيال', NULL, '10', NULL, NULL, NULL, NULL, 1486, '2022-08-17', NULL, 0, 'Human immunoglobulin G is indicated for the following conditions:



### Primary Immunodeficiency

- for the treatment of primary immunodeficiency in adult and pediatric patients[L39920, L39930, L39935, L39940, L39945, L39950, L39955, L39960, L39965, L39975, L39980, L40029, L40034, L40044]

- in combination with [hyaluronidase (human recombinant)] for the treatment of primary immunodeficiency in patients ≥2 years of age.[L42760]



### Immune Thrombocytopenic Purpura (ITP)

- for the treatment of acute or chronic immune thrombocytopenic purpura in adult and pediatric patients[L39940, L39950, L39960, L39965, L39970, L39975, L39980]



### Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

- for the treatment of CIDP in adult patients[L39955, L39965, L39975, L39980, L40034]

- in combination with hyaluronidase (human recombinant) as a maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)[L40039]



### Multifocal Motor Neuropathy (MMN)

- for maintenance therapy to improve muscle strength and disability in adult patients with MMN[L39955]



### Prophylaxis of Bacterial Infection

- for the prevention of bacterial infections in patients with hypogammaglobulinemia and/or B-cell chronic lymphocytic leukemia[L39960]



### Coronary Artery Aneurysm Associated With Kawasaki Syndrome

- for the prevention of coronary artery aneurysms in pediatric patients with Kawasaki syndrome[L39960]



### Dermatomyositis

- for the treatment of dermatomyositis in adult patients[L39970]

', 'IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different effector cells of the immune system (B and T lymphocytes, dendritic cells, etc.) and regulates a wide range of genes. Its main mechanism of actions are believed to be Fc-dependent and F(ab'')2-dependent. IVIg competitively blocks gamma Fc receptors, preventing the binding and ingestion of phagocytes and suppressing platelet depletion. IVIg contains a number of different antobodies, which prevent infection by attaching to the surface of invading pathogens and aiding in their disposal before they can infect cells. Antibodies remove pathogens via complement activation, agglutination or precipitation, pathogen receptor blocking, macrophage “tagging” or neutralization (via binding) of pathogen toxins. Intact IVIg and F(ab′)2 fragments of IVIg can also neutralize the activity of various autoantibodies. By triggering the production of interleukin-1 receptor antagonist, IVIg modulates of the production of cytokines and cytokine antagonists. It also prevents the generation of the C5b-9 membrane attack complex and subsequent complement-mediated tissue damage by binding active complement components.', 'Used as a replacement therapy in inherited humoral immunodeficiency disorders such as severe combined immunodeficiency syndrome, x-linked agammaglobulinemia, and Wiskott-Aldrich Syndrome. The immunoglobulins target, bind and kill bacterial cells as well as viral particles. IgG is the monomeric immunoglobulin of which there are four subclasses (IgG1, IgG2, IgG3 and IgG4) in differing abundances (66%, 23%, 7% and 4%). IgAs represent about 15% of the immunoglobulins in the blood. These target inhaled or ingested pathogens.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nova-profen 200mg 30 tabs.', 23784, 'نوفا-بروفين 200 مجم 30 قرص', '9', NULL, 'Nsaid.propionic acid derivatives', 'Nsaid.propionic acid derivatives', NULL, 'Ibuprofen', 'Sanofi', 'Tab', 'أقراص', '200mg', '3', NULL, NULL, 'about ibuprofen nsaid a propionic acid derivative analgesic and anti-inflammatory. mechanism of action of ibuprofen ibuprofen has analgesic anti-inflammatory and antipyretic action. it acts by inhibiting prostaglandin (pgs) synthesis and their release at', NULL, 753, '2022-07-09', NULL, 0, 'Ibuprofen is the most commonly used and prescribed NSAID. It is a very common over-the-counter medication widely used as an analgesic, anti-inflammatory and antipyretic.[A39096]



The use of ibuprofen and its enantiomer [DB09213] in a racemic mix is common for the management of mild to moderate pain related to dysmenorrhea, headache, migraine, postoperative dental pain, spondylitis, osteoarthritis, rheumatoid arthritis, and soft tissue disorder.[A39097]



Due to its activity against prostaglandin and thromboxane synthesis, ibuprofen has been attributed to alteration of platelet function and prolongation of gestation and labour.[A39092]



As ibuprofen is a widely used medication, the main therapeutic indications are:



* Patent Ductus Arteriosus - it is a neonatal condition wherein the ductus arteriosus (blood vessel that connects the main pulmonary artery to the proximal descending aorta) fails to close after birth causing severe risk of heart failure. The prostaglandin inhibition of ibuprofen has been studied for the treatment of this condition as it is known that prostaglandin E2 is responsible for keeping the ductus arteriosus open.[A39100]



* Rheumatoid- and osteo-arthritis - ibuprofen is very commonly used in the symptomatic treatment of inflammatory, musculoskeletal and rheumatic disorders.[A39176]



* Cystic fibrosis - the use of high dosages of ibuprofen has been proven to decrease inflammation and decreasing polymorphonuclear cell influx in the lungs.[A39177]



* Orthostatic hypotension - ibuprofen can induce sodium retention and antagonize the effect of diuretics which has been reported to be beneficial for patients with severe orthostatic hypotension.[A1651]



* Dental pain - ibuprofen is used to manage acute and chronic orofacial pain.[A10901]



* Pain - ibuprofen is widely used to reduce minor aches and pains as well as to reduce fever and manage dysmenorrhea. It is very commonly used for the relief of acute indications such as fever and tension headaches.[A39092] It is also used to manage mild to moderate pain and moderate to severe pain as an adjunct to opioid analgesics.[L40208]



* Investigational uses - efforts have been put into developing ibuprofen for the prophylaxis of Alzheimer''s disease, Parkinson disease, and breast cancer.[A39092]', 'The exact mechanism of action of ibuprofen is unknown. However, ibuprofen is considered an NSAID and thus it is a non-selective inhibitor of cyclooxygenase, which is an enzyme involved in prostaglandin (mediators of pain and fever) and thromboxane (stimulators of blood clotting) synthesis via the arachidonic acid pathway.[L4614]



Ibuprofen is a non-selective COX inhibitor and hence, it inhibits the activity of both COX-1 and COX-2. The inhibition of COX-2 activity decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever, and swelling while the inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration.[A39195]', 'Ibuprofen has multiple actions in different inflammatory pathways involved in acute and chronic inflammation. The main effects reported in ibuprofen are related to the control of pain, fever and acute inflammation by the inhibition of the synthesis of prostanoids by COX-1 and COX-2. Pain relief is attributed to peripheral affected regions and central nervous system effects in the pain transmission mediated by the dorsal horn and higher spinothalamic tract. Some reports have tried to link the pain regulation with a possible enhancement on the synthesis of endogenous cannabinoids and action on the NMDA receptors. The effect on pain has been shown to be related to the cortically evoked potentials.[A39190]



The antipyretic effect is reported to be linked to the effect on the prostanoid synthesis due to the fact that the prostanoids are the main signaling mediator of pyresis in the hypothalamic-preoptic region.[A39190]



The use of ibuprofen in dental procedures is attributed to the local inhibition of prostanoid production as well as to anti-oedemic activity and an increase of plasma beta-endorphins. Some reports have suggested a rapid local reduction of the expression of COX-2 in dental pulp derived by the administration of ibuprofen.[A39190]



The administration of ibuprofen in patients with rheumatic diseases has shown to control joint symptoms.[A39092] 



Ibuprofen is largely used in OTC products such as an agent for the management of dysmenorrhea which has been proven to reduce the amount of menstrual prostanoids and to produce a reduction in the uterine hypercontractility.[A39181] As well, it has been reported to reduce significantly the fever and the pain caused by migraines.[A39182, A39183] This effect is thought to be related to the effect on platelet activation and thromboxane A2 production which produces local vascular effects in the affected regions. This effect is viable as ibuprofen can enter in the central nervous system.[A39190]



In the investigational uses of ibuprofen, it has been reported to reduce neurodegeneration when given in low doses over a long time.[A39184] On the other hand, its use in Parkinson disease is related to the importance of inflammation and oxidative stress in the pathology of this condition.[A39185] The use of ibuprofen for breast cancer is related to a study that shows a decrease of 50% in the rate of breast cancer.[A39186]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Davalindi 10.000 i.u. 30 tabs.', 13418, 'دافاليندي 10.000وحدة دولية 30 قرص', '78', '54.5', 'Vitamin d', 'Vitamin d', NULL, 'Cholecalciferol(vitamin d3)', 'Mup', 'Tab', 'أقراص', NULL, '1', NULL, NULL, 'description derivative of 7-dehydroxycholesterol formed by ultraviolet rays breaking of the c9-c10 bond. it differs from ergocalciferol in having a single bond between c22 and c23 and lacking a methyl group at c24 indication for the treatment of vitamin d deficiency', '6221508516211', 6228, '2024-08-17', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Calcium folinate 50mg vial powder for inj.', 15673, 'كالسيوم فولينات 50مجم فيال بودرة للحقن', '38', NULL, 'Folic acid supplement', 'Folic acid supplement', NULL, 'Leucovorin calcium=folinic acid=calcium folinate', 'Shanxi pude pharm. > acdima international trading', 'Inj', 'حقن', '50mg', '1', NULL, NULL, 'indication for the treatment of osteosarcoma (after high dose methotrexate therapy). used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists and to treat megalo', NULL, 889, '2022-07-11', NULL, 0, 'For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.', 'As leucovorin is a derivative of folic acid, it can be used to increase levels of folic acid under conditions favoring folic acid inhibition (following treatment of folic acid antagonists such as methotrexate). Leucovorin enhances the activity of fluorouracil by stabilizing the bond of the active metabolite (5-FdUMP) to the enzyme thymidylate synthetase.', 'Leucovorin is one of several active, chemically reduced derivatives of folic acid. It is useful as an antidote to drugs which act as folic acid antagonists. Leucovorin is a mixture of the diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid (THF). The biologically active compound of the mixture is the (-)-l-isomer, known as Citrovorum factor or (-)-folinic acid. Leucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of &ldquo;one-carbon&rdquo; moieties. Administration of leucovorin can counteract the therapeutic and toxic effects of folic acid antagonists such as methotrexate, which act by inhibiting dihydrofolate reductase. Leucovorin has also been used to enhance the activity of fluorouracil.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Magnisol 0.5gm/5ml 6 amps', 7691, 'ماجنيسول 0.5جم/5مل 6 امبولات', '66', '45', 'Magnesium supplements', 'Magnesium supplements', NULL, 'Magnesium sulphate', 'Memphis', 'Amp', 'أمبول', '0.5gm', '6', NULL, NULL, NULL, '6221050010830', 1820, '2024-07-29', NULL, 0, 'Used for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children. Also indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia. Also used in uterine tetany as a myometriat relaxant.', 'Magnesium is the second most plentiful cation of the intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Magnesium sulfate reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural junction. Additionally, Magnesium inhibits Ca<sup>2+</sup> influx through dihydropyridine-sensitive, voltage-dependent channels. This accounts for much of its relaxant action on vascular smooth muscle.', 'Magnesium sulfate is a small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. Magnesium sulfate is gaining popularity as an initial treatment in the management of various dysrhythmias, particularly torsades de pointes, and dyrhythmias secondary to TCA overdose or digitalis toxicity.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Unitense 20 mg 10 f.c. tabs.', 28766, 'يونيتينس 20مجم 10 اقراص', '17', NULL, 'Antihypertensive.ace', 'Antihypertensive.ace', NULL, 'Benazepril', 'International drug agency (idi)', 'Tab', 'أقراص', '20 mg', '1', NULL, NULL, 'about benazepril angiotensin - converting enzyme inhibitor (ace - inhibitor) anti hypertensive. mechanism of action of benazepril it is a prodrug and converted in to active benazeprilat; which is an angiotensin converting enzyme inhibitor prevents the con', NULL, 725, '2022-07-25', NULL, 0, 'Benazepril is indicated for the treatment of hypertension[A840]. It may be used alone or in combination with thiazide diuretics[FDA Label].', 'Benazeprilat, the active metabolite of Benazepril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II[FDA Label]. Inhibition of ACE results in decreased plasma angiotensin II[FDA Label]. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion[FDA Label].', 'Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by esterases to its active Benazeprilat[A836], is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients[A840,A838,A837]. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals[A840,A836]. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II[FDA Label]. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex[FDA Label].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Jakavi 5 mg 56 tabs.', 21126, 'جاكافي 5مجم 56 قرص', '25,232', '18860', 'Antineoplastic', 'Antineoplastic', NULL, 'Ruxolitinib', 'Novartis', 'Tab', 'أقراص', '5 mg', '4', 'لعلاج الأورام -- علاج السرطان', NULL, 'ruxolitinib is a drug for the treatment of intermediate or high-risk myelofibrosis a type of myeloproliferative disorder that affects the bone marrow and for polycythemia vera (pcv) when there has been an inadequate response to or intolerance of hydroxyur', NULL, 2294, '2024-11-07', NULL, 0, 'Ruxolitinib is indicated for the treatment of the following conditions:



- intermediate or high-risk myelofibrosis (MF), including prima1y MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults.[L31938] It is also used to treat disease-related splenomegaly or symptoms in adult patients with these conditions.[L32073] 

- polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.[L31938]

- steroid-refracto1y acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.[L31938]

- chronic GVHD in patients aged 12 years and older who have failed one or two lines of systemic therapy.[L31938]



Topical ruxolitinib is indicated for:



- the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.[L39125]

- the treatment of non-segmental vitiligo in adult and pediatric patients 12 years of age and older.[L39125, L46068]', 'The Janus kinase (JAK) family of protein tyrosine kinases comprises JAK1, JAK2, JAK3, and non-receptor tyrosine kinase 2 (TYK2).[A229703] JAKs play a pivotal role in intracellular signalling pathways of various cytokines and growth factors essential to hematopoiesis, such as interleukin, erythropoietin, and thrombopoietin.[A7450] JAKs have diverse functions: JAK1 and JAK3 promote lymphocyte differentiation, survival, and function, while JAK2 promotes signal transduction of erythropoietin and thrombopoietin.[A229703, A229753] JAKs are in close proximity to the cytokine and growth factor receptor’s cytoplasmic region. Upon binding of cytokines and growth factors, JAKs are activated, undergoing cross-phosphorylation and tyrosine phosphorylation. This process also reveals selective binding sites for STATs, which are DNA-binding proteins that also bind to the cytoplasmic region of cytokine or growth factor receptors. Activated JAKs and STATs translocate to the nucleus as transcription factors to regulate gene expression of pro-inflammatory cytokines such as IL-6, IL-10, and nuclear factor κB (NF-κB).[A229938] They also activate downstream pathways that promote erythroid, myeloid, and megakaryocytic development.[A229703] 



The molecular pathogenesis of myeloproliferative neoplasms is not fully understood; however, JAK2 is constitutively activated and the JAK-STAT signalling pathway becomes deregulated and aberrant.[A7450, A229938] Ruxolitinib is a selective and potent inhibitor of JAK2 and JAK1, with some affinity against JAK3 and TYK2. Anticancer effects of ruxolitinib are attributed to its inhibition of JAKs and JAK-mediated phosphorylation of STAT3.[L31938] By downregulating the JAK-STAT pathway, ruxolitinib inhibits myeloproliferation and suppresses the plasma levels of pro-inflammatory cytokines such as IL-6 and TNF-α.[A229703] 



Activated JAKs are also implicated in graft-versus-host-disease (GVHD), which is a severe immune complication of allogeneic hematopoietic cell transplantation GVHD is associated with significant morbidity and mortality, especially for patients who do not respond well to corticosteroid therapy. Activated JAKS stimulate T-effector cell responses, leading to increased proliferation of effector T cells and heightened production of pro-inflammatory cytokines. By blocking JAK1 and JAk2, ruxolitinib inhibits donor T-cell expansion and suppresses pro-inflammatory responses.[A229913]', 'Ruxolitinib is an antineoplastic agent that inhibits cell proliferation, induces apoptosis of malignant cells, and reduces pro-inflammatory cytokine plasma levels by inhibiting JAK-induced phosphorylation of signal transducer and activator of transcription (STAT).[A229703] Inhibition of STAT3 phosphorylation, which is used as a marker of JAK activity, [A7450] by ruxolitinib is achieved at two hours after dosing which returned to near baseline by 10 hours in patients with myelofibrosis and polycythemia vera.[L31938] In clinical trials, ruxolitinib reduced splenomegaly and improved symptoms of myelofibrosis.[A229703] In a mouse model of myeloproliferative neoplasms, administration of ruxolitinib was associated with prolonged survival.[A7450] Ruxolitinib inhibits both mutant and wild-type JAK2 [A229703]; however, JAK2V617F mutation, which is often seen in approximately 50% of patients with myelofibrosis, was shown to reduce ruxolitinib sensitivity, which may also be associated with possible resistance to JAK inhibitor treatment.[A229933]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Targocid 200 mg vial for i.v/i.m inj.', 11186, 'تارجوسيد 200مجم فيال', '408', '285', 'Antibiotic with glycopeptide', 'Antibiotic with glycopeptide', NULL, 'Teicoplanin', 'Gruppo lepetit > sanofi', 'Inj', 'حقن', '200 mg', '1', NULL, NULL, 'about teicoplanin glycopeptide antibiotic antibiotic similar to vancomycin. mechanism of action of teicoplanin teicoplanin binds to the terminal dipeptide (amino d alanyl d alanine residue) sequence of peptidoglycan and inhibits the association and cross', '3582910016021', 1932, '2024-12-15', NULL, 0, 'For the treatment of bacterial infections caused by susceptible microorganisms.', 'Teicoplanin inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death.', 'It is a glycopeptide antiobiotic extracted from <i>Actinoplanes teichomyceticus</i>, with a similar spectrum of activity to vancomycin. Its mechanism of action is to inhibit bacterial cell wall synthesis. Oral teicoplanin has been demonstrated to be effective in the treatment of pseudomembranous colitis and Clostridium difficile-associated diarrhoea, with comparable efficacy to vancomycin.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cytarabine stada 50mg/ml (1g) vial', 17029, 'سيتارابين ستادا 50مجم / مل فيال', '134', NULL, 'Antiviral.nucleoside', 'Antiviral.nucleoside', NULL, 'Cytarabine', 'Stada > germa pharm', 'Vial', 'فيال', '50mg', '1', NULL, NULL, 'description a pyrimidine nucleoside analog that is used mainly in the treatment of leukemia especially acute non-lymphoblastic leukemia. indication for the treatment of acute non-lymphocytic leukemia acute lymphocytic leukemia and blast phase of chronic m', NULL, 979, '2022-07-24', NULL, 0, 'For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.



Cytarabine is indicated in combination with [daunorubicin] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.[L32843]', 'Cytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. Although the mechanism of action is not completely understood, it appears that cytarabine acts through the inhibition of DNA polymerase. A limited, but significant, incorporation of cytarabine into both DNA and RNA has also been reported.', 'Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ambroxol 7.5mg/ml oral drops 15 ml', 510, 'امبروكسول نقط بالفم 15 مل', '16', '10.5', 'Mucolytic', 'Mucolytic', NULL, 'Ambroxol', 'Glaxo smithkline', 'Drops', 'نقط', '7.5mg', '1', 'مذيب بلغم', NULL, '(indications): this medication is a mucolytic agent prescribed for various respiratory diseases such as emphysema with bronchitis pneumoconiosis chronic inflammatory pulmonary conditions tracheobronchitis (respiratory tract inflammation) bronchiectasis br', '6221045001621', 5800, '2024-11-11', NULL, 0, 'Ambroxol is indicated for secretolytic therapy in bronchoplmonary disease with abnormal mucus secretion and transport. It allows the mucus to be more easily cleared and ease a patient''s breathing.', 'Ambroxol is a mucolytic agent. Excessive Nitric oxide (NO) is associated with inflammatory and some other disturbances of airways function. NO enhances the activation of soluble guanylate cyclase and cGMP accumulation. Ambroxol has been shown to inhibit the NO-dependent activation of soluble guanylate cyclase. It is also possible that the inhibition of NO-dependent activation of soluble guanylate cyclase can suppress the excessive mucus secretion, therefore it lowers the phlegm viscosity and improves the mucociliary transport of bronchial secretions.', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Inhibamet 12.5/1000 mg 30 f.c. tabs.', 20834, 'انهيباميت 12.5 / 1000 مجم 30 قرص', '174', '124.5', 'Anti-diabetic.secretagogues.dpp-4 inhibitors', 'Anti-diabetic.secretagogues.dpp-4 inhibitors', NULL, 'Alogliptin+metformin', 'Hikma pharma', 'Tab', 'أقراص', '1000 mg', '3', NULL, NULL, 'alogliptin is an orally administered anti-diabetic drug in the dpp-4 inhibitor class. like other medications for the treatment of type 2 diabetes alogliptin does not decrease the risk of heart attack and stroke. like other members of the gliptin class it', NULL, 2338, '2025-04-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Xola 2% eye drops 5 ml', 29767, 'زولا قطرة عين 5مل', '87', '75', 'Antiglaucoma', 'Antiglaucoma', NULL, 'Dorzolamide', 'Jamjoom pharmaceuticals', 'Drops', 'نقط', '2%', '1', NULL, NULL, 'about dorzolamide carbonic anhydrase inhibitor thiophene derivative a sulfonamide antiglucoma. mechanism of action of dorzolamide dorzolamide is a sulfonamide used as topical carbonic anhydrase inhibitor. inhibition of carbonic anhydrase-2 in ciliary proc', NULL, 1210, '2024-08-31', NULL, 0, 'Dorzolamide is indicated for the management of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.[L11377] It can also be used in combination with [timolol] for the same indication in patients who are insufficiently responsive to ophthalmic beta-blockers.[L11380]



Its pre-operative use was also investigated to prevent elevated intraocular pressure after neodynium yttrium aluminum garnet laser posterior capsulotomy.[A190183]', 'Elevated intraocular pressure is a characteristic manifestation of ocular hypertension or open-angle glaucoma. The level of intraocular pressure (IOP) is governed by the balance between the production of aqueous humour (by ocular ciliary processes) and its outflow from the anterior segment of the eye via trabecular (conventional) or uveoscleral (unconventional) pathways. When there is an increase in the resistance to the trabecular outflow of aqueous humour, the intraocular pressure is elevated. Subsequently, optic nerve damage can occur from blood flow restrictions and mechanical distortion of ocular structures. Optic nerve damage can further result in optic disc cupping and progressive visual field loss (and blindness in some cases).[A1304] 



Carbonic anhydrase (CA) is a ubiquitous enzyme that catalyzes the reversible hydration of carbon dioxide to bicarbonate ions and dehydration of carbonic acid.[A1304,L11377] In the ocular ciliary processes, the local production of bicarbonate by CAs promotes sodium and fluid transport. CA-II is a key isoenzyme found primarily in red blood cells (RBCs) that regulates aqueous humour production.[A1304] Dorzolamide is a highly specific CA-II inhibitor, where it displays a 4000-fold higher affinity for carbonic anhydrase II than carbonic anhydrase I.[A1304] The inhibition of CA-II in the ciliary process disrupts the formation of bicarbonate ions and reduces sodium and fluid transport, which leads to decreased aqueous humour secretion and reduced intraocular pressure.[A1304,L11377]', 'Dorzolamide is a carbonic anhydrase inhibitor that reduces elevated intraocular pressure in open-angle glaucoma or ocular hypertension. When used in combination with topic beta-adrenergic antagonists, dorzolamide has an additive effect of lowering intraocular pressure. The peak ocular hypotensive effect of dorzolamide is observed at about 2 hours following ophthalmic administration.[A1304]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Perfectil plus nails 60 tabs. (illegal import)', 24741, 'بيرفيكتيل بلس للاظافر 60 اقراص', '0', NULL, 'Multivitamins', 'Multivitamins', NULL, NULL, 'Vitabiotics', 'Tab', 'أقراص', NULL, '6', NULL, NULL, 'perfectil plus nails provides an advanced comprehensive formula to complement your daily beauty routine. it includes specially selected nutrients and beauty minerals to nourish tissue in the nail matrix and bed including: -extra selenium which contributes', NULL, 694, '2022-07-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Allevo 5mg 20 f.c. tab.', 400, 'اليفو 5مجم 20 قرص', '52', '21', 'Antihistamine.non-sedative.third-generation', 'Antihistamine.non-sedative.third-generation', NULL, 'Levocetirizine', 'Chemipharm', 'Tab', 'أقراص', '5mg', '2', 'مضاد للحساسية -- مضاد للحكة', NULL, NULL, '6222006501020', 3120, '2024-02-20', NULL, 0, 'Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria.[L7694] It is also used over the counter for a variety of mild allergy symptoms.[A181748]', 'Levocetirizine selectively inhibits histamine H<sub>1</sub> receptors.[L7694] This action prevents histamine from activating this receptor and causing effects like smooth muscle contraction, increased permeability of vascular endothelium, histidine uptake in basophils, stimulation of cough receptors, and stimulation of flare responses in the nervous system.[A181790]', 'Levocetirizine is a second generation histamine H<sub>1</sub> antagonist used to treat various allergic symptoms.[A181748,A181790,L7694] It has a long duration of action as it is generally taken once daily, and a wide therapeutic window as animal studies show the maximal nonlethal dose is over 100x a normal dose.[L7694] Patients are cautioned to avoid tasks that require complete alertness, avoid alertness, and use caution in patients with factors predisposing urinary retention.[L7694]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Metanium everyday barrier ointment 40 gm', 24167, 'ميتانيوم ايفريداي بارير مرهم 40 جم', '200', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Stada', 'Ointment', 'مرهم', '40 gm', '1', NULL, NULL, NULL, NULL, 720, '2023-04-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ibrance 125mg 21 caps', 20678, 'ايبرانس 125مجم 21 كبسولة', '53,747', NULL, 'Antineoplastic agent.cyclin-dependent kinase inhibitor', 'Antineoplastic agent.cyclin-dependent kinase inhibitor', NULL, 'Palbociclib', 'Pfizer', 'Cap', 'كبسولة', '125mg', '1', 'مضاد للاورام', NULL, NULL, NULL, 14769, '2023-02-03', NULL, 0, 'Palbociclib is indicated in combination with [letrozole] as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with [fulvestrant] in patients with disease progression with prior endocrine therapy.[A176783]



In the official labeling, the use of palbociclib should be accompanied with either an aromatase inhibition, no restricted to letrozole, as initial endocrine-based therapy in postmenopausal women or in man.[L48076]



The breast cancer starts as a group of cancer cells that grow into and destroy the nearby breast tissue. This growth can spread into other parts of the body which is called metastasis. According to the location of the cancer cells, it can be categorized in ductal carcinoma and lobular carcinoma. However, other types of breast cancer include inflammatory breast cancer, Paget disease of the breast, triple negative breast cancer non-Hodgkin lymphoma and soft tissue sarcoma.[L5870] In males, breast cancer is usually treated as the cases of postmenopausal women and almost all the cases are ductal carcinoma.[L5873]', 'Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor[A176783] that acts by binding to the ATP pocket with an IC50 in the range of 9-15 nmol/L. It is important to consider that it presents low to absent activity against other kinases.[A176798] 



The CDK4/6 kinase is involved, with coregulatory partner cyclin D, in the G1-S transition. Hence, inhibition of this step prevents cell cycle progression in cells in whose this pathway is functioning. This step includes the pathways of the phosphorylation of retinoblastoma protein and the E2F family of transcription factors.[A176798]', 'Due to its mechanism of action, palbociclib inhibits cell growth and suppresses DNA replication in retinoblastoma tumor suppressor gene (RB) proficient cancer cells. As expected, these RB cells present a significant increase in the proportion of cells in G1 state and the presence of palbociclib produces effective dephosphorylation of RB, reduce proliferation and induce senescence causing cell-cycle arrest.[A176810]



In vitro studies showed the potential for palbociclib to reduce cellular proliferation of estrogen receptor-positive breast cancer cell lines through the inhibition of the cell-cycle progression from G1 to S phase. In this study, it was demonstrated that the sensitivity of the cells significantly increased with the expression of _RB1_ and _CCND1_ and low expression of _CDKN2A_. As well, palbociclib, combined with antiestrogens, enhanced _in vivo_ antitumor activity in estrogen receptor-positive breast cancer mouse models.[A176792]



In clinical trials, palbociclib, in combination with letrozole, was shown to significantly increase the progression-free survival (PFS) in patients with metastatic breast cancer without prior endocrine treatment. In the results, the PFS increased from 4.5 to 9.5 months with an overall response rate (ORR) of 24.6%.[A176789]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Strepsils strawberry sugar free 16 lozenges', 27568, 'ستربسلز بالفراولة خالي من السكر 16 قطعة', '125', NULL, 'Sore throat', 'Sore throat', NULL, 'Dichlorophenylcarbinol+amylmetacresol', 'Reckitt benckiser healthcare > united partners company', 'Lozenges', 'استحلاب', NULL, '2', '1- تخفيف احتقان الحلق في نزلات البرد.', NULL, 'soothing effective relief for sore throats for children 6 years and above', '5000158101166', 907, '2022-12-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Normo tears eye drops 15 ml', 9009, 'نورمو تيرز قطرة عين 15 مل', '26', '17', 'Eye lubricant', 'Eye lubricant', NULL, 'Dextran+hydroxypropyl methylcellulose', 'Eipico', 'Drops', 'نقط', '15 ml', '1', 'قطرة مرطبه للعين تعالج جفاف العين', NULL, NULL, '6221032233004', 4949, '2024-09-21', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Immulant n syrup 120 ml', 6412, 'اميولانت ان شراب 120 مل', '50', '30', 'Immune enhancer', 'Immune enhancer', NULL, 'Echinacea dry extract+nigella sativa oil', 'Mepaco', 'Syrup', 'شراب', '120 ml', '1', 'علاج لضعف المناعة.', NULL, 'echinacea dry extract 83.5 mg/5ml', '6223002211807', 7447, '2025-01-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rotmoov massage cream 40 gm', 31262, 'روتموف مساج كريم 40 جرام', '35', '30', NULL, NULL, NULL, NULL, '> rotex pharma', 'Cream', 'كريم', '40 gm', '1', '1- تخفيف آلام العضلات الناتجة عن الألم والإرهاق.', NULL, NULL, NULL, 1519, '2025-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Brain-ox 30 mg s.r. 20 caps.', 1697, 'برين-اوكس 30مجم اس ار 20 كبسولة', '170', '108', 'Cerebral circulatory inhancer', 'Cerebral circulatory inhancer', NULL, 'Vincamine', 'October pharma', 'Cap', 'كبسولة', '30 mg', '2', 'محسن للدورة الدموية التي تصل الي الدماغ -- يحسن التركيز والذاكرة', NULL, NULL, '6221088021334', 11157, '2025-04-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ventamor acne gel 40 gm', 7055, 'فنتامور اكن جل لحب الشباب 40 جرام', '210', NULL, 'Skin care.anti-acne', 'Skin care.anti-acne', NULL, NULL, 'Prime pharma', 'Gel', 'جل', '40 gm', '1', NULL, NULL, NULL, NULL, 775, '2025-08-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bradipect 5 mg 28 f.c. tabs', 15457, 'براديبكت 5مجم 28 قرص', '168', '120', 'Anti-ischemic', 'Anti-ischemic', NULL, 'Ivabradine', 'October pharma', 'Tab', 'أقراص', '5 mg', '4', 'امراض القلب والضغط', NULL, NULL, '6221088011236', 2648, '2023-12-06', NULL, 0, 'Ivabradine is indicated by the FDA to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. It is also indicated for treatment of stable symptomatic heart failure as a result of dilated cardiomyopathy for pediatric patients 6 months of age or more[FDA Label].', 'Ivabradine lowers heart rate by selectively inhibiting If channels ("funny channels") in the heart in a concentration-dependent manner without affecting any other cardiac ionic channels (including calcium or potassium). Ivabradine binds by entering and attaching to a site on the channel pore from the intracellular side and disrupts If ion current flow, which prolongs diastolic depolarization, lowering heart rate. The If currents are located in the sinoatrial node and are the home of all cardiac pacemaker activity. Ivabradine therefore lowers the pacemaker firing rate, consequently lowering heart rate and reducing myocardial oxygen demand. This allows for an improved oxygen supply and therefore mitigation of ischemia, allowing for a higher exercise capacity and reduction in angina episodes. ', 'The funny channels (If) open during repolarization and close during depolarization, making ivabradine''s activity dependent on heart rate or the closing and opening of the channels. Therefore ivabradine exhibits use-dependence and is more pharmacologically active at higher heart rates. Ivabradine exhibits a linear dose-dependent heart-rate lowering activity (bradycardic effect) until a maximum dose of 30-40mg. At higher doses, the concentration of ivabradine tends to plateau, reducing risk of serious sinus bradycardia.  It has been shown that the metabolite of ivabradine lowers heart rate as well, contributing to ivabradine''s overall effect. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vigilant conditioner (leave in)', 7610, 'فيجيلانت كوندشنر (ليف ان)', '200', NULL, 'Conditioner ( leave in)', 'Conditioner ( leave in)', NULL, 'Sodium hyaluronate+biotin+shea butter+natural oils', 'Levisage pharma', 'Conditioner', 'بلسم', NULL, '1', NULL, NULL, NULL, NULL, 750, '2025-10-06', NULL, 0, 'For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.', 'Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.', 'Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Amophage 500mg 30 tab', 614, 'اموفاج 500 مجم 30 قرص', '11', NULL, 'Anti-diabetic.sensitizers.biguanide', 'Anti-diabetic.sensitizers.biguanide', NULL, 'Metformin', 'Amoun', 'Tab', 'أقراص', '500mg', '3', 'علاج مرضى السكر النوع الثاني', NULL, NULL, '6221025010179', 2057, '2022-12-01', NULL, 0, '**Metformin immediate-release formulations**

 

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.[L40243]



**Metformin extended-release tablet (XR)**



The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.[L12207]



**Metformin combination products**



Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263] in combination with SGLT2 inhibitors ([canagliflozin], [empagliflozin], [ertugliflozin], or [dapagliflozin]),[L11479,L30503,L1134,L13679,L38729] or in combination with [pioglitazone].[L11419]', 'Metformin''s mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.[L12207] It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.[A36534, A36557]   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.



After ingestion, the organic cation transporter-1 (OCT1) is responsible for the uptake of metformin into hepatocytes (liver cells). As this drug is positively charged, it accumulates in cells and in the mitochondria because of the membrane potentials across the plasma membrane as well as the mitochondrial inner membrane. Metformin inhibits mitochondrial complex I, preventing the production of mitochondrial ATP leading to increased cytoplasmic ADP:ATP and AMP:ATP ratios.[A36534] These changes activate AMP-activated protein kinase (AMPK), an enzyme that plays an important role in the regulation of glucose metabolism.[A176348] Aside from this mechanism, AMPK can be activated by a lysosomal mechanism involving other activators.  Following this process, increases in AMP:ATP ratio also inhibit _fructose-1,6-bisphosphatase_ enzyme, resulting in the inhibition of gluconeogenesis, while also inhibiting _adenylate cyclase_ and decreasing the production of cyclic adenosine monophosphate (cAMP),[A36534] a derivative of ATP used for cell signaling [A176351]. Activated AMPK phosphorylates two isoforms of acetyl-CoA carboxylase enzyme, thereby inhibiting fat synthesis and leading to fat oxidation, reducing hepatic lipid stores and increasing liver sensitivity to insulin.[A36534] 



In the intestines, metformin increases anaerobic glucose metabolism in enterocytes (intestinal cells), leading to reduced net glucose uptake and increased delivery of lactate to the liver. Recent studies have also implicated the gut as a primary site of action of metformin and suggest that the liver may not be as important for metformin action in patients with type 2 diabetes. Some of the ways metformin may play a role on the intestines is by promoting the metabolism of glucose by increasing glucagon-like peptide I (GLP-1) as well as increasing gut utilization of glucose.[A36534] 



In addition to the above pathway, the mechanism of action of metformin may be explained by other ways, and its exact mechanism of action has been under extensive study in recent years.[A36535, A36554, A36555, A36557]', '**General effects**



Insulin is an important hormone that regulates blood glucose levels.[T514] Type II diabetes is characterized by a decrease in sensitivity to insulin, resulting in elevations in blood glucose when the pancreas can no longer compensate. In patients diagnosed with type 2 diabetes, insulin is unable to exert adequate effects on tissues and cells (i.e. insulin resistance)[T514] and insulin deficiency may also be present.[L5753]



Metformin reduces hepatic production of glucose, decreases the intestinal absorption of glucose, and enhances insulin sensitivity by increasing both peripheral glucose uptake and utilization. In contrast with drugs of the sulfonylurea class, which lead to hyperinsulinemia, the secretion of insulin is unchanged with metformin use.[L12207]



**Effect on fasting plasma glucose (FPG) and Glycosylated hemoglobin (HbA1c)**



HbA1c is an important periodic measure of glycemic control used to monitor diabetic patients. Fasting plasma glucose is also a useful and important measure of glycemic control. In a 29-week clinical trial of subjects diagnosed with type II diabetes, metformin decreased the fasting plasma glucose levels by an average of 59 mg/dL from baseline, compared to an average increase of 6.3 mg/dL from baseline in subjects taking a placebo.[L12207]  Glycosylated hemoglobin (HbA1c) was decreased by about 1.4% in subjects receiving metformin, and increased by 0.4% in subjects receiving placebo only.[L12207]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Axomyelin ultra 600 mg 30 f.c. tabs', 2045, 'اكسومايلين الترا 600مجم 30 قرص', '460', NULL, 'Dietary supplement', 'Dietary supplement', NULL, 'Alpha lipoic acid+benfotiamine+pyridoxine hcl+cyanobalamin+cholecalciferol', 'Parkville', 'Tab', 'أقراص', '600 mg', '3', NULL, NULL, NULL, '6223012633248', 2438, '2025-01-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Biorun massage spray 100 ml', 30196, 'بيوران مساج سبراي 100 مل', '279', '179', 'Massage spray', 'Massage spray', NULL, 'Menthol crystals+methyl salicylate+camphor oil+eucalyptus oil+vit e', 'Dreams > doctor pharma', 'Spray', 'بخاخ', '100 ml', '1', 'مخدر موضعى لعلاج التهاب المفاصل والعضلات والتشنجات الموضعية والام العمود الفقرى', NULL, 'biorun pain reliever is the #1 clinically used and recommended topical analgesic of hands-on healthcare professionals. ï¿½chiropractors physical therapists massage therapists podiatrists and athletic trainers use biorun to provide immediate relief from ma', NULL, 3159, '2024-10-28', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dapagloza 10mg 30 tabs', 7975, 'داباجلوزا 10مجم 30 قرص', '299', NULL, 'Anti-diabetic.secretagogues.sglt2 inhibitors', 'Anti-diabetic.secretagogues.sglt2 inhibitors', NULL, 'Dapagliflozin', 'Averroes pharma', 'Tab', 'أقراص', '10mg', '3', NULL, NULL, NULL, NULL, 820, '2025-11-12', NULL, 0, 'Dapagliflozin is indicated as an adjunct treatment, alongside diet and exercise, to improve glycemic control in patients ≥10 years of age with type 2 diabetes mellitus.[L51023,A6757,A6758] For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure.[L46372] Dapagliflozin is also indicated to either reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.[L46372] Combination products with dapagliflozin also exist, either as a dapagliflozin-saxagliptin or dapagliflozin-metformin hydrochloride formulation.[L38724,L38729] Both are used as an adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes.[L38724,L38729]', 'Dapagliflozin inhibits the sodium-glucose cotransporter 2(SGLT2) which is primarily located in the proximal tubule of the nephron.[A6757] SGLT2 facilitates 90% of glucose reabsorption in the kidneys and so its inhibition allows for glucose to be excreted in the urine.[A6757] This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.[A6757] ', 'Dapagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, lowering both pre- and afterload of the heart and downregulation of sympathetic activity, and decreased intraglomerular pressure which is believed to be mediated by increased tubuloglomerular feedback.[L48246]



Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following the administration of dapagliflozin. Dapagliflozin doses of 5 or 10 mg per day in patients with type 2 diabetes mellitus for 12 weeks resulted in excretion of approximately 70 grams of glucose in the urine per day at Week 12. A near-maximum glucose excretion was observed at the dapagliflozin daily dose of 20 mg. This urinary glucose excretion with dapagliflozin also results in increases in urinary volume. After discontinuation of dapagliflozin, on average, the elevation in urinary glucose excretion approaches baseline by about 3 days for the 10 mg dose.[L48246]



Dapagliflozin was not associated with clinically meaningful prolongation of QTc interval at daily doses up to 150 mg (15 times the recommended maximum dose) in a study of healthy subjects. In addition, no clinically meaningful effect on QTc interval was observed following single doses of up to 500 mg (50 times the recommended maximum dose) of dapagliflozin in healthy subjects.[L48246]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Entocid comp. 15 sachet for oral susp.', 4207, 'انتوسيد مركب اكياس 15 كيس', '33', '6', 'Antidiarrheal', 'Antidiarrheal', NULL, 'Diiodohydroxyquinoline+kaolin+nicotinamide+pectin+streptomycin+succinylsulphathiazole+sulphadiazine', 'Cid', 'Susp', 'معلق', NULL, '1', NULL, NULL, NULL, '6221043011042', 1323, '2024-11-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lignocaine 5% cream 20 gm', 7311, 'لجنوكايين 5% كريم 20 جرام', '24', '16', 'Analgesic.local anesthetic', 'Analgesic.local anesthetic', NULL, 'Lidocaine', 'El nile.', 'Cream', 'كريم', '5%', '1', 'مخدر موضعي', NULL, 'indication for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural tech', '6221077072316', 7774, '2024-09-17', NULL, 0, 'Lidocaine is an anesthetic of the amide group indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks [F4349, L5930].', 'Lidocaine is a local anesthetic of the amide type [F4349, L5930, L5948]. It is used to provide local anesthesia by nerve blockade at various sites in the body [F4349, L5930, L5948]. It does so by stabilizing the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action [F4349, L5930, L5948]. In particular, the lidocaine agent acts on sodium ion channels located on the internal surface of nerve cell membranes [F4349, L5930, L5948]. At these channels, neutral uncharged lidocaine molecules diffuse through neural sheaths into the axoplasm where they are subsequently ionized by joining with hydrogen ions [F4349, L5930, L5948]. The resultant lidocaine cations are then capable of reversibly binding the sodium channels from the inside, keeping them locked in an open state that prevents nerve depolarization [F4349, L5930, L5948]. As a result, with sufficient blockage, the membrane of the postsynaptic neuron will ultimately not depolarize and will thus fail to transmit an action potential [F4349, L5930, L5948]. This facilitates an anesthetic effect by not merely preventing pain signals from propagating to the brain but by aborting their generation in the first place [F4349, L5930, L5948].



In addition to blocking conduction in nerve axons in the peripheral nervous system, lidocaine has important effects on the central nervous system and cardiovascular system [F4349, L5930, L5948]. After absorption, lidocaine may cause stimulation of the CNS followed by depression and in the cardiovascular system, it acts primarily on the myocardium where it may produce decreases in electrical excitability, conduction rate, and force of contraction [F4349, L5930, L5948].', 'Excessive blood levels of lidocaine can cause changes in cardiac output, total peripheral resistance, and mean arterial pressure [F4349, L5930]. With central neural blockade these changes may be attributable to the block of autonomic fibers, a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system, and/or the beta-adrenergic receptor stimulating action of epinephrine when present [F4349, L5930]. The net effect is normally a modest hypotension when the recommended dosages are not exceeded [F4349, L5930].



In particular, such cardiac effects are likely associated with the principal effect that lidocaine elicits when it binds and blocks sodium channels, inhibiting the ionic fluxes required for the initiation and conduction of electrical action potential impulses necessary to facilitate muscle contraction [F4349, L5930, L5948]. Subsequently, in cardiac myocytes, lidocaine can potentially block or otherwise slow the rise of cardiac action potentials and their associated cardiac myocyte contractions, resulting in possible effects like hypotension, bradycardia, myocardial depression, cardiac arrhythmias, and perhaps cardiac arrest or circulatory collapse [F4349, L5930, L5948].



Moreover, lidocaine possesses a dissociation constant (pKa) of 7.7 and is considered a weak base [L5948]. As a result, about 25% of lidocaine molecules will be un-ionized and available at the physiological pH of 7.4 to translocate inside nerve cells, which means lidocaine elicits an onset of action more rapidly than other local anesthetics that have higher pKa values [L5948]. This rapid onset of action is demonstrated in about one minute following intravenous injection and fifteen minutes following intramuscular injection [L5930]. The administered lidocaine subsequently spreads rapidly through the surrounding tissues and the anesthetic effect lasts approximately ten to twenty minutes when given intravenously and about sixty to ninety minutes after intramuscular injection [L5930].



Nevertheless, it appears that the efficacy of lidocaine may be minimized in the presence of inflammation [L5948]. This effect could be due to acidosis decreasing the amount of un-ionized lidocaine molecules, a more rapid reduction in lidocaine concentration as a result of increased blood flow, or potentially also because of increased production of inflammatory mediators like peroxynitrite that elicit direct actions on sodium channels [L5948].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Beesline lip care flavour free 4.5 gm', 15014, 'بيزلين للعناية بالشفاه خالي من النكهات 4.5 جم', '95', NULL, 'Lip care', 'Lip care', NULL, NULL, 'Beesline > pharma cruise medical', 'Unknown', 'غير محدد', '4.5 gm', '1', NULL, NULL, 'active ingredients beeswax sweet almond oil wheat germ oil carnauba wax carrot vitamin c & vitamin e. the ultimate cure for dry chapped lips! soothes moisturises & regenerates the lips sensitive skin through natureï¿½s healing beeswax & precious oils whil', NULL, 865, '2022-07-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Complete hair oil 120 ml', 2957, 'كومبليت زيت شعر 120 مل', '175', '165', 'Hair care', 'Hair care', NULL, 'Olive oil+emu oil+sesame oil+wheat germ oil+rocket oil+castor oil', 'Hi-care > health well egypt', 'Hair oil', 'زيت شعر', '120 ml', '1', 'زيت للشعر لترطيبه -- سهولة تمشيطه -- علاج الهيشان والتقصف -- تقوية الشعر وتغذيته', NULL, NULL, '6224000911027', 5658, '2025-01-06', NULL, 0, 'In a clinical context, olive oil is used as a source of calories and fatty acids in patients requiring parenteral nutrition. A formulation called Clinolipid, comprising olive oil and [soybean oil], is indicated in all age groups, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated.[L51013]', 'Fatty acids act as a substrate in energy production through beta-oxidation as well as important components of cell membrane structures and prescursors for bioactive molecules like prostaglandins.', 'Provides a source of calories and fatty acids.[L51013]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Danabol ds 10 mg 500 cap', 3296, 'دانابول دي اس 10 مجم 500 كبسولة', '480', NULL, 'Androgen', 'Androgen', NULL, 'Danazol', 'Company', 'Cap', 'كبسولة', '10 mg', '1', NULL, NULL, NULL, NULL, 2265, '2022-07-29', NULL, 0, 'For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.', 'As a gonadotropin inhibitor, danazol suppresses the pituitary-ovarian axis possibly by inhibiting the output of pituitary gonadotropins. Danazol also depresses the preovulatory surge in output of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), thereby reducing ovarian estrogen production. Danazol may also directly inhibits ovarian steroidogenesis; bind to androgen, progesterone, and glucocorticoid receptors; bind to sex-hormone-binding globulin and corticosteroid-binding globulin; and increases the metabolic clearance rate of progesterone. Another mechanism of action by which danazol may use to facilitate regression of endometriosis is by decreasing IgG, IgM, and IgA concentrations, as well as phospholipid and IgG isotope autoantibodies. In the treatment of endometriosis, as a consequence of suppression of ovarian function,  danazol causes both normal and ectopic endometrial tissues to become inactive and atrophic. This leads to anovulation and associated amenorrhea. In fibrocystic breast disease, the exact mechanism of action of danazol is unknown, but may be related to suppressed estrogenic stimulation as a result of decreased ovarian production of estrogen. A direct effect on steroid receptor sites in breast tissue is also possible. This leads to a disappearance of nodularity, relief of pain and tenderness, and possibly changes in the menstrual pattern. In terms of hereditary angioedema, danazol corrects the underlying biochemical deficiency by increasing serum concentrations of the deficient C1 esterase inhibitor, resulting in increased serum concentrations of the C4 component of the complement system. (Source: PharmGKB)', 'Danazol is a derivative of the synthetic steroid ethisterone, a modified testosterone. It was approved by the U.S. Food and Drug Administration (FDA) as the first drug to specifically treat endometriosis, but its role as a treatment for endometriosis has been largely replaced by the gonadotropin-releasing hormone (GnRH) agonists. Danazol has antigonadotropic and anti-estrogenic activities. Danazol acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Enzymorave 30 tabs', 586, 'انزيموراف 30 قرص', '135', '120', 'Enzyme replacement therapy & anti inflammatory & anti edema', 'Enzyme replacement therapy & anti inflammatory & anti edema', NULL, 'Trypsin 300 usp+chymotrypsin 300 usp', 'Brave pharma', 'Tab', 'أقراص', NULL, '3', NULL, NULL, NULL, NULL, 2943, '2025-09-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ketofan 200mg sr 14 cap', 6875, 'كيتوفان اس ار 200 مجم 14 كبسولة', '36', '23.75', 'Nsaid.propionic acid derivatives', 'Nsaid.propionic acid derivatives', NULL, 'Ketoprofen', 'Amirya', 'Cap', 'كبسولة', '200mg', '2', 'مسكن عام للجسم __ تقليل الالام العظام و الاسنان', NULL, NULL, '6221075020036', 1429, '2024-12-07', NULL, 0, 'For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.', 'The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. ', 'Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ejadaxtin 60 mg 3 f.c. tabs.', 6862, 'ايجاداكستين 60مجم 3 اقراص', '30', NULL, NULL, NULL, NULL, 'Dapoxetine', 'Wadi elneel benta', 'Tab', 'أقراص', '60 mg', '3', NULL, NULL, NULL, NULL, 867, '2025-08-16', NULL, 0, 'For the treatment of premature ejaculation.', 'The drug''s mechanism of action is thought to be related to inhibition of neuronal reuptake of serotonin and subsequent potentiation of serotonin activity. The central ejaculatory neural circuit comprises spinal and cerebral areas that form a highly interconnected network. The sympathetic, parasympathetic, and somatic spinal centers, under the influence of sensory genital and cerebral stimuli integrated and processed at the spinal cord level, act in synergy to command physiologic events occurring during ejaculation. Experimental evidence indicates that serotonin (5-HT), throughout brain descending pathways, exerts an inhibitory role on ejaculation. To date, three 5-HT receptor subtypes (5-HT(1A), 5-HT(1B), and 5-HT(2C)) have been postulated to mediate 5-HT''s modulating activity on ejaculation.', 'Dapoxetine is a selective serotonin reuptake inhibitor currently undergoing trials through Alza (under license from GenuPro, a collaboration between Eli Lilly and PPD). Dapoxetine is a short-acting SSRI drug currently being considered for approval by the Food and Drug Administration (FDA) for the treatment of premature ejaculation in men, which would make it the first drug approved for such treatment. Despite two clinical trials finished in 2006, experts doubt it will be approved by the FDA soon because SSRIs come with undesirable side-effects after long-term use, such as psychiatric problems, dermatological reactions, increase in body weight, lower sex-drive, nausea, headache, upset stomach and weakness, thus not significantly outweighing the benefit of premature ejaculation medication versus the risks. By contrast with SSRIs approved for depression, which take 2 weeks or longer to reach steady-state concentration, dapoxetine has a unique pharmacokinetic profile, with a short time to maximum serum concentration (about 1 h) and rapid elimination (initial half-life of 1-2 h).', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Grandtal 10 sachets', 20042, 'جراندتال 10 اكياس', '160', NULL, 'Dietary supplement', 'Dietary supplement', NULL, 'Vitamin(a+b1+b2+b6+b12+c+d+e)+folic+biotin+calcium+magnesium+zinc+selenium', 'Nutrixia > omega international group', 'Sachet', 'أكياس', NULL, '1', 'مكمل غذائي __ مصدر للكالسيوم وفيتامين ب __ مقوي للاعصاب __ يساعد علي تقوية العظام __ مصدر للطاقة', NULL, 'use : dissolve 1 sachet in half cup of water once daily.', NULL, 1582, '2022-04-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rheumarene 75mg/3ml 3 amp. i.m', 26019, 'رومارين 75مجم/3مل 3 امبولات', '27', '16.5', 'Nsaid.acetic acid derivatives', 'Nsaid.acetic acid derivatives', NULL, 'Diclofenac sodium', 'Sedico', 'Amp', 'أمبول', '75mg', '3', NULL, NULL, 'description a non-steroidal anti-inflammatory agent (nsaid) with antipyretic and analgesic actions. it is primarily available as the sodium salt. indication : for the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthr', '6221042401035', 4229, '2024-07-16', NULL, 0, 'Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma. It is often used in combination with [misoprostol] as a gastro-protective agent in patients with high risk of developing NSAID-induced ulcers.', 'Diclofenac inhibits cyclooxygenase-1 and -2, the enzymes responsible for production of prostaglandin (PG) G<sub>2</sub> which is the precursor to other PGs.[label,T116] These molecules have broad activity in pain and inflammation and the inhibition of their production is the common mechanism linking each effect of diclofenac.



PGE<sub>2</sub> is the primary PG involved in modulation of nociception.[A179023] It mediates peripheral sensitization through a variety of effects.[T116,A179023] PGE<sub>2</sub> activates the G<sub>q</sub>-coupled EP<sub>1</sub> receptor leading to increased activity of the inositol trisphosphate/phospholipase C pathway. Activation of this pathway releases intracellular stores of calcium which directly reduces action potential threshold and activates protein kinase C (PKC) which contributes to several indirect mechanisms. PGE<sub>2</sub> also activates the EP<sub>4</sub> receptor, coupled to G<sub>s</sub>, which activates the adenylyl cyclase/protein kinase A (AC/PKA) signaling pathway. PKA and PKC both contribute to the potentiation of transient receptor potential cation channel subfamily V member 1 (TRPV1) potentiation, which increases sensitivity to heat stimuli. They also activate tetrodotoxin-resistant sodium channels and inhibit inward potassium currents. PKA further contributes to the activation of the P2X3 purine receptor and sensitization of T-type calcium channels. The activation and sensitization of depolarizing ion channels and inhibition of inward potassium currents serve to reduce the intensity of stimulus necessary to generate action potentials in nociceptive sensory afferents. PGE<sub>2</sub> act via EP<sub>3</sub> to increase sensitivity to bradykinin and via EP<sub>2</sub> to further increase heat sensitivity. Central sensitization occurs in the dorsal horn of the spinal cord and is mediated by the EP<sub>2</sub> receptor which couples to G<sub>s</sub>. Pre-synaptically, this receptor increases the release of pro-nociceptive neurotransmitters glutamate, CGRP, and substance P. Post-synaptically it increases the activity of AMPA and NMDA receptors and produces inhibition of inhibitory glycinergic neurons. Together these lead to a reduced threshold of activating, allowing low intensity stimuli to generate pain signals. PGI<sub>2</sub> is known to play a role via its G<sub>s</sub>-coupled IP receptor although the magnitude of its contribution varies. It has been proposed to be of greater importance in painful inflammatory conditions such as arthritis. By limiting sensitization, both peripheral and central, via these pathways NSAIDs can effectively reduce inflammatory pain.



PGI<sub>2</sub> and PGE<sub>2</sub> contribute to acute inflammation via their IP and EP<sub>2</sub> receptors.[T116,A179044] Similarly to β adrenergic receptors these are G<sub>s</sub>-coupled and mediate vasodilation through the AC/PKA pathway. PGE<sub>2</sub> also contributes by increasing leukocyte adhesion to the endothelium and attracts the cells to the site of injury.[T116] PGD<sub>2</sub> plays a role in the activation of endothelial cell release of cytokines through its DP<sub>1</sub> receptor.[A179044] PGI<sub>2</sub> and PGE<sub>2</sub> modulate T-helper cell activation and differentiation through IP, EP<sub>2</sub>, and EP<sub>4</sub> receptors which is believed to be an important activity in the pathology of arthritic conditions. By limiting the production of these PGs at the site of injury, NSAIDs can reduce inflammation.



PGE<sub>2</sub> can cross the blood-brain barrier and act on excitatory G<sub>q</sub> EP<sub>3</sub> receptors on thermoregulatory neurons in the hypothalamus.[T116] This activation triggers an increase in heat-generation and a reduction in heat-loss to produce a fever. NSAIDs prevent the generation of PGE<sub>2</sub> thereby reducing the activity of these neurons.

', 'Diclofenac reduces inflammation and by extension reduces nociceptive pain and combats fever.[label,T116] It also increases the risk of developing a gastrointestinal ulcer by inhibiting the production of protective mucus in the stomach.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ginso plus 20 caps', 32900, 'جينسو بلس 20 كبسولة', '110', '69', 'Multivitamins', 'Multivitamins', NULL, 'Ginseng + royal jelly + bee pollen + omega-3 + l-arginine + wheat grem oil + vitamin b1 + vitamin b2 + vitamin b6 + vitamin b12 + vitamin c + vitamin d + manganese + zinc + copper', 'Diamond pharma company', 'Cap', 'كبسولة', NULL, '2', NULL, NULL, '-ginseng ... 100 mg -royal jelly ... 1000 -bee pollen ... 250 mg -omega-3 ... 50 mg -l- arginine ... 50 mg -wheat grem oil ... 250 mg -vitamin b1 ... 10 mg -vitamin b2 ... 2 mg -vitamin b6 ... 10 mg -vitamin b12 ... 50 mcg -vitamin c ... 50 mg -vitamin d', NULL, 1284, '2025-08-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Novalgin 500mg 100 tab.', 23778, 'نوفالجين 500مجم 100 اقراص', '32', NULL, 'Antipyretic', 'Antipyretic', NULL, 'Dipyrone(metamizole)', 'Sanofi', 'Tab', 'أقراص', '500mg', '1', NULL, NULL, 'indication used in the past as a powerful painkiller and fever reducer. pharmacodynamics dipyrone is a non-steroidal anti-inflammatory drug (nsaid) commonly used in the past as a powerful painkiller and fever reducer.', NULL, 1006, '2022-07-30', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Safe white cream 25 gm', 26445, 'سيف كريم 25جم', '33', NULL, 'Whitening topical', 'Whitening topical', NULL, 'Kojic acid+wheat germ oil+ascorbyl palmitate(vitamin c)+liquorice ext', 'Beauty pharm international > pioneer leaders', 'Cream', 'كريم', '25 gm', '1', NULL, NULL, 'natural whitening cream ** use: to be applied once or twice a day at night.', '6224008851066', 775, '2022-07-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Awadist migraine 20 f.c. tabs.', 31922, 'اواديست ميجرين 20 قرص', '26', NULL, 'Antimigraine', 'Antimigraine', NULL, 'Paracetamol(acetaminophen)+caffeine+ergotamine', 'High performance pharma (hp pharma)', 'Tab', 'أقراص', NULL, '2', NULL, NULL, 'paracetamol ... 300 mg ergotamine ... 1 mg caffeine ... 100 mg', NULL, 1100, '2023-05-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Urinex 36 caps', 4907, 'يورينكس 36 كبسولة', '66', '42', 'Urinary.analgesic.antiseptic', 'Urinary.analgesic.antiseptic', NULL, 'Alpha pinene+anethol+beta pinene+borneol+camphene+cineol+fenchonel', 'Pharco', 'Cap', 'كبسولة', NULL, '3', NULL, NULL, NULL, '6221151628156', 1286, '2025-09-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Konakion 10 mg 100 tab', 6989, 'كوناكيون 10 مجم 100 قرص', '35', NULL, 'Vitamin k', 'Vitamin k', NULL, 'Phytomenadione', 'F.hoffman la roche > multipharma', 'Tab', 'أقراص', '10 mg', '1', NULL, NULL, NULL, '6224010051102', 2213, '2022-08-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rolart 30 piece', 31818, 'رولارت 30 قطعة', '80', NULL, 'Multivitamin', 'Multivitamin', NULL, 'Vitamins+iron', 'Nutrixia > solvax', 'Piece', 'قطعة', NULL, '3', 'مكمل مكمل غذائى يستخدم لعلاج الانيميا ويدعم صحة الجسم', NULL, 'food supplement product - jar contain 30 pieces each one contain iron and vitamins', NULL, 929, '2023-03-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Liptomilk 1 milk 400 gm', 7418, 'ليبتوميلك 1 لبن اطفال', '75', NULL, 'Milk products.first stage (age 0-6 months)', 'Milk products.first stage (age 0-6 months)', NULL, 'Milk formula stage 1', 'Liptis', 'Unknown', 'غير محدد', '400 gm', '1', NULL, NULL, NULL, '610644911114', 1679, '2022-12-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Labipress 5 mg/ml i.v. inf./bolus vial', 7023, 'لابيبريس 5مجم/مل فيال وريدي', '42', NULL, 'Anti-hypertensive.beta blocker.unselective', 'Anti-hypertensive.beta blocker.unselective', NULL, 'Labetalol', 'Debeiky > novell pharma', 'Vial', 'فيال', '5 mg', '1', NULL, NULL, 'about labetalol a mixed alpha/beta adrenergic antagonist antihypertensive(pregnancy-induced hypertension). mechanism of action of labetalol labetalol is an adrenergic antagonist capable of blocking alpha-1 beta-1 and beta-2 receptors and additional weak b', NULL, 1260, '2022-08-07', NULL, 0, 'Labetalol injections are indicated to control blood pressure in severe hypertension.[L7727] Labetalol tablets are indicated alone or in combination with antihypertensives like thiazides and loop diuretics to manage hypertension.[L7730]', 'Labetalol non-selectively antagonizes beta-adrenergic receptors, and selectively antagonizes alpha-1-adrenergic receptors.[A181901] Following oral administration, labetalol has 3 times the beta-blocking ability than alpha-blocking ability.[A181901] This increases to 6.9 times following intravenous administration.[A181901] Antagonism of alpha-1-adrenergic receptors leads to vasodilation and decreased vascular resistance.[A181907] This leads to a decrease in blood pressure that is most pronounced while standing.[A181910] Antagonism of beta-1-adrenergic receptors leads to a slight decrease in heart rate.[L7727] Antagonism of beta-2-adrenergic receptors leads to some of the side effects of labetalol such as bronchospasms, however this may be slightly attenuated by alpha-1-adrenergic antagonism.[A181910] Labetalol leads to sustained vasodilation over the long term without a significant decrease in cardiac output or stroke volume, and a minimal decrease in heart rate.[A181907,A181910]', 'Labetalol antagonizes various adrenergic receptors to decrease blood pressure.[A181901,A181907,A181910,L7727] The duration of action is long as it is generally given twice daily, and the therapeutic window is wide as patients usually take 200-400mg twice daily.[L7730] Patients susceptible to bronchospasms should not use labetalol unless they are unresponsive to or intolerant of other antihypertensives.[L7730]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Oralex oral gel 15 gm', 24209, 'اوراليكس جل للفم 15 جم', '12', NULL, 'Oral care', 'Oral care', NULL, 'Sodium perborate+clove oil+peppermint oil+tea tree oil+sorbitol', 'Kato prestige cosmetics > pharmaserve medical', 'Gel', 'جل', '15 gm', '1', 'جل لعلاج التهابات وقرح الفم واللثة', NULL, NULL, NULL, 978, '2022-07-13', NULL, 0, 'For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.', 'Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.', 'Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Pelembap calamine 100 ml lotion', 2801, 'بيليمباب كالامين 100 مل لوشن', '49', NULL, 'Skin care', 'Skin care', NULL, 'Calamine zinc oxide collagen ceramide', 'Yojeen', 'Lotion', 'لوشن', '100 ml', '1', NULL, NULL, NULL, NULL, 937, '2025-02-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vibramycin 100mg 10 caps.', 29237, 'فيبراميسين 100مجم 10 كبسولات', '65', '42.5', 'Antibiotic.tetracycline', 'Antibiotic.tetracycline', NULL, 'Doxycycline', 'Pfizer', 'Cap', 'كبسولة', '100mg', '2', NULL, NULL, 'about doxycycline tetracycline derivative antibiotic. mechanism of action of doxycycline doxycycline is a broad spectrum antibiotic which acts against both gram positive and gram negative organisms. it exerts its bacteriostatic action by accumulating insi', '6774433700007', 6816, '2024-11-08', NULL, 0, 'Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:



- Early Lyme disease (as evidenced by erythema migraines) due to _Borrelia burgdorferi_ in adults and pediatric patients 8 years of age and older weighing 45 kg and above [L42875]

- Rickettsial infections,[L42870] such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers [L42880]

- Sexually transmitted infections [L42870]

- Respiratory tract infections [L42870] caused by _Mycoplasma pneumoniae_ and _Haemophilus influenzae_ [L42880]

- Specific bacterial infections [L42870] after indicative bacteriologic testing. These include infections caused by _Escherichia coli_, _Enterobacter aerogenes_, _Shigella_ species, _Acinetobacter_ species, and _Klebsiella_ species [L42880]

- Ophthalmic infections,[L42870] such as inclusion conjunctivitis caused by _Chlamydia trachomatis_ [L42880]

- Anthrax, including inhalational anthrax (post-exposure) [L42870]

- Alternative treatment for selected infections when [penicillin] is contraindicated [L42870]

- Adjunctive therapy in acute intestinal amebiasis and severe acne [L42870, L42880]

- Lymphogranuloma venereum caused by _Chlamydia trachomatis_ [L42880]

- Psittacosis (ornithosis) caused by _Chlamydophila psittaci_ [L42880]

- Trachoma caused by _Chlamydia trachomatis_, although the infectious agent is not always eliminated, as judged by immunofluorescence [L42880]

- Uncomplicated urethral, endocervical, or rectal infections in adults caused by _Chlamydia trachomatis_ [L42880]

- Nongonococcal urethritis caused by _Ureaplasma urealyticum_ [L42880]

- Relapsing fever due to _Borrelia recurrentis_ [L42880]

- Prophylaxis of malaria due to _Plasmodium falciparum_ in short-term travelers (<4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains [L42870, L42880]



It is also used to treat infections caused by the following gram-negative microorganisms:



- Chancroid caused by _Haemophilus ducreyi_ [L42880]

- Plague due to _Yersinia pestis_ [L42880]

- Tularemia due to _Francisella tularensis_ [L42880]

- Cholera caused by _Vibrio cholerae_ [L42880]

- Campylobacter fetus infections caused by _Campylobacter fetus_ [L42880]

- Brucellosis due to _Brucella_ species (in conjunction with [streptomycin]) [L42880]

- Bartonellosis due to _Bartonella bacilliformis_ [L42880]

- Granuloma inguinale caused by _Klebsiella granulomatis_ [L42880]', 'Protein synthesis is essential for survival and functioning of cells, including bacteria.[A251725] Doxycycline inhibits bacterial protein synthesis by allosterically binding to the 30S prokaryotic ribosomal subunit.[A251730, L42870] The drug blocks the association charged aminoacyl-tRNA (aa-tRNA) with the ribosomal A site, which is the acceptor site on the mRNA-ribosome complex. Doxycycline ultimately impedes the elongation phase of protein synthesis and halts the production of essential proteins for bacterial survival and functioning.[A251725, A251730]



Doxycycline mediates anti-inflammatory actions by preventing calcium-dependent microtubular assembly and lymphocytic proliferation, thereby inhibiting leukocyte movement during inflammation.[A251730] It also inhibits nitric oxide synthase, which is an enzyme that produces nitric oxide, an inflammatory signaling molecule.[A251730]', 'Doxycycline and other tetracyclines are mainly bacteriostatic and are thought to exert antimicrobial effects by the inhibition of protein synthesis. They suppress the growth of bacteria or keep them in the stationary phase of growth.[A174025] Tetracyclines have antimicrobial spectrum of activity against a variety of gram-positive and gram-negative microorganisms.[L42870] Cross-resistance of these microorganisms to tetracyclines is a common occurrence.[L42870] 



As it is a highly lipophilic drug, doxycycline crosses multiple membranes of target molecules.[A251730] Doxycycline shows favorable intra-cellular penetration, with bacteriostatic activity against a wide range of bacteria.[A174028] Doxycycline also exhibits antiparasitic properties [A372, A373, A174025] and anti-inflammatory actions.[A174031, A251730] Its anti-inflammatory effects were investigated in various inflammatory skin conditions, such as bullous dermatoses [A251730] and rosacea.[A174031, A251730]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Azactam 1 gm vial i.v./i.m. (cancelled)', 1180, 'ازاكتام حقن 1 جم فيال', '35', NULL, 'Antibiotic.monocyclic beta-lactam', 'Antibiotic.monocyclic beta-lactam', NULL, 'Aztreonam', 'Bristol-myers squibb', 'Vial', 'فيال', '1 gm', '1', NULL, NULL, 'mechanism of action monobactam; inhibits cell wall synthesis by binding to penicillin binding proteins. a monocyclic beta-lactam antibiotic originally isolated from chromobacterium violaceum. it is resistant to beta-lactamases and is used in gram-negative', NULL, 3611, '2022-09-06', NULL, 0, 'For the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections.', 'The bactericidal action of aztreonam results from the inhibition of bacterial cell wall synthesis due to a high affinity of aztreonam for penicillin binding protein 3 (PBP3). By binding to PBP3, aztreonam inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. It is possible that aztreonam interferes with an autolysin inhibitor.', 'Aztreonam is a monocyclic beta-lactam antibiotic (a monobactam) originally isolated from <i>Chromobacterium violaceum</i>. Aztreonam exhibits potent and specific activity in vitro against a wide spectrum of gram-negative aerobic pathogens including <i>Pseudomonas aeruginosa</i>. It has no useful activity against gram-positive bacteria or anaerobes, but has very broad spectrum against gram-negative aerobes, including <i>Pseudomonas aeruginosa</i>. This has given it the nickname "the magic bullet for aerobic gram-negative bacteria". Aztreonam, unlike the majority of beta-lactam antibiotics, does not induce beta-lactamase activity and its molecular structure confers a high degree of resistance to hydrolysis by beta-lactamases (such as penicillinases and cephalosporinases) produced by most gram-negative and gram-positive pathogens; it is, therefore, usually active against gram-negative aerobic microorganisms that are resistant to antibiotics hydrolyzed by beta-lactamases. It is active against many strains that are multiply-resistant to other antibiotics, such as certain cephalosporins, penicillin, and aminoglycosides. Aztreonam maintains its antimicrobial activity over a pH range of 6 to 8 in vitro, as well as in the presence of human serum and under anaerobic conditions.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Baby rash free 30% oint.', 1246, 'بيبي راش فري 30 % مرهم', '5', NULL, 'Diaper rash', 'Diaper rash', NULL, 'Zinc oxide', 'Alexandria > millenium pharma-egypt', 'Oint', 'مرهم', '30%', '1', 'يستخدم لالتهاب الحفاضات', NULL, 'about zinc oxide zinc compound a sunscreen antipruritic. mechanism of action of zinc oxide it works by providing a skin barrier and helps in healing and prevent skin irritation. it acts as a sunscreen which absorbs incident solar radiation in the uva rang', NULL, 1094, '2022-09-18', NULL, 0, 'For adjunctive treatment of diaper dermatitis. Also, it can be used to treat minor skin irritations (eg, cuts, burns, and scrapes, poison ivy).

Zinc oxide can be used in ointments, creams, and lotions to protect against sunburn and other damage to the skin caused by ultraviolet light.', 'It acts by providing a physical barrier to prevent skin irritation and help heal damaged skin.', 'Zinc oxide has astringent, soothing and protective properties and is used in topical preparations for eczema, slight excoriations, wounds and haemorrhoids. It also reflects ultraviolet radiation and can be used as a physical sunscreen.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cortiphen eye oint. 5 gm', 3079, 'كورتيفن مرهم عين 5 جم', '4', NULL, 'Antibiotic with glucocorticoid', 'Antibiotic with glucocorticoid', NULL, 'Chloramphenicol+prednisolone', 'Misr', 'Oint', 'مرهم', '5 gm', '1', 'كريم مضاد حيوى واسع المدى ومضاد للالتهابات ويستخدم فى علاج العديد من التهابات العين', NULL, 'about chloramphenicol bacteriostatic antibiotic a systemic broad ? spectrum antibacterial agent. mechanism of action of chloramphenicol chloramphenicol is a broad spectrum antibiotic which is primarily bacteriostatic & exerts some bactericidal action at h', '6221035006018', 831, '2022-12-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Biosertazol 2% top. cream 30 gm', 15299, 'بيوسيرتازول 2% كريم 30 جم', '46', '31', 'Antifungals.imidazoles', 'Antifungals.imidazoles', NULL, 'Sertaconazole', 'Biopharm egypt > saja pharmaceuticals', 'Cream', 'كريم', '2%', '1', NULL, NULL, 'indication for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older caused by trichophyton rubrum trichophyton mentagrophytes and epidermophyton floccosum. mechanism of action sertaconazole interacts with', '6221126000345', 1753, '2024-11-13', NULL, 0, 'For the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by <i>Trichophyton rubrum</i>, <i>Trichophyton mentagrophytes</i>, and <i>Epidermophyton floccosum</i>.', 'Sertaconazole interacts with 14-&alpha; demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Sertaconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.', 'Sertaconazole is an imidazole/triazole type antifungal agent. Sertaconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 &alpha;-demethylation via the inhibition of the enzyme cytochrome P450 14&alpha;-demethylase. This enzyme converts lanosterol to ergosterol, and is required in fungal cell wall synthesis. The subsequent loss of normal sterols correlates with the accumulation of 14 &alpha;-methyl sterols in fungi and may be partly responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Sertaconazole exhibits <i>in vitro</i> activity against <i>Cryptococcus neoformans</i> and <i>Candida spp.</i> Fungistatic activity has also been demonstrated in normal and immunocompromised animal models for systemic and intracranial fungal infections due to <i>Cryptococcus neoformans</i> and for systemic infections due to Candida albicans.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Feramix fe 20 tab', 18961, 'فيرامكس حديد 20 قرص', '110', '95', 'Anemia.iron supplement combined with folic acid', 'Anemia.iron supplement combined with folic acid', NULL, 'Ferrous fumerate+folic acid+vitamin c+zinc+copper+magnesium', 'Drug pharma egypt', 'Tab', 'أقراص', NULL, '1', 'علاج الانيميا -- علاج نقص الحديد في الجسم -- مقوي للمناعة', NULL, NULL, NULL, 5831, '2024-08-29', NULL, 0, 'Ferrous sulfate is used for the prevention and treatment of iron deficiency anemia in adults and children.[A190804,L2240,L11800]

', 'Iron is required to maintain optimal health, particularly for helping to form red blood cells (RBC) that carry oxygen around the body. A deficiency in iron indicates that the body cannot produce enough normal red blood cells.[A32514,L11800] Iron deficiency anemia occurs when body stores of iron decrease to very low levels, and the stored iron is insufficient to support normal red blood cell (RBC) production. Insufficient dietary iron, impaired iron absorption, bleeding, pregnancy, or loss of iron through the urine can lead to iron deficiency.[A32514,L11794]  Symptoms of iron deficiency anemia include fatigue, breathlessness, palpitations, dizziness, and headache.



Taking iron in supplement form, such as ferrous sulfate, allows for more rapid increases in iron levels when dietary supply and stores are not sufficient.[L2175] Iron is transported by the divalent metal transporter 1 (DMT1) across the endolysosomal membrane to enter the macrophage. It can then can be incorporated into ferritin and be stored in the macrophage or carried of the macrophage by ferroportin. This exported iron is  oxidized by the enzyme to ceruloplasmin to Fe3+, followed by sequestration by transferrin for transport in the serum to various sites, including the bone marrow for hemoglobin synthesis or into the liver.[A32524] Iron combines with porphyrin and globin chains to form hemoglobin, which is critical for oxygen delivery from the lungs to other tissues.[L2263]', 'Ferrous sulfate replenishes iron, an essential component in hemoglobin, myoglobin, and various enzymes. It replaces the iron that is usually found in hemoglobin and myoglobin. Iron participates in oxygen transport and storage, electron transport and energy metabolism, antioxidant and beneficial pro-oxidant functions, oxygen sensing, tissue proliferation and growth, as well as DNA replication and repair.[A32524,A32514]



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tolyax hair serum 120 ml', 28266, 'تولياكس سيروم للشعر 120مل', '155', NULL, 'Hair care', 'Hair care', NULL, NULL, 'Hi-care > novell pharma', 'Serum', 'سيروم', '120 ml', '1', 'سيرم يحتوي على تركيبة مرطبة للشعر للمساعدة في الحفاظ قوة ولمعان الشعر.ومنع التساقط', NULL, NULL, NULL, 969, '2022-07-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Provit paediatric syrup 100 ml', 25447, 'بروفيت شراب للاطفال 100مل', '75', '40', 'Multivitamins', 'Multivitamins', NULL, 'Vitamins(a+b1+b2+b6+c+d3+e)+nicotinamide+panthenol+calcium gluconate+calcium phospholactate', 'Sigma > international trading office', 'Syrup', 'شراب', '100 ml', '1', NULL, NULL, 'essential vitamins for children from 3 years.', NULL, 880, '2025-09-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rivamash 1.5 mg 30 caps.', 26193, 'ريفاماش 1.5مجم 30 كبسول', '153', '55.5', 'Anticholinesterase', 'Anticholinesterase', NULL, 'Rivastigmine', 'Mash premiere', 'Cap', 'كبسولة', '1.5 mg', '3', NULL, NULL, 'about rivastigmine a central reversible non competitive anticholinesterase antidementia. mechanism of action of rivastigmine alzheimer`s disease may result from a deficiency in neurotransmitters used by nerves in the brain to communicate with one another.', NULL, 727, '2025-01-03', NULL, 0, 'For the treatment of mild to moderate dementia associated with Parkinson''s disease or of the Alzheimer''s type.', 'Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.', 'Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. An early pathophysiological feature of Alzheimer''s disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine''s action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine''s effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Timouni gel 50 ml', 28200, 'تيموني جل 50مل', '170', NULL, 'Vaginal care', 'Vaginal care', NULL, 'Bio-identical estrogen+hydroxyethyl cellulose', 'Benostan > magic pharma-egypt', 'Gel', 'جل', '50 ml', '1', NULL, NULL, 'bio-identical estrogen -improves remodeling of vaginal connective tissue after trauma. -increases collagen & elastin percentage in fibromuscular vaginal wall. hydroxyethyl cellulose -hydroxyethyl cellulose is a natural thickening agent . -has excellent mu', NULL, 929, '2022-07-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Egyurso 500mg 7 f.c.tab.', 4043, 'ايجي اورسو 500 مجم 7 اقراص', '102', '15', 'Liver support supplements', 'Liver support supplements', NULL, 'Ursodeoxycholic acid', 'Egyphar', 'Tab', 'أقراص', '500mg', '1', 'يعمل على علاج الحصوات المرارية', NULL, NULL, '6224001026300', 1451, '2024-10-01', NULL, 0, 'Ursodeoxycholic acid is indicated for the treatment of patients with primary biliary cholangitis.[L44627] 



It is used for the short-term treatment of radiolucent, noncalcified gallbladder stones in patients selected for elective cholecystectomy. It is also used to prevent gallstone formation in obese patients experiencing rapid weight loss.[L44793]', 'Endogenous hydrophobic bile acids such as deoxycholic acid and chenodeoxycholic acid can exert hepatotoxic effects. Ursodeoxycholic acid is a hydrophilic bile acid that mediates its biological effects via several mechanisms. Ursodeoxycholic acid (UDCA) protects hepatocytes and cholangiocytes from bile acid-induced damage, such as reactive oxygen species (ROS)-induced inflammation and mitochondrial dysfunction.[A256267] UDCA was shown to reserve hepatocyte cell structures and stimulate anti-apoptotic pathways.[A256267,A256272,A256458,A256463] It was also shown to prevent the production of ROS by Kupffer cells and resident macrophages in the liver, thus attenuating oxidative stress in the liver.[A256267] 



UDCA can also change the hydrophobicity index of the bile acid pool: following oral administration, UDCA forms a major fraction of the human bile acid pool and competitively displaces the hydrophobic or more toxic bile acids.[A256272,A256267] It increases the absorption of hydrophilic bile acids.[A256267] There are several proposed mechanisms of choleretic actions of UDCA: UDCA increases intracellular calcium levels, stimulating transport proteins and vesicular exocytosis in cholestatic hepatocytes.[A256267] UDCA may also upregulate the expression of membrane transport proteins like the chloride-bicarbonate anion exchanger (AE2),[A256267,A256458] which is involved in biliary secretion and is often observed to be defective in primary biliary cholangitis.[A256448] In rats, UDCA reduced hepatic expression of major histocompatibility complex (MHC) class I antigens, suggesting immunomodulating effects.[A256267] UDCA acts as a partial agonist at the bile acid receptor, also known as the farnesoid X receptor (FXR), and has negligible effects on cholesterol and lipid synthesis.[A256272]', 'Ursodeoxycholic acid (UDCA) is a secondary bile acid with cytoprotectant, immunomodulating, and choleretic effects. It reduces the cholesterol fraction of biliary lipids.[A256267]



UDCA inhibits the absorption of cholesterol in the intestine and the secretion of cholesterol into bile, decreasing biliary cholesterol saturation.[A256267] UDCA increases bile acid flow and promotes the secretion of bile acids.[A256267,A256277,A256463]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Panadol extra 48 f.c. tabs.', 9565, 'بانادول اكسترا 48 قرص', '108', '68', 'Mild analgesic', 'Mild analgesic', NULL, 'Caffeine+paracetamol(acetaminophen)', 'Alexandria > glaxo smithkline', 'Tab', 'أقراص', NULL, '4', NULL, NULL, NULL, '6222010611326', 14341, '2024-07-29', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Selengena anti-dandruff shampoo 120 ml', 26724, 'سيلينجينا شامبو ضد القشرة 120 مل', '105', '85', 'Hair care', 'Hair care', NULL, 'Selenium sulphide', 'Egyptian company for cosmetics > parkville pharmaceuticals', 'Amp', 'أمبول', '120 ml', '1', NULL, NULL, NULL, '6224000547943', 1611, '2024-06-07', NULL, 0, 'For treatment of tinea versicolor, tinea capitis, dandruff and seborrheic dermatitis of the scalp.', 'Topical selenium sulfide may act by an antimitotic action, resulting in a reduction in the turnover of epidermal cells. It also has local irritant, antibacterial, and mild antifungal activity, which may contribute to its effectiveness. An antimitotic mechanism of action is suggested by data showing that selenium sulfide decreases the rate of incorporation of radioactively labeled thymidine into the DNA of dermal epithelial cells. The following organisms are generally considered susceptible to selenium sulfide in vitro: <i>Malassezia furfur</i>, <i>Microsporum sp.</i> including <i>Microsporum audouinii</i> and <i>Microsporum canis</i>, <i>Pityrosporon sp.</i>, <i>Trichophyton sp.</i> including <i>Trichophyton schoenleinii</i> and <i>Trichophyton tonsurans</i>. Selenium sulfide has been shown to be sporicidal to <i>T. tonsurans</i>, the most common etiologic agent of tinea capitis. One in-vitro study demonstrated that 2.5% selenium sulfide was equivalent in sporicidal activity to both 1% and 2% zinc pyrithione.', 'Selenium sulfide is an antifungal agent often used in shampoos for the treatment of dandruff and seborrheic dermatitis. Selenium sulfide is highly active in inhibiting the growth of <i>P. ovale</i>. It is also a proven cytostatic agent, slowing the growth of both hyperproliferative and normal cells in dandruff and seborrheic dermatitis. A 0.6% micronized form of selenium sulfide is also safe and effective for dandruff.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Panthenose nasal spray with escin 20 ml', 24526, 'بانثينوز بخاخ انف مع الأسين', '100', NULL, 'Cold drugs', 'Cold drugs', NULL, 'Panthenol+escin', 'Pharmadar', 'Spray', 'بخاخ', '20 ml', '1', 'يعمل على تخفيف التهاب الجيوب الأنفية ونزلات البرد', NULL, 'relieves rhinitis & common cold.', NULL, 1106, '2022-05-26', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dekadel chrono 500mg 30 e.c.tab', 17191, 'ديكاديل كرونو 500مجم 30 قرص', '131', '105', 'Anti-epileptic.fatty acid', 'Anti-epileptic.fatty acid', NULL, 'Sodium valproate', 'Delta pharma', 'Tab', 'أقراص', '500mg', '1', 'تساعد في السيطرة على نوبات الصرع والتحكم بها، مما يقلل من نسبت حدوثها عند المريض', NULL, NULL, '6221163012684', 8591, '2025-08-03', NULL, 0, 'For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.', 'Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.', 'Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nplate 250mcg vial', 23825, 'انبليت 250مكجم فيال', '11,959', '8650', 'Idiopathic thrombocytopenic purpura (itp)', 'Idiopathic thrombocytopenic purpura (itp)', NULL, 'Romiplostim', 'Amgen > multipharma', 'Vial', 'فيال', '250mcg', '1', NULL, NULL, 'romiplostim is a fusion protein analog of thrombopoietin a hormone that regulates platelet production. romiplostim is indicated as a potential treatment for chronic idiopathic (immune) thrombocytopenic purpura (itp). romiplostim treatment is generally adm', NULL, 3141, '2024-10-21', NULL, 0, 'Treatment of chronic immune thrombocytopenic purpura. ', 'Romiplostim is a thrombopoietin receptor agonist that activates intracellular transcriptional pathways via c-Mpl to increase production of platelets. It also works similarly to thrombopoietin (TPO), an endogenous glycoprotein hormone that regulates the production of platelets in the bone marrow. ', 'Responses to platelet increase varies between patients thus indicating a need for individualization of dose. However, a dose dependent-increase in platelet counts have been observed in clinical trials. Does not affect platelet destruction. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lanoxin 0.25mg 100 tab.', 7094, 'لانوكسين 0.25مجم 100 قرص', '119', '36', 'Heart failure.cardiotonic agents', 'Heart failure.cardiotonic agents', NULL, 'Digoxine', 'Glaxo smithkline', 'Tab', 'أقراص', '0.25mg', '4', 'علاج قصور القلب -- علاج النظم التسرعي للقلب -- علاج الصدمة القلبية', NULL, NULL, '6221045009788', 14068, '2024-10-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Paclitaxel stragen 6mg/ml concentrate sol. for i.v. inf.', 24443, 'باكليتاكسل ستراجين 6مجم/مل محلول مركز حقن وريدي', '800', NULL, 'Antineoplastic', 'Antineoplastic', NULL, 'Paclitaxel', 'Haupt pharma -germany > al zahraa trade-egypt', 'Sol', 'محلول', '6mg', '1', NULL, NULL, 'about paclitaxel taxane derivative microtubule inhibitor(mitotic inhibitor) antineoplastic. mechanism of action of paclitaxel drug binds specifically to the beta- tubuline and then enhances the polymerization of tubuline to stable microtubules. it also in', NULL, 758, '2022-07-18', NULL, 0, 'Used in the treatment of Kaposi''s sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.', 'Paclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell''s ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the &beta; subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.', 'Paclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Etocoxam 90 mg 21 tabs', 7668, 'ايتوكوكسام 90 مجم 21 قرص', '174', NULL, 'Nsaid.selective cox-2 inhibitors', 'Nsaid.selective cox-2 inhibitors', NULL, 'Etoricoxib', NULL, 'Tab', 'أقراص', '90 mg', '3', 'لعلاج الآلام بعد إجراءات الأسنان البسيطة وجراحة أمراض النساء والألم المرتبط بعسر الطمث الأولي', NULL, NULL, '6224001514333', 1078, '2025-10-13', NULL, 0, 'For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.', 'Like any other COX-2 selective inhibitor Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2), preventing production of prostaglandins (PGs) from arachidonic acid.', 'Etoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1).', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Seam-lite scar gel 50 gm', 33604, 'سيم-لايت سكار جل 50 جم', '550', '300', 'Anti scar gel', 'Anti scar gel', NULL, 'Decamethyltetrasiloxane+polydimethylsiloxane+cyclopentasiloxane', 'Megamed company', 'Gel', 'جل', '50 gm', '1', 'مرطب يستخدم فى شد البشرة وتفتيحها وتخفيف الندوب وتوحيد لون البشرة', NULL, NULL, NULL, 4337, '2024-04-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Neocate infant dha/ara powder 400 gm', 33257, 'نيوكات انفانت دي اتش ايه/ايه ار ايه بودر 400جم', '880', '490', 'Hypo-allergenic milk', 'Hypo-allergenic milk', NULL, 'Hypo-allergenic milk formula', 'United company for distribution', 'Powder', 'بودرة', '400 gm', '1', NULL, NULL, 'for infants 0-12 months. neocateï- infant dha/ara (docosahexaenoic acid/arachidonic acid) is specially formulated for the dietary management of infants with cow milk allergy (cma) multiple food allergies (mfa) and related conditions. neocate is: -hypoalle', NULL, 1130, '2025-02-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bisadyl 10mg/37ml enema', 15330, 'بيساديل 10مجم/37مل حقنة شرجية', '6', NULL, 'Laxative', 'Laxative', NULL, 'Bisacodyl', 'Amriya', 'Unknown', 'غير محدد', '10mg', '1', NULL, NULL, 'about bisacodyl diphenyl methane derivative stimulant (irritant)laxative mechanism of action of bisacodyl bisacodyl is a stimulant (irritant) laxative. it acts directly on the colonic mucosa-where it stimulates sensory nerve endings in the walls of the in', '6221075070338', 974, '2023-02-04', NULL, 0, 'Bisacodyl is indicated to relieve occasional constipation and irregularity.[L13362]', 'Bisacodyl is deacetylated to the active bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM) by an intestinal deacetylase.[A233290,A233300,A207700] BHPM can stimulate parasympathetic nerves in the colon directly to increase motility and secretions.[A233300]



Bisacodyl stimulates adenylate cyclase, increasing cyclic AMP, leading to active transport of chloride and bicarbonate out of cells.[A233300] Sodium ions, potassium ions, and water passively leave the cell; while sodium and chloride ions are unable to be reabsorbed.[A233300]



Water is also be transported from the luminal side of cells into the vasculature by aquaporin 3.[A233395] Bisacodyl decreases expression of aquaporin 3, preventing water from moving into the vasculature, which may contribute to increased water in the colon.[A233395]



Bisacodyl directly stimulates parasympathetic nerves in the colon, stimulating contraction of longitudinal smooth muscle but not circular smooth muscle.[A233280,A233300]', 'Patients should be counselled regarding abdominal pain, nausea, vomiting, or a change in bowel function that lasts longer than 2 weeks.[L13362] It has a wide therapeutic index, as patients can take 5-15 mg orally.[L13362] Patients taking bisacodyl should be counselled before taking the medication if they are already experiencing abdominal pain, nausea, vomiting, or a change in bowel function lasting longer than 2 weeks.[L13362] Patients should also be counselled to stop taking the medication if they experience rectal bleeding or no bowel movement in 12 hours.[L13362]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sfn-10 nail mycosis solution 3.3 ml', 26891, 'اس اف ان 10 للاظافر محلول 3.3 مل', '298', NULL, 'Antifungal', 'Antifungal', NULL, 'Ethyl lactate+aqua+acetic acid+undecylenic acid+methylisothiazolinone', 'Crab sinergy > rotabiogen for pharmaceutical invest.', 'Solution', 'محلول', '3.3 ml', '1', NULL, NULL, NULL, NULL, 1235, '2023-06-29', NULL, 0, 'Investigated for use/treatment in burns and burn infections, cardiac surgery, inflammatory disorders (unspecified), ischemic reperfusion injury, and sepsis and septicemia.', 'CTI-01 inhibits the systemic release of cytokines, such as TNF-alpha and HMGB1, which promote the body''s inflammatory response. The over-expression of these cytokines has been linked to diseases that occur in critical care settings, such as severe organ damage following cardiopulmonary bypass (CPB) and post-operative ileus following abdominal surgery.', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ciprocin 750mg 10 f.c. tab.', 2633, 'سيبروسين 750مجم 10 اقراص', '69', '52.5', 'Antibiotic.quinolone', 'Antibiotic.quinolone', NULL, 'Ciprofloxacin', 'Eipico', 'Tab', 'أقراص', '750mg', '2', 'مضاد حيوي', NULL, 'about ciprofloxacin it is a broad spectrum fluoroquinolone with activity against pseudomonas aeruginosa. indications for ciprofloxacin 1.urinary tract infection 2.respiratory tract infection 3.bone and joint infections 4.infectious diarrhoea 5.gonorrhoea', '6221032115393', 4302, '2023-11-18', NULL, 0, 'Ciprofloxacin is only indicated in infections caused by susceptible bacteria.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493]



Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.[L6481,L6478]



A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa.[L6469,L6484] Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa.[L6490] A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.[L6493]



A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis.[L6472] A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.[L6475]



A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.[L6487]', 'Ciprofloxacin acts on bacterial topoisomerase II (DNA gyrase) and topoisomerase IV.[A178885] Ciprofloxacin''s targeting of the alpha subunits of DNA gyrase prevents it from supercoiling the bacterial DNA which prevents DNA replication.[A178876,A178882]', 'Ciprofloxacin is a second generation fluoroquinolone that is active against many Gram negative and Gram positive bacteria.[A178870,L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] It produces its action through inhibition of bacterial DNA gyrase and topoisomerase IV.[A178885] Ciprofloxacin binds to bacterial DNA gyrase with 100 times the affinity of mammalian DNA gyrase.[A178894] There is no cross resistance between fluoroquinolones and other classes of antibiotics, so it may be of clinical value when other antibiotics are no longer effective.[A178894] Ciprofloxain and its derivatives are also being investigated for its action against malaria, cancers, and AIDS.[A178885]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Claviperdone 3 mg 30 orally disint. tabs.', 3880, 'كلافيبيردون 3مجم 30 قرص ذائب بالفم', '129', NULL, 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Risperidone', 'Clavita pharma', 'Tab', 'أقراص', '3 mg', '3', NULL, NULL, NULL, NULL, 1096, '2025-05-26', NULL, 0, 'Risperidone is indicated for the treatment of schizophrenia [L12885,L44692,L46297] and irritability associated with autistic disorder.[L12885] It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.[L12885,L44692]



Risperidone is additionally indicated in Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches.[L12906]



Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression.[A177226]', 'Though its precise mechanism of action is not fully understood, current focus is on the ability of risperidone to inhibit the D2 dopaminergic receptors and 5-HT2A serotonergic receptors in the brain. Schizophrenia is thought to result from an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively.[A1115, A1116, A1117]



D2 dopaminergic receptors are transiently inhibited by risperidone, reducing dopaminergic neurotransmission, therefore decreasing positive symptoms of schizophrenia, such as delusions and hallucinations.[A251765] Risperidone binds transiently and with loose affinity to the dopaminergic D2 receptor, with an ideal receptor occupancy of 60-70% for optimal effect.[A1119,A31773] Rapid dissociation of risperidone from the D2 receptors contributes to decreased risk of extrapyramidal symptoms (EPS), which occur with permanent and high occupancy blockade of D2 dopaminergic receptors.[A1118,A1119] Low-affinity binding and rapid dissociation from the D2 receptor distinguish risperidone from the traditional antipsychotic drugs. A higher occupancy rate of D2 receptors is said to increase the risk of extrapyramidal symptoms and is therefore to be avoided.[A1118,A1119,A31771] 

 

Increased serotonergic mesocortical activity in schizophrenia results in negative symptoms, such as depression and decreased motivation. The high-affinity binding of risperidone to 5-HT2A receptors leads to a decrease in serotonergic activity. In addition, 5-HT2A receptor blockade results in decreased risk of extrapyramidal symptoms, likely by increasing dopamine release from the frontal cortex, and not the nigrostriatal tract. Dopamine level is therefore not completely inhibited.[A1117,A1119] Through the above mechanisms, both serotonergic and D2 blockade by risperidone are thought to synergistically work to decrease the risk of extrapyramidal symptoms. 

 

Risperidone has also been said to be an antagonist of alpha-1 (α1), alpha-2 (α2), and histamine (H1) receptors.[A37034] Blockade of these receptors is thought to improve symptoms of schizophrenia, however the exact mechanism of action on these receptors is not fully understood at this time.[L12885]', 'The primary action of risperidone is to decrease dopaminergic and serotonergic pathway activity in the brain, therefore decreasing symptoms of schizophrenia and mood disorders.[A1115,A1116]



Risperidone has a high binding affinity for serotonergic 5-HT2A receptors when compared to dopaminergic D2 receptors in the brain.[A1114,A1115] Risperidone binds to D2 receptors with a lower affinity than first-generation antipsychotic drugs, which bind with very high affinity. A reduction in extrapyramidal symptoms with risperidone, when compared to its predecessors, is likely a result of its moderate affinity for dopaminergic D2 receptors.[A1119,A1117]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dolcicana 1 gm*100 sachets', 17762, 'دولسيكانا 1 جم 100 كيس', '45', NULL, 'Sweetener', 'Sweetener', NULL, 'Sucralose+maltodextrin', 'Mup', 'Sachet', 'أكياس', '1 gm', '1', NULL, NULL, '1 sachet is equivalent to 2 spoons of sugar.', NULL, 757, '2022-07-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dispercam 20 mg/ml 6 amp.', 3750, 'ديسبركام 20مجم/مل 6 امبول', '48', '33', 'Nsaid.oxicam', 'Nsaid.oxicam', NULL, 'Piroxicam', 'Mup', 'Amp', 'أمبول', '20 mg', '6', 'مسكن الآلام --علاج لالتهاب المفاصل الروماتيزمي', NULL, 'about piroxicam nsaid oxicam derivative analgesic antiinflammatory. mechanism of action of piroxicam drug inhibits the biosynthesis and release of prostaglandins by inhibiting cyclooxygenase enzyme in a reversible manner. in this way it reduces the pg (pr', '6221508170420', 9775, '2024-12-05', NULL, 0, 'For treatment of osteoarthritis and rheumatoid arthritis.', 'The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets.', 'Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Potassium chloride 15% 10ml conc.inf. 100 amp.', 25089, 'بوتاسيوم كلوريد 15% 10مل مركز 100 امبول', '250', NULL, 'Potassium supplement', 'Potassium supplement', NULL, 'Potassium chloride', 'Pharmaceutical solution industries > al kamal importing & marketing co', 'Amp', 'أمبول', '15%', '100', NULL, NULL, NULL, NULL, 1016, '2022-07-07', NULL, 0, 'For use as an electrolyte replenisher and in the treatment of hypokalemia.', 'Supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.', 'The potassium ion is in the principle intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle, and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine. If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mebefac 200 mg sr 30 f.c. tabs', 22423, 'ميبيفاك 200مجم اس ار 30 قرص', '99', '66', 'Antispasmodic', 'Antispasmodic', NULL, 'Mebeverine', 'Mash premiere', 'Tab', 'أقراص', '200 mg', '3', 'مضاد للتقلصات', NULL, NULL, '6222001400908', 4547, '2024-07-14', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Max diet 120 caps.', 6171, 'ماكس دايت 120 كبسولة', '500', NULL, 'Weight loss', 'Weight loss', NULL, 'Green coffee ext.+white kidney bean ext.+african mango+raspberry ketone', 'Dbk', 'Cap', 'كبسولة', NULL, '1', NULL, NULL, NULL, NULL, 920, '2025-07-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ethoxa 250mg/5ml syrup 120ml', 4440, 'ايثوكسا 250 مجم/5 مل شراب 120 مل', '99', '62', 'Anti-epileptic.succinimide', 'Anti-epileptic.succinimide', NULL, 'Ethosuximide', 'Delta pharma', 'Syrup', 'شراب', '250mg', '1', NULL, NULL, 'about ethosuximide imide derivative a succinimide anticonvulsant(mainly in absence seizures). mechanism of action of ethosuximide ethosuximide reduces low threshold t current in ca2+ channel in thalamic neurons. thalamus is responsible for the production', '6221163003613', 2645, '2024-12-04', NULL, 0, 'For the treatment of petit mal epilepsy.', 'Binds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.', 'Used in the treatment of epilepsy. Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rosemond 2 mg 10 tabs.', 26307, 'روزموند 2مجم 10 اقراص', '9', NULL, 'Anti-diabetic.secretagogues.glinides', 'Anti-diabetic.secretagogues.glinides', NULL, 'Repaglinide', 'Copad pharma', 'Tab', 'أقراص', '2 mg', '1', NULL, NULL, 'about repaglinide meglitinide derivative insulin secretagogue oral anti-diabetic drug. mechanism of action of repaglinide it is a quick and short acting antidiabetic drug which exerts it`s action by stimulating insulin release from ?-cells of pancreas. it', NULL, 703, '2022-07-16', NULL, 0, 'As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ', 'Repaglinide activity is dependent on the presence functioning &beta; cells and glucose. In contrast to sulfonylurea insulin secretatogogues, repaglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, repaglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of repaglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Repaglinide appears to be selective for pancreatic &beta; cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue. ', 'Insulin secretion by pancreatic &beta; cells is partly controlled by cellular membrane potential. Membrane potential is regulated through an inverse relationship between the activity of cell membrane ATP-sensitive potassium channels (ABCC8) and extracellular glucose concentrations. Extracellular glucose enters the cell via GLUT2 (SLC2A2) transporters. Once inside the cell, glucose is metabolized to produce ATP. High concentrations of ATP inhibit ATP-sensitive potassium channels causing membrane depolarization. When extracellular glucose concentrations are low, ATP-sensitive potassium channels open causing membrane repolarization. High glucose concentrations cause ATP-sensitive potassium channels to close resulting in membrane depolarization and opening of L-type calcium channels. The influx of calcium ions stimulates calcium-dependent exocytosis of insulin granules. Repaglinide increases insulin release by inhibiting ATP-sensitive potassium channels in a glucose-dependent manner. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Glucophage xr 1000 mg 30 tabs.', 5609, 'جلوكوفاج اكس ار 1000مجم 30 قرص', '126', '75', 'Anti-diabetic.sensitizers.biguanide', 'Anti-diabetic.sensitizers.biguanide', NULL, 'Metformin', 'Mina pharm', 'Tab', 'أقراص', '1000 mg', '3', 'علاج مرضى السكر النوع الثاني', NULL, 'about metformin biguanide derivative oral anti-diabetic. mechanism of action of metformin it is a biguanide which exerts antidiabetic action. the drug suppresses gluconeogenesis in liver and thus suppresses hepatic glucose output. it enhance insulin media', '6222003702482', 30695, '2024-08-29', NULL, 0, '**Metformin immediate-release formulations**

 

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.[L40243]



**Metformin extended-release tablet (XR)**



The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.[L12207]



**Metformin combination products**



Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263] in combination with SGLT2 inhibitors ([canagliflozin], [empagliflozin], [ertugliflozin], or [dapagliflozin]),[L11479,L30503,L1134,L13679,L38729] or in combination with [pioglitazone].[L11419]', 'Metformin''s mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.[L12207] It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.[A36534, A36557]   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.



After ingestion, the organic cation transporter-1 (OCT1) is responsible for the uptake of metformin into hepatocytes (liver cells). As this drug is positively charged, it accumulates in cells and in the mitochondria because of the membrane potentials across the plasma membrane as well as the mitochondrial inner membrane. Metformin inhibits mitochondrial complex I, preventing the production of mitochondrial ATP leading to increased cytoplasmic ADP:ATP and AMP:ATP ratios.[A36534] These changes activate AMP-activated protein kinase (AMPK), an enzyme that plays an important role in the regulation of glucose metabolism.[A176348] Aside from this mechanism, AMPK can be activated by a lysosomal mechanism involving other activators.  Following this process, increases in AMP:ATP ratio also inhibit _fructose-1,6-bisphosphatase_ enzyme, resulting in the inhibition of gluconeogenesis, while also inhibiting _adenylate cyclase_ and decreasing the production of cyclic adenosine monophosphate (cAMP),[A36534] a derivative of ATP used for cell signaling [A176351]. Activated AMPK phosphorylates two isoforms of acetyl-CoA carboxylase enzyme, thereby inhibiting fat synthesis and leading to fat oxidation, reducing hepatic lipid stores and increasing liver sensitivity to insulin.[A36534] 



In the intestines, metformin increases anaerobic glucose metabolism in enterocytes (intestinal cells), leading to reduced net glucose uptake and increased delivery of lactate to the liver. Recent studies have also implicated the gut as a primary site of action of metformin and suggest that the liver may not be as important for metformin action in patients with type 2 diabetes. Some of the ways metformin may play a role on the intestines is by promoting the metabolism of glucose by increasing glucagon-like peptide I (GLP-1) as well as increasing gut utilization of glucose.[A36534] 



In addition to the above pathway, the mechanism of action of metformin may be explained by other ways, and its exact mechanism of action has been under extensive study in recent years.[A36535, A36554, A36555, A36557]', '**General effects**



Insulin is an important hormone that regulates blood glucose levels.[T514] Type II diabetes is characterized by a decrease in sensitivity to insulin, resulting in elevations in blood glucose when the pancreas can no longer compensate. In patients diagnosed with type 2 diabetes, insulin is unable to exert adequate effects on tissues and cells (i.e. insulin resistance)[T514] and insulin deficiency may also be present.[L5753]



Metformin reduces hepatic production of glucose, decreases the intestinal absorption of glucose, and enhances insulin sensitivity by increasing both peripheral glucose uptake and utilization. In contrast with drugs of the sulfonylurea class, which lead to hyperinsulinemia, the secretion of insulin is unchanged with metformin use.[L12207]



**Effect on fasting plasma glucose (FPG) and Glycosylated hemoglobin (HbA1c)**



HbA1c is an important periodic measure of glycemic control used to monitor diabetic patients. Fasting plasma glucose is also a useful and important measure of glycemic control. In a 29-week clinical trial of subjects diagnosed with type II diabetes, metformin decreased the fasting plasma glucose levels by an average of 59 mg/dL from baseline, compared to an average increase of 6.3 mg/dL from baseline in subjects taking a placebo.[L12207]  Glycosylated hemoglobin (HbA1c) was decreased by about 1.4% in subjects receiving metformin, and increased by 0.4% in subjects receiving placebo only.[L12207]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Butoconazole 2% vaginal cream 5 gm', 15586, 'بوتوكونازول 2% كريم مهبلي 5 جم', '22', NULL, 'Antifungal', 'Antifungal', NULL, 'Butoconazole', 'Sabaa', 'Cream', 'كريم', '2%', '1', NULL, NULL, 'indication: vulvo-vaginal candidiasis use: only one dose of one tube intravaginally.', '6224000808198', 1053, '2022-08-05', NULL, 0, 'For the local treatment of vulvovaginal candidiasis (infections caused by Candida)', 'The exact mechanism of the antifungal action of butoconazole is unknown, however, it is presumed to function as other imidazole derivatives via inhibition of steroid synthesis. Imidazoles generally inhibit the conversion of lanosterol to ergosterol via the inhibition of the enzyme cytochrome P450 14&alpha;-demethylase, resulting in a change in fungal cell membrane lipid composition. This structural change alters cell permeability and, ultimately, results in the osmotic disruption or growth inhibition of the fungal cell.', 'Butoconazole is an imidazole derivative that has fungicidal activity <i>in vitro</i> against <i>Candida</i> spp. and has been demonstrated to be clinically effective against vaginal infections due to <i>Candida albicans</i>. <i>Candida albicans</i> has been identified as the predominant species responsible for vulvovaginal candidasis.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Acetyl - c corcept 20 cap', 5869, 'اسيتيل سي كورسيبت 20 كبسولة', '110', NULL, NULL, NULL, NULL, NULL, 'Company', 'Cap', 'كبسولة', NULL, '2', NULL, NULL, NULL, '6224011494274', 815, '2025-07-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Natamycin 5% eye drops 10 ml', 8595, 'ناتاميسين 5% قطرة عين 10 مل', '74', '51', 'Antifungal', 'Antifungal', NULL, 'Natamycin', 'Orchidia pharmaceutical industries', 'Drops', 'نقط', '5%', '1', 'قطرة عين مضادة للفطريات', NULL, NULL, NULL, 3960, '2025-12-03', NULL, 0, 'For the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including <i>Fusarium solani</i> keratitis.', 'Like other polyene antibiotics, Natamycin inhibits fungal growth by binding to sterols. Specifically, Natamycin binds to ergosterol in the plasma membrane, preventing ergosterol-dependent fusion of vacuoles, as well as membrane fusion and fission. This differs from the mechanism of most other polyene antibiotics, which tend to work by altering fungal membrane permeability instead.', 'Natamycin is an antifungal drug for topical ophthalmic administration. It is a tetraene polyene antibiotic derived from <i>Streptomyces natalensis</i>. It possesses in vitro activity against a variety of yeast and filamentous fungi, including <i>Candida</i>, <i>Aspergillus</i>, <i>Cephalosporium</i>, <i>Fusarium</i> and <i>Penicillium</i>. Although the activity against fungi is dose-related, natamycin is predominantly fungicidal. Natamycin is not effective in vitro against gram-positive or gram-negative bacteria. Topical administration appears to produce effective concentrations of natamycin within the corneal stroma but not in intraocular fluid.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rota panthenol cream 30 gm', 26323, 'روتا بانثينول كريم 30 جم', '30', '20', 'Skin care', 'Skin care', NULL, 'Panthenol', 'Egyptian co. for cosmetics > rotex pharma', 'Cream', 'كريم', '30 gm', '1', '1- مرطب قوي للجلد لتجديد خلايا البشرة.', NULL, 'about panthenol alcohol analog of pantothenic acid (vitamin b5) and is thus a provitamin of b5. mechanism of action of panthenol skin:it binds to the hair shaft readily and it coats the hair and seals its surface lubricating the hair shaft and making stra', NULL, 7230, '2024-05-20', NULL, 0, 'Panthenol (containing a racemic mixture of dexpanthenol and levopanthenol) is not currently available in any FDA-approved products and therefore does not have an indication.



Please see [DB09357] for FDA-approved uses of the dextrorotatory form of Panthenol. ', 'Panthenol is an alcohol derivative of pantothenic acid, a component of the B complex vitamins and an essential component of a normally functioning epithelium. Dexpanthenol, the active form of panthenol, is enzymatically cleaved to form pantothenic acid (Vitamin B5), which is an essential component of Coenzyme A that acts as a cofactor in many enzymatic reactions that are important for protein metabolism in the epithelium [A32373].



Dermatological effects of the topical use of dexpanthenol include increased fibroblast proliferation and accelerated re-epithelialization in wound healing. Furthermore, it acts as a topical protectant, moisturizer, and has demonstrated anti-inflammatory properties [A32377].', 'Pantothenic acid is a precursor of coenzyme A, which serves as a cofactor for a variety of enzyme-catalyzed reactions involving transfer of acetyl groups. The final step in the synthesis of acetylcholine consists of the choline acetylase transfer of acetyl group from acetylcoenzyme A to choline. Acetylcholine is the neurohumoral transmitter in the parasympathetic system and as such maintains the normal functions of the intestine. Decrease in acetylcholine content would result in decreased peristalsis and in extreme cases adynamic ileus. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Trosyd 1% dermal powder 30 gm', 11736, 'تروسيد 1% باودر للجلد 30 جم', '10', NULL, 'Antifungals.imidazoles', 'Antifungals.imidazoles', NULL, 'Tioconazole', 'Pfizer', 'Powder', 'بودرة', '1%', '1', NULL, NULL, NULL, '6221180000695', 1172, '2022-12-13', NULL, 0, 'For the local treatment of vulvovaginal candidiasis (moniliasis).', 'Tioconazole interacts with 14-&alpha; demethylase, a cytochrome P-450 enzyme that converts lanosterol to ergosterol, an essential component of the yeast membrane. In this way, tioconazole inhibits ergosterol synthesis, resulting in increased cellular permeability. Tioconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms and the uptake of purine, impair triglyceride and/or phospholipid biosynthesis, and inhibit the movement of calcium and potassium ions across the cell membrane by blocking the ion transport pathway known as the Gardos channel.', 'Tioconazole is a broad-spectrum imidazole antifungal agent that inhibits the growth of human pathogenic yeasts. Tioconazole exhibits fungicidal activity in vitro against <i>Candida albicans</i>, other species of the genus Candida, and against <i>Torulopsis glabrata</i>. Tioconazole prevents the growth and function of some fungal organisms by interfering with the production of substances needed to preserve the cell membrane. In addition to its broad spectrum antifungal effects with tioconazole being effective against commonly occurring dermatophyte and yeast-like fungal species, tioconazole also has antibacterial effects on certain Gram-positive cocci bacteria.[L50166]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Femto oral spray 60 ml', 18936, 'فيمتو سبراي للفم 60 مل', '35', NULL, 'Oral care', 'Oral care', NULL, 'Lavender+clove+thyme+peppermint+propylene glycol', 'Hi-care > mega pharma group', 'Spray', 'بخاخ', '60 ml', '1', 'للعناية بالفم واللثة -- الحفاظ علي رائحة ذكية للفم --', NULL, 'for buccal cavity care', '6222001407853', 1011, '2022-07-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Floxia 42 tablets', 19163, 'فلوكسيا 42 قرص', '150', NULL, 'Hair care', 'Hair care', NULL, NULL, 'Floxia international sarl > bio-earth egypt', 'Tablet', 'أقراص', NULL, '1', 'اقراص تعمل علي تغذية الشعر وعدم تقصفه __ تساعد علي تنعيم الشعر وترطيبه', NULL, 'floxia food supplement formula is based on the combination of active ingredients which have been selected for their key role in the growth of hair and nails. floxia food supplement supplies all the daily ingredients necessary to get a strong and hearty ha', NULL, 4842, '2023-02-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sodium chloride 0.45% (ultimate) i.v. inf. 500 ml', 27155, 'صوديوم كلوريد 0.45% التيميت محلول وريدي 500 مل', '9', NULL, 'Normal saline', 'Normal saline', NULL, 'Sodium chloride', 'El nasr > ultimate pharma', 'Unknown', 'غير محدد', '0.45%', '1', NULL, NULL, NULL, NULL, 765, '2022-07-09', NULL, 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Blink intensive tears eye drops 10 ml', 15375, 'بلينك انتنسيف تيرز قطرة عين 10 مل', '320', '280', 'Eye lubricant', 'Eye lubricant', NULL, NULL, 'Abbott laboratories > ultra vision for international trade', 'Drops', 'نقط', '10 ml', '1', 'قطرة مرطبة للعين تستخدم في علاج جفاف العين والتخفيف من الحكة والتهيج وخاصة عند ارتداء العدسات وبعد الخضوع للعمليات الجراحية والليزك', NULL, '*long lasting relief from feeling of dry tired eyes. *can be used with contact lenses.', '5050474104525', 9804, '2025-05-31', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tamilavir 75mg 10 caps.', 27874, 'تاميلافير 75مجم 10 كبسولات', '242', '169', 'Anti-viral.release phase', 'Anti-viral.release phase', NULL, 'Oseltamivir', 'Eva pharma', 'Cap', 'كبسولة', '75mg', '1', 'مضاد للفيروسات', NULL, NULL, '6223004517242', 1470, '2025-12-13', NULL, 0, 'According to FDA prescribing information, oseltamivir is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours [F3094]. In particular, this agent is indicated in adults and children including full-term neonates who present with symptoms typical of influenza when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of the first onset of symptoms.[F3097]



Oseltamivir is also indicated for the prophylaxis of influenza in patients one year and older [F3094]. Specifically, post-exposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community qualifies for such prophylactic therapy. Oseltamivir would only be indicated for post-exposure prevention of influenza in infants less than 1 year of age during a pandemic influenza outbreak. [F3097]', 'Oseltamivir phosphate is a pro-drug of the active metabolite (oseltamivir carboxylate) which is a potent and selective inhibitor of influenza virus neuraminidase enzymes, which are glycoproteins found on the virion surface. Viral neuraminidase enzyme activity is important for viral entry into uninfected cells, for the release of recently formed virus particles from infected cells, and for the further spread of the infectious virus in the body.[F3097, L5161, F3115] Oseltamivir activity reduces viral shedding and infectivity.



Oseltamivir is effective agaisnt viral neuraminidases of influenza A (including pandemic H1N1) and influenza B.[F3097, L5161, F3115] ', 'There have been postmarketing reports of delirium and abnormal behavior leading to injury, and in some cases resulting in fatal outcomes, in patients with influenza who were receiving oseltamivir. Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made but they appear to be uncommon based on oseltamivir. These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution. The contribution of oseltamivir to these events has not been established. Influenza can be associated with a variety of neurologic and behavioral symptoms that can include events such as hallucinations, delirium, and abnormal behavior, in some cases resulting in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can occur without obvious severe disease.[F3097, A180586, A180589]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Concor plus 5/12.5mg 30 f.c. tabs.', 2976, 'كونكور 5 بلس 5/12.5مجم 30 قرص', '72', '51', 'Antihypertensive.combined beta blocker with diuretic', 'Antihypertensive.combined beta blocker with diuretic', NULL, 'Bisoprolol fumarate+hydrochlorothiazide', 'Amoun > merck kgaa f.r.germany', 'Tab', 'أقراص', '12.5mg', '3', 'علاج ارتفاع ضغط الدم', NULL, NULL, '6221025032355', 11158, '2024-07-14', NULL, 0, 'Bisoprolol is indicated for the treatment of mild to moderate hypertension.[L7219] It may be used off-label to treat heart failure, atrial fibrillation, and angina pectoris.[A180460,A180463]', 'Though the mechanism of action of bisoprolol has not been fully elucidated in hypertension, it is thought that therapeutic effects are achieved through the antagonism of β-1adrenoceptors to result in lower cardiac output. Bisoprolol is a competitive, cardioselective β1-adrenergic antagonist. When β1-receptors (located mainly in the heart)[T640] are activated by adrenergic neurotransmitters such as epinephrine, both the blood pressure and heart rate increase, leading to greater cardiovascular work, increasing the demand for oxygen.  Bisoprolol reduces cardiac workload by decreasing contractility and the need for oxygen through competitive inhibition of β1-adrenergic receptors.[A180502,T640]



Bisoprolol is also thought to reduce the output of renin in the kidneys, which normally increases blood pressure. Additionally, some central nervous system effects of bisoprolol may include diminishing sympathetic nervous system output from the brain, decreasing blood pressure and heart rate.[L7219]', 'Bisoprolol decreases heart rate (chronotropy), decreases contractility (inotropy), and reduces blood pressure.[T640,L7219] The results of various clinical studies indicate that bisoprolol reduces cardiovascular mortality and all-cause mortality in patients with heart failure and decreased cardiac ejection fraction (EF).[A180466,A180505] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sebaclar tonic lotion 200 ml', 26636, 'سيباكلار لوشن مقوي 200مل', '286', '248', 'Anti-acne', 'Anti-acne', NULL, NULL, 'Egyptian company for cosmetics > hayah lab.', 'Lotion', 'لوشن', '200 ml', '1', NULL, NULL, 'sebum-regulator anti-enlarged pores mattifying care - oily & acne-prone skin', NULL, 884, '2025-04-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nuxe gentle exfoliating gel with rose petals 75 ml', 23867, 'نوكس جل 75مل', '305', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Nuxe laboratory > biotech egypt', 'Gel', 'جل', '75 ml', '1', NULL, NULL, 'this facial exfoliating gel with rose petals gently exfoliates and eliminates dead skin cells. a gel texture with gentle exfoliating grains to reveal refined skin. leaves skin soft and clear and more radiant than ever. use massage onto your moist or dry f', NULL, 632, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Drinking powder 10 sachets 5 gm', 857, 'درينكينج اعشاب 10 اكياس 5 جم', '35', '25', NULL, NULL, NULL, NULL, 'Pharma net', 'Powder', 'بودرة', '5 gm', '1', NULL, NULL, NULL, '6224009673124', 1061, '2024-03-30', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Moodapex 50mg 30 f.c.tab.', 8322, 'مودابكس 50مجم 30 قرص', '111', '111', 'Psychiatric.antidepressants', 'Psychiatric.antidepressants', NULL, 'Sertraline', 'Multi-apex', 'Tab', 'أقراص', '50mg', '3', 'مضاد للاكتئاب __ يحسن الحالة المزاجية __ يحسن من التواصل الاجتماعي', NULL, 'about sertraline selective serotonin reuptake inhibitor (ssri) antidepressant antidepressant mechanism of action of sertraline sertraline blocks the re-uptake of neurotransmitter serotonin from the synapse in to the presynaptic nerve terminal in the cns.', '6223003200459', 16926, '2025-10-21', NULL, 0, 'Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]

', 'Sertraline selectively inhibits the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane, thereby increasing serotonergic activity. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission.[T28,L9016] These changes are believed to be responsible for the antidepressant action and beneficial effects in obsessive-compulsive (and other anxiety related disorders). It has been hypothesized that obsessive-compulsive disorder, like depression, is also caused by the disregulation of serotonin.[A187165]



In animal studies, chronic administration of sertraline results in down-regulation of brain norepinephrine receptors.[L9016] Sertraline displays affinity for sigma-1 and 2 receptor binding sites[A31941], but binds with stronger affinity to sigma-1 binding sites.[A31940] In vitro, sertraline shows little to no affinity for GABA, dopaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors.[L9016] It exerts weak inhibitory actions on the neuronal uptake of norepinephrine and dopamine[A1844] and exhibits no inhibitory effects on the monoamine oxidase enzyme.[L9016]', 'Sertraline improves or relieves the symptoms of depression, OCD, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder via the inhibition of serotonin reuptake.[A187075,L9016] Clinical studies have shown that it improves cognition in depressed patients.[A1846] It has less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because it does not exert significant anticholinergic, antihistamine, or adrenergic (alpha1, alpha2, beta) blocking activity.[A1844] The onset of action and beneficial effects are usually noticed after 4-6 weeks, for reasons that are not fully understood and currently under investigation.[A188493,L10677]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Psycholanz 6/25 mg 30 capsules', 25471, 'سيكولانز 6/25 مجم 30 كبسولة', '174', '129', 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Fluoxetine+olanzapine', 'Biomed pharmaceuticals', 'Capsule', 'كبسولة', '25 mg', '3', 'امراض نفسية', NULL, NULL, '6222001402353', 11477, '2024-09-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Atomoxapex 25mg 30 caps.', 1081, 'اتوموكسابكس 25 مجم 30 كبسولة', '252', '180', 'Attention-deficit hyperactivity disorder', 'Attention-deficit hyperactivity disorder', NULL, 'Atomoxetine', 'Multi-apex', 'Cap', 'كبسولة', '25mg', '3', 'علاج لمرض فرط الحركة وتشتت الذهن', NULL, 'description: atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (adhd). dose: dosing of children and adolescents up to 70 kg body weight initial: the recommended dose is 0.5 mg/kg and increas', '6223003203351', 2737, '2025-05-08', NULL, 0, 'Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.', 'Atomoxetine is known to be a potent and selective inhibitor of the norepinephrine transporter (NET),[A175723] which prevents cellular reuptake of norepinephrine throughout the brain, which is thought to improve the symptoms of ADHD. More recently, positron emission tomography (PET) imaging studies in rhesus monkeys have shown that atomoxetine also binds to the serotonin transporter (SERT),[A178111] and blocks the N-methyl-d-aspartate (NMDA) receptor,[A18263] indicating a role for the glutamatergic system in the pathophysiology of ADHD. ', 'Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Atomoxetine has been shown to specifically increase norepinephrine and dopamine within the prefrontal cortex, which results in improved ADHD symptoms.[A18262, A18262, F4639]



Due to atomoxetine''s noradrenergic activity, it also has effects on the cardiovascular system such as increased blood pressure and tachycardia.[T244] Sudden deaths, stroke, and myocardial infarction have been reported in patients taking atomoxetine at usual doses for ADHD. Atomoxetine should be used with caution in patients whose underlying medical conditions could be worsened by increases in blood pressure or heart rate such as certain patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease. It should not be used in patients with severe cardiac or vascular disorders whose condition would be expected to deteriorate if they experienced clinically important increases in blood pressure or heart rate. Although the role of atomoxetine in these cases is unknown, consideration should be given to not treating patients with clinically significant cardiac abnormalities. Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during atomoxetine treatment should undergo a prompt cardiac evaluation.[F4639]



In general, particular care should be taken in treating ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in patients at risk for bipolar disorder. Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by atomoxetine at usual doses. If such symptoms occur, consideration should be given to a possible causal role of atomoxetine, and discontinuation of treatment should be considered.[F4639]



Atomoxetine capsules increased the risk of suicidal ideation in short-term studies in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). All pediatric patients being treated with atomoxetine  should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.[F4639]



Postmarketing reports indicate that atomoxetine can cause severe liver injury. Although no evidence of liver injury was detected in clinical trials of about 6000 patients, there have been rare cases of clinically significant liver injury that were considered probably or possibly related to atomoxetine use in postmarketing experience. Rare cases of liver failure have also been reported, including a case that resulted in a liver transplant. Atomoxetine should be discontinued in patients with jaundice or laboratory evidence of liver injury, and should not be restarted. Laboratory testing to determine liver enzyme levels should be done upon the first symptom or sign of liver dysfunction (e.g., pruritus, dark urine, jaundice, right upper quadrant tenderness, or unexplained “flu like” symptoms).[F4639]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Probiontal 5 mg 10 tab.', 25284, 'بروببيونتال 5مجم 10 اقراص', '3', NULL, 'Biotin supplement', 'Biotin supplement', NULL, 'Biotin', 'Hikma pharma', 'Tab', 'أقراص', '5 mg', '1', NULL, NULL, 'mechanism of action of biotin biotin excerts it`s pharmacological action by influencing metabolic reactions. it acts as a coenzyme for carbohydrate fat and protein metabolism. it is required for cell growth and production of fatty acids. it is required fo', NULL, 1286, '2022-07-13', NULL, 0, 'For nutritional supplementation, also for treating dietary shortage or imbalance.', 'Biotin is necessary for the proper functioning of enzymes that transport carboxyl units and fix carbon dioxide, and is required for various metabolic functions, including gluconeogenesis, lipogenesis, fatty acid biosynthesis, propionate metabolism, and catabolism of branched-chain amino acids.', 'Biotin is a water-soluble B-complex vitamin which is composed of an ureido ring fused with a tetrahydrothiophene ring, which attaches a valeric acid substituent at one of its carbon atoms. Biotin is used in cell growth, the production of fatty acids, metabolism of fats, and amino acids. It plays a role in the Kreb cycle, which is the process in which energy is released from food. Biotin not only assists in various metabolic chemical conversions, but also helps with the transfer of carbon dioxide. Biotin is also helpful in maintaining a steady blood sugar level. Biotin is often recommended for strengthening hair and nails. Consequenty, it is found in many cosmetic and health products for the hair and skin. Biotin deficiency is a rare nutritional disorder caused by a deficiency of biotin. Initial symptoms of biotin deficiency include: Dry skin, Seborrheic dermatitis, Fungal infections, rashes including erythematous periorofacial macular rash, fine and brittle hair, and hair loss or total alopecia. If left untreated, neurological symptoms can develop, including mild depression, which may progress to profound lassitude and, eventually, to somnolence; changes in mental status, generalized muscular pains (myalgias), hyperesthesias and paresthesias. The treatment for biotin deficiency is to simply start taking some biotin supplements. A lack of biotin in infants will lead to a condition called seborrheic dermatitis or "cradle cap". Biotin deficiencies are extremely rare in adults but if it does occur, it will lead to anemia, depression, hair loss, high blood sugar levels, muscle pain, nausea, loss of appetite and inflamed mucous membranes.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Synobar-b clarifying gel 100 ml', 27819, 'سينوبار بي جل تفتيح 100 مل', '220', '185', 'Skin care.acne', 'Skin care.acne', NULL, 'Tea tree oil+irgasan+lavendula oily extract+wheat germ oil+salicylic acid+thyme oil+clove oil+pine o', 'Macro group pharmaceuticals', 'Gel', 'جل', '100 ml', '1', NULL, NULL, NULL, '6224000437947', 872, '2025-03-06', NULL, 0, 'Indicated for topical use to help protect against infection in minor cuts, scrapes, and burns. No FDA-approved therapeutic indications.', 'The components of tea tree oil, particularly terpinen-4-ol and α-terpineol, mediate antimicrobial actions by disrupting the structural and functional integrity of bacterial membrane. Hydrocarbons are capable of partitioning into the cell and cytoplasmic membrane of microorganisms and disrupt their vital functions, which may result in leakage of ions such as potassium, and the inhibition of respiration [A32439]. Eventually, cell lysis may occur due to weakening of the cell wall, and loss of turgor pressure and subsequent rupture of the cytoplasmic membrane [A32441]. The loss of 260-nm-absorbing material may be indicative of a damaged cytoplasmic membrane and loss of nucleic acids [A32441]. In _E. coli_, perturbed potassium homeostasis, glucose-dependent respiration, cell morphology, and ability to exclude propidium iodide was observed. 



Tea tree oil also mediates its antifungal actions in a similar way, where it alters the permeability of Candida albicans and inhibits its respiration in a dose-dependent manner [A32439]. Plasma and mitochondrial membranes of fungal species are also thought to be negatively affected by inhibition of glucose-induced medium acidification by tea tree oil, which involves inhibition of membrane ATPase responsible for the expulsion of protons [A32439]. Tea tree oil also inhibits the formation of germ tubes, or mycelial conversion, in _C. albicans_, thereby disrupting cell morphogenesis [A32439]. Water-soluble fraction of TTO, terpinen-4-ol, and α-terpineol, can inhibit the lipopolysaccharide-induced production of the inflammatory mediators such as TNF-α, IL-1β and IL-10 by human peripheral monocytes by approximately 50% and that of prostaglandin E2 by about 30% after 40 h [A32439]. These components of tea tree oil may also suppress superoxide production by agonist-stimulated monocytes and decrease the production of reactive oxygen species by both stimulated neutrophils and monocytes [A32439].', 'Tea tree oil exhibits antibacterial, antifungal, antiviral, and antiprotozoal activities [A32439]. It mostly mediates bactericidal actions at concentrations of 1.0% or less in most bacteria such as _Staphylococcus aureus_ and _Escherichia coli_, and causes bacteriostatic effects at lower concentrations [A32439]. Organisms such as commensal skin staphylococci and micrococci, _Enterococcus faecalis_, and Pseudomonas aeruginosa_emphasized text_ were susceptible to tea tree oil concentrations of 2% [A32439]. It is proposed that water-soluble components of tea tree oil are capable in inducing anti-inflammatory actions; terpinen-4-ol attenuates the vasodilation and plasma extravasation associated with histamine-induced inflammation in humans [A32438].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Power freeze spray100ml', 32344, 'باور فريز سبراي 100 مل', '85', NULL, 'Massage spray topical analgesic', 'Massage spray topical analgesic', NULL, 'Magnesium chloride+menthol+mentha piperita oil+eucalyptus oil+cinnamoum camphora bark oil+clove oil+almond oil+thyme oil+thymol', 'El nile for cosmetics > effect pharma', 'Spray', 'بخاخ', '100ml', '1', NULL, NULL, NULL, NULL, 958, '2023-04-23', NULL, 0, 'Used for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children. Also indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia. Also used in uterine tetany as a myometriat relaxant.', 'Magnesium is the second most plentiful cation of the intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Magnesium sulfate reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural junction. Additionally, Magnesium inhibits Ca<sup>2+</sup> influx through dihydropyridine-sensitive, voltage-dependent channels. This accounts for much of its relaxant action on vascular smooth muscle.', 'Magnesium sulfate is a small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. Magnesium sulfate is gaining popularity as an initial treatment in the management of various dysrhythmias, particularly torsades de pointes, and dyrhythmias secondary to TCA overdose or digitalis toxicity.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vital hair shampoo 200 ml', 29477, 'فيتال شامبو للشعر 200 مل', '150', '120', 'Hair care', 'Hair care', NULL, 'Eruca oil+jojoba oil+nigella oil+garlic oil+olive oil+saw palmetto+vitamin a+vitamin e+thyme extract', 'Hi-care > pixel pharmaceutical company', 'Amp', 'أمبول', '200 ml', '1', 'شامبو للشعر لنظافته -- تقوية الشعر وتنعيمه -- امداد الشعر بالتغذية المناسبة', NULL, 'uses: hair fall - hair damage - split ends - dry hair', '6224001202087', 1421, '2024-10-28', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Chitosan 500mg 30 caps.', 2496, 'شيتوزان 500مجم كبسولة', '54', NULL, 'Weight loss', 'Weight loss', NULL, 'Chitosan', 'Debeiky > pharma green', 'Cap', 'كبسولة', '500mg', '3', NULL, NULL, NULL, NULL, 1444, '2023-01-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Max diet 60 caps.', 6173, 'ماكس دايت 60 كبسولة', '350', NULL, 'Weight loss', 'Weight loss', NULL, 'Green coffee ext.+white kidney bean ext.+african mango+raspberry ketone', 'Dbk', 'Cap', 'كبسولة', NULL, '1', NULL, NULL, NULL, NULL, 993, '2025-07-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Enhertu 100 mg pwd. i.v. inf. vial', 23618, 'انهريتو 100 مجم فيال وريد', '43,575', '0', 'Antineoplastic', 'Antineoplastic', NULL, 'Trastuzumab deruxtecan', 'Egyptian pharmaceutical trading company', 'Vial', 'فيال', '100 mg', '1', NULL, NULL, NULL, NULL, 2706, '2023-04-28', NULL, 0, 'Trastuzumab deruxtecan is indicated for the following conditions: 



**HER2-Positive Breast Cancer**



- This indication is approved in the US, Canada, and Europe.

- It is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen.[L50662, L42240, L48576] In the US and Canada, it is used either in the metastatic setting or in the neoadjuvant or adjuvant setting in patients who have developed disease recurrence during or within six months of completing therapy.[L50662, L42240]

- In Canada, it is also used in patients who have received prior treatment with trastuzumab emtansine (T-DM1).[L42240]



**HER2-Low Breast Cancer**



- This indication is approved in the US, Canada, and Europe.

- It is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.[L50662, L42240, L48576]



**Non-small cell lung cancer (NSCLC)**



- This indication is approved in the US and Europe.

- It is indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have activating HER2 (ERBB2) mutations and who have received prior systemic therapy.[L50662, L48576] In Europe, it is used in patients who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.[L48576]



**Gastric cancer**



- This indication is approved in the US and Europe.

- It is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.[L50662, L48576]



**Solid Tumors**



- This indication is approved in the US.

- It is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options.[L50662]', 'Trastuzumab deruxtecan is a humanized anti-HER2 IgG1 antibody, targeting cancer cause by mutation of the HER2 gene. In addition, the small molecule portion of this drug, deruxtecan (DXd), is a topoisomerase I inhibitor.[A188976,L10842]  It is attached to the antibody by a peptide linker. After trastuzumab deruxtecan binds to HER2 found on malignant cells, it is internalized and linker cleavage occurs through the actions of lysosomal enzymes. After it is released through cleavage, DXd causes targeted DNA damage and apoptosis in cancer cells, due to the ability to cross cell membranes.[A188988,L10842]



Normally, drugs in this class (antibody-drug conjugates) present a challenge. The monoclonal antibody accurately targets cancer cells, however exert limited killing action. The addition of a cytotoxic agent (a topoisomerase I inhibitor in this case) effectively kills dividing cancer cells, including those in the healthy tissues, leading to various adverse effects.  The peptide linker used to formulate this drug is cleavable, which is unique to other antibody-drug conjugates, allowing for increased efficacy and reduced drug resistance to topoisomerase.[A188988]', 'Trastuzumab demonstrates antitumor activity against certain types of HER2 positive breast cancer, however, clinical trials are still ongoing to confirm its efficacy.[A188982,L10842,L10845]  By exploiting both targeted antibody and cytotoxic effects, trastuzumab deruxtecan can effectively destroy tumors.[A188988] 



The FDA label warns of a potential risk for neutropenia, interstitial lung disease/pneumonitis, and left ventricular dysfunction following the use of this drug.[L10842]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Fluca eye susp. drop 5 ml', 4983, 'فلوكا قطرة عين معلق 5 مل', '66', '45.5', 'Glucocorticoid', 'Glucocorticoid', NULL, 'Fluorometholone+sodium cromoglycate', 'Jamjoom pharmaceuticals', 'Susp', 'معلق', '5 ml', '1', 'علاج التهاب العين والتهيج الناجم عن الحساسية.', NULL, 'about fluorometholone (eye.prep.) a synthetic glucocorticoid in steroid responsive inflammations of eye( topical anti-inflammatory). mechanism of action of fluorometholone (eye.prep.) the drug exerts its pharmacological action by penetrating and binding t', '6281263035082', 6170, '2025-07-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hiderm cream 50 gm', 20468, 'هاي ديرم كريم 50 جرام', '55', '48', 'Moisturizing topicals', 'Moisturizing topicals', NULL, 'Glycerin+zinc oxide+olive oil+menthol+titanium dioxide+lanolin', 'Hi-care > avano pharma', 'Cream', 'كريم', '50 gm', '1', 'كريم ترطيب غنى بالفيتامينات لعلاج التسلخات والاحمرار', NULL, 'moisturizing lotion used for sunburns skin roughness diaper rash and insect bites.', '6224007611975', 2640, '2025-01-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Spasmomen 40mg 20 tab.', 10766, 'سبازمومين 40مجم 20 قرص', '80', '52', 'Antispasmodic', 'Antispasmodic', NULL, 'Otilonium bromide', 'Mina pharm > menarini', 'Tab', 'أقراص', '40mg', '2', 'مضاد للتقلصات', NULL, NULL, '6222003700501', 5439, '2025-05-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cuteca facial cleanser 120 ml', 16970, 'كيوتيكا منظف ​​للوجه 120 مل', '44', NULL, 'Facial wash', 'Facial wash', NULL, 'Ammonium lauryl sulfate+triclosan+panthenol+cocamidopropylebetain', 'Hi-care > aitd pharma', 'Cleanser', 'منظف', '120 ml', '1', NULL, NULL, 'moiusturizing facial cleanser', NULL, 821, '2022-07-09', NULL, 0, '1. Expectorant in cough syrups.

2. The ammonium ion (NH4+) in the body plays an important role in the maintenance of acid-base balance. The kidney uses ammonium (NH4+) in place of sodium (Na+) to combine with fixed anions in maintaining acid-base balance, especially as a homeostatic compensatory mechanism in metabolic acidosis.

The therapeutic effects of Ammonium Chloride depend upon the ability of the kidney to utilize ammonia in the excretion of an excess of fixed anions and the conversion of ammonia to urea by the liver, thereby liberating hydrogen (H+) and chloride (Cl–) ions into the extracellular fluid.

Ammonium Chloride Injection, USP, after dilution in isotonic sodium chloride injection, may be indicated in the treatment of patients with:

 (1) hypochloremic states and (2) metabolic alkalosis.', 'Ammonium chloride increases acidity by increasing the amount of hydrogen ion concentrations.



Ammonium chloride can be used as an expectorant due to its irritative action on the bronchial mucosa. This effect causes the production of respiratory tract fluid which in order facilitates the effective cough.', 'Systemic acidifier. In liver ammonium chloride is converted into urea with the liberation of hydrogen ions ( which lowers the pH) and chloride. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rivaxarelt 10mg 10 f.c. tab.', 26206, 'ريفاكساريلت 10مجم 10 اقراص', '180', NULL, 'Antiplatelet.direct factor xa inhibitor', 'Antiplatelet.direct factor xa inhibitor', NULL, 'Rivaroxaban', 'Penta pharma-egypt', 'Tab', 'أقراص', '10mg', '1', 'علاج التجلطات -- الحفاظ علي الدورة الدموية -- الحفاظ علي صحة القلب و الاوعية الدموية', NULL, NULL, NULL, 2527, '2022-12-03', NULL, 0, 'Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Its use is also not recommended in those with severe renal impairment (<30mL/min).[L12819]



Rivaroxaban is also indicated for the treatment and prevention of VTE in pediatric patients (from birth to 18 years of age) and for thromboprophylaxis in pediatric patients ≥2 years old with congenital heart disease following the Fontan procedure.[L12819]

', 'Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible.

 

', 'Rivaroxaban is an anticoagulant which binds directly to factor Xa. Thereafter, it effectively blocks the amplification of the coagulation cascade, preventing the formation of thrombus. Rivaroxaban is a unqiue anticoagulant for two reasons. First of all, it is does not involve antithrombin III (ATIII) to exert its anticoagulant effects. Secondly, it is an oral agent whereas the widely used unfractionated heparin and low molecular weight heparins are for parenteral use only. Although the activated partial thromboplastin time (aPTT) and HepTest (a test developed to assay low molecular weight heparins) are prolonged in a dose-dependant manner, neither test is recommended for the assessment of the pharmacodynamic effects of rivaroxaban. Anti-Xa activity and inhibition of anti-Xa activity monitoring is also not recommended despite being influenced by rivaroxaban.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Glomethasone 8mg/2ml im/iv 3 amp', 19877, 'جلوميثازون 8مجم/2مل 3 امبولات', '66', '45', 'Glucocorticoid', 'Glucocorticoid', NULL, 'Betamethasone disodium phosphate', 'Global pharmaceutical industries', 'Amp', 'أمبول', '8mg', '3', 'مضاد قوي للالتهابات بالجسم ولكن تحت اشراف الطبيب', NULL, NULL, '6224000821609', 10025, '2025-02-13', NULL, 0, 'As a member of the corticosteroid family, betamethasone is indicated for the treatment of several inflammatory conditions. As topical monotherapy, betamethasone is indicated to relieve pruritic and inflammatory symptoms of corticosteroid-responsive-dermatoses.[L11991,L10782,L11997] Betamethasone can be used topically in combination with a vitamin D analog such as calcipotriene to treat plaque psoriasis.[L12000] The corticosteroid is also available as an injectable suspension and can be used to manage a range of inflammatory conditions including endocrine disorders, gastrointestinal disorders, and rheumatic disorders among other conditions.[L11994]

', 'Glucocorticoids inhibit neutrophil apoptosis and demargination, and inhibit NF-Kappa B and other inflammatory transcription factors.[A187463] They also inhibit phospholipase A2, leading to decreased formation of arachidonic acid derivatives.[A187463] In addition, glucocorticoids promote anti-inflammatory genes like interleukin-10.[A187463]



Corticosteroids like betamethasone can act through nongenomic and genomic pathways.[A31458] The genomic pathway is slower and occurs when glucocorticoids activate glucocorticoid receptors and initiate downstream effects that promote transcription of anti-inflammatory genes including phosphoenolpyruvate carboxykinase (PEPCK), IL-1-receptor antagonist, and tyrosine amino transferase (TAT).[A31458] On the other hand, the nongenomic pathway is able to elicit a quicker response by modulating T-cell, platelet and monocyte activity through the use of existing membrane-bound receptors and second messengers.[A31458]', 'Corticosteroids bind to the glucocorticoid receptor inhibiting pro-inflammatory signals, while promoting anti-inflammatory signals.[A187463] Corticosteroids have a wide therapeutic window as patients may require doses that are multiples of what the body naturally produces.[A187463] Patients who require long-term treatment with a corticosteroid should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.[A187463]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ozempic 0.25 mg pre-filled pen', 271, 'اوزمبك 0.25مجم اقلام معبأة للحقن', '4,000', '2500', 'Anti-diabetic.glp-1 receptor agonist', 'Anti-diabetic.glp-1 receptor agonist', NULL, 'Semaglutide', 'Novo nordisk', 'Pen', 'قلم', '0.25 mg', '1', 'احتل عقار "أوزمبك" (Ozempic) عناوين الأخبار التي تحدثت عن نجاح من يتلقونه في فقدان الوزن وتحسين السيطرة على سكر الدم، منهم طبيب كتبه لمرضاه ثم استعمله ليفقد 12 كيلوغراما. فكيف يعمل هذا العقار؟ وما فقدان الوزن المتوقع عند استعماله؟ وهل له محاذير؟', NULL, 'mechanism of action: *diabetes type 2: incretins such as glp-1 enhance glucose-dependent insulin secretion by pancreatic beta-cells suppress inappropriately elevated glucagon secretion and slow gastric emptying. *weight management: glp-1 is a physiologica', '301694181137', 10749, '2024-12-02', NULL, 0, 'Semaglutide is always intended to be used with a reduced calorie diet and increased physical activity. It is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus.[L8678,L8681] However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis.  Semaglutide is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosis.[L8678]



Semaglutide is indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol).[L34475,L41335]. Semaglutide it is also indicated for chronic weight management in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex.[L44552]



Semaglutide is also used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.[L50452]', '**Mechanism of glycemic control**



GLP-1 is a physiological hormone that promotes glycemic control via several different mechanisms, including insulin secretion, slowing gastric emptying, and reducing postprandial glucagon secretion. The homeostasis of glucose is dependent on hormones such as insulin and amylin, which are secreted by the beta cells of the pancreas.  Semaglutide is 94% similar to human GLP-1. Analogs of this hormone such as semaglutide stimulate the synthesis of insulin[A31424] by stimulating pancreatic islet cells and reducing glucagon secretion.[A31424]  They directly bind with selectivity to the GLP-1 receptor, causing various beneficial downstream effects that reduce blood glucose in a glucose-dependent fashion.[L8681] 



**Mechanism of cardiovascular benefit and weight loss**



 In hypercholesterolemia, semaglutide is believed to reduce the progression of atherosclerosis via decreased gut permeability and decreased inflammation.[A186065] Weight loss is believed to occur via the reduction of appetite and food cravings after semaglutide administration. [A31423,A186074]', 'Semaglutide reduces HbA1c, systolic blood pressure, and body weight.[A186062] After 12 weeks of treatment, semaglutide decreased fasting and postprandial glucose by increasing insulin production and decreasing glucagon secretion (which is normally associated with increases in blood sugar). Semaglutide also lowers fasting triglycerides and VLDL cholesterol, exerting beneficial effects on cardiovascular health.[A186053,L1067]



Semaglutide has been shown to cause medullary thyroid cell carcinoma in rodents. While its clinical relevance to humans is unknown, the FDA advises not to administer this drug in those with a personal or family history of medullary thyroid carcinoma.  Semaglutide also poses a risk of pancreatitis and dehydration. Patients must be adequately hydrated while on semaglutide and are advised to seek medical attention immediately in cases of abdominal pain radiating to the back. Because this drug delays gastric emptying, it is important to monitor for the efficacy or adverse effects of other drugs that are administered orally.[L8681]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('A1 cream 50 gm', 13254, 'ايه وان كريم 50 جم', '30', NULL, 'Soothing topical', 'Soothing topical', NULL, 'Castor oil+zinc oxide+arachis oil+bees wax', 'Egpi > egd', 'Cream', 'كريم', '50 gm', '1', 'التهابات الحفاضات والتسلخات للأطفال والكبار', NULL, 'soothing cream for napkin area', '6223003932084', 1145, '2023-01-07', NULL, 0, 'Indicated for over-the-counter use as a laxative for oral use and as a soothing agent for topical use on skin and hair. ', 'Castor oil is a mix of triglycerides consisting of mainly ricinolein, linoleic acid, oleic acid, palmitic acid, stearic acid, dihydroxystearic acid, and traces of other fatty acids [F70]. The main pharmacodynamic effects of castor oil are mediated by ricinoleic acid, a hydroxylated fatty acid released from castor oil by intestinal lipases [A33043]. It was believed that ricinoleic acid acts as an anionic surfactant that reduces net absorption of fluid and electrolytes, and stimulates intestinal peristalsis [F70]. However, a recent study suggests that ricinoleic acid interacts with EP3 prostanoid receptors expressed on intestinal and uterine smooth muscles. Via activating EP3 prostanoid receptors on intestinal and uterine smooth muscle cells, ricinoleic acid promotes laxation and uterus contraction, respectively [A33043]. EP3 receptor act as the major prostanoid receptor in the intestine mediating propulsive effects on gut motility, and activation of EP3 receptors has been demonstrated to evoke contraction of uterine smooth muscle [A33043]. ', 'Castor oil is a potent laxative that was shown to be effective for short-term constipation. In a prospective study, the group receiving oral castor oil was associated with a higher likelihood of initiation of labour compared to the placebo group [A33050]. Castor oil is known to induce diarrhea, and has been used in studies to assess anti-diarrheal effect of some compounds [F70]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Osteocare liquid 120 ml', 9426, 'اوستيوكير شراب 120 مل', '65', '65', 'Calcium supplement', 'Calcium supplement', NULL, 'Calcium carbonate+magnesium carbonate+vitamin d3+zinc', 'Vitabiotics', 'Unknown', 'غير محدد', '120 ml', '1', NULL, NULL, NULL, '6224001078729', 12065, '2024-11-04', NULL, 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Alejon eye contour serum 30 ml', 32368, 'اليجون سيروم لمحيط العين 30 مل', '290', '275', 'Eye contour', 'Eye contour', NULL, 'Peptide complex+vitamin k+collalift 18+alpha arbutin+niacinamide+liposomal vitamin c', 'Alejon co.', 'Serum', 'سيروم', '30 ml', '1', NULL, NULL, 'eye contour with concealer - anti dark circles ï¿½ anti puffiness', '6224010497146', 669, '2025-06-24', NULL, 0, 'Investigated for use/treatment in metabolic disease and obesity.', 'PYY 3-36 acts via the presynaptic Y2 receptor in the ARC. It decreases neuropeptide Y (NPY) release from static hypothalamic explants and thus acts to decrease food intake.', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Aqua b 30 tabs', 893, 'اكوا بي 30 قرص', '105', NULL, 'Multivitamin', 'Multivitamin', NULL, 'Methylecobalamine+vit b6+methyle folate', 'New pharma', 'Tab', 'أقراص', NULL, '3', NULL, NULL, NULL, NULL, 2526, '2024-06-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Pregnarole 20 f.c tab', 4776, 'بريجنارول 20 قرص مغلف', '120', NULL, 'Dietary supplement', 'Dietary supplement', NULL, 'Vitamin D3 10mcg + Vitamin E 4mg + Vitamin K 70mcg + Vitamin C 70mg + Vitamin B1 3mg + Vitamin B2 2mg + Vitamin B3 20mg + Vitamin B6 10mg + Folate 400mcg DFE + Vitamin B12 6mcg + Biotin 150mcg + Pantothenic acid 6mg + Magnesium 150mg + Iron 17mg + Zinc 15mg + Copper 1000mcg + Selenium 30mcg + Iodine 150mcg + Betacarotene 2mg', 'تصنيع ميديكير لصالح امازون فارم للمكملات الغذائية', 'Tab', 'أقراص', NULL, '1', NULL, NULL, NULL, NULL, 885, '2025-06-20', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vesicare 10 mg 30 f.c. tab', 29195, 'فيسيكير 10مجم 30 قرص', '487', '373', 'Urinary incontinence.antispasmodics.muscarinic antagonists', 'Urinary incontinence.antispasmodics.muscarinic antagonists', NULL, 'Solifenacin succinate', 'Astellas pharma > multipharma', 'Tab', 'أقراص', '10 mg', '3', NULL, NULL, NULL, '8718692510180', 2148, '2024-07-29', NULL, 0, 'Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.[L7511]', 'Solifenacin is a competitive muscarinic receptor antagonist.[L7511] It has the highest affinity for M3, M1, and M2 muscarinic receptors.[A181247] 80% of the muscarinic receptors in the bladder are M2, while 20% are M3.[A181262] Solifenacin''s antagonism of the M3 receptor prevents contraction of the detrusor muscle, while antagonism of the M2 receptor may prevent contraction of smooth muscle in the bladder.[A181262]', 'Solifenacin antagonizes the M2 and M3 muscarinic receptors in the bladder to treat an overactive bladder.[L7511,A181262] It has a long duration of action as it is usually taken once daily.[L7511] Patients taking solifenacin should be aware of the risks of angioedema and anaphylaxis.[L7511]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Unsiatem 120 mg 30 tabs.', 31533, 'انسياتم 120مجم 30 قرص', '150', '90', 'Antigout', 'Antigout', NULL, 'Febuxostat', 'Liptis', 'Tab', 'أقراص', '120 mg', '3', 'علاج النقرس -- الوقاية من حصوات الكلي -- علاج ارتفاع مستوي حمض اليوريك في الدم', NULL, 'indication: treatment of hyperuricaemia in conditions where urate deposition has already occured. dose: 1 tablet once daily', NULL, 1089, '2024-07-14', NULL, 0, 'Febuxostat is indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of [allopurinol], who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.[L46073] It is not recommended for the treatment of asymptomatic hyperuricemia [L32238] or secondary hyperuricemia.[A230583] ', 'Gout is a form of acute arthritis that is characterized by the accumulation of crystals of monosodium urate and urate crystals in or around a joint, leading to inflammation and persistent urate crystal deposition in bones, joints, tissues, and other organs that may exacerbate over time. Hyperuricemia is closely related to gout, whereby it may exist for many years before the first clinical attack of gout; thus, aberrated serum uric acid levels and hyperuricemia are believed to be the biochemical aberration involved in the pathogenesis of gout.[A230548] Xanthine oxidoreductase (XOR) can act as a xanthine oxidase or xanthine dehydrogenase. In humans, it is a critical enzyme for uric acid production as it catalyzes the oxidation reaction steps from hypoxanthine to xanthine and from xanthine to uric acid in the pathway of purine metabolism.[A19658] Febuxostat potently inhibits XOR, blocking both its oxidase and dehydrogenase activities. With high affinity, febuxostat binds to XOR in a molecular channel leading to the molybdenum-pterin active site, where [allopurinol] demonstrates relatively weak competitive inhibition.[A230548] 



XOR is mainly found in the dehydrogenase form under normal physiological conditions; however, in inflammatory conditions, XOR can be converted into the xanthine oxidase form, which catalyzes reactions that produce reactive oxygen species (ROS), such as peroxynitrite. ROS contribute to vascular inflammation and alterations in vascular function. As febuxostat can inhibit both forms of XOR, it can inhibit ROS formation, oxidative stress, and inflammation.[A2743] In a rat model, febuxostat suppressed renal ischemia-reperfusion injury by attenuating oxidative stress.[A2744]', 'Febuxostat is a novel, selective xanthine oxidase/dehydrogenase inhibitor that works by decreasing serum uric acid in a dose-dependent manner. In healthy subjects, febuxostat decreased the mean serum uric acid and serum xanthine concentrations, as well as the total urinary uric acid excretion. Febuxostat at daily doses of 40-80 mg reduced the 24-hour mean serum uric acid concentrations by 40 to 55%.[L32238] Closely related to the drug-induced reduction of serum uric acid levels and mobilization of urate crystals in tissue deposits, febuxostat is associated with gout flares.[A230583] 



Unlike [allopurinol] and [oxypurinol], febuxostat has no inhibitory actions against other enzymes involved in purine and pyrimidine synthesis and metabolism, because it does not structurally resemble purines or pyrimidines.[A230548] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Fortijoint 30 tablets', 6733, 'فورتيجوينت 30 قرص', '280', NULL, 'Anti-rheumatic.osteoarthritis anabolic agents', 'Anti-rheumatic.osteoarthritis anabolic agents', NULL, 'Glucosamin+chondroitin+collagen+msm', 'Revax group - ziax', 'Tablet', 'أقراص', NULL, '3', NULL, NULL, NULL, NULL, 749, '2025-08-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Villa borghini colour protector treatment', 29332, 'فيلا بورجيني', '259', NULL, 'Hair care', 'Hair care', NULL, NULL, 'Villa borghini s.r.l > spring', 'Unknown', 'غير محدد', NULL, '1', NULL, NULL, NULL, NULL, 572, '2022-08-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Feldene 20mg 10 disp. tab', 4762, 'فلدين 20مجم 10 اقراص سريع الذوبان', '43', '28', 'Nsaid.oxicam', 'Nsaid.oxicam', NULL, 'Piroxicam', 'Pfizer', 'Tab', 'أقراص', '20mg', '2', 'مسكن عام للالام -- تقليل الالام و الاتهابات', NULL, NULL, '6221180000329', 5081, '2024-07-11', NULL, 0, 'For treatment of osteoarthritis and rheumatoid arthritis.', 'The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets.', 'Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Gastrocure 30mg 20 caps.', 5357, 'جاستروكيور 30 مجم 20 كبسولة', '87', '33.6', 'Peptic ulcer.proton pump inhibitor', 'Peptic ulcer.proton pump inhibitor', NULL, 'Lansoprazole', 'Alfacure pharmaceuticals', 'Cap', 'كبسولة', '30mg', '2', NULL, NULL, NULL, '6224000875565', 1288, '2024-06-21', NULL, 0, 'Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. [A4892][A177065][FDA Label]  It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis.[FDA Label] Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. [FDA Label]  Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. [FDA Label]  Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy). [FDA Label]', 'As a PPI, lansoprazole is a prodrug and requires protonation via an acidic environment to become activated. [A174244]  Once protonated, lansoprazole is able to react with cysteine residues, specifically Cys813 and Cys321, on parietal H+,K+-ATPase resulting in stable disulfides.[A174244][A177077]  PPI''s in general are able to provide prolonged inhibition of acid secretion due to their ability to bind covalently to their targets.[A174244]   ', 'Lansoprazole decreases gastric acid secretion by targeting H+,K+-ATPase, which is the enzyme that catalyzes the final step in the acid secretion pathway in parietal cells. [A177080]  Conveniently, lansoprazole administered any time of day is able to inhibit both daytime and nocturnal acid secretion.[A177080]  The result is that lansoprazole is effective at healing duodenal ulcers, reduces ulcer-related pain, and offers relief from symptoms of heartburn [A177080]  Lansoprazole also reduces pepsin secretion, making it a useful treatment option for hypersecretory conditions such as Zollinger-Ellison syndrome.[A177089][A177080]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sterile water for injection usp 20', 27507, 'مياه معقمة للحقن', '20', NULL, 'Water for injection', 'Water for injection', NULL, 'Purified water', 'Cid', 'Injection', 'حقن', NULL, '1', 'مياة معقمة للحقن', NULL, 'puï-riï-fied waï-ter water obtained by distillation or deionization.', NULL, 1233, '2022-05-29', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Piperacillin/tazobactam kabi 4.5 gm 10 pd. for i.v. vial', 4436, 'بيبراسيللين/تازوباكتام كابي 4.5 جم 10 فيال وريد', '2,570', '1105', 'Antibiotic', 'Antibiotic', NULL, 'Piperacillin+tazobactam', 'Fresenius kabi', 'Vial', 'فيال', '4.5 gm', '10', NULL, NULL, NULL, NULL, 1088, '2024-11-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cymbatex 30 mg 30 caps.', 3231, 'سيمباتكس 30مجم 30 كبسولة', '228', '228', 'Psychiatric.antidepressants', 'Psychiatric.antidepressants', NULL, 'Duloxetine', 'Eva pharma', 'Cap', 'كبسولة', '30 mg', '3', 'مضاد للاكتئاب.', NULL, 'about duloxetine a serotonin-norepinephrine reuptake inhibitor thiophene derivative antidepressant. mechanism of action of duloxetine duloxetine preferentially inhibits the re-uptake of noradrenaline and serotonin (5 ht) in the cns nerve terminals .this w', '6223002459711', 9495, '2024-11-16', NULL, 0, '**Indicated** for:



1) Management of Major Depressive Disorder.[label]



2) Management of Generalized Anxiety Disorder.[label]



3) Management of diabetic peripheral neuropathy.[label]



4) Management of fibromyalgia.[label]



5) Management of chronic musculoskeletal pain.[label]



6) Management of osteoarthritis of the knee in adults.[L6364]



7) Management of chronic lower back pain in adults.[L6364]



8) Management of stress urinary incontinence in adult women.[L6367]



**Off-label** uses include:



1) Management of chemotherapy-induced peripheral neuropathy.[A178603]



2) Management of stress urinary incontinence in adult men after prostatectomy until recovery is complete.[L6370]', 'Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake.[A178714] Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors.



Action on the external urinary sphincter is mediated via duloxetine''s CNS effects. Increased serotonin and norepinephrine concentrations in Onuf''s nucleus leads to increased activation of 5-HT<sub>2</sub>, 5-HT<sub>3</sub>, and α<sub>1</sub> adrenergic receptors.[A178663,A178666] 5-HT<sub>2</sub> and α<sub>1</sub> are both G<sub>q</sub> coupled and their activation increases the activity of the inositol trisphosphate/phospholipase C (IP<sub>3</sub>/PLC) pathway.[T116] This pathway leads to release of intracellular calcium stores, increasing intracellular calcium concentrations, and facilitating neuronal excitability. 5-HT<sub>3</sub> functions as a ligand-gated sodium channel which allows sodium to flow into the neuron when activated. Increased flow of sodium into the neuron contributes to depolarization and activation of voltage gated channels involved in action potential generation. The combined action of these three receptors contributes to increased excitability of the pudendal motor nerve in response to glutamate.



Also related to duloxetine''s action at the spinal cord is its modulation of pain. Increasing the concentration of serotonin and norepinephrine in the dorsal horn of the spinal cord increases descending inhibition of pain through activation of 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>2</sub>, 5-HT<sub>3</sub>, α<sub>1</sub>-adrenergic, and α<sub>2</sub>-adrenergic receptors.[A178705] 5-HT<sub>2</sub>, 5-HT<sub>3</sub>, and α<sub>1</sub>-adrenergic mediate neuronal activation as described above. The activated neuron in this case is the GABAergic inhibitory interneuron which synapses onto the nociceptive projection neuron to inhibit the transmission of painful stimuli to the brain. The 5-HT<sub>1</sub> and α<sub>2</sub> receptors are G<sub>i</sub>/G<sub>o</sub> coupled and their activation leads to increased potassium current through inward rectifier channels and decreased adenylyl cyclase/protein kinase A signaling which contributes to neuronal inhibition.[A178705,T116] These inhibitory receptors are present on the projection neuron itself as well as the dorsal root ganglion which precedes it and serves to directly suppress the transmission of painful stimuli.



The mechanisms involved in duloxetine''s benefits in depression and anxiety have not been fully elucidated. Dysfunctional serotonin and norepinephrine signaling are thought to be involved and increases in the availability of these neurotransmitters at the synaptic cleft thought to mediate a therapeutic effect.[A178666] It is postulated that the involvement of serotonin and norepinephrine in area responsible for emotional modulation such as the limbic system contributes to the effects in mood disorders specifically but this has yet to be confirmed.



Duloxetine''s hypertensive effect is related to its intended pharmacological effect. Increased availability of norepinephrine leads to activation of adrenergic receptors on the vascular endothelium. Since the action of α<sub>1</sub> receptors predominates, vasoconstriction results as the G<sub>q</sub> coupled receptor mediates calcium release from the sarcoplasmic reticulum to facilitate smooth muscle contraction.[T116]', 'Duloxetine, through increasing serotonin and norepinephrine concentrations in Onuf''s nucleus, enhances glutamatergic activation of the pudendal motor nerve which innervates the external urethral sphinter.[A178663,A178666] This enhanced signaling allows for stronger contraction. Increased contraction of this sphincter increases the pressure needed to produce an incontinence episode in stress urinary incontinence. Duloxetine has been shown to improve Patient Global Impression of Improvement and Incontinence Quality of Life scores.[A178669] It has also been shown to reduce the median incontinence episode frequency at doses of 40 and 80 mg.



Action at the dorsal horn of the spinal cord allows duloxetine to strengthen the the serotonergic and adrenergic pathways involved in descending inhibition of pain.[A178666,A178705] This results in an increased threshold of activation necessary to transmit painful stimuli to the brain and effective relief of pain, particularly in neuropathic pain. Pain relief has been noted in a variety of painful conditions including diabetic peripheral neuropathy, fibromyalgia, and osteoarthritis using a range of pain assessment surveys.[A178711]



While duloxetine has been shown to be effective in both animal models of mood disorders and in clinical trials for the treatment of these disorders in humans, the broad scope of its pharmacodynamic effects on mood regulation in the brain has yet to be explained.[A178714]



Increased blood pressure is a common side effect with duloxetine due to vasoconstriction mediated by the intended increase in norepinephrine signaling.[label,T116]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Pantopi 40mg 14 tab', 9611, 'بانتوبي 40مجم 14 اقراص', '96', '67', 'Peptic ulcer.proton pump inhibitor', 'Peptic ulcer.proton pump inhibitor', NULL, 'Pantoprazole', 'El-obour', 'Tab', 'أقراص', '40mg', '2', 'علاج التهابات القولون والمعدة -- تقليل الالام المعدة والقولون', NULL, NULL, '6223004600272', 9347, '2024-07-20', NULL, 0, '

**Pantoprazole Injection**:



**Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis**



Pantoprazole for injection is indicated for short-term treatment (7-10 days) of patients having gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayed-release tablets. _Safety and efficacy of pantoprazole injection as the initial treatment of patients having GERD with a history of erosive esophagitis have not been demonstrated at this time_.[FDA label]



**Pathological Hypersecretion Associated with Zollinger-Ellison Syndrome**



Pantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions.[FDA label]



**Pantoprazole delayed-release oral suspension**:



**Short-Term Treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD)**



Indicated in adults and pediatric patients five years of age and above for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been determined.[F3202]



**Maintenance of healing of erosive esophagitis**



Indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD.[F3202]



**Pathological hypersecretory conditions including Zollinger-Ellison syndrome**



Indicated for the long-term treatment of the above conditions.[F3202]', 'Hydrochloric acid (HCl) secretion into the gastric lumen is a process regulated mainly by the H(+)/K(+)-ATPase of the proton pump, expressed in high quantities by the parietal cells of the stomach.[A174295] ATPase is an enzyme on the parietal cell membrane that facilitates hydrogen and potassium exchange through the cell, which normally results in the extrusion of potassium and formation of HCl (gastric acid). 



Proton pump inhibitors such as pantoprazole are substituted _benzimidazole_ derivatives, weak bases, which accumulate in the acidic space of the parietal cell before being converted in the _canaliculi_  (small canal) of the gastric parietal cell, an acidic environment, to active _sulfenamide_ derivatives. This active form then makes disulfide bonds with important cysteines on the gastric acid pump, inhibiting its function.[A174247] Specifically, pantoprazole binds to the _sulfhydryl group_ of H+, K+-ATPase, which is an enzyme implicated in accelerating the final step in the acid secretion pathway. The enzyme is inactivated, inhibiting gastric acid secretion.[A174253] The inhibition of gastric acid secretion is stronger with proton pump inhibitors such as pantoprazole and lasts longer than with the H(2) antagonists.[A174295] ', 'This drug acts to decrease gastric acid secretion, which reduces stomach acidity. Pantoprazole administration leads to long-lasting inhibition of gastric acid secretion.[F3193]



**General Effects**



Pantoprazole has been shown to reduce acid reflux-related symptoms, heal inflammation of the esophagus, and improve patient quality of life more effectively than histamine-2 receptor antagonists (H2 blockers). This drug has an excellent safety profile and a low incidence of drug interactions. It can be used safely in various high-risk patient populations, including the elderly and those with renal failure or moderate hepatic dysfunction.[A174226]



Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as pantoprazole have been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal _C. difficile_), reduced absorption of micronutrients including iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.[A177571]



PPIs such as pantoprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes [A177577, A177580]. 



**A note on laboratory testing abnormalities**



During treatment with antisecretory medicinal products such as pantoprazole, serum gastrin (a peptide hormone that stimulates secretion of gastric acid) increases in response to the decreased acid secretion caused by proton pump inhibition. The increased gastrin level may interfere with investigations for neuroendocrine tumors. Published evidence suggests that proton pump inhibitors should be stopped 14 days before chromogranin A (CgA) measurements. This permits chromogranin A levels, that might be falsely elevated after proton pump inhibitor treatment, to return to the normal reference range.[F3217] 



Reports have been made of false-positive results in urine screening tests for tetrahydrocannabinol (THC) in patients receiving the majority of proton pump inhibitors, including pantoprazole. A confirmatory method should be used.[F3217]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Viavag 100 mg 10 f.c.tabs.', 12271, 'فيافاج 100مجم 10 اقراص', '80', '55', 'Tonic for men', 'Tonic for men', NULL, 'Sildenafil', 'Hi-pharm', 'Tab', 'أقراص', '100 mg', '10', 'مقوي للرجال', NULL, 'about sildenafil citrate phosphodiesterase-5 enzyme inhibitor anti-erectile dysfunction agent. mechanism of action of sildenafil citrate sildenafil is a phosphodiesterase enzyme (pde5) inhibitor. this enzyme is responsible for the degradation cyclic guano', '6224001050527', 9962, '2025-01-25', NULL, 0, 'Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:



(1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and



(2) treatment of pulmonary hypertension, where:

a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850];



b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and



c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].', 'Sildenafil is an oral therapy for erectile dysfunction [A175582, F3853, F3856, F3886, L5611]. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis [A175582, F3853, F3856, F3886, L5611].



The physiological mechanism responsible for the erection of the penis involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation [A175582, F3853, F3856, F3886, L5611]. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood [A175582, F3853, F3856, F3886, L5611].



Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP [A175582, F3853, F3856, F3886, L5611]. Sildenafil has a peripheral site of action on erections [A175582, F3853, F3856, F3886, L5611]. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of NO on this tissue [A175582, F3853, F3856, F3886, L5611]. When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP [A175582, F3853, F3856, F3886, L5611]. Therefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects [A175582, F3853, F3856, F3886, L5611].



Moreover, apart from the presence of PDE5 in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature [A175579, F3850, F3859, F3883, L5614]. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation [A175579, F3850, F3859, F3883, L5614]. In patients with pulmonary arterial hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation [A175579, F3850, F3859, F3883, L5614].', 'In vitro studies have shown that sildenafil is selective for phosphodiesterase-5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Its effect is more potent on PDE5 than on other known phosphodiesterases [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. In particular, there is a 10-times selectivity over PDE6 which is involved in the phototransduction pathway in the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. There is an 80-times selectivity over PDE1, and over 700-times over PDE 2, 3, 4, 7, 8, 9, 10 and 11 [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. And finally, sildenafil has greater than 4,000-times selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (via the use of RigiScan®), after sildenafil administration compared with placebo [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Most studies assessed the efficacy of sildenafil approximately 60 minutes post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The erectile response, as assessed by RigiScan®, generally increased with increasing sildenafil dose and plasma concentration [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Sildenafil causes mild and transient decreases in systemic blood pressure which, in the majority of cases, do not translate into clinical effects [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mmHg respectively [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mmHg)[F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614] . At the recommended dose of 20 mg three times a day no reductions in systolic or diastolic pressure were seen [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension no clinically relevant effects on the ECG were reported either [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Mean pulmonary systolic blood pressure decreased by 9% [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil showed no effect on cardiac output and did not impair blood flow through the stenosed coronary arteries [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Mild and transient differences in color discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The postulated mechanism for this change in color discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil has no effect on visual acuity or contrast sensitivity. In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in visual tests conducted (which included visual acuity, Amsler grid, color discrimination simulated traffic light, and the Humphrey perimeter and photostress test) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rosaseef 30 caps', 26300, 'روزاسيف 30 كبسولة', '120', '43.25', 'Evening primrose oil', 'Evening primrose oil', NULL, 'Evening primrose oil+fish oil+vitamin e', 'Safe pharma', 'Cap', 'كبسولة', NULL, '3', 'مصدر لزيت البريماروز وفيتامين اي -- تجديد وترميم البشرة المتضررة --تفتيح البشرة -- ترطيب وتلطيف الجلد', NULL, NULL, '6224009435067', 5303, '2024-05-11', NULL, 0, 'Evening primrose oil is used as part of over-the-counter dietary supplements.[L1113]



It is also used for the treatment of systemic inflammatory diseases and for women''s health conditions such as cyclical mastalgia. These indications do not have sufficient evidence of their effectiveness. It was used for the treatment of atopic dermatitis in the United Kingdom but it is currently withdrawn due to lack of evidence of effectiveness.[A33131]', 'Evening primrose oil presents a content of 74% [DB00132] and 9% [DB13854] from which the later seems to be the key active ingredient of this oil. These major essential fatty acids are required for the normal structure of cell membranes and they are not synthesized endogenously.[T218] The therapeutic activity of evening primrose oil is attributed to the direct action of its essential fatty acids on immune cells as well as to an indirect effect on the synthesis of eicosanoids. The actions of highly unsaturated fatty acids in tissues and eicosanoids are thought to be implicated in inflammatory and immunologic pathogeneses.[A33131]



The essential fatty acids found in evening primrose oil are involved in the biosynthesis of prostaglandin. For this activity, the main involved component is the [DB13854]. The presence of this essential fatty acid allows the synthesis of anti-inflammatory substances such as 15-hydroxy-eicosatrienoic acid and prostaglandin E1.[T218] ', 'The effectivity of evening primrose oil is debatable as the evidence is very limited.[F111] Evening primrose oil improves the essential fatty acid content in plasma, erythrocyte, and platelet lipids. It has also been registered to increase alpha-tocopherol levels in non-diabetic and type I diabetic patients. Evening primrose oil affects the fatty acid composition of serum lipids and adipose tissue as well as it helps maintain normal cellular structures and it serves as a prostaglandin precursor. Administration of evening primrose oil is part of long-term therapy and thus, immediate results are never expected.[T218]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rotadrip spray', 8389, 'روتادريب سبراي', '135', NULL, NULL, NULL, NULL, NULL, NULL, 'Spray', 'بخاخ', NULL, '1', NULL, NULL, NULL, NULL, 804, '2022-08-10', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Coronavine 5 mg 10 tab.', 16807, 'كورونافين 5 مجم 10 قرص', '6', NULL, 'Antihypertensive.selective calcium channel blocker', 'Antihypertensive.selective calcium channel blocker', NULL, 'Amlodipine', 'Pharopharma', 'Tab', 'أقراص', '5 mg', '1', NULL, NULL, 'about amlodipine calcium channel blocker anti hypertensive anti angina. mechanism of action of amlodipine amlodipine is a second generation dihydropyridine ca channel blocker. it exerts it`s antihypertensive antianginal actions through blocking the influx', NULL, 1094, '2022-07-24', NULL, 0, 'Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions [FDA label]:



• Hypertension 



• Coronary artery disease



• Chronic stable angina



• Vasospastic angina (Prinzmetal’s or Variant angina) 



• Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%', '**Mechanism of action on blood pressure**



Amlodipine is considered a peripheral arterial vasodilator that exerts its action directly on vascular smooth muscle to lead to a reduction in peripheral vascular resistance, causing a decrease in blood pressure. Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the influx of calcium ions into both vascular smooth muscle and cardiac muscle. Experimental studies imply that amlodipine binds to both _dihydropyridine_ and _nondihydropyridine_ binding sites, located on cell membranes. The contraction of cardiac muscle and vascular smooth muscle are dependent on the movement of extracellular calcium ions into these cells by specific ion channels. Amlodipine blocks calcium ion influx across cell membranes with selectivity. A stronger effect of amlodipine is exerted on vascular smooth muscle cells than on cardiac muscle cells [FDA label]. Direct actions of amlodipine on vascular smooth muscle result in reduced blood pressure [F3757]. 



**Mechanism of action in angina**



The exact mechanism by which amlodipine relieves the symptoms of angina have not been fully elucidated to this date, however, the mechanism of action is likely twofold:



Amlodipine has a dilating effect on peripheral arterioles, reducing the total peripheral resistance (afterload) against which the cardiac muscle functions. Since the heart rate remains stable during amlodipine administration, the reduced work of the heart reduces both myocardial energy use and oxygen requirements [F3757].



Dilatation of the main coronary arteries and coronary arterioles, both in healthy and ischemic areas, is another possible mechanism of amlodipine reduction of blood pressure. The dilatation causes an increase in myocardial oxygen delivery in patients experiencing coronary artery spasm (Prinzmetal''s or variant angina) and reduces coronary vasoconstriction caused by smoking [F3757].', '**General pharmacodynamic effects**



Amlodipine has a strong affinity for cell membranes, modulating calcium influx by inhibiting selected membrane calcium channels. This drug''s unique binding properties allow for its long-acting action and less frequent dosing regimen [A573], [FDA label].  



**Hemodynamic effects**



After the administration of therapeutic doses of amlodipine to patients diagnosed with hypertension, amlodipine causes vasodilation, which results in a reduction of supine and standing blood pressure. During these blood pressure reductions, there are no clinically significant changes in heart rate or plasma catecholamine levels with long-term use. Acute intravenous administration of amlodipine reduces arterial blood pressure and increases heart rate in patients with chronic stable angina, however, chronic oral administration of amlodipine in clinical studies did not cause clinically significant alterations in heart rate or blood pressures in patients diagnosed with angina and normal blood pressure. With long-term, once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours [FDA label]. 



**Electrophysiologic effects**



Amlodipine does not change sinoatrial (SA) nodal function or atrioventricular (AV) conduction in animals or humans. In patients who were diagnosed with chronic stable angina, the intravenous administration of 10 mg of amlodipine did not cause clinically significant alterations A-H and H-V conduction and sinus node recovery time after cardiac pacing. Patients administered amlodipine with concomitant beta-blockers produced similar results. In clinical trials in which amlodipine was given in combination with beta-blockers to patients diagnosed with hypertension or angina, no adverse effects on electrocardiographic parameters were noted. In clinical studies comprised of angina patients alone, amlodipine did not change electrocardiographic intervals or produce high degrees of AV block [FDA label]. 



**Effects on angina**



Amlodipine relieves the symptoms of chest pain associated with angina. In patients diagnosed with angina, daily administration of a single amlodipine dose increases total exercise time, the time to angina onset, and the time to 1 mm ST-segment depression on ECG studies, decreases anginal attack frequency, and decreases the requirement for nitroglycerin tablets [F3757]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dia-furyl 220mg/5ml oral susp. 60 ml', 3588, 'دايا-فيوريل 60 مل معلق', '9', NULL, 'Antidiarrheal', 'Antidiarrheal', NULL, 'Nifuroxazide', 'Borg', 'Susp', 'معلق', '220mg', '1', NULL, NULL, 'indications infectious diarrhea in children and adults chronic colitis enterocolitis as an adjunctive treatment in combined therapy of intestinal dysbiosis. contraindication hypersensitivity to 5-nitrofurane derivatives and/or other components of the drug', '6223002570225', 1197, '2022-12-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Placy lore hair repair serum 60 ml', 24980, 'بلاسي لور سيرم لعلاج الشعر 60مل', '80', NULL, 'Hair care', 'Hair care', NULL, NULL, 'Cosmo pack > bioserve pharma', 'Serum', 'سيروم', '60 ml', '1', NULL, NULL, NULL, NULL, 791, '2022-07-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Quantamash 4gm 12 sachets', 25528, 'كوانتاماش 4مجم 12 كيس', '83', NULL, 'Antihyperlipidemic.bile acid sequestrants', 'Antihyperlipidemic.bile acid sequestrants', NULL, 'Cholestyramine', 'Debeiky > mash premiere', 'Sachet', 'أكياس', '4gm', '1', 'خفض مستوي الكوليسترول في الدم -- علاج الحكة الناتجة عن انسداد القنوات الصفراوية -- علاج بعض انواع الاسهال', NULL, NULL, '6222001404746', 4726, '2022-11-08', NULL, 0, 'Indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Also for the relief of pruritus associated with partial biliary obstruction.', 'Cholestyramine forms a resin that acts as a bile acid sequestrant to limit the reabsorption of bile acids in the gastrointestinal tract. Cholestyramine resin is a strong anion exchange resin, allowing it to exchange its chloride anions with anionic bile acids present in the gastrointestinal tract and form a strong resin matrix. Cholestyramine consists of a functional group, which is a quaternary ammonium group attached to an inert styrene-divinylbenzene copolymer, in the anion exchange resin.', 'Cholesterol is probably the sole precursor of bile acids. During normal digestion, bile acids are secreted into the intestines. A major portion of the bile acids is absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation. Only very small amounts of bile acids are found in normal serum. Cholestyramine resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces. This results in a partial removal of bile acids from the enterohepatic circulation by preventing their absorption.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rogitamine 10mg/ml 5 amps.', 26250, 'روجيتامين 10مجم/مل 5 امبول', '415', '290', 'Antihypertensive.non selective alpha receptors blockers', 'Antihypertensive.non selective alpha receptors blockers', NULL, 'Phentolamine', 'Alexandria > egypharma', 'Amp', 'أمبول', '10mg', '1', NULL, NULL, 'about phentolamine mesylate a reversible nonselective alpha-adrenergic antagonist imidazoline derivative peripheral vasodilator antihypertensive. mechanism of action of phentolamine mesylate phentolamine is a quick & short acting non selective competitive', '6224000870140', 1657, '2024-12-25', NULL, 0, 'When used intravenously or intramuscularly, phentolamine is used to prevent or control hypertensive episodes that may occur in a patient with pheochromocytoma due to stress or manipulation during preoperative preparation and surgical excision. It is also used to prevent or treat dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. It may be used to diagnose pheochromocytoma by the phentolamine-blocking test.[L48420]



Submucosal injection of phentolamine is indicated for the reversal of soft-tissue anesthesia (e.g. anesthesia of the lip and tongue) and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor in patients three years old and older.[L48415]



Phentolamine ophthalmic solution is used to treat pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.[L48390]', 'Phentolamine is a reversible, competitive antagonist at alpha-1 and alpha-2 adrenergic receptors.[A261766, L48390] It causes vasodilation of vascular smooth muscles.[L48415] Pupil dilation is primarily controlled by the radial iris dilator muscles surrounding the pupil, which are activated by the alpha-1 adrenergic receptors. Phentolamine reversibly binds to these receptors and reduces pupil diameter. By blocking alpha-1 adrenergic receptors, phentolamine can also be used to reverse mydriasis induced by muscarinic antagonists.[L48390]', 'Phentolamine produces an alpha-adrenergic block of a relatively short duration.[L48415] Phentolamine induces vasodilatation of vascular smooth muscle and pupils.[L48415, L48390] When used in an ophthalmic solution, the onset of pupil dilation generally occurred in 30 minutes, with the maximal effect seen in 60 to 90 minutes. Pupil dilation lasted for at least 24 hours.[L48390] Phentolamine also has direct but less marked positive inotropic and chronotropic effects on cardiac muscle and vasodilator effects on vascular smooth muscle;[L48420] however, phentolamine is not believed to affect contractile or adenyl cyclase function.[A261781] Large doses can lead to a mild sympatholytic action.[A261781] 



Some evidence suggests that phentolamine also stimulates beta-adrenergic receptors, thereby causing peripheral vasodilation.[A261781] Phentolamine was shown to stimulate insulin secretion, possibly related to its blocking actions on ATP-sensitive K<sup>+</sup> channels.[A261781, A261761]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Care heav hair shampoo 250 ml', 15873, 'كير هيف شامبو 250 مل', '100', NULL, 'Hair care', 'Hair care', NULL, NULL, 'Egyptian co. for cosmetics > heaven pharma group', 'Amp', 'أمبول', '250 ml', '1', 'شامبو لتنظيف وتغذية وترطيب الشعر ومنع التساقط والهيشان', NULL, '** ingredients: dimethicone + sodium chloride + glycol distearate + sodium benzoate + arginine + salicylic acid + carbomer + methyl cocoate + citric acid + glyceryl oleate + argan oil + caffeine + keratin + whey protein powder + aloe vera extract + garlic', NULL, 1184, '2022-07-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Helixbrom syrup 120 ml', 32945, 'هليكسبروم شراب 120 مل', '35', '27', 'Cough products', 'Cough products', NULL, 'Ivy leaves+thyme+liquorice extract', 'Bromed', 'Syrup', 'شراب', '120 ml', '1', 'مكمل غذائى مضاد للسعال ويدعم الجهاز التنفسي ويخفف من اعراض البرد', NULL, NULL, NULL, 3519, '2024-06-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Gamunex-c 10% i.v. vial 50 ml', 30583, 'جاميونكس -سي 10% فيال 50 مل', '20,000', '5200', 'Immunoglobulin', 'Immunoglobulin', NULL, 'Immunoglobulin', 'Grifols biological inc.-usa > biolinx medical inc.', 'Vial', 'فيال', '10%', '1', NULL, NULL, NULL, NULL, 747, '2025-01-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dermedic capilarte normalising shampoo 300 ml', 17349, 'ديرميدك شامبو 300 مل', '190', NULL, 'Hair care', 'Hair care', NULL, NULL, 'Biogened s.a. > multitrade', 'Cap', 'كبسولة', '300 ml', '1', NULL, NULL, 'active ingredients: pilotantumtm niacinamide birch juice pca zinc salicylic acid d-panthenol gently cleanses the scalp stimulates hair growth and prevents excessive hair loss nourishes the hair follicles strengthens the hair shafts. regulates and soothes', NULL, 711, '2022-07-29', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Follitrope 225 i.u. prefilled syringe', 19296, 'فوليتروب 225 وحدة دولية حقن مملوءة', '329', NULL, 'Infertility drugs.follicle stimulating hormone', 'Infertility drugs.follicle stimulating hormone', NULL, 'Follitropin (recombinant fsh)', 'Biopharma > pharma over seas', 'Syringe', 'حقنة', NULL, '1', NULL, NULL, NULL, NULL, 941, '2022-07-12', NULL, 0, 'In women having been diagnosed with primary ovarian failure, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. In men with hypogonadotrophic hypogonadism, it is used to induce spermatogenesis. Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).', 'Follitropin is a recombinant form of endogenous follicle stimulating hormone (FSH). FSH binds to the follicle stimulating hormone receptor which is a G-coupled transmembrane receptor. Binding of the FSH to its receptor seems to induce phosphorylation and activation of the PI3K (Phosphatidylinositol-3-kinase) and Akt signaling pathway, which is known to regulate many other metabolic and related survival/maturation functions in cells.', 'Used for the treatment of female infertility, Follitropin beta or follicle stimulating hormone (FSH) stimulates ovarian follicular growth in women who do not have primary ovarian failure. FSH, the active component of Follitropin beta is the primary hormone responsible for follicular recruitment and development.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Epicephin 500mg i.v. vial', 18373, 'ابيسيفين 500مجم فيال وريد', '47', '33', 'Antibiotic.cephalosporin.third-generation', 'Antibiotic.cephalosporin.third-generation', NULL, 'Ceftriaxone', 'Eipico', 'Vial', 'فيال', '500mg', '1', NULL, NULL, NULL, '6221032335814', 1070, '2024-12-05', NULL, 0, 'Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms.[L15082] Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabilis, E. coli, Klebsiella spp, M. catarrhalis, B. burgdorferi, and some oral anaerobes.[A215582] ', 'Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall.[T324,L15082] The beta-lactam moiety of ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. Binding of ceftriaxone to these enzymes causes the enzyme to lose activity; therefore, the bacteria produce defective cell walls, causing cell death.', 'Ceftriaxone is a cephalosporin/cephamycin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms.[L15082] Ceftriaxone has <i>in vitro</i> activity against gram-positive aerobic, gram-negative aerobic, and anaerobic bacteria.[L15087] The bactericidal activity of ceftriaxone results from the inhibition of cell wall synthesis and is mediated through ceftriaxone binding to penicillin-binding proteins (PBPs).[T324] Ceftriaxone is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended-spectrum beta-lactamases.[L15082] However, resistance to ceftriaxone usually occurs through beta-lactamase hydrolysis, altered PBPs, or reduced bacterial cell permeability.[T324] Ceftriaxone should not be mixed with or giving in the same IV line as diluents/products containing calcium as they may cause ceftriaxone to precipitate.[L15082] Ceftriaxone use may also cause biliary sludge or gallbladder pseudolithiasis.[L15082,A215602] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Conistova 2 mg 14 f.c.tabs.', 32671, 'كونيستوفا 2 مجم 14 قرص', '124', '95', 'Laxative', 'Laxative', NULL, 'Prucalopride', 'Mash premiere', 'Tab', 'أقراص', '2 mg', '2', NULL, NULL, 'prucalopride is a drug acting as a selective high affinity 5-ht4 receptor agonist which targets the impaired motility associated with chronic constipation thus normalizing bowel movements. prucalopride a first in class dihydro-benzofuran-carboxamide is a', '6222001405224', 950, '2024-11-07', NULL, 0, 'Prucalopride is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.[L4882]



CIC is one of the most common chronic functional gastrointestinal disorders worldwide. The diagnosis of this agent is very hard and it can be confirmed if the patient experience at least two of the following:



-Straining during more than 25% of the bowel movements.



-Lumpy or hard stools in 25% of the bowel movements.



-Sensation of incomplete evacuation in more than 25% of all bowel movements.



-Sensation of anorectal blockage or obstruction in more than 25% of the bowel movements.



-Manual maneuvers required in more than 25% of the bowel movements.



-Fewer than 3 bowel movements per week.[L4883]', 'Prucalopride acts as a selective stimulator of the 5-HT4 receptors while having no interaction with hERG channel or 5-HT1 receptors which reduces significantly the cardiovascular risk found in other similar drugs.[A40250]



5-HT4 receptors can be found throughout the gastrointestinal tract primarily in smooth muscle cells, enterochromaffin cells, and myenteric plexus. Its activation produces the release of acetylcholine which is the major excitatory neurotransmitter in the GI tract.[A37348]



Hence, prucalopride stimulates motility by interacting specifically with 5-HT4 receptors in the GI tract which causes a release of acetylcholine and further contraction of the muscle layer of the colon and relaxation of the circular muscle layer leading to the propulsion of luminal content.[A14331]', 'In animal studies, prucalopride induced a dose-dependent stimulation of contractile activity in the proximal colon and inhibition of the contractility in the distal colon.[A40253] As well it has been shown that prucalopride stimulates and amplifies giant migratory contraction which is the high-amplitude type of contraction that initiates the urge to defecate. Thus, prucalopride not only accelerates the colonic transit but also accelerates gastric emptying and small bowel transit.[A37348] 



In supratherapeutic concentrations, prucalopride can be observed to interact with hERG potassium channels and L-type calcium channels.[A37348]



In clinical trials, prucalopride showed to significantly increase the spontaneous bowel movements with a standardized mean difference of about 0.5 after the use of 1 mg when compared with the placebo group.[A40254] In this studies as well, it was observed a numerical improvement in mean colonic transit time and a significant increase in spontaneous complete bowel movement without marked changes in the anorectal function.[A40254] 



In phase III clinical trials, 86% of the tested individuals opted to continue with the open-label study and based on Patients Assessments, 67% of the patients increase more than one point improvement in their satisfaction.[A40254]



In the final set of clinical trials for approval, there was a significant increase in the number of patients that reached over 3 complete spontaneous bowel movements per week when compared with the placebo.[L4882]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Marketova panthenol cream 50gm', 6547, 'ماركيتوفا بانثينول كريم 50 جم', '45', NULL, 'Skin cream', 'Skin cream', NULL, 'Panthenol+cocos nucifera oil+lavender angustlfolia oil', 'Marketova pharma health care', 'Cream', 'كريم', '50gm', '1', NULL, NULL, NULL, NULL, 691, '2025-08-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Geneman jar 30 tabs', 7293, 'جينيمان برطمان 30 قرص', '300', NULL, NULL, NULL, NULL, NULL, NULL, 'Tab', 'أقراص', NULL, '1', NULL, NULL, NULL, NULL, 542, '2025-08-31', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cobal 500mcg 30 f.c.tab', 16593, 'كوبال 500مكجم 30 قرص', '38', '33', 'Vitamin b', 'Vitamin b', NULL, 'Mecobalamin', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '500mcg', '3', 'مكمل غذائى يدعم صحة الاعصاب ويعالج حالات فر الدم ويمد الجسم بالطاقة', NULL, NULL, '6223002143153', 2486, '2025-07-10', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Allinphi 8 b 30 tabs', 4188, 'الينفي 8 بي 30 قرص', '150', NULL, 'Vitamin b complex', 'Vitamin b complex', NULL, 'Vitamin b complex 8 forms: vitamin b1+vit b2+vit b3+vit b5+vit b6+vit b7+vit b9+vit b12', 'Zativa pharmaceuticals- phi medical', 'Tab', 'أقراص', NULL, '3', NULL, NULL, NULL, NULL, 641, '2025-06-15', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Calcium cid 12 sachets', 15670, 'كالسيوم سيد 12 كيس', '6', NULL, 'Calcium supplement', 'Calcium supplement', NULL, 'Calcium carbonate', 'Cid', 'Sachet', 'أكياس', NULL, '1', NULL, NULL, NULL, NULL, 989, '2022-07-15', NULL, 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Potassium chloride conc. 15% amp. for i.v inf.', 25092, 'بوتاسيوم كلوريد 15%امبول', '4', NULL, 'Potassium supplement', 'Potassium supplement', NULL, 'Potassium chloride', 'Al mottahedoon pharma', 'Amp', 'أمبول', '15%', '1', NULL, NULL, NULL, NULL, 1004, '2022-07-18', NULL, 0, 'For use as an electrolyte replenisher and in the treatment of hypokalemia.', 'Supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.', 'The potassium ion is in the principle intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle, and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine. If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Clinitol mouth wash', 2774, 'كلينتول غسول فم', '3', NULL, 'Mouth wash', 'Mouth wash', NULL, 'Hexetidine+lidocaine+methyl salicylate', 'Misr > apc (arab perfumes chemicals and pharmaceutical co.)', 'Mouth wash', 'غسول للفم', NULL, '1', NULL, NULL, NULL, NULL, 905, '2023-04-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vagiprost 25 mcg 4 vag. tabs', 12026, 'فاجي بروست 25 مجم 4 اقراص مهبلية', '12', NULL, 'Labour inducer', 'Labour inducer', NULL, 'Misoprostol', 'Adwia', 'Tab', 'أقراص', '25 mcg', '1', 'محفز للطلق لتسهيل الولادة', NULL, NULL, '6223002976850', 6523, '2023-02-03', NULL, 0, 'Misoprostol is indicated as a tablet to reduce the risk of NSAID induced gastric ulcers but not duodenal ulcers in high risk patients.[L7616] Misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcers.[L7619] Misoprostol is used off label for the management of miscarriages, prevention of post partum hemorrhage, and is also used alone or in combination with mifepristone in other countries for first trimester abortions.[A181589,A181583,A181697]', 'Misoprostol is a synthetic prostaglandin E1 analog that stimulates prostaglandin E1 receptors on parietal cells in the stomach to reduce gastric acid secretion.[A181586] Mucus and bicarbonate secretion are also increased along with thickening of the mucosal bilayer so the mucosa can generate new cells.[A181586] 



Misoprostol binds to smooth muscle cells in the uterine lining to increase the strength and frequency of contractions as well as degrade collagen and reduce cervical tone.[A181586]', 'Misoprostol is a prostaglandin E1 analog used to reduce the risk of NSAID induced gastric ulcers by reducing secretion of gastric acid from parietal cells.[A181586,L7616,L7619] Misoprostol is also used to manage miscarriages and used alone or in combination with mifepristone for first trimester abortions.[A181589,A181583,A181598] An oral dose of misoprostol has an 8 minute onset of action and a duration of action of approximately 2 hours, a sublingual dose has an 11 minute onset of action and a duration of action of approximately 3 hours, a vaginal dose has a 20 minute onset of action and a duration of action of approximately 4 hours, and a rectal dose has a 100 minute onset of action and a duration of action of approximately 4 hours.[A181607]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dolcicana 1 gm*25 sachets', 17763, 'دولسيكانا 1 جم 25 كيس', '15', NULL, 'Sweetener', 'Sweetener', NULL, 'Sucralose+maltodextrin', 'Mup', 'Sachet', 'أكياس', '1 gm', '1', NULL, NULL, '1 sachet is equivalent to 2 spoons of sugar.', NULL, 705, '2022-07-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Moon face soap 80 gm', 8324, 'مون فيس صابونة 80 جم', '45', '32', 'Skin care', 'Skin care', NULL, NULL, 'Rony pharma', 'Soap', 'صابون', '80 gm', '1', NULL, NULL, NULL, '6224008147046', 1759, '2024-07-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mydrapid 0.5% eye drops 10 ml', 23163, 'ميدرابيد 0.5% قطرة للعين 10مل', '27', '17.5', 'Mydriatic', 'Mydriatic', NULL, 'Tropicamide', 'Alexandria', 'Drops', 'نقط', '0.5%', '1', NULL, NULL, 'about tropicamide anticholinergic (muscarinic blocker) ophthalmic agent mydriatic cycloplegic. mechanism of action of tropicamide tropicamide is a muscarinic receptor blocker. it nonselectively inhibits the muscarinic actions of acetylcholine. tropicamide', '6223000172124', 1123, '2025-05-28', NULL, 0, 'Tropicamide is indicated to induce mydriasis (dilation of the pupil) for diagnostic procedures and in conditions where short-term pupil dilation is desired, either as monotherapy [L32103] or in combination with [hydroxyamphetamine] [L32178] or [phenylephrine].[L46332] It provides clinically significant mydriasis with partial cycloplegia.[L32178]', 'Muscarinic acetylcholine receptors are involved in numerous ocular functions. The M<sub>3</sub> subtype is predominantly expressed by smooth muscle cells of the sphincter pupillae, which is a circular muscle of the iris, and ciliary muscles. In response to light or binding of acetylcholine, M<sub>3</sub> receptor signalling leads to contraction of the sphincter pupillae and pupil constriction. Contraction of the ciliary muscle via M<sub>3</sub> receptor signalling also leads to accommodation, adjusting the lens for near vision.[A230178] The eye is also innervated by parasympathetic nerves: ciliary ganglion neurons project to the ciliary body and the sphincter pupillae muscle of the iris to control ocular accommodation and pupil constriction.[A230183] 



Tropicamide is a non-selective muscarinic antagonist that binds to all subtypes of muscarinic receptors. By binding to muscarinic receptors, tropicamide relaxes the pupillary sphincter muscle and causes pupil dilation.[A229958] By blocking the muscarinic receptors of the ciliary body, tropicamide also prevents accommodation.[A230178] Like other muscarinic antagonists, tropicamide inhibits the parasympathetic drive, allowing the sympathetic nervous system responses to dominate.[A229958] Tropicamide is thought to ameliorate sialorrhea by blocking M<sub>4</sub> receptors expressed on salivary glands and reducing hypersalivation.[A229958]', 'Tropicamide is an anticholinergic drug and that works by non‐selectively blocking muscarinic receptors to cause mydriasis and cycloplegia. It relaxes the pupillary sphincter to dilate the pupil.[A229958] The onset of tropicamide‐induced mydriasis is about 10 to 15 minutes,[A230103] with optimal effect occurring 25 to 30 minutes post-administration. Mydriasis caused by tropicamide wears off within four to eight hours, but it was seen up to 24 hours in some individuals. Tropicamide hinders accommodation by causing the contraction of the ciliary muscle. The cycloplegic effect occurs within 20 to minutes following administration, with a duration of action of four to 10 hours. Tropicamide can elevate intraocular pressure.[A229958] The ophthalmic use of tropicamide is not typically associated with serious systemic adverse events.[A230173]



One randomized pilot study showed that oral tropicamide alleviated perceived symptoms of sialorrhea in patients with Parkinson''s Disease: anticholinergics are believed to restore the dopaminergic to cholinergic activity imbalance in neurodegenerative diseases.[A229958] Similarly in one case report, tropicamide administered via ophthalmic solution relieved clozapine-induced sialorrhea.[A230093] Interestingly, in rodent models, tropicamide suppressed drug-induced tremulous jaw movements which are often used as a model of parkinsonian tremor: the significance of this finding requires further investigations.[A5677]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Atacand 4mg 14 tab', 1058, 'اتاكاند 4مجم 14 قرص', '40', NULL, 'Antihypertensive', 'Antihypertensive', NULL, 'Candesartan cilexetil', 'Astra zenica', 'Tab', 'أقراص', '4mg', '2', 'حالات الضغط المرتفع', NULL, NULL, '6223003270001', 2027, '2022-12-03', NULL, 0, 'May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.', 'Candesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion.', 'Candesartan cilexetil is an ARB prodrug that is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS. RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sfira moisturizing cream 60 gm', 26889, 'سفيرا كريم مرطب 60 جم', '69', NULL, 'Moisturizing cream', 'Moisturizing cream', NULL, 'Aloe vrea+jojoba oil+panthenol+shea butter+olive oil+caffeine+glycerin+vitamin e', 'El-helou perfumes & cosmetics > biotrade pharmaceutical', 'Cream', 'كريم', '60 gm', '1', 'كريم مرطب للجلد __ يعمل علي تنعيم وترطيب الجلد', NULL, NULL, NULL, 2637, '2022-04-24', NULL, 0, 'Indicated for use as a topical agent to soothe sensitive skin and to relieve symptoms of various skin conditions, including contact or atopic dermatitis, eczema, dermatitis and acne urticata, first- and second-degree burns, radiation dermatitis, and sunburn. ', 'It is suggested that aloe polysaccharides mediate skin-protectant effects in damaged skin, induced by internal or other external factors such as radiation, via inhibiting apoptosis of normal cell lines _in vitro_ and thrombocytes _in vivo_ [A32473]. Following irradiation, aloe polysaccharides block the upregulation of pro-apoptotic p53, Bax, and Bad while blocking downregulating anti-apoptotic Bcl-2 [A32473]. _In vivo_, aloe polysaccharides may act as a scavenger for oxygen free radicals including DPPH, alkyl radicals, superoxides, and singlet oxygen and hydroxyl radicals that may also be generated by superoxides [A32470, A32476]. Hydrogen peroxide, which is a weak initiate lipid peroxidation, may also be effectively scavenged by aloe polysaccharides [A32476]. In a Fenton reaction system, aloe polysaccharides demonstrated a concentration-dependent scavenging activity against hydroxyl radical that were generated during the reaction [A32476]. Aloe polysaccharides may also compete with oxygen to react with nitric oxide (NO), thereby inhibiting the generation of nitrite and peroxynitrite anions that act as free radicals [A32476]. 



Findings from a study investigating the effects of aloe polysaccharides on doxorubicin-induced oxidative stress suggest that aloe polysaccharides mediate potent antioxidant actions _in vivo_ [A32476]. Doxorubicin, known to generate reactive oxygen species such as superoxide and hydroxy radicals, was administered to albino rats. This led to myocardial oxidative stress and cardiac injury accompanied by leakage of LDH and CPK from cardiac myocytes and to serum due to lipid peroxidation of cardiac membranes, reduced levels of antioxidant coenzyme GSH, and increased levels of SOD from a compensatory and combative mechanism of oxidative stress [A32476]. Treatment with aloe polysaccharides resulted in a significant decrease in serum LDH and CPK levels, indicating that aloe polysaccharides are capable in stabilizing cardiac membranes from peroxidative damage. Restored levels of endogenous GSH and SOD in a dose-dependent manner were also observed with the treatment of aloe polysaccharides, suggesting that aloe polysaccharides exhibit potent antioxidant properties [A32476].



In a study of rats with open cutaneous back wounds, treatment with aloe polysaccharides decreased the levels of matrix metalloproteinase-3 (MMP-3) and induced tissue inhibitors of matrix metalloproteinase-2 (TIMP-2) during the early stage of wound repair, resulting in decreased collagen breakdown and increased preservation of collagen content in the injured area [A32471]. A study proposes that acemannan, a common aloe polysaccharide, stimulates BMSC proliferation, ALPase activity, expression of VEGF, BMP-2, OPN, BSP, and mineralization leading to osteoblast differentiation and bone formation during socket healing [A32475]. ', 'Aloe polysaccharides mediate antioxidant and anti-inflammatory actions, as well as immunoregulatory activities. Various studies indicate that aloe polysaccharides possess effective free radical scavenging activity _in vitro_, and produce potent antioxidant potential during oxidative stress _in vivo_ [A32476]. According to the findings of studies _in vitro_ and _in vivo_, aloe polysaccharides exhibit radioprotective activity. Treatment with acemmanan, which is a common aloe polysaccharide, on CH3 mice with radiation-induced skin reactions resulted in reduced signs of those reactions [A32473]. Studies suggest that aloe polysaccharides may evidently attenuate tumor growth in mice [A32473]. Treatment of aloe polysaccharides in Vero cells as well as in the in vivo zebrafish model led to protective effects against AAPH-indued oxidative stress resulting from accumulation of free radical species and improved cell viability [A32470]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Riscure 2mg 30 f.c. tab.', 26160, 'ريسكيور 2مجم 30 قرص', '110', NULL, 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Risperidone', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '2mg', '3', NULL, NULL, NULL, '6223002146666', 1037, '2023-01-05', NULL, 0, 'Risperidone is indicated for the treatment of schizophrenia [L12885,L44692,L46297] and irritability associated with autistic disorder.[L12885] It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.[L12885,L44692]



Risperidone is additionally indicated in Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches.[L12906]



Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression.[A177226]', 'Though its precise mechanism of action is not fully understood, current focus is on the ability of risperidone to inhibit the D2 dopaminergic receptors and 5-HT2A serotonergic receptors in the brain. Schizophrenia is thought to result from an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively.[A1115, A1116, A1117]



D2 dopaminergic receptors are transiently inhibited by risperidone, reducing dopaminergic neurotransmission, therefore decreasing positive symptoms of schizophrenia, such as delusions and hallucinations.[A251765] Risperidone binds transiently and with loose affinity to the dopaminergic D2 receptor, with an ideal receptor occupancy of 60-70% for optimal effect.[A1119,A31773] Rapid dissociation of risperidone from the D2 receptors contributes to decreased risk of extrapyramidal symptoms (EPS), which occur with permanent and high occupancy blockade of D2 dopaminergic receptors.[A1118,A1119] Low-affinity binding and rapid dissociation from the D2 receptor distinguish risperidone from the traditional antipsychotic drugs. A higher occupancy rate of D2 receptors is said to increase the risk of extrapyramidal symptoms and is therefore to be avoided.[A1118,A1119,A31771] 

 

Increased serotonergic mesocortical activity in schizophrenia results in negative symptoms, such as depression and decreased motivation. The high-affinity binding of risperidone to 5-HT2A receptors leads to a decrease in serotonergic activity. In addition, 5-HT2A receptor blockade results in decreased risk of extrapyramidal symptoms, likely by increasing dopamine release from the frontal cortex, and not the nigrostriatal tract. Dopamine level is therefore not completely inhibited.[A1117,A1119] Through the above mechanisms, both serotonergic and D2 blockade by risperidone are thought to synergistically work to decrease the risk of extrapyramidal symptoms. 

 

Risperidone has also been said to be an antagonist of alpha-1 (α1), alpha-2 (α2), and histamine (H1) receptors.[A37034] Blockade of these receptors is thought to improve symptoms of schizophrenia, however the exact mechanism of action on these receptors is not fully understood at this time.[L12885]', 'The primary action of risperidone is to decrease dopaminergic and serotonergic pathway activity in the brain, therefore decreasing symptoms of schizophrenia and mood disorders.[A1115,A1116]



Risperidone has a high binding affinity for serotonergic 5-HT2A receptors when compared to dopaminergic D2 receptors in the brain.[A1114,A1115] Risperidone binds to D2 receptors with a lower affinity than first-generation antipsychotic drugs, which bind with very high affinity. A reduction in extrapyramidal symptoms with risperidone, when compared to its predecessors, is likely a result of its moderate affinity for dopaminergic D2 receptors.[A1119,A1117]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Meiacton 200mg 20 f.c. tabs', 22487, 'مياكتون 200 مجم 10قرص', '100', NULL, 'Antibiotic.cephalosporin.third-generation', 'Antibiotic.cephalosporin.third-generation', NULL, 'Cefditoren', 'Tabuk pharmaceutical manufacturing company > al ansar for marketing', 'Tab', 'أقراص', '200mg', '2', NULL, NULL, 'about cefditoren third generation cephalosporins mechanism of action of cefditoren cefditoren is an orally active 3rd generation cephalosporin which exerts its bactericidal action against both gram positive & gram negative organisms by inhibiting bacteria', '6281102236076', 382, '2022-12-06', NULL, 0, 'For the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.', 'The bactericidal activity of cefditoren results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefditoren is stable in the presence of a variety of b-lactamases, including penicillinases and some cephalosporinases.', 'Cefditoren pivoxil is a prodrug which is hydrolyzed by esterases during absorption, and the drug is distributed in the circulating blood as active cefditoren. Cefditoren is a cephalosporin with antibacterial activity against gram-positive and gram-negative pathogens. Cefditoren is effective against <i>Staphylococcus aureus</i> (methicillin-susceptible strains, including b-lactamase-producing strains), penicillin-susceptible strains of <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i>, <i>Streptococcus pyogenes</i>, <i>Haemophilus influenzae</i> (including b-lactamase-producing strains), <i>Haemophilus parainfluenzae</i> (including b-lactamase-producing strains), <i>Moraxella catarrhalis</i> (including b-lactamase-producing strains), <i>Streptococcus agalactiae</i>, <i>Streptococcus</i> Groups C and G, and <i>Streptococcus</i>, viridans group (penicillin-susceptible and -intermediate strains).', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Megy-one 10mg 20 f.c. tablets', 22486, 'ميجي وان 10مجم 20 قرص', '29', NULL, 'Anti-diabetic.secretagogues.glinides', 'Anti-diabetic.secretagogues.glinides', NULL, 'Mitiglinide', 'Sigma > andalous pharma', 'Tablet', 'أقراص', '10mg', '2', NULL, NULL, 'indication for the treatment of type 2 diabetes. pharmacodynamics mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs. it is approved for use in japan but has not yet gained fda approval. mechanism of action mitiglinide is thought', '6224000396169', 663, '2022-08-03', NULL, 0, 'For the treatment of type 2 diabetes.', 'Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive K(+) (K(ATP)) channels (Kir6.2/SUR1 complex, KATP channels) in pancreatic beta-cells. Closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules. ', 'Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs. It is approved for use in Japan but has not yet gained FDA approval.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Isis caraway 20 filter bags', 30708, 'ايزيس كراوية 20 فلتر باكو', '35', '17.5', 'Drinks', 'Drinks', NULL, 'Caraway', 'Atos pharma', 'Unknown', 'غير محدد', NULL, '1', NULL, NULL, NULL, '6223000470022', 639, '2024-10-19', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Senolin cream 60 gm', 26767, 'سينولين كريم 60 جم', '36', NULL, 'Whitening topical', 'Whitening topical', NULL, 'Licorice extract+castor oil+panthenol', 'Egyptian company for cosmetics > cura sanata pharmaceuticals', 'Cream', 'كريم', '60 gm', '1', 'كريم تفتيح', NULL, 'whitening cream', NULL, 1000, '2022-05-31', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Myocool cream 100 gm', 23181, 'ميوكول كريم 100 جرام', '125', '105', 'Massage', 'Massage', NULL, 'Winter green oil+peppermint oil+silicon oil+cetyl alcohol+propyl paraben+petrolium jelly+stearic aci', 'Leader cosmetics > purex health care', 'Cream', 'كريم', '100 gm', '1', NULL, NULL, 'indications * osteoarthritis * rheumatoid arthritis * chronic low back pain * chronic musculoskeletal disorders mode of action myocool cream as a treatment for arthritis& joint and muscle pain through containing topical glucosamine and chondroitin sulphat', '6224001085017', 4057, '2025-03-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Beclosone inhaler 50 mcg/dose 200 doses', 1342, 'بكلوزون بخاخ للاستنشاق 50مكجم/جرعة 200 بخة', '74', '22.5', 'Bronchodilator.anti-inflammatory.glucocorticoid steroid', 'Bronchodilator.anti-inflammatory.glucocorticoid steroid', NULL, 'Beclomethasone dipropionate', 'Arab drug company.', 'Inhaler', 'جهاز استنشاق', '50 mcg', '1', 'موسع للشعب الهوائية', NULL, 'about beclomethasone dipropionate potent glucocorticoid potent anti-inflammatory agent in respiratory tract and nasal passages. indications : 1.eczema 2.psoriasis 3.contact dermatitis 4.anal and vulval pruritis 5.inflammation of the skin contra-indication', '6221060002702', 6049, '2024-11-30', NULL, 0, 'Indicated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. The aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasm.[L6871]



Indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevent the recurrence of nasal polyps following surgical removal.[L6880]



Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older.[L10782] Corticosteroid-responsive dermatoses include psoriasis, contact dermatitis (dermatitis venenata), atopic dermatitis (infantile eczema, allergic dermatitis), neurodermatitis (lichen simplex chronicus, lichen planus, eczema, eczematous dermatitis), intertrigo, dyshidroses (pompholyx), seborrheic dermatitis, exfoliative dermatitis, solar dermatitis, stasis dermatitis, and anogenital and senile pruritus.[L6886]', 'Beclomethasone dipropionate is a corticosteroid and prodrug that is rapidly activated by hydrolysis to the active monoester, 17 monopropionate (17-BMP), which mediates anti-inflammatory actions. 17-BMP has been shown _in vitro_ to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 13 times that of dexamethasone and 25 times that of beclomethasone dipropionate.[L6871] Upon binding of the ligand, the glucocorticoid receptors dimerize and translocate into the nucleus, where they subsequently bind to glucocorticoid response elements (GRE) on glucocorticoid-responsive genes, leading to changes in transcription. There are several proposed mechanisms for the anti-inflammatory action of corticosteroids. Corticosteroids may work by increasing the transcription of genes coding for anti-inflammatory proteins, including lipocortin-1 and interleukin-10.[A179875] Corticosteroids were also shown to inhibit the expression of multiple genes that encode pro-inflammatory factors, such as cytokines, chemokines, and adhesion molecules, that are activated during the chronic inflammatory process.[A31449] This is thought to be due to the direct inhibitory interaction between activated glucocorticoid receptors and activated pro-inflammatory transcription factors, such as nuclear factor-kappa B and activator protein-1.[A179875] Chronic inflammation is often characterized by enhanced expression of these transcription factors that bind to and activate coactivator molecules, which then acetylate core histones to switch on gene transcription to further amplify the inflammatory process.[A31449] Corticosteroids suppress the multiple inflammatory gene expression by promoting histone deacetylation, resulting in tighter coiling of DNA and reduced access of transcription factors to their binding sites.[A179875] ', 'Inflammatory conditions, including asthma, dermatoses, and allergic rhinitis, involve the activation of cascades by inflammatory mediators. Inflammation is a primary defense mechanism and the homeostatic response of the immune system; however, a prolonged inflammatory response in certain disorders may lead to tissue damage, pain, and swelling. Beclomethasone dipropionate works by attenuating the inflammatory responses associated with asthma, allergic rhinitis, nasal polyps, and corticosteroid-responsive dermatoses. It suppresses the actions of inflammatory cells, such as mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils. It also inhibits the release of inflammatory mediators, such as histamine, eicosanoids, leukotrienes, and cytokines.[L6871] Beclomethasone dipropionate is reported to exhibit potent topical activity while possessing low systemic effects.[A179845] 



Beclomethasone dipropionate is a corticosteroid drug with anti-inflammatory and vasoconstrictive effects used to treat chronic inflammatory processes such as asthma, allergic rhinitis, corticosteroid-responsive dermatoses. When inhaled, it improves lung function, decreases airway hyper-reactivity, and reduces the severity of asthmatic symptoms.[A180160] Although inhaled corticosteroids, including beclomethasone dipropionate, are reported to mainly act locally in the lungs, systemic effects such as disruption of hypothalamic-pituitary-adrenal (HPA) axis function, bone turnover, osteoporosis, and growth suppression may still be observed with chronic use or high dose administration. There were varying findings from clinical studies examining the effect of beclomethasone dipropionate on growth suppression in pediatric patients.[A180160] It was shown to suppress the hypothalamo-pituitary-adrenal (HPA) axis in a dose-dependent manner.[A179917] HPA axis is a central hormonal response system to stress and activation of HPA axis leads to the production of endogenous steroid hormone production.[A179920] Long-term use of high-dose systemic corticosteroids, including those inhaled, was often associated with signs and symptoms of adrenal insufficiency when exposed to stress conditions, such as trauma, surgery, or infections. As corticosteroids work by suppressing the immune system, there may be an increased risk for developing infections.[L6871] Cases of _Candida albicans_ infection of the mouth and throat have been reported with inhaled beclomethasone dipropionate therapy.[A180010]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Coloverin 135mg 30 tablets', 16667, 'كولوفيرين 135 مجم 30 قرص', '78', '51', 'Antimuscarinic.irritable bowel syndrome', 'Antimuscarinic.irritable bowel syndrome', NULL, 'Mebeverine', 'Chemipharm', 'Tablet', 'أقراص', '135mg', '3', NULL, NULL, NULL, '6222006501402', 1897, '2025-05-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Encephohol 200mg i.v.infusion', 18303, 'انسيفوهول 200مجم محلول وريد', '18', NULL, 'Nootropic', 'Nootropic', NULL, 'Pyritinol', 'Merck kgaa f.r.germany > merck kgaa f.r-egypt', 'Unknown', 'غير محدد', '200mg', '1', NULL, NULL, NULL, NULL, 705, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Betabalance 24 mg 30 tab.', 15103, 'بيتابالانس 24 مجم 30 قرص', '30', NULL, 'Diamine oxidase inhibitor', 'Diamine oxidase inhibitor', NULL, 'Betahistine', 'Bioriginal international group pharma egypt > arabian international group (aig)', 'Tab', 'أقراص', '24 mg', '3', NULL, NULL, 'about betahistine h1 selective histamine analogue diamine oxidase inhibitor anti vertigo and in meniere s syndrome. mechanism of action of betahistine betahistine is a histamine substitute. it produces vasodilatation and improves blood flow to the labyrin', NULL, 965, '2022-07-20', NULL, 0, 'Betahistine is indicated for the reduction of recurrent vertigo episodes associated with Ménière''s disease in patients 18 years old and above.[L16388]', 'Vertigo is a disturbing sensation of movement caused by dysfunction of the labyrinth (inner ear), vestibular nerve, cerebellum, brainstem, or Central Nervous System (CNS). Vestibular forms of vertigo are often accompanied by auditory dysfunctions such as hyperacusis, hearing loss, and tinnitus.[A220328] In most cases, adaptive mechanisms of the CNS lead to functional recovery after episodes of vertigo, however, syndromes such as Ménière''s disease tend to cause the recurrence of vertigo symptoms. This significantly impacts the quality of life and the ability to carry out daily activities.[A220318] 



**H1-receptor activity**



The mechanism of action of betahistine is multifactorial. Ménière''s disease is thought to result from a disruption of endolymphatic fluid homeostasis in the ear.[A220438] Betahistine mainly acts as a histamine H1-receptor agonist. The stimulation of H1-receptors in the inner ear causes a vasodilatory effect leading to increased permeability of blood vessels and a reduction in endolymphatic pressure; this action prevents the rupture of the labyrinth, which can contribute to the hearing loss associated with  Ménière''s disease. Betahistine is also purported to act by reducing the asymmetrical functioning of sensory vestibular organs and increasing vestibulocochlear blood flow, relieving symptoms of vertigo.[A220433]



**H3-receptor activity**



In addition to the above mechanisms, betahistine also acts as a histamine H3-receptor antagonist, increasing the turnover of histamine from postsynaptic histaminergic nerve receptors, subsequently leading to an increase in H1-agonist activity. H3-receptor antagonism elevates levels of neurotransmitters including serotonin in the brainstem, inhibiting the activity of vestibular nuclei, thus restoring proper balance and decreasing vertigo symptoms.[A220328]', 'Through its actions on the histamine receptors, betahistine provides relief from vertigo associated with Ménière''s disease.[A220328,A220433,L16388] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lactevenor 0.03mg 35 coated tab.', 21534, 'لاكتيفينور 0.03مجم 35 قرص', '28', '25', 'Contraceptives', 'Contraceptives', NULL, 'Levonorgestrel', 'Acdima international trading', 'Tab', 'أقراص', '0.03mg', '1', NULL, NULL, 'about levonorgestrel a synthetic progestagen . hormonal contraception. mechanism of action of levonorgestrel it is a progestin derivative exerts it`s action through nuclear progesterone receptors situated in female genital tract breast cns and pituitary.', '6224000588403', 8615, '2024-11-25', NULL, 0, '**Emergency contraception**



Levonorgestrel, in the single-agent emergency contraceptive form, is indicated for the prevention of pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse. It is distributed by prescription for patients under 17, and over the counter for those above this age.[L7760] This levonorgestrel-only form of contraception is not indicated for regular contraception and must be taken as soon as possible within 72 hours after intercourse.[A181976,L7760] It has shown a lower efficacy when it is used off label within 96 hours.[T659]



**Long-term contraception or nonemergency contraception**



In addition to the above indication in emergency contraception, levonorgestrel is combined with other contraceptives in contraceptive formulations designed for regular use, for example with ethinyl estradiol.[L7766] It is used in various hormone-releasing intrauterine devices for long-term contraception ranging for a duration of 3-5 years.[L7778,L7781,L7787] Product labeling for Mirena specifically mentions that it is recommended in women who have had at least 1 child and can be indicated for the prevention of pregnancy for up to 8 years.[L7778,L42950] A subdermal implant is also available for the prevention of pregnancy for up to 5 years.[L7823]



**Hormone therapy and off-label uses**



Levonorgestrel is prescribed in combination with estradiol as hormone therapy during menopause to manage vasomotor symptoms and to prevent osteoporosis.[L7805]Off-label, levonorgestrel may be used to treat menorrhagia, endometrial hyperplasia, and endometriosis.[T659]', '**Mechanism of action on ovulation**



Oral contraceptives containing levonorgestrel suppress gonadotropins, inhibiting ovulation. Specifically, levonorgestrel binds to progesterone and androgen receptors and slows the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus. This process results in the suppression of the normal physiological luteinizing hormone (LH) surge that precedes ovulation. It inhibits the rupture of follicles and viable egg release from the ovaries. Levonorgestrel has been proven to be more effective when administered before ovulation.[T659]



**Mechanism of action in cervical mucus changes**



Similar to other levonorgestrel-containing contraceptives, the intrauterine (IUD) forms of levonorgestrel likely prevent pregnancy by increasing the thickness of cervical mucus, interfering with the movement and survival of sperm, and inducing changes in the endometrium, where a fertilized ovum is usually implanted.[L7778,L7781] Levonorgestrel is reported to alter the consistency of mucus in the cervix, which interferes with sperm migration into the uterus for fertilization. Levonorgestrel is not effective after implantation has occurred.[A181976] 

Interestingly, recent evidence has refuted the commonly believed notion that levonorgestrel changes the consistency of cervical mucus when it is taken over a short-term period, as in emergency contraception. Over a long-term period, however, levonorgestrel has been proven to thicken cervical mucus.[A181976] The exact mechanism of action of levonorgestrel is not completely understood and remains a topic of controversy and ongoing investigation.[A181976,L7760]



*Effects on implantation**



The effects of levonorgestrel on endometrial receptivity are unclear, and the relevance of this mechanism to the therapeutic efficacy of levonorgestrel is contentious.[A175372,A218666] Prescribing information for levonorgestrel IUDs state that they exert local morphological changes to the endometrium (e.g. stromal pseudodecidualization, glandular atrophy) that may play a role in their contraceptive activity.[L7778,L7781]



**Mechanism of action in hormone therapy**



When combined with estrogens for the treatment of menopausal symptoms and prevention of osteoporosis, levonorgestrel serves to lower the carcinogenic risk of unopposed estrogen therapy via the inhibition of endometrial proliferation. Unregulated endometrial proliferation sometimes leads to endometrial cancer after estrogen use.[L7808]', 'Levonorgestrel prevents pregnancy by interfering with ovulation, fertilization, and implantation. The levonorgestrel-only containing emergency contraceptive tablet is 89% effective if it is used according to prescribing information within 72 hours after intercourse.[A181976,A181988] The intrauterine and implantable devices releasing levonorgestrel are more than 99% in preventing pregnancy.[A182123,L7778,L7781] Levonorgestrel utilized as a component of hormonal therapy helps to prevent endometrial carcinoma associated with unopposed estrogen administration.[A182042]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Raspberry ketones 100 mg 120 caps. (illegal import)', 25730, 'راسبيري كيتونز 100مجم 120 كبسول مستورد', '0', NULL, 'Weight loss', 'Weight loss', NULL, 'Raspberry ketones', 'Puritans pride', 'Cap', 'كبسولة', '100 mg', '1', NULL, NULL, 'in the last decade scientists took note of the fact that raspberry ketone is molecularly similar to capsaicin. capsaicin is the chemical in chili peppers that gives it heat. as more studies about raspberry ketone are conducted the scientific community is', NULL, 1049, '2022-07-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Avene ultra rich cleansing soap 100 gm', 14726, 'افين الترا ريتش صابونة غسول 100 جرام', '155', NULL, 'Soap', 'Soap', NULL, NULL, 'Pierre - fabre france > biotech egypt', 'Soap', 'صابون', '100 gm', '1', NULL, NULL, 'an extremely gentle ultra-rich cleansing bar perfectly suited to the needs of dry skin. emulsifies with water to produce a milky low foaming cleanser that deeply nourishes skin. avï¿½ne s unique cold cream formula offers intense hydration leaving a film o', NULL, 961, '2022-06-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tranex 500mg 30 tab.', 28397, 'ترانكس 500مجم 30 قرص', '117', '78', 'Bleeding.fibrinolytics inhibitors', 'Bleeding.fibrinolytics inhibitors', NULL, 'Tranexamic acid', 'Egpi', 'Tab', 'أقراص', '500mg', '3', 'حالات النزيف الشديد', NULL, NULL, '6223003932060', 4585, '2024-10-28', NULL, 0, 'Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema,[L31883] cyclic heavy menstrual bleeding in premenopausal females,[L31858] and other instances of significant bleeding in the context of hyperfibrinolysis.[L31883] Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.[L31853]', 'Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage.[L31858]', 'Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin.[L31858] At much higher concentrations it behaves as a noncompetitive inhibitor of plasmin similar to [aminocaproic acid], a similar antifibrinolytic which is 10-fold less potent.[L31883] Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).[A230113] 



Off-target antagonism of GABA(A) receptors may be associated with the development of convulsions and hyperexcitability following tranexamic acid administration[A229383] - the risk appears higher with improper administration or administration during cardiovascular surgery.[L31883] Consider EEG monitoring of patients with a history of seizure.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Arzo comp cream', 10760, 'ارزو كومب كريم', '50', '40', NULL, NULL, NULL, 'Panthenol+olive oil', 'Arz pharma', 'Cream', 'كريم', NULL, '1', NULL, NULL, NULL, NULL, 941, '2024-04-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Furfact 320 mg 7 f.c. tab.', 19483, 'فورفاكت 320مجم 7 اقراص', '80', NULL, 'Antibiotic.quinolone', 'Antibiotic.quinolone', NULL, 'Gemifloxacin', 'Future pharmaceutical industries (fpi) > tabuk pharmaceutical manufacturing company', 'Tab', 'أقراص', '320 mg', '1', NULL, NULL, 'about gemifloxacin fourth-generation fluoroquinolone(respiratory) antibacterial oral broad-spectrum fluoroquinolone antibiotic. mechanism of action of gemifloxacin gemifloxacin act by inhibiting the enzyme dna gyrase (topoisomerase 2) and topoisomerase 4.', NULL, 1084, '2022-07-16', NULL, 0, 'For the treatment of bacterial infection caused by susceptible strains such as <i>S. pneumoniae</i>, <i>H. influenzae</i>, <i>H. parainfluenzae</i>, or <i>M. catarrhalis</i>, <i>S. pneumoniae</i> (including multi-drug resistant strains [MDRSP]), <i>M. pneumoniae</i>, <i>C. pneumoniae</i>, or <i>K. pneumoniae</i>.', 'The bactericidal action of gemifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.', 'Gemifloxacin is a quinolone/fluoroquinolone antibiotic. Gemifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Gemifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Kalmerenda emollient cream 50 gm', 21224, 'كالميريندا كريم ملطف 50 جم', '59', '40', 'Healing topical', 'Healing topical', NULL, 'Propolis+honey+aloe vera+chamomile+calendula+lavender+panthenol+urea+vitamin a+vitamin e+vitamin c+glycerin', 'Cosmopack for cosmetics > infinity pharma for pharmaceuticals', 'Cream', 'كريم', '50 gm', '1', 'كريم ملطف ومرطب للجلد -- حالات التشقق الجلدي', NULL, 'skin healing repairing and protection for burns and wounds emollient.', NULL, 4152, '2023-09-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vividol hair cream 100 gm', 29551, 'فيفيدول كريم شعر 100 جرام', '170', '155', 'Hair care', 'Hair care', NULL, 'Silicon oil+dimethicone+panthenol+tea tree oil+chamomile oil+almond oil+jojoba oil+sunflower oil+eru', 'Macro group pharmaceuticals', 'Cream', 'كريم', '100 gm', '1', 'علاج تساقط الشعر', NULL, 'controls hair loss brittleness and split ends', '6224000437404', 6446, '2025-03-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Atrozemb 40/10mg 30 f.c. tab.', 14599, 'اتروزيمب 40/10مجم 30 قرص', '243', '186', 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', NULL, 'Atorvastatin+ezetimibe', 'Liptis', 'Tab', 'أقراص', '10mg', '3', NULL, NULL, NULL, '6224007706435', 2396, '2024-12-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Genvical calcium chocolate 20 soft chews pieces', 19740, 'جينفيكال كالسيوم شوكولاتة 20 قطعة', '50', NULL, 'Calcium supplement', 'Calcium supplement', NULL, 'Calcium+vitamin d3+magnesium', 'Family pharmacia > vamira pharmaceuticals', 'Piece', 'قطعة', NULL, '2', NULL, NULL, NULL, NULL, 853, '2022-08-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Biluron 50 mg 28 f.c.tabs.(n/a yet)', 30186, 'بيلورون 50مجم 28 قرص', '570', '432', 'Antineoplastic', 'Antineoplastic', NULL, 'Bicalutamide', 'Synthon hispania s.l. > aboukir trading', 'Tab', 'أقراص', '50 mg', '4', NULL, NULL, 'about bicalutamide non steroidal anti estrogen anti neoplastic. mechanism of action of bicalutamide this antiandrogenic drug binds to the receptor of androgens on the cells of prostate gland. thus it blocks the action of androgen on prostate gland and pre', NULL, 1234, '2025-05-02', NULL, 0, 'Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.[L40478]', 'Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.', 'Bicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hessta 50 mg cream', 30648, 'هيستا كريم 50 جم', '80', NULL, 'Healing and moisturizer cream', 'Healing and moisturizer cream', NULL, 'Beta sitosterol+beeswax+calendula ex.+triclosan+alpha bisabolol+alpha pinene', 'Cosmopack > master pharm', 'Cream', 'كريم', '50 mg', '1', NULL, NULL, NULL, NULL, 484, '2023-05-04', NULL, 0, 'Beta-carotene is FDA approved to be used as a nutrient supplement and to be even added in infant formula as a source of vitamin A.[L2191] It is also approved to be used as a color additive for food products,[L2192] drugs (with the label of "only as a color additive")[L2193] and cosmetics.[L2194]



It is used commonly for the reduction of photosensitivity in patients with erythropoietic protoporphyria and other photosensitivity diseases.[A32485]', 'Beta-carotene is an antioxidant that presents significant efficacy against the reactive oxygen species singlet oxygen.[T159] Beta-carotene acts as a scavenger of lipophilic radicals within the membranes of every cell compartments. It also presents an oxidative modification of LDL.[T160] The presence of long chains of conjugated double bonds is responsible for its antioxidative properties by allowing beta-carotene to chelate oxygen-free radicals and dissipate their energy.[T162] The chelation of free radicals inhibits the peroxidation of lipids.[T163]



The effect of beta-carotene in the immune response is thought to be related to the direct effect on the thymus which increases the production of immune cells.[L2202]', 'Oral administration of beta-carotene increases the serum concentration of beta-carotene by 60% but it does not change the concentration found in the heart, liver or kidneys.[T159] In vitro studies in hepatocytes have shown that beta-carotene ameliorates oxidative stress, enhances antioxidant activity and decreases apoptosis.[T161]



Other than the antioxidant activities, some other actions have been correlated to beta-carotene. It is thought to have detoxifying properties, as well as to help increase resistance to inflammation and infection and increase immune response and enhance RNA production.[L2202]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Postine-s syrup 120ml', 25072, 'بوستين اس شراب 120مل', '5', NULL, 'Digestive enzymes', 'Digestive enzymes', NULL, 'Amylocaine+diastase+papain+pepsin', 'Alexandria', 'Syrup', 'شراب', '120ml', '1', NULL, NULL, NULL, '6223000171936', 926, '2022-12-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Calcybox syrup 120 ml', 32231, 'كالسيبوكس شراب 120 مل', '98', '78', 'Calcium supplement', 'Calcium supplement', NULL, 'Calcium+zinc+magnesium+vitamin d3+vitamin k1+vitamin k2', 'Pharmazad > biohealth company for medicines', 'Syrup', 'شراب', '120 ml', '1', 'مكمل غذائى يساعد على نمو العظام الطبيعى ويمنع هشاشة ولين العظام', NULL, NULL, NULL, 4042, '2025-08-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Aspo nasr 300mg 200 tab.', 14490, 'اسبو نصر 300 مجم 200 قرص', '14', NULL, 'Nsaid.salicylates', 'Nsaid.salicylates', NULL, 'Acetylsalicylic acid', 'El nasr', 'Tab', 'أقراص', '300mg', '10', NULL, NULL, 'description: belongs to a group of medicines called non-steroidal anti-inflammatory drugs (nsaids) indication: mild to moderate pain including headache migraine nerve pain (neuralgia) toothache sore throat period pain. relieving aches pains and fever asso', NULL, 1010, '2022-07-20', NULL, 0, '**Pain, fever, and inflammation**



Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures [FDA label]. 



The _extra strength_ formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound)[FDA label].



**Other indications**



ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include: 



Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) [FDA label]. 



Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction [FDA label].



For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) [FDA label].



For the prevention of thromboembolism after hip replacement surgery [FDA label]. 



For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) [FDA label].



Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site [FDA Label]. 



**Important note regarding use of the extended-release formulation [F4405]**



In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action [Label, F4405]. The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA [F4405].





 ', 'Acetylsalicylic acid (ASA) blocks prostaglandin synthesis. It is non-selective for COX-1 and COX-2 enzymes [A177241, A10989, A32682]. Inhibition of COX-1 results in the inhibition of platelet aggregation for about 7-10 days (average platelet lifespan). The acetyl group of acetylsalicylic acid binds with a serine residue of the cyclooxygenase-1 (COX-1) enzyme, leading to irreversible inhibition. This prevents the production of pain-causing prostaglandins. This process also stops the conversion of arachidonic acid to thromboxane A2 (TXA2), which is a potent inducer of platelet aggregation [FDA label].  Platelet aggregation can result in clots and harmful venous and arterial thromboembolism, leading to conditions such as pulmonary embolism and stroke. 



It is important to note that there is 60% homology between the protein structures of COX-1 and COX-2. ASA binds to serine 516 residue on the active site of COX-2 in the same fashion as its binding to the serine 530 residue located on the active site of COX-1. The active site of COX-2 is, however, slightly larger than the active site of COX-1, so that arachidonic acid (which later becomes prostaglandins) manages to bypass the aspirin molecule inactivating COX-2 [A32682, A177256].  ASA, therefore, exerts more action on the COX-1 receptor rather than on the COX-2 receptor [A177268]. A higher dose of acetylsalicylic acid is required for COX-2 inhibition [A177325]. ', '**Effects on pain and fever**



Acetylsalicylic acid disrupts the production of prostaglandins throughout the body by targeting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) [A177241, A10989, A32682]. Prostaglandins are potent, irritating substances that have been shown to cause headaches and pain upon injection into humans.  Prostaglandins increase the sensitivity of pain receptors and substances such as histamine and bradykinin. Through the disruption of the production and prevention of release of prostaglandins in inflammation, this drug may stop their action at pain receptors, preventing symptoms of pain. Acetylsalicylic acid is considered an antipyretic agent because of its ability to interfere with the production of brain prostaglandin E1. Prostaglandin E1 is known to be an extremely powerful fever-inducing agent [FDA label]. 



**Effects on platelet aggregation**



The inhibition of platelet aggregation by ASA occurs because of its interference with thromboxane A2 in platelets, caused by COX-1 inhibition. Thromboxane A2 is an important lipid responsible for platelet aggregation, which can lead to clot formation and future risk of heart attack or stroke  [FDA label]. 



**A note on cancer prevention**



ASA has been studied in recent years to determine its effect on the prevention of various malignancies [A177325]. In general, acetylsalicylic acid is involved in the interference of various cancer signaling pathways, sometimes inducing or upregulating tumor suppressor genes [A177325, A177403]. Results of various studies suggest that there are beneficial effects of long-term ASA use in the prevention of several types of cancer, including stomach, colorectal, pancreatic, and liver cancers [A177400].   Research is ongoing.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Probo-zone drops 15 ml', 4782, 'بروبو-زون نقط 15 مل', '105', '89', 'Dietary supplement', 'Dietary supplement', NULL, 'Probiotic', 'Egypt international', 'Drops', 'نقط', '15 ml', '1', NULL, NULL, NULL, '6224002280091', 1329, '2025-07-17', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Centrum forte 100 tab ( imported)', 2329, 'سنترم فورت 100 قرص استيراد', '120', NULL, 'Multivitamins', 'Multivitamins', NULL, 'Multivitamins', 'Pfizer', 'Tab', 'أقراص', NULL, '10', NULL, NULL, NULL, '5054563994011', 2034, '2022-09-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Phara fero 27 plus - 20 chocolate pills', 24783, 'فرافيرو 27 بلس 20 كبسولة', '185', '185', 'Iron supplement', 'Iron supplement', NULL, 'Lactoferrin+amino acids chelated minerals with vitamins', 'Delta pharma > devartlab pharma', 'Unknown', 'غير محدد', NULL, '1', NULL, NULL, NULL, '6223006935129', 4419, '2025-01-21', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Avene cold cream for hands 75 ml', 14694, 'افين كولد كريم لليدين 75 مل', '235', '189', 'Skin care', 'Skin care', NULL, NULL, 'Pierre - fabre france > biotech egypt', 'Cream', 'كريم', '75 ml', '1', NULL, NULL, 'rich non-greasy hand cream that nourishes and helps repair dry cracked hands and nails. clinically proven to last through six hand washings this premium hand cream offers long-lasting moisture. paraben-free. ï¿½ nourishing and hydrating formula ï¿½ new en', '3282779026161', 846, '2023-09-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lintovic 14 tabs', 32200, 'لينتوفيك 14 قرص', '50', NULL, 'Mulivitamin', 'Mulivitamin', NULL, 'Selenium+vitamin a+e+c', 'Amcomed > galaxo', 'Tab', 'أقراص', NULL, '1', NULL, NULL, NULL, NULL, 608, '2023-04-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lipinorm 10 mg 7 f.c.tab.', 7355, 'ليبينورم 10 مجم 7 اقراص', '28', '21', 'Antihyperlipidemic.statins', 'Antihyperlipidemic.statins', NULL, 'Atorvastatin', 'Mup', 'Tab', 'أقراص', '10 mg', '1', 'يعمل على خفض الدهون والكوليسترول بالجسم', NULL, NULL, '6221508511919', 1605, '2025-06-03', NULL, 0, 'Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.[A177397]



Dyslipidemia describes an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.[L6025] 



Atorvastatin is indicated, in combination with dietary modifications, to prevent cardiovascular events in patients with cardiac risk factors and/or abnormal lipid profiles.[A177397]



Atorvastatin can be used as a preventive agent for myocardial infarction, stroke, revascularization, and angina, in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factors.[A177397]



Atorvastatin may be used as a preventive agent for non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure and angina in patients with coronary heart disease.[A177397]



Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]', 'Atorvastatin is a statin medication and a competitive inhibitor of the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.[A177388,A181421] Atorvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low-density lipoprotein (LDL) receptors, which increases hepatic uptake of LDL. Atorvastatin also reduces Very-Low-Density Lipoprotein-Cholesterol (VLDL-C), serum triglycerides (TG) and Intermediate Density Lipoproteins (IDL), as well as the number of apolipoprotein B (apo B) containing particles, but increases High-Density Lipoprotein Cholesterol (HDL-C). 



_In vitro_ and _in vivo_ animal studies also demonstrate that atorvastatin exerts vasculoprotective effects independent of its lipid-lowering properties, also known as the pleiotropic effects of statins.[A181424] These effects include improvement in endothelial function, enhanced stability of atherosclerotic plaques, reduced oxidative stress and inflammation, and inhibition of the thrombogenic response. Statins were also found to bind allosterically to β2 integrin function-associated antigen-1 (LFA-1), which plays an essential role in leukocyte trafficking and T cell activation.[A181559]', 'Atorvastatin is an oral antilipemic agent that reversibly inhibits HMG-CoA reductase. It lowers total cholesterol, low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), non-high density lipoprotein-cholesterol (non-HDL-C), and triglyceride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease, and high ratios are associated with a higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality.[A174580,A181087,A181406,A181925] 



Elevated cholesterol levels (and high low-density lipoprotein (LDL) levels in particular) are an important risk factor for the development of CVD.[A181087] Clinical studies have shown that atorvastatin reduces LDL-C and total cholesterol by 36-53%.[A177415] In patients with dysbetalipoproteinemia, atorvastatin reduced the levels of intermediate-density lipoprotein cholesterol.[A177397] It has also been suggested that atorvastatin can limit the extent of angiogenesis, which can be useful in the treatment of chronic subdural hematoma.[A177388]



**Myopathy/Rhabdomyolysis**



Atorvastatin, like other HMG-CoA reductase inhibitors, is associated with a risk of drug-induced myopathy characterized by muscle pain, tenderness, or weakness in conjunction with elevated levels of creatine kinase (CK). Myopathy often manifests as rhabdomyolysis with or without acute renal failure secondary to myoglobinuria. The risk of statin-induced myopathy is dose-related, and the symptoms of myopathy are typically resolved upon drug discontinuation. Results from observational studies suggest that 10-15% of people taking statins may experience muscle aches at some point during treatment.[A182258]



**Liver Dysfunction**



Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (> 3 times the upper limit of normal [ULN] occurring on two or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials. This effect appears to be dose-related.[F4670,F4673]



**Endocrine Effects**



Statins are associated with a risk of increased serum HbA1c and glucose levels. An _in vitro_ study demonstrated a dose-dependent cytotoxic effect on human pancreatic islet β cells following treatment with atorvastatin. Moreover, insulin secretion rates decreased relative to control.[A182012]



HMG-CoA reductase inhibitors interfere with cholesterol synthesis and may theoretically interfere with the production of adrenal and/or gonadal steroids. Clinical studies with atorvastatin and other HMG-CoA reductase inhibitors have suggested that these agents do not affect plasma cortisol concentrations, basal plasma testosterone concentration, or adrenal reserve. However, the effect of statins on male fertility has not been fully investigated. The effects of statins on the pituitary-gonadal axis in premenopausal women are unknown.[F4673]



**Cardiovascular**



Significant decreases in circulating ubiquinone levels in patients treated with atorvastatin and other statins have been observed. The clinical significance of a potential long-term statin-induced deficiency of ubiquinone has not been established. It has been reported that a decrease in myocardial ubiquinone levels could lead to impaired cardiac function in patients with borderline congestive heart failure.[F4673]



**Lipoprotein A**



In some patients, the beneficial effect of lowered total cholesterol and LDL-C levels may be partly blunted by the concomitant increase in Lp(a) lipoprotein concentrations. Present knowledge suggests the importance of high Lp(a) levels as an emerging risk factor for coronary heart disease.[F4673] Further studies have demonstrated statins affect Lp(a) levels differently in patients with dyslipidemia depending on their apo(a) phenotype; statins increase Lp(a) levels exclusively in patients with the low molecular weight apo(a) phenotype.[A181418]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Marleoce shampoo 150 ml', 22307, 'مارليوس شامبو 150 مل', '195', '175', 'Hair care', 'Hair care', NULL, 'Coal tar+zinc pyrithion+tea tree oil+caffeine+silicon oil+panthenol+aloe vera+vitamin e', 'El-helou perfumes & cosmetics > master care pharma', 'Amp', 'أمبول', '150 ml', '1', 'للعناية بالشعر', NULL, NULL, NULL, 6756, '2025-05-30', NULL, 0, 'Relieving itching, irritation, redness, dryness, scaling, and flaking of the skin caused by psoriasis, seborrhea, or eczema. ', 'Coal tar ointment is a keratolytic. It works by slowing bacterial growth and loosening and softening scales and crust.', 'Decrease bacterial growth. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ectomethrin 5% lotion 50 ml', 3993, 'اكتومثرين 5% لوسيون 50 مل', '55', '37', 'Scabicide', 'Scabicide', NULL, 'Permethrin', 'Misr > apc (arab perfumes chemicals and pharmaceutical co.)', 'Lotion', 'لوشن', '5%', '1', 'مضاد للهرش والحكة والجرب', NULL, 'about permethrin synthetic pyrethroid antiparasitic pediculicide scabicide. mechanism of action of permethrin permethrin exerts its action by inhibiting sodium ion channel and delays depolarization. this will leads to (neuronal) paralysis of insects. perm', '6224009656073', 26738, '2024-06-10', NULL, 0, 'For the treatment of infestation with <i>Sarcoptes scabiei</i> (scabies).', 'Permethrin acts on the nerve cell membrane to disrupt the sodium channel current by which the polarization of the membrane is regulated. Delayed repolarization and paralysis of the pests are the consequences of this disturbance.', 'Permethrin, a pyrethroid, is active against a broad range of pests including lice, ticks, fleas, mites, and other arthropods.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Becozym syrup 125 ml', 1355, 'بيكوزيم شراب 125 مل', '4', NULL, NULL, NULL, NULL, 'Vitamin b complex', 'Bayer consumer care seitzerland > bayer healthcare', 'Syrup', 'شراب', '125 ml', '1', NULL, NULL, NULL, NULL, 2104, '2023-01-05', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Oxaleptal 600mg 30 f.c. tabs.', 9475, 'اوكساليبتال 600مجم 30 قرص', '303', '231', 'Anti-epileptic.carboxamides', 'Anti-epileptic.carboxamides', NULL, 'Oxcarbazepine', 'Mash premiere', 'Tab', 'أقراص', '600mg', '3', 'علاج الصرع -- تقليل التشنجات الناتجة عن الصرع', NULL, NULL, '6222001406764', 4042, '2024-07-10', NULL, 0, 'In the United States, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.[L8627] 



In Canada, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in patients 6 years of age and older.[L8630]', 'The exact mechanism through which oxcarbazepine and its active metaoblite, MHD, exert their anti-epileptic effects is unclear, but is thought to primarily involve the blockade of voltage-gated sodium channels.[L8627,L8630,L8633,A186104] The opening and closing of sodium channels allows for the propagation of action potentials along neurons - in epilepsy, these action potentials can occur in excess of that required for normal function, and the repetitive and pathological firing of these action potentials leads to seizure activity. Both oxcarbazepine and MHD are thought to inhibit seizure activity by binding to the inactive state of voltage-gated sodium channels, thus prolonging the period in which the receptor is unavailable for action potential propagation.[A186101] This helps to stabilize hyperexcited neuronal membranes, inhibit repetitive neuron firing, and prevent the spread of seizure activity within the CNS without affecting normal neuronal transmission.[L8627,L8630,L8633]



Increased potassium conductance and modulation of voltage-activated calcium channels is also thought to play a role in the anti-seizure activity of oxcarbazepine.[L8627,L8630,L8633] Inhibition of glutamatergic activity was thought to contribute to oxcarbazepine''s activity[A34516], but this effect could not be replicated _in vivo_.[A186104]', 'Oxcarbazepine is an anticonvulsant drug that reduces the incidence of seizures in epilepsy by inhibiting abnormal electrical activity in the brain.[L8627,L8630,L8633]



There have been rare reports of oxcarbazepine resulting in the development of hematologic abnormalities, including agranulocytosis and aplastic anemia. Patients should be undergo frequent laboratory testing and should be monitored closely for signs and symptoms of blood dyscrasias. Oxcarbazepine has also been associated with the development of dermatologic reactions which can progress from a simple rash to potentially fatal reactions such as toxic epidermal necrolysis (TEN) or Stevens-Johnson Syndrome (SJS). Patients with the HLA-A 3101 and/or HLA-B 1502 alleles may be at higher risk of this reaction. Oxcarbazepine should be discontinued at the first sign of a drug-induced skin reaction.[L8627,L8630,L8633]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Apigent-p eye/ear drops 5 ml', 862, 'ابيجينت-بي نقط عين/اذن 5 مل', '7', NULL, 'Antibiotic with glucocorticoid', 'Antibiotic with glucocorticoid', NULL, 'Gentamicin+prednisolone', 'Amoun', 'Drops', 'نقط', '5 ml', '1', NULL, NULL, 'about gentamicin aminoglycoside antibiotic. mechanism of action of gentamicin gentamicin exerts its bactericidal action against gram negative organisms & some of gram positive organisms by inhibiting bacterial protein synthesis. the process involves 1. pe', '6221025002976', 958, '2022-12-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Aspegic 6 vial', 1016, 'اسبجيك 6 فيال', '18', NULL, 'Nsaid', 'Nsaid', NULL, 'Glycine+lysine acetylsalicylate', 'Amriya > sanofi aventis', 'Vial', 'فيال', NULL, '6', 'مسكن للألم -- خافض للحرارة', NULL, NULL, '6221075070048', 1614, '2022-12-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ecrinal strenthening eyelashes gel 8ml', 18055, 'اكرينال جل مقوي للرموش 8 مل', '350', NULL, NULL, NULL, NULL, NULL, 'Asepta laboratoires > biotech egypt', 'Gel', 'جل', '8ml', '1', NULL, NULL, 'this gel makes eyelashes and eyebrows nicer and help strengthen and stimulate re-growth. totally invisible. can be used as a night treatment. (anpï¿½ castor oil)', NULL, 733, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lezberg trio 40/5/12.5mg 30 f.c.tabs.', 31006, 'ليزبيرج تريو 40/5/12.5مجم 30 قرص', '144', '108', 'Anti-hypertensive.combined angiotensin blocker & ca++ channel blocker & diuretic', 'Anti-hypertensive.combined angiotensin blocker & ca++ channel blocker & diuretic', NULL, 'Amlodipine+olmesartan+hydrochlorothiazide', 'Global advanced pharmaceuticals (gap)', 'Tab', 'أقراص', '12.5mg', '3', NULL, NULL, NULL, '6223005941305', 679, '2024-08-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Curam 228.5mg/5ml pd. for oral susp. 75ml', 16944, 'كيورام 228.5مجم/5مل معلق 75 مل', '31', NULL, 'Penicillins.penicillin with b-lactamase inhibitor', 'Penicillins.penicillin with b-lactamase inhibitor', NULL, 'Amoxicillin+clavulanic acid', 'Pharco > novartis', 'Susp', 'معلق', '228.5mg', '1', NULL, NULL, 'amoxicillin is an analog of ampicillin derived from the basic penicillin nucleus 6-aminopenicillanic acid clavulanic acid is produced by the fermentation of streptomyces clavuligerus. it is a beta-lactam structurally related to the penicillins and possess', '6223002642342', 1033, '2022-12-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ebixa 10mg 28 f.c. tab.', 18026, 'ابيكسا 10 مجم 28 قرص', '475', '362.5', 'Dopamine d2 agonist', 'Dopamine d2 agonist', NULL, 'Memantine', 'Lundbeck > multipharma', 'Tab', 'أقراص', '10mg', '2', 'حالات الزهايمر -- حالات الخرف في كبار السن -- يؤخذ تحت اشراف طبي', NULL, 'about memantine n-methyl-d-aspartate receptor antagonist dopamine d2 agonist antidementia agent in alzheimer`s disease. mechanism of action of memantine memantine in an uncompetitive (low to moderate affinity to) nmda (n-methyl-d-aspartate) receptor antag', '5702150146069', 2953, '2024-08-24', NULL, 0, 'Memantine is used to manage moderate to severe Alzheimer''s dementia [FDA label]. 



A more recent systemic review and meta-analysis [A177106] indicates that memantine is beneficial as a first line drug for the treatment of Alzheimer''s dementia.  Cholinesterase inhibitors may be added to memantine for further beneficial effects on behavioral symptoms and other symptoms of dementia [A177106].', 'Continuous activation of the N-methyl-D-aspartate (NMDA) receptors in the central nervous system caused by _glutamate_ is thought to cause some of the Alzheimer''s disease symptoms. This overactivation is thought to contribute to neurotoxicity due to the excitatory properties of glutamate [T556]. The pharmacological effect of memantine likely occurs via the drug''s behavior as an uncompetitive (open-channel) NMDA receptor antagonist, preventing glutamate action on this receptor.  Memantine has a preference for the NMDA receptor-operated cation channels. Despite these antagonist effects, memantine has not been proven to prevent or retard the neurodegeneration seen in patients diagnosed with Alzheimer’s disease [FDA label].', '**General effects**



This drug inhibits calcium influx into cells that is normally caused by chronic NMDA receptor activation by glutamate [A1640]. This leads to the improvement of Alzheimer''s dementia symptoms, demonstrated by increased cognition and other beneficial central nervous system effects [A1640]. 



**Effects on neuroplasticity**



Like other NMDA receptor antagonists, memantine at high doses can reduce neuronal synaptic plasticity that is involved in learning and memory processes. At lower concentrations, which are normally used in the clinical setting, memantine can enhance neuronal synaptic plasticity in the brain, improve memory, and act as a neuroprotectant against the destruction of neurons caused by excitatory neurotransmitters [A1639]. 



**Effect on various receptors**



Memantine has demonstrated minimal activity for GABA, benzodiazepine, dopamine, adrenergic, histamine, and glycine receptors, as well as voltage-dependent Ca2+, Na+ or K+ channels. This drug has shown antagonist activity at the 5HT3 receptors. Laboratory studies suggest that memantine does not affect the reversible inhibition of the acetylcholinesterase normally caused by donepezil, galantamine, or tacrine [FDA label].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cordalen 100 ml oil spray', 20109, 'كوردالين اويل سبراي 100 مل', '100', '80', 'Massage oil spray', 'Massage oil spray', NULL, 'Paraffinium liquidum+clove oil+menthol+pepperment oil+thyme extract+cinnamon oil+apri oil+jasmin oil+pomegranate oil+canola oil+camphor+bha+eucalyptus oil+isopropyl alcohol', 'Bme pharma', 'Spray', 'بخاخ', '100 ml', '1', NULL, NULL, NULL, NULL, 1071, '2025-08-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Argento night cream 30 gm', 14379, 'ارجنتو نايت كريم 30 جم', '119', '105', 'Healing topical', 'Healing topical', NULL, 'Collagen+caffeine+liquorice ext+green tea ext+wheat germ oil+almond oil+chamomlie ext+glycolic acid', 'Hi-catr > alba pharma', 'Cream', 'كريم', '30 gm', '1', NULL, NULL, 'firming - moisturizing - skin nourishing - skin rejuvenation ** ingredients: collagen + caffeine + liquorice extract + green tea extract + wheat germ oil + almond oil + chamomlie extract + glycolic acid + panthenol + hyaluronic acid + glycerine + royal je', NULL, 972, '2025-04-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Prontogest 50mg/ml 5 i.m. amp', 4504, 'برونتوجيست 50 مجم/مل 5 امبولات', '85', NULL, 'Progesterone supplement', 'Progesterone supplement', NULL, 'Progesterone', 'Marcyrl pharmaceutical industries (mpi)', 'Amp', 'أمبول', '50mg', '5', NULL, NULL, NULL, NULL, 897, '2025-06-17', NULL, 0, '**Gelatinized capsules**



The gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea [FDA label]. 



**Vaginal gel**



Progesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (“ART”) treatment for infertile women with progesterone deficiency.  The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel [F3898].



**Vaginal insert**



This form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women [F3901].



**Injection (intramuscular)**



This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer [F3907]. 



**Tablets, contraceptive**



The tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy [F3904]. ', 'Progesterone binds and activates its nuclear receptor, _PR_, which plays an important part in the signaling of stimuli that maintain the endometrium during its preparation for pregnancy.



Progesterone receptor (PR) is a member of the nuclear/steroid hormone receptor (SHR) family of ligand-dependent transcription factors that is expressed primarily in female reproductive tissue as well as the central nervous system. As a result of its binding its associated steroid hormone, progesterone, the progesterone receptor (PR) modulates the expression of genes that regulate the development, differentiation, and proliferation of target tissues [A175666]. In humans, PR is found to be highly expressed in the stromal (connective tissue) cells during the secretory phase and during pregnancy [A175651]. 



Progesterone may prevent pregnancy by changing the consistency of cervical mucus to be unfavorable for sperm penetration, and by inhibiting follicle-stimulating hormone (FSH), which normally causes ovulation.  With perfect use, the first-year failure rate for progestin-only oral contraceptives is approximately 0.5%. The typical failure rate, however, is estimated to be approximately 5%, due to late or missed pills [F3904].', 'Progesterone, depending on concentration and dosage form, and timing of exposure may have several pharmacodynamic effects.  These actions, according, to various preparations, are listed below:



General effects



Progesterone is the main hormone of the corpus luteum and the placenta. It acts on the uterus by changing the proliferative phase to the secretory phase of the endometrium (inner mucous lining of the uterus).   This hormone, stimulated by a hormone called _luteinizing hormone_ (LH) is the main hormone during the secretory phase to prepare the corpus luteum and the endometrium for implantation of a fertilized ovum. As the luteal phase concludes, the progesterone hormone sends negative feedback to the anterior pituitary gland in the brain to decrease FSH (follicle stimulating hormone) and LH (luteinizing hormone) levels. This prevents ovulation and maturation of oocytes (immature egg cells). The endometrium then prepares for pregnancy by increasing its vascularity (blood vessels) and stimulating mucous secretion. This process occurs by progesterone stimulating the endometrium to decrease endometrial proliferation, leading to a decreased uterine lining thickness, developing more complex uterine glands, collecting energy in the form of glycogen, and providing more uterine blood vessel surface area suitable for supporting a growing embryo. As opposed to cervical mucous changes observed during the proliferative phase and ovulation, progesterone decreases and thickens the cervical mucus, rendering it less elastic. This change occurs because the fertilization time period has passed, and a specific consistency of mucous amenable to sperm entry is no longer required [T490].



**Gelatinized capsules**



Progesterone capsules are an oral dosage form of micronized progesterone which, chemically identical to progesterone of ovarian origin. Progesterone capsules have all the properties of endogenous progesterone with induction of a secretory phase endometrium with gestagenic, antiestrogenic, slightly antiandrogenic and anti-aldosterone effects [F3913]. Progesterone opposes the effects of estrogen on the uterus, and is beneficial in women with unopposed estrogen exposure, which carries an increased risk of malignancy [F3913].





**Vaginal gel and vaginal insert**



 The gel preparation mimics the effects of naturally occurring progesterone. In the presence of adequate levels of estrogen, progesterone converts a proliferative endometrium into secretory endometrium. This means that the endometrium changes from a growing and thickening stage into a subsequent preparation stage for pregnancy, which involves further preparatory changes. Progesterone is necessary for the development of decidual tissue (specialized tissue amenable to supporting a possible pregnancy). Progesterone is required to increase endometrial receptivity for the implantation of a fertilized embryo. Once an embryo is implanted, progesterone helps to maintain the pregnancy [F3898]. 





**Injection (intramuscular)**



 Intramuscularly injected progesterone increases serum progesterone and aids in the prevention of endometrial tissue overgrowth due to unopposed estrogen (which leads to abnormal uterine bleeding and sometimes uterine cancer) [L5638], [F3916]. In the absence or deficiency of progesterone, the endometrium continually proliferates, eventually outgrowing its limited blood supply, shedding incompletely, and leading to abnormal and/or profuse bleeding as well as malignancy [L5638].



**Tablets, contraceptive**



Progesterone-only contraceptive tablets prevent conception by suppressing ovulation in about half of users, causing a thickening of cervical mucus to inhibit sperm movement, lowering the midcycle LH and FSH hormone peaks, slowing the movement of the ovum through the fallopian tubes, and causing secretory changes in the endometrium as described above [F3904].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Alergaway 5 mg 20 oral disinteg. tabs.', 13669, 'الرجاواي 5 مجم 20 قرص', '36', NULL, 'Antihistamine.antiallergy', 'Antihistamine.antiallergy', NULL, 'Desloratadine', 'Egpi > jasper for pharmaceutical industries', 'Tab', 'أقراص', '5 mg', '2', 'مضاد للحساسية', NULL, 'about desloratadine second generation long-acting tricyclic h1 antagonist antihistamine. mechanism of action of desloratadine this second generation antihistamine has a selective peripheral h1-antagonist action.desloratadine competes with free histamine f', NULL, 1183, '2022-05-30', NULL, 0, 'For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.', 'Like other H1-blockers, Desloratadine competes with free histamine for binding at H<sub>1</sub>-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine.', 'Desloratadine is a long-acting second-generation H<sub>1</sub>-receptor antagonist which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated," releasing other chemicals which produce the effects that we associate with allergies. Desloratadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Desloratadine does not enter the brain from the blood and, therefore, does not cause drowsiness.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tizyl 4mg 10 tab.', 28231, 'تايزيل 4مجم 10 اقراص', '12', NULL, 'Cns.analgesic.skeletal muscle relaxant.alpha2 agonist', 'Cns.analgesic.skeletal muscle relaxant.alpha2 agonist', NULL, 'Tizanidine', 'October pharma > pharmagin-egypt', 'Tab', 'أقراص', '4mg', '1', NULL, NULL, 'about tizanidine a centrally acting a-2 adrenergic agonist centrally acting muscle relaxant (short-acting). mechanism of action of tizanidine this drug is a centrally acting alpha2 agonist at alpha2-adrenergic receptor sites and presumably reduces spastic', '6221088010758', 997, '2022-12-13', NULL, 0, 'Tizanidine is indicated for the relief of muscle spasticity, which can interfere with daily activities.  The general recommendation is to reserve tizanidine use for periods of time when there is a particular need for relief, as it has a short duration of action [FDA label, F4471]. ', 'Tizanidine reduces spasticity by causing presynaptic inhibition of motor neurons via agonist actions at Alpha-2 adrenergic receptor sites.

This drug is centrally acting and leads to a reduction in the release of excitatory amino acids like glutamate and aspartate, which cause neuronal firing that leads to muscle spasm. The above reduction and excitatory neurotransmitter release results in presynaptic inhibition of motor neurons. The strongest effect of tizanidine has been shown to occur on spinal polysynaptic pathways.   The anti-nociceptive and anticonvulsant activities of tizanidine may also be attributed to agonist action on Alpha-2 receptors.  Tizanidine also binds with weaker affinity to the Alpha-1 receptors, explaining its slight and temporary effect on the cardiovascular system [T574]. ', '**A note on spasticity**



Spasticity is an increase in muscle accompanied by uncontrolled, repetitive contractions of skeletal muscles which are involuntary.

The patient suffering from muscle spasticity may have reduced mobility and high levels of pain, contributing to poor quality of life and problems performing activities of personal hygiene and care [A177640]. 



**General effects**



Tizanidine is a rapidly acting drug used for the relief of muscle spasticity when it is required for performing specific activities. It acts as an agonist at Alpha-2 adrenergic receptor sites and relieves symptoms of muscle spasticity, allowing the continuation of normal daily activities. In animal models, tizanidine has not been shown to exert direct effects on skeletal muscle fibers or the neuromuscular junction, and has shown no significant effect on monosynaptic spinal reflexes (consisting of the communication between only 1 sensory neuron and 1 motor neuron) [L6064]. The frequency of muscle spasm and clonus are shown to be decreased by tizanidine [T574]. Tizanidine shows a stronger action on polysynaptic reflexes, which involve several interneurons (relay neurons) communicating with motor neurons stimulating muscle movement [L6064].



**Effects on blood pressure and heart rate**



This drug decreases heart rate and blood pressure in humans [A177559, A177589].  Despite this, rebound hypertension and tachycardia along with increased spasticity can occur when tizanidine is abruptly discontinued [A177643]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Haemofarin 1mg 100 tab.', 20164, 'هيموفارين 1مجم 100 قرص', '6', NULL, 'Anticoagulant.clotting factors activation inhibitors', 'Anticoagulant.clotting factors activation inhibitors', NULL, 'Warfarin', 'El nasr', 'Tab', 'أقراص', '1mg', '1', NULL, NULL, 'about warfarin synthetic coumarin derivative vitamin k antagonist anticoagulant. mechanism of action of warfarin it exerts it`s pharmacological action by inhibiting regeneration of active hydroquinone from vitamin k and also behaves as a competitive antag', NULL, 828, '2022-10-29', NULL, 0, '**Indicated** for:[label,L6616]



1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.



2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.



3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.



4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.



**Off-label** uses include:



1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.[A179182]', 'Warfarin is a [vitamin K] antagonist which acts to inhibit the production of vitamin K by vitamin K epoxide reductase.[label,A179221,T116] The reduced form of vitamin K, vitamin KH<sub>2</sub> is a cofactor used in the γ-carboxylation of coagulation factors VII, IX, X, and thrombin. Carboxylation induces a conformational change allowing the factors to bind Ca<sup>2+</sup> and to phospholipid surfaces. Uncarboxylated factors VII, IX, X, and thrombin are biologically inactive and therefore serve to interrupt the coagulation cascade. The endogenous anticoagulation proteins C and S also require  γ-carboxylation to function. This is particularly true in the case of thrombin which must be activated in order to form a thrombus. vitamin KH<sub>2</sub> is converted to vitamin K epoxide as part of the γ-carboxylation reaction catalyzed by γ-glutamyl carboxylase. Vitamin K epoxide is then converted to vitamin K<sub>1</sub> by vitamin K epoxide reductase then back to vitamin KH<sub>2</sub> by vitamin K reductase. Warfarin binds to vitamin K epoxide reductase complex subunit 1 and irreversibly inhibits the enzyme thereby stopping the recycling of vitamin K by preventing the conversion of vitamin K epoxide to vitamin K<sub>1</sub>. This process creates a hypercoagulable state for a short time as proteins C and S degrade first with half lives of 8 and 24 hours, with the exception of factor VII which has a half life of 6 hours.[A179221] Factors IX, X, and finally thrombin degrade later with half lives of 24, 36, and 50 hours resulting in a dominant anticoagulation effect.[A179221] In order to reverse this anticoagulation vitamin K must be supplied, either exogenously or by removal of the vitamin K epoxide reductase inhibition, and time allowed for new coagulation factors to be synthesized.[label,A179221,T116] It takes approximately 2 days for new coagulation factors to be synthesized in the liver. Vitamin K<sub>2</sub>, functionally identical to vitamin K<sub>1</sub>, is synthesized by gut bacteria leading to interactions with antibiotics as elimination of these bacteria can reduce vitamin K<sub>2</sub supply and result in a greater anticoagulation effect.[T116]', 'Warfarin is an anticoagulant, as such it disrupts the coagulation cascade to reduce frequency and extent of thrombus formation.[label,L6616] In patients with deep vein thrombosis or atrial fibrillation there is an increased risk of thrombus formation due to the reduced movement of blood.[T622] For patients with cardiac valve disease or valve replacements this increased coagulability is due to tissue damage. Thrombi due to venous thrombosis can travel to the lungs and become pulmonary emboli, blocking circulation to a portion of lung tissue. Thrombi which form in the heart can travel to the brain and cause ischemic strokes. Prevention of these events is the primary goal of warfarin therapy.



Limitation of thrombus formation is also a source of adverse effects. In patients with atheroscelotic plaques rupture typically results in thrombus formation.[A179212] When these patients are anticoagulated plaque rupture can allow the escape of cholesterol from the lipid core in the form of atheroemboli or cholesterol microemboli. These emboli are smaller than thrombi and block smaller vessels, usually less than 200 μm in diameter. The consequences of this are varied and depend on the location of the blockage. Effects include visual disturbances, acute kidney injury or worsening of chronic kidney disease, central nervous system ischemia, and purple or blue toe syndrome.[label,A179212] Blue toe syndrome can be reversed if it has not progressed to tissue necrosis but the other effects of microemboli are often permanent.



Antocoagulation appears to mediate warfarin-related nephropathy, a seemingly spontaneous kidney injury or worsening of chronic kidney disease associated with warfarin therapy.[A179215] Nephropathy in this case appears to be due to increased passage of red blood cells through the glomerulus and subsequent blockage of renal tubules with red blood cell casts. This is worsened or possibly triggered by pre-existing kidney damage. Increased risk of warfarin-related nephropathy occurs at INRs over 3.0 but risk does not increase as a function of INR beyond this point.



Warfarin has been linked to the development of calciphylaxis.[label] This is thought to be due to warfarin''s inhibition of [vitamin K](VKA) recycling as VKA is needed for the carboxylation of matrix Gla protein.[A179218] This protein is an anti-calcification factor and its inhibition through preventing the carboxylation step in its production leads to a shift in calcification balance in favor of calciphylaxis. 



Tissue necrosis can occur early on in warfarin therapy.[label] This is attributable to half lives of the clotting factors impacted by inhibition of vitamin K recycling.[label,A179221] Proteins C and S are anticoagulation factors with half lives of 8 and 24 hours respectively. The coagulation factors IX, X, VII, and thrombin (factor II) have half lives of 24, 36, 6, and 50 hours respectively. This means proteins C and S are inactivated sooner than pro-coagulation proteins, with the exception of factor VII, resulting in a pro-thrombotic state for the first few days of therapy. Thrombi which form in this time period can occlude arterioles in various locations, blocking blood flow and causing tissue necrosis due to ischemia.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sugarlo 50mg 30 tabs.', 27610, 'شوجارلو 50مجم 30 قرص', '123', '93', 'Anti-diabetic.secretagogues.dpp-4 inhibitors', 'Anti-diabetic.secretagogues.dpp-4 inhibitors', NULL, 'Vildagliptin', 'Al esraa pharmaceutical optima', 'Tab', 'أقراص', '50mg', '3', 'لمرضى السكر', NULL, NULL, '6223004160479', 5470, '2024-08-20', NULL, 0, 'Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.[L32803] It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thiazolidinedione in adults patients with insufficient glycemic control despite maximal tolerated dose of monotherapy.[L32803] 



Vildagliptin is also marketed in a combination product with [metformin] for the treatment of adults with type II diabetes mellitus who inadequately respond to either monotherapy of vildagliptin or metformin. This fixed-dose formulation can be used in combination with a sulphonylurea or insulin (i.e., triple therapy) as an adjunct to diet and exercise in adults who do not achieve adequate glycemic control with monotherapy or dual therapy.[L32813]', 'Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are incretin hormones that regulate blood glucose levels and maintain glucose homeostasis. It is estimated that the activity of GLP-1 and GIP contribute more than 70% to the insulin response to an oral glucose challenge. They stimulate insulin secretion in a glucose-dependent manner via G-protein-coupled GIP and GLP-1 receptor signalling. In addition to their effects on insulin secretion, GLP-1 is also involved in promoting islet neogenesis and differentiation, as well as attenuating pancreatic beta-cell apoptosis. Incretin hormones also exert extra-pancreatic effects, such as lipogenesis and myocardial function.[A232523] In type II diabetes mellitus, GLP-1 secretion is impaired, and the insulinotropic effect of GIP is significantly diminished.[A232488]



Vildagliptin exerts its blood glucose-lowering effects by selectively inhibiting dipeptidyl peptidase-4 (DPP-4), an enzyme that rapidly truncates and inactivates GLP-1 and GIP upon their release from the intestinal cells. DPP-4 cleaves oligopeptides after the second amino acid from the N-terminal end. Inhibition of DPP-4 substantially prolongs the half-life of GLP-1 and GIP, increasing the levels of active circulating incretin hormones.[A232523] The duration of DPP-4 inhibition by vildagliptin is dose-dependent.[A232533] Vildagliptin reduces fasting and prandial glucose and HbA1c. It enhances the glucose sensitivity of alpha- and beta-cells and augments glucose-dependent insulin secretion. Fasting and postprandial glucose levels are decreased, and postprandial lipid and lipoprotein metabolism are also improved.[A232488,A232528]', 'Vildagliptin works to improve glycemic control in type II diabetes mellitus by enhancing the glucose sensitivity of beta-cells (β-cells) in pancreatic islets and promoting glucose-dependent insulin secretion. Increased GLP-1 levels leads to enhanced sensitivity of alpha cells to glucose, promoting glucagon secretion. Vildagliptin causes an increase in the insulin to glucagon ratio by increasing incretin hormone levels: this results in a decrease in fasting and postprandial hepatic glucose production. Vildagliptin does not affect gastric emptying. It also has no effects on insulin secretion or blood glucose levels in individuals with normal glycemic control.[L32803]



In clinical trials, treatment with vildagliptin 50-100 mg daily in patients with type 2 diabetes significantly improved markers of beta-cells, proinsulin to insulin ratio, and measures of beta-cell responsiveness from the frequently-sampled meal tolerance test. [L32803] Vildagliptin has improves glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) levels.[A232488]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cospo sachet', 32319, 'كوسبو اكياس', '150', NULL, 'Diatry supplement', 'Diatry supplement', NULL, 'Marine collagen+vit c+calcium', 'Med care > chemist pharma', 'Sachet', 'أكياس', NULL, '1', NULL, NULL, NULL, NULL, 667, '2023-04-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Olfen 75mg/2ml 6 amp', 9198, 'اولفين 75مجم/2مل 6 امبولات', '66', '39', 'Nsaid.acetic acid derivatives', 'Nsaid.acetic acid derivatives', NULL, 'Diclofenac sodium', 'Mup > acino', 'Amp', 'أمبول', '75mg', '6', NULL, NULL, NULL, NULL, 5841, '2024-11-13', NULL, 0, 'Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma. It is often used in combination with [misoprostol] as a gastro-protective agent in patients with high risk of developing NSAID-induced ulcers.', 'Diclofenac inhibits cyclooxygenase-1 and -2, the enzymes responsible for production of prostaglandin (PG) G<sub>2</sub> which is the precursor to other PGs.[label,T116] These molecules have broad activity in pain and inflammation and the inhibition of their production is the common mechanism linking each effect of diclofenac.



PGE<sub>2</sub> is the primary PG involved in modulation of nociception.[A179023] It mediates peripheral sensitization through a variety of effects.[T116,A179023] PGE<sub>2</sub> activates the G<sub>q</sub>-coupled EP<sub>1</sub> receptor leading to increased activity of the inositol trisphosphate/phospholipase C pathway. Activation of this pathway releases intracellular stores of calcium which directly reduces action potential threshold and activates protein kinase C (PKC) which contributes to several indirect mechanisms. PGE<sub>2</sub> also activates the EP<sub>4</sub> receptor, coupled to G<sub>s</sub>, which activates the adenylyl cyclase/protein kinase A (AC/PKA) signaling pathway. PKA and PKC both contribute to the potentiation of transient receptor potential cation channel subfamily V member 1 (TRPV1) potentiation, which increases sensitivity to heat stimuli. They also activate tetrodotoxin-resistant sodium channels and inhibit inward potassium currents. PKA further contributes to the activation of the P2X3 purine receptor and sensitization of T-type calcium channels. The activation and sensitization of depolarizing ion channels and inhibition of inward potassium currents serve to reduce the intensity of stimulus necessary to generate action potentials in nociceptive sensory afferents. PGE<sub>2</sub> act via EP<sub>3</sub> to increase sensitivity to bradykinin and via EP<sub>2</sub> to further increase heat sensitivity. Central sensitization occurs in the dorsal horn of the spinal cord and is mediated by the EP<sub>2</sub> receptor which couples to G<sub>s</sub>. Pre-synaptically, this receptor increases the release of pro-nociceptive neurotransmitters glutamate, CGRP, and substance P. Post-synaptically it increases the activity of AMPA and NMDA receptors and produces inhibition of inhibitory glycinergic neurons. Together these lead to a reduced threshold of activating, allowing low intensity stimuli to generate pain signals. PGI<sub>2</sub> is known to play a role via its G<sub>s</sub>-coupled IP receptor although the magnitude of its contribution varies. It has been proposed to be of greater importance in painful inflammatory conditions such as arthritis. By limiting sensitization, both peripheral and central, via these pathways NSAIDs can effectively reduce inflammatory pain.



PGI<sub>2</sub> and PGE<sub>2</sub> contribute to acute inflammation via their IP and EP<sub>2</sub> receptors.[T116,A179044] Similarly to β adrenergic receptors these are G<sub>s</sub>-coupled and mediate vasodilation through the AC/PKA pathway. PGE<sub>2</sub> also contributes by increasing leukocyte adhesion to the endothelium and attracts the cells to the site of injury.[T116] PGD<sub>2</sub> plays a role in the activation of endothelial cell release of cytokines through its DP<sub>1</sub> receptor.[A179044] PGI<sub>2</sub> and PGE<sub>2</sub> modulate T-helper cell activation and differentiation through IP, EP<sub>2</sub>, and EP<sub>4</sub> receptors which is believed to be an important activity in the pathology of arthritic conditions. By limiting the production of these PGs at the site of injury, NSAIDs can reduce inflammation.



PGE<sub>2</sub> can cross the blood-brain barrier and act on excitatory G<sub>q</sub> EP<sub>3</sub> receptors on thermoregulatory neurons in the hypothalamus.[T116] This activation triggers an increase in heat-generation and a reduction in heat-loss to produce a fever. NSAIDs prevent the generation of PGE<sub>2</sub> thereby reducing the activity of these neurons.

', 'Diclofenac reduces inflammation and by extension reduces nociceptive pain and combats fever.[label,T116] It also increases the risk of developing a gastrointestinal ulcer by inhibiting the production of protective mucus in the stomach.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Miacalcic 200 i.u./ml nasal spray 3 bottles', 8118, 'مياكالسيك 200وحدة/مل بخاخ للانف 3 زجاجات', '390', NULL, 'Osteoporosis.antiresorptives', 'Osteoporosis.antiresorptives', NULL, 'Calcitonin', 'Novartis', 'Spray', 'بخاخ', NULL, '3', NULL, NULL, 'prescribed for: injectable calcitonin is used to treat osteoporosis and paget s disease. injectable calcitonin also is used to treat seriously elevated blood calcium levels. the nasal spray is used only for osteoporosis in women who are at least 5 years p', '6223002641277', 1587, '2023-04-13', NULL, 0, 'Investigated for use/treatment in myocardial infarction, heart disease, and asthma.', 'While current drugs for treating HF and MI have a single mechanism of action, CGRP appears to work on several levels: for example, it (1) increases local blood flow enhancing hemodynamic proficiency; (2) protects heart muscle cells from the damage due to lack of oxygen (ischemia); and, (3) modulates the immune system by boosting anti-inflammatory cytokine expression while suppressing pro-inflammatory cytokines, which reduces the inflammatory response to provide a cardioprotective effect. All these actions are meant to minimize heart muscle damage and subsequent scar tissue formation, while promoting the healing process.', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Gedimadel 4 mg 30 tab.', 19634, 'جيديماديل 4 مجم 30 قرص', '30', '15', 'Anti-diabetic.secretagogues.sulfonylurea', 'Anti-diabetic.secretagogues.sulfonylurea', NULL, 'Glimepiride', 'Jedco int. co. for pharmaceuticals', 'Tab', 'أقراص', '4 mg', '3', NULL, NULL, 'indications : this medication is a sulfonylurea antidiabetic agent prescribed for type 2 diabetes. it works by causing the pancreas to produce insulin dosage : the recommended starting dose is 1-2 mg once daily with food.maximum: 2mg/day contraindications', NULL, 711, '2024-03-22', NULL, 0, 'Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy. 



It may also be indicated for use in combination with metformin or insulin to lower blood glucose in patients with type 2 diabetes whose high blood sugar levels cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic (a drug used to lower blood sugar levels) agent alone.[L10322]', 'ATP-sensitive potassium channels on pancreatic beta cells that are gated by intracellular ATP and ADP. The hetero-octomeric complex of the channel is composed of four pore-forming Kir6.2 subunits and four regulatory sulfonylurea receptor (SUR) subunits. Alternative splicing allows the formation of channels composed of varying subunit isoforms expressed at different concentrations in different tissues.[A177730] In pancreatic beta cells, ATP-sensitive potassium channels play a role as essential metabolic sensors and regulators that couple membrane excitability with glucose-stimulated insulin secretion (GSIS).[A177727] When there is a decrease in the ATP:ADP ratio, the channels are activated and open, leading to K+ efflux from the cell, membrane hyperpolarization, and suppression of insulin secretion.[A177727] In contrast, increased uptake of glucose into the cell leads to elevated intracellular ATP:ADP ratio, leading to the closure of channels and membrane depolarization. Depolarization leads to activation and opening of the voltage-dependent Ca2+ channels and consequently an influx of calcium ions into the cell.[A177727] Elevated intracellular calcium levels causes the contraction of the filaments of actomyosin responsible for the exocytosis of insulin granules stored in vesicles.[A177715] Glimepiride blocks the ATP-sensitive potassium channel by binding non-specifically to the B sites of both sulfonylurea receptor-1 (SUR1) and sulfonylurea receptor-2A (SUR2A) subunits as well as the A site of SUR1 subunit of the channel to promote insulin secretion from the beta cell.[A177715] ', 'Glimepiride stimulates the secretion of insulin granules from the pancreatic beta cells and improves the sensitivity of peripheral tissues to insulin to increase peripheral glucose uptake, thus reducing plasma blood glucose levels and glycated hemoglobin (HbA1C) levels. A multi-center, randomized, placebo-controlled clinical trial evaluated the efficacy of glimepiride (1–8 mg) as monotherapy titrated over 10 weeks compared with placebo in T2DM subjects who were not controlled by diet alone.[A177703] In this study, there was a reduction in fasting plasma glucose (FPG) by 46 mg/dL, post-prandial glucose (PPG) by 72 mg/dL, and HbA1c by 1.4% more than the placebo.[A177703] In another randomized study comprising of patients with T2DM receiving either placebo or one of the three doses (1, 4, or 8 mg) of glimepiride during a 14-week study period, all glimepiride regimens significantly reduced FPG, PPG, and HbA1c values (P < 0.001) compared to placebo by the end of the study period.[A177703] The 4- and 8-mg doses of glimepiride were more effective than the 1-mg dose; however, the 4-mg dose provided a nearly maximal antihyperglycemic effect.[A177703]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Contrahistadin 20mg 20 tabs.', 16752, 'كونتراهيستادين 20مجم 20 قرص', '55', '44', 'Anti-histamine.second-generation', 'Anti-histamine.second-generation', NULL, 'Bilastine', 'Global advanced pharmaceuticals (gap)', 'Tab', 'أقراص', '20mg', '2', '1- مضاد حساسية من الجيل الثاني (بيلاستين).', NULL, NULL, '6223005941060', 10611, '2023-08-18', NULL, 0, 'For symptomatic relief of nasal and non-nasal symptoms of seasonal rhinitis in patients 12 years of age and older and for symptomatic relief in chronic spontaneous urticaria in patients 18 years of age and older [FDA Label].', 'Bilastine is a selective histamine H1 receptor antagonist (Ki = 64nM) [FDA Label]. During allergic response mast cells undergo degranulation which releases histamine and other subastances. By binding to and preventing activation of the H1 receptor, bilastine reduces the development of allergic symptoms due to the release of histamine from mast cells.', 'Bilastine is an antiallergenic and acts to reduce allergic symptoms such as nasal congestion and urticaria [FDA Label].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lokazanda mouth spray 60 ml', 33114, 'لوكازاندا سبراى للفم 60 مل', '65', '55', 'Mouth spray', 'Mouth spray', NULL, 'Mentol crystal+tea tree oil+lidocaine', 'Care and cure pharma', 'Spray', 'بخاخ', '60 ml', '1', 'بخاخ للفم معطر ومسكن للالام', NULL, NULL, NULL, 2392, '2025-08-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Candesar 16 mg 14 tab.', 15749, 'كانديسار 16 مجم 14 قرص', '12', NULL, 'Antihypertensive.arbs', 'Antihypertensive.arbs', NULL, 'Candesartan cilexetil', 'Pharopharma', 'Tab', 'أقراص', '16 mg', '2', NULL, NULL, 'about candesartan cilexetil angiotensin || antagonist antihypertensive agent mechanism of action of candesartan cilexetil it is a antagonist of angiotensin 2 at at-1 receptor.it decreases peripheral resistance and lowers bp in hypertensive individuals. it', NULL, 1210, '2022-07-24', NULL, 0, 'May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.', 'Candesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion.', 'Candesartan cilexetil is an ARB prodrug that is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS. RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dobutamine 250mg/5ml 5 amps. for i.v. inf.', 17741, 'دوبوتامين 250 مجم / 5 مل 5 امبول', '106', NULL, 'Heart failure.beta agonist', 'Heart failure.beta agonist', NULL, 'Dobutamine', 'Eimc', 'Amp', 'أمبول', '250mg', '5', NULL, NULL, 'about dobutamine adrenergic agonist agent cardiac stimulant in chf directly acting inotropic agent. mechanism of action of dobutamine dobutamine exerts its pharmacological action by selectively stimulating beta-1 adrenergic receptors. it is a positive ino', NULL, 759, '2022-08-03', NULL, 0, 'Indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.', 'Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output.', 'Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with negligible effects on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Prexal 5 mg 30 caplets', 25222, 'بريكسال 5مجم 30 قرص', '230', '168', 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Olanzapine', 'Joswe medical-jordan > space medical', 'Cap', 'كبسولة', '5 mg', '3', NULL, NULL, 'indication for the acute and maintenance treatment of schizophrenia and related psychotic disorders as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. intramuscular olanzapine is indicated for the rapid control of agitated patien', '6251599000627', 2409, '2024-02-01', NULL, 0, 'Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.[A177014] 



Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.[FDA label]



As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.[A177014]



Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.[FDA label]



Schizophrenia is a complex biochemical brain disorder that affects the person''s ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.[L5936]



Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.[L5939]



Olanzapine is also indicated in combination with [samidorphan] for the treatment of bipolar I disorder, either as an adjunct to lithium or valproate or as monotherapy for the acute treatment of manic or mixed episodes or as maintenance therapy, and for the treatment of schizophrenia in adults.[L34359]', 'The activity of olanzapine is achieved by the antagonism of multiple neuronal receptors including the dopamine receptor D1, D2, D3 and D4 in the brain, the serotonin receptors 5HT2A, 5HT2C, 5HT3 and 5HT6, the alpha-1 adrenergic receptor, the histamine receptor H1 and multiple muscarinic receptors.[A176993, A176999]



As abovementioned, olanzapine presents a wide profile of targets, however, its antagonistic effect towards the dopamine D2 receptor in the mesolimbic pathway is key as it blocks dopamine from having a potential action at the post-synaptic receptor. The binding of olanzapine to the dopamine D2 receptors is easily dissociable and hence, it allows for a certain degree of dopamine neurotransmission.[A177014]



On the other hand, olanzapine acts in the serotonin 5HT2A receptors in the frontal cortex in a similar manner than the reported on dopamine D2 receptors. This determined effect allows for a decrease in adverse effects.[A177014]', 'The effect of olanzapine in the D2 receptor is reported to produce the positive effects of this drug such as a decrease in hallucinations, delusions, disorganized speech, disorganized thought, and disorganized behavior. On the other hand, its effect on the serotonin 5HT2A receptor prevents the onset of anhedonia, flat affect, alogia, avolition and poor attention.[A177014] Based on the specific mechanism of action, olanzapine presents a higher affinity for the dopamine D2 receptor when compared to the rest of the dopamine receptor isotypes. This characteristic significantly reduces the presence of side effects.[T554]



Clinical trials for the original use of olanzapine demonstrated significant effectiveness in the treatment of schizophrenia and bipolar disorder in adults and acute manic or mixed episodes associated with bipolar disorder in adolescents.[A177008]



The effect of olanzapine on dopamine and serotonin receptors has been suggested to reduce chemotherapy-induced nausea and vomiting as those receptors are suggested to be involved in this process. For this effect, several clinical trials have been conducted and it has been shown that olanzapine can produce a significant increase in total control of nausea and vomiting.[A176993] In a high-level study of the effect of olanzapine for this condition, a complete response on the delay phase was observed in 84% of the individual and control of emesis of over 80% despite the phase.[A176999]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Curetyfollic hair tonic vials 4*5ml', 5490, 'كيوريتي فوليك لتقوية الشعر 4 فيال *5 مل', '440', NULL, 'Hair shaft disorders', 'Hair shaft disorders', NULL, 'Fiberhance solution+trichogen', 'Atlas pharmaceutical', 'Vial', 'فيال', '5ml', '1', NULL, NULL, NULL, NULL, 674, '2025-06-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Eudyna 0.05% cream 20 gm (n/a)', 18629, 'يودينا 0.05% كريم 20 جم', '3', NULL, 'Anti-acne', 'Anti-acne', NULL, 'Tretinoin', 'Alexandria > abbott laboratories', 'Cream', 'كريم', '0.05%', '1', NULL, NULL, 'about tretinoin retinoid vitamin a metabolite anti-acne in hyperpigmentation. mechanism of action of tretinoin tretinoin is all trans retinoic acid (acid form of vitamin a). tretinoin is a potent comedolytic. it stimulates mitosis and epidermal cell turno', '6223000176870', 932, '2022-07-24', NULL, 0, 'Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated.[L45349]



Topical tretinoin is also indicated alone [L45389] or in combination with [benzoyl peroxide] [L34869] or [clindamycin] [L45384] for the treatment of acne vulgaris. It is also used in prescription and over-the-counter for treating various skin conditions such as melasma,[L45394] hyperpigmentation,[A257474] and photoaging [A258180] alone or in combination with other drugs.', 'The exact mechanism of action of tretinoin in skin conditions and acute promyelocytic leukemia (APL) has not been fully elucidated; however, several proposed mechanisms exist. Tretinoin is believed to exert its pharmacological actions by binding to and activating two types of nuclear receptors - retinoic acid receptors (RARs) alpha, beta, and gamma and retinoid X receptors (RXRs). In the human skin, RARs (especially RAR-alpha) form heterodimers with RXR to act as inducible transcription regulators of genes involved in cell differentiation by binding to retinoic acid response elements.[A257724,A258185] Tretinoin binds to RXRs to promote epidermal proliferation. It also blocks the actions of inflammatory mediators, enhancing procollagen production and collagen type I and III formations.[A257474,A257629,A257609,A257699] Some animal and human studies suggest that tretinoin induces the expression of transforming growth factor beta (TGF-β), which stimulates the transcription of several types of collagen messenger RNA. Collagen formation curtails further solar UV-induced skin damage and aging processes.[A257699]



Acne is associated with abnormal follicular formation from excessive keratinization of epithelial cells. Tretinoin promotes cornified cell detachment and enhances keratinocyte shedding. It also stimulates mitotic activity and loosely-adherent corneocyte turnover to expel comedo contents, reducing microcomedo precursor lesions of acne vulgaris.[A257474,L34869] Tretinoin may reduce epidermal melanin and pigmentation by increasing keratinocyte turnover and reducing tyrosinase activity.[A257609,A258180]



RAR-alpha and -beta have also been implicated in APL.[A257724] APL is characterized by a t(15;17) chromosomal translocation, which fuses the promyelocytic myeloid leukemia (PML) gene with the RAR-alpha gene.[A257689,A257694] The resulting PML-RAR-alpha fusion protein plays a role in the pathogenesis of APL by aberrating promyelocyte differentiation. The PML-RAR-alpha fusion protein is found to be predominant in leukemic cells, exerting a dominant negative effect on RAR, RXR and PML function.[A257689] Tretinoin induces terminal differentiation in hemopoietic precursor cell lines and APL cells.[A257694] Tretinoin is believed to promote caspase-mediated cleavage and proteasome-dependent degradation to cause apoptosis and degradation of the PML-RAR-alpha fusion protein.[A257474] It may also convert the fusion protein from a transcription repressor to an activator.[A257474]', 'Tretinoin is a vitamin A derivative that promotes cell production, proliferation, and differentiation. When used topically, tretinoin regulates epidermal cell turnover and collagen production. It also prevents collagen loss, reduces inflammation, and blocks the induction of matrix metalloproteinase (MMP), which are enzymes that disrupt collagen and elastic fibres.[A257474,A257629,A257609,A258180] In short-term and long-term studies, topical application of tretinoin at doses ranging from 0.001% to 0.1% was associated with improvements in clinical signs of photoaging and fine wrinkles, increased epidermal thickness, compaction of the stratum corneum, and decreased melanin content.[A257684,A258180,A258185,A257699] It also improved melanocyte differentiation and distribution, promotion of epidermal hyperplasia, and angiogenesis.[A257699]



Tretinoin exhibits antineoplastic activities when given orally.[L45349] Tretinoin was shown to induce differentiation in tumour cells.[A257694] It induced cytodifferentiation and decreased acute promyelocytic leukemia (APL) cell proliferation in culture and _in vivo_. In patients with APL, tretinoin promoted the initial maturation of the primitive promyelocytes derived from the leukemic clone, followed by a repopulation of the bone marrow and peripheral blood by normal, polyclonal hematopoietic cells in patients achieving complete remission.[L45349]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Timaspan 1000 mg 10 ext. rel. f.c. tabs', 28190, 'تيماسبان 1000مجم 10 اقراص', '29', NULL, 'Antioxidant', 'Antioxidant', NULL, 'Niacin', 'Medizen pharmaceutical industries > al esraa pharmaceutical optima', 'Tab', 'أقراص', '1000 mg', '1', 'مضاد للاكسدة ويستخدم فى خفض مستوى الكوليسترول بالدم', NULL, NULL, NULL, 2099, '2022-06-17', NULL, 0, 'Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections.[L7550,L7553,L7556,L7559] Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia.[L7562,L7565] It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia.[L7562,L7565] Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia.[L7562,L7565] Finally niacin is indicated to treat severe hypertriglyceridemia.[L7562,L7565]', 'Niacin performs a number of functions in the body and so has many mechanisms, not all of which have been fully described.[A19555] Niacin can decrease lipids and apolipoprotein B (apo B)-containing lipoproteins by modulating triglyceride synthesis in the liver, which degrades apo B, or by modulating lipolysis in adipose tissue.[A19555]



Niacin inhibits hepatocyte diacylglycerol acyltransferase-2.[A19555] This action prevents the final step of triglyceride synthesis in hepatocytes, limiting available triglycerides for very low density lipoproteins (VLDL).[A19555] This activity also leads to intracellular degradation of apo B and decreased production of low density lipoproteins, the catabolic product of VLDL.[A19555]



Niacin also inhibits a high density lipoprotein (HDL) catabolism receptor, which increases the levels and half life of HDL.[A19555]', 'Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] Niacin acts to decrease levels of very low density lipoproteins and low density lipoproteins, while increasing levels of high density lipoproteins.[A19555] Niacin has a wide therapeutic window with usual oral doses between 500mg and 2000mg.[L7550] Patients with diabetes, renal failure, uncontrolled hypothyroidism, and elderly patients taking niacin with simvastatin or lovastatin are at increased risk of myopathy and rhabdomyolysis.[L7550]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Splendo vag.douche 250 ml', 27417, 'سبليندو غسول مهبلي 250 مل', '40', NULL, 'Vaginal wash', 'Vaginal wash', NULL, 'Thyme extract+calendula extract+triclosan+tea tree oil', 'Hi-care > pharma cure pharmaceuticals', 'Unknown', 'غير محدد', '250 ml', '1', NULL, NULL, NULL, '6224000651220', 1432, '2022-12-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Amoebyl 500mg 20 tabs.', 13984, 'اميبيل 500 مجم 20 قرص', '5', NULL, 'Luminal amebicide', 'Luminal amebicide', NULL, 'Diloxanide furoate', 'Mup', 'Tab', 'أقراص', '500mg', '2', 'علاج الديدان في الامعاء', NULL, 'about diloxanide furoate dichloroacetamide derivative anti-protozoal luminal amebicides. mechanism of action of diloxanide furoate diloxanide furoate is a dicloroacetamide derivative which acts as a luminal amoebicide. it exerts its action by directly kil', '6221508010511', 1143, '2022-12-01', NULL, 0, 'Diloxanide is used alone as a primary agent in the treatment of asymptomatic (cyst passers) intestinal amebiasis caused by Entamoeba histolytica. Diloxanide may also be used concurrently, or sequentially, with other agents such as the nitroimidazoles (eg. metronidazole) in the treatment of invasive or extraintestinal forms of amebiasis.

', 'Unknown. Diloxanide may inhibit protein synthesis. ', 'Diloxanide is a luminal amebicide, however the mechanism of action of diloxanide is unknown. Diloxanide destroys the trophozoites of E. histolytica that eventually form into cysts. The cysts are then excreted by persons infected with asymptomatic amebiasis. Diloxanide furoate is a prodrug, and is hydrolyzed in the gastrointestinal tract to produce diloxanide, the active ingredient. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cefpirome 1 gm vial i.v.', 2273, 'سيفبيروم 1 جم فيال', '34', NULL, 'Antibiotic.cephalosporin.fourth-generation', 'Antibiotic.cephalosporin.fourth-generation', NULL, 'Cefpirome', 'Kahira > eva pharma', 'Vial', 'فيال', '1 gm', '1', NULL, NULL, 'properties: pharmacological actions:cefpirome is a cephalosporin antibiotic for parenteral use.as a beta-lactam antibiotic it acts bactericidally by preventing cell wall synthesis in bacteria. cefpirome is effective against numerous clinically significant', '6223002454884', 882, '2022-12-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Orgoroxaban 15 mg 20 f.c.tabs.', 31045, 'اورجوركسابان 15مجم 20 قرص', '342', '260', 'Antiplatlet.direct factor xa inhibitor', 'Antiplatlet.direct factor xa inhibitor', NULL, 'Rivaroxaban', 'Organopharma > organo', 'Tab', 'أقراص', '15 mg', '2', NULL, NULL, 'rivaroxaban is used for: preventing and treating blood clots in certain patients. it is also used to reduce the risk of stroke and serious blood clots in certain patients with atrial fibrillation. rivaroxaban is also used to treat and prevent deep vein th', NULL, 812, '2025-05-26', NULL, 0, 'Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Its use is also not recommended in those with severe renal impairment (<30mL/min).[L12819]



Rivaroxaban is also indicated for the treatment and prevention of VTE in pediatric patients (from birth to 18 years of age) and for thromboprophylaxis in pediatric patients ≥2 years old with congenital heart disease following the Fontan procedure.[L12819]

', 'Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible.

 

', 'Rivaroxaban is an anticoagulant which binds directly to factor Xa. Thereafter, it effectively blocks the amplification of the coagulation cascade, preventing the formation of thrombus. Rivaroxaban is a unqiue anticoagulant for two reasons. First of all, it is does not involve antithrombin III (ATIII) to exert its anticoagulant effects. Secondly, it is an oral agent whereas the widely used unfractionated heparin and low molecular weight heparins are for parenteral use only. Although the activated partial thromboplastin time (aPTT) and HepTest (a test developed to assay low molecular weight heparins) are prolonged in a dose-dependant manner, neither test is recommended for the assessment of the pharmacodynamic effects of rivaroxaban. Anti-Xa activity and inhibition of anti-Xa activity monitoring is also not recommended despite being influenced by rivaroxaban.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Adancor 10mg 30 breakable tabs.', 144, 'ادانكور 10مجم 30 قرص', '83', '69', 'Anti-ischemic', 'Anti-ischemic', NULL, 'Nicorandil', 'Merck kgaa f.r.germany > merck limited egypt', 'Tab', 'أقراص', '10mg', '3', 'مرضى قصور الدورة الدموية', NULL, 'about nicorandil a potassium channel opener a vasodilator antianginal. mechanism of action of nicorandil the drug exerts antianginal action by activating atp sensitive potassium channels which leads to hyperpolarizing vascular smooth muscle and ultimate v', '6222003702437', 5729, '2023-09-18', NULL, 0, 'Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes. ', 'Nicorandil mediates its therapeutic efficacy via two main mechanisms. Nicorandil is an activator and opener of ATP-sensitive (ATP-dependent) potassium channels (KATP channels) that are composed of Kir6.x-type subunits and sulfonylurea receptor (SUR) subunits. Nicorandil binding sites are located in the sulfonylurea receptor 2 (SUR2) in the ATP-sensitive potassium channel [A20322], which are regulatory subunits of the channel that exhibit an ATPase activitiy [A12436]. There are 2 types of SUR2 subunits (2A/2B) that have identical nucleotide binding domains (NBD), where SUR2A is more predominantly expressed in skeletal and cardiac myocytes and SUR2B in smooth muscle cells [A12436]. Nicorandil more potently activates SUR2B/Kir6.2 than SUR2A/Kir6.2 channels to cause hyperpolarization. ATP-NBD1 interaction influences the channel signalling by nicorandil, and the response of the channel to nicorandil is also facilitated and heightened by the interaction of ATP or ADP with NBD2 [A20321]. Potentiated activity of ATP-sensitive channels have cardioprotective role by limiting the duration of action potentials and preventing intraceullar calcium overload [A20326]. This attenuates cellular injury by preserving cellular energetics and ultimately cell survival [A20324]. KATP channel-dependent membrane hyperpolarization can also lead to vasodilation via reduction in Ca2+ influx through the voltage-gated Ca2+ channels and regulation of intracellular Ca2+ mobilization in smooth muscle cells [A20324]. 

Nicorandil contain a nitrate moiety in its structure, making it a good dilator of vascular smooth muscle like other nitroglycerin esters [A20323]. Direct relaxation of venous vascular system arises from NO-donor mediated stimulation of guanylyl cyclase and increased levels of intracellular cyclic GMP (cGMP). Elevated levels of cGMP contributes to the total relaxing effect of nicorandil at higher concentrations of the drug [A7839]. ', 'Nicorandil is a potassium channel opener with nitrovasodilator (NO donor) actions, making it both an arterial and a venous dilator [T28]. It causes sustained dilation of both the arterial resistance and conductive vessels that increases coronary blood flow, however the effect of the drug on coronary arteries does not involve the coronary steal phenomenon [L887]. Activation of potassium channels lead to hyperpolarization of the smooth muscle cells, followed by arterial dilation and afterload reduction. Nicorandil is shown to increase pooling in the capacitance vessels with a decrease in preload through relaxing the venous vascular system. Overall, improved blood flow and reduced infarct size are achieved through reduction of end-diastolix pressure and decreased extravascular component of vascular resistance [L887]. Open studies showed the effectiveness of nicorandil treatment on various types of angina pectoris [A20327]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Femtucam vag.douche 200 ml', 18937, 'فيمتوكام دوش مهبلي 200 مل', '22', NULL, 'Vaginal wash', 'Vaginal wash', NULL, NULL, 'Hi-care > glenmark pharmaceuticals', 'Unknown', 'غير محدد', '200 ml', '1', NULL, NULL, NULL, NULL, 715, '2022-07-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Flexilax 30 f.c.tab', 19127, 'فليكسيلاكس 30 قرص', '84', '57', 'Cns.analgesic.skeletal muscle relaxant', 'Cns.analgesic.skeletal muscle relaxant', NULL, 'Diclofenac potassium+methocarbamol', 'Hikma pharma', 'Tab', 'أقراص', NULL, '3', NULL, NULL, NULL, '6221000000614', 10495, '2024-08-03', NULL, 0, 'Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma. It is often used in combination with [misoprostol] as a gastro-protective agent in patients with high risk of developing NSAID-induced ulcers.', 'Diclofenac inhibits cyclooxygenase-1 and -2, the enzymes responsible for production of prostaglandin (PG) G<sub>2</sub> which is the precursor to other PGs.[label,T116] These molecules have broad activity in pain and inflammation and the inhibition of their production is the common mechanism linking each effect of diclofenac.



PGE<sub>2</sub> is the primary PG involved in modulation of nociception.[A179023] It mediates peripheral sensitization through a variety of effects.[T116,A179023] PGE<sub>2</sub> activates the G<sub>q</sub>-coupled EP<sub>1</sub> receptor leading to increased activity of the inositol trisphosphate/phospholipase C pathway. Activation of this pathway releases intracellular stores of calcium which directly reduces action potential threshold and activates protein kinase C (PKC) which contributes to several indirect mechanisms. PGE<sub>2</sub> also activates the EP<sub>4</sub> receptor, coupled to G<sub>s</sub>, which activates the adenylyl cyclase/protein kinase A (AC/PKA) signaling pathway. PKA and PKC both contribute to the potentiation of transient receptor potential cation channel subfamily V member 1 (TRPV1) potentiation, which increases sensitivity to heat stimuli. They also activate tetrodotoxin-resistant sodium channels and inhibit inward potassium currents. PKA further contributes to the activation of the P2X3 purine receptor and sensitization of T-type calcium channels. The activation and sensitization of depolarizing ion channels and inhibition of inward potassium currents serve to reduce the intensity of stimulus necessary to generate action potentials in nociceptive sensory afferents. PGE<sub>2</sub> act via EP<sub>3</sub> to increase sensitivity to bradykinin and via EP<sub>2</sub> to further increase heat sensitivity. Central sensitization occurs in the dorsal horn of the spinal cord and is mediated by the EP<sub>2</sub> receptor which couples to G<sub>s</sub>. Pre-synaptically, this receptor increases the release of pro-nociceptive neurotransmitters glutamate, CGRP, and substance P. Post-synaptically it increases the activity of AMPA and NMDA receptors and produces inhibition of inhibitory glycinergic neurons. Together these lead to a reduced threshold of activating, allowing low intensity stimuli to generate pain signals. PGI<sub>2</sub> is known to play a role via its G<sub>s</sub>-coupled IP receptor although the magnitude of its contribution varies. It has been proposed to be of greater importance in painful inflammatory conditions such as arthritis. By limiting sensitization, both peripheral and central, via these pathways NSAIDs can effectively reduce inflammatory pain.



PGI<sub>2</sub> and PGE<sub>2</sub> contribute to acute inflammation via their IP and EP<sub>2</sub> receptors.[T116,A179044] Similarly to β adrenergic receptors these are G<sub>s</sub>-coupled and mediate vasodilation through the AC/PKA pathway. PGE<sub>2</sub> also contributes by increasing leukocyte adhesion to the endothelium and attracts the cells to the site of injury.[T116] PGD<sub>2</sub> plays a role in the activation of endothelial cell release of cytokines through its DP<sub>1</sub> receptor.[A179044] PGI<sub>2</sub> and PGE<sub>2</sub> modulate T-helper cell activation and differentiation through IP, EP<sub>2</sub>, and EP<sub>4</sub> receptors which is believed to be an important activity in the pathology of arthritic conditions. By limiting the production of these PGs at the site of injury, NSAIDs can reduce inflammation.



PGE<sub>2</sub> can cross the blood-brain barrier and act on excitatory G<sub>q</sub> EP<sub>3</sub> receptors on thermoregulatory neurons in the hypothalamus.[T116] This activation triggers an increase in heat-generation and a reduction in heat-loss to produce a fever. NSAIDs prevent the generation of PGE<sub>2</sub> thereby reducing the activity of these neurons.

', 'Diclofenac reduces inflammation and by extension reduces nociceptive pain and combats fever.[label,T116] It also increases the risk of developing a gastrointestinal ulcer by inhibiting the production of protective mucus in the stomach.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Visipaque 270mg i/ml (100ml) vial (hospitals price)', 29436, 'فيسيباك 270مجم 100 مل فيال', '170', NULL, 'Radiographic procedures.contrast agent', 'Radiographic procedures.contrast agent', NULL, 'Iodixanol', 'Amersham health - ireland > new technology', 'Vial', 'فيال', '270mg', '1', NULL, NULL, NULL, NULL, 813, '2022-08-06', NULL, 0, 'Iodixanol is a contrast agent during coronary angiography.', 'Organic iodine compounds attenuate x-rays as they pass through the body, thereby allowing the body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intravascular administration, iodixanol makes opaque those internal structures in its path of flow, allowing their visualization until significant hemodilution and elimination occur.', 'Iodixanol is a contrast agent commonly used during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. It is an imaging contrast agent with the same osmolality as blood (290mOsm/kg H20).', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cytarabine 100mg/5ml amp.', 17025, 'سيتارابين 100مجم/5مل امبول', '15', NULL, 'Antiviral.nucleoside', 'Antiviral.nucleoside', NULL, 'Cytarabine', 'Choongwae pharma-korea > general technology-egypt', 'Amp', 'أمبول', '100mg', '1', NULL, NULL, NULL, NULL, 1248, '2022-07-01', NULL, 0, 'For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.



Cytarabine is indicated in combination with [daunorubicin] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.[L32843]', 'Cytarabine acts through direct DNA damage and incorporation into DNA. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G1 phase to the S-phase. Although the mechanism of action is not completely understood, it appears that cytarabine acts through the inhibition of DNA polymerase. A limited, but significant, incorporation of cytarabine into both DNA and RNA has also been reported.', 'Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hypolact 0.5 mg 2 tablets', 20639, 'هايبولاكت 0.5مجم 2 قرص', '103', '72', 'Dopamine agonist & prolactin inhibitor', 'Dopamine agonist & prolactin inhibitor', NULL, 'Cabergoline', 'Egpi > paxal pharmaceutical', 'Tablet', 'أقراص', '0.5 mg', '1', 'مضاد لهرمون اللبن -- علاج بعض حالات تأخر الحمل في السيدات -- مضاد لهرمون البرولاكتين لتنشيف اللبن بعد فطام الطفل', NULL, NULL, '6225000356719', 7403, '2024-12-04', NULL, 0, 'For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease. ', 'The dopamine D<sub>2</sub> receptor is a 7-transmembrane G-protein coupled receptor associated with G<sub>i</sub> proteins. In lactotrophs, stimulation of dopamine D<sub>2</sub> causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca<sup>2+</sup> from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D<sub>2</sub> receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D1, &alpha;<sub>1</sub>,- and &alpha;<sub>2</sub>- adrenergic, and 5-HT<sub>1</sub>- and 5-HT<sub>2</sub>-serotonin receptors.', 'Cabergoline stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D<sub>1</sub> and D<sub>5</sub> subreceptors, which are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D<sub>2</sub>, D<sub>3</sub> and D<sub>4</sub> subreceptors, which are associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D<sub>2</sub> and D<sub>3</sub> receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D2 stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D<sub>2</sub>- and D<sub>3</sub>-receptors. It also exhibits: agonist activity (in order of decreasing binding affinities) on 5-hydroxytryptamine (5-HT)<sub>2B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>1D</sub>, dopamine D<sub>4</sub>, 5-HT<sub>1A</sub>, dopamine D<sub>1</sub>, 5-HT<sub>1B</sub> and 5-HT<sub>2C</sub> receptors and antagonist activity on &alpha;<sub>2B</sub>, &alpha;<sub>2A</sub>, and &alpha;<sub>2C</sub> receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT<sub>2A</sub> agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hepafence 3gm/5gm 10 granules in sachets', 20335, 'هيبافينس 3جم/5جم حبيبات اكياس', '50', NULL, 'Liver support supplement', 'Liver support supplement', NULL, 'L-ornithine-l-aspartate', 'Idi > novell pharma', 'Sachet', 'أكياس', '3gm', '1', 'مكمل يدعم وظائف الكبد', NULL, '(indications) : this medication is a stable salt of the amino acids ornithine and aspartic acid prescribed for the treatment of high ammonia levels or severe liver impairment. it is also used for end-stage cirrhosis. (contraindications): contraindicated i', NULL, 773, '2022-05-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Recicarnate 30 f.c. tabs.', 25764, 'ريسيكارنيت 30 قرص', '50', NULL, 'Calcium supplement plus vitamin d', 'Calcium supplement plus vitamin d', NULL, 'Calcium+vitamin d3', 'Organopharma > planet cure', 'Tab', 'أقراص', NULL, '3', 'مصدر للكالسيوم المقوس للعظام والاسنان __ الحماية من هشاشة العظام __ ومصدر لفيتامين د الذي يساعد الكالسيوم علي امتصاصه بالجسم', NULL, 'formerly known as calcium d', NULL, 1223, '2022-04-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lacteol forte 5 billion 12 cap', 7040, 'لاكتيول فورت 5 بليون 12 كبسولة', '126', '86', 'Antidiarrheal', 'Antidiarrheal', NULL, 'Lactobacillus acidophilus', 'Rameda>axcan pharma france', 'Cap', 'كبسولة', NULL, '3', 'علاج حالات الاسهال المزمن', NULL, NULL, '6223003970116', 7516, '2024-10-06', NULL, 0, NULL, 'Lactobacillus coryniformis has immunomodulatory activity. Administration of a Lc K8 probiotic prior to the influenza vaccine in adults over the age of 65 showed a higher percentage of vaccine responders and a significantly lower incidence of respiratory symptoms associated with respiratory infections.', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cogentin 2mg 25 tab', 2880, 'كوجنتين 2مجم 25 قرص', '6', NULL, NULL, NULL, NULL, 'Benzatropine', 'Kahira', 'Tab', 'أقراص', '2mg', '1', 'تخفيف اعراض مرض الشلل الرعاش -- تخفيف الحركات اللاارادية والاثار الجانبية لبعض الادوية النفسية', NULL, NULL, '6221068904633', 1970, '2023-05-30', NULL, 0, 'Benztropine is indicated to be used as an adjunct in the therapy of all forms of parkinsonism. It can also be used for the control of extrapyramidal disorders due to neuroleptic drugs.[T203]



The extrapyramidal symptoms are defined as drug-induced disorders that include symptoms of dystonia, akathisia, parkinsonism, bradykinesia, tremors, and dyskinesia.[A175120] 



Parkinsonism is a general term that refers to the group of neurological disorders that produce symptoms similar to Parkinson''s disease such as tremors, slow movement, and stiffness. The parkinsonism includes a large number of disorders and some of them have not been clearly defined.[L5509]', 'Benztropine is an agent with anti-muscarinic and antihistaminic effects. Its main mechanism of action is presented by the selective inhibition of dopamine transporters but it also presents affinity for histamine and muscarine receptors.[A175084]



It is widely known that benztropine is a potent inhibitor of presynaptic carrier-mediated dopamine transport. As well, it is known to be an analog of atropine and hence, it has a large affinity for muscarinic receptors M1 in the human brain. Once bound, benztropine blocks the activity of the muscarinic receptors mainly in the striatum.[A1628]



The increased advantage of benztropine lays on the antagonism of acetylcholine activity which corrects the imbalance between dopamine and acetylcholine in Parkinson patients.[F3679]', 'The inhibition of dopamine reuptake by benztropine produces a dose-dependent increase of dopamine in the nerve terminal of the dopaminergic system.[A1628] 



Clinically the activity of benztropine is observed after 1-2 hours of oral administration and after a few minutes of intramuscular administration with a last-longing effect of about 24 hours. Reports have indicated that benztropine has a very large sedative effect.[A1628]



The antihistaminic effect of benztropine is very similar to the effect found in [pyrilamine] and the anticholinergic activity was found to be equal to [atropine] _ex vivo_ and of about 50% activity _in vivo_.[F3679]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rifampson 150/300 mg 10 caps.', 26082, 'ريفامبسون 150/300مجم 10 كبسول', '10', NULL, 'Antitubercular', 'Antitubercular', NULL, 'Isoniazid+rifampicin', 'Memphis', 'Cap', 'كبسولة', '300 mg', '1', NULL, NULL, 'about isoniazid hydrazine derivative antitubercular agent. mechanism of action of isoniazid isoniazid is a bactericidal drug. i t inhibits the mycolic acid synthesis which is essential for the cell wall formation. it also inhibits dna rna and protein synt', NULL, 689, '2022-08-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Beesline kids sunscreen lotion spf 50 - 200 ml', 15012, 'بيزلين صن بلوك للاطفال بمعامل حماية 50 200مل', '440', NULL, 'Sun block', 'Sun block', NULL, NULL, 'Beesline > pharma cruise medical', 'Lotion', 'لوشن', '200 ml', '1', NULL, NULL, 'active ingredients sunflower oil sweet almond oil titanium dioxide sesame oil beeswax henna honey wheatgerm oil nigella seed oil & vitamin e. with wet skin technology to provide water-resistant broad spectrum protection. easy to spread & rich in nourishin', NULL, 995, '2022-07-08', NULL, 0, NULL, NULL, NULL, NULL);
